{"docstore/data": {"e2245dea-0889-4d04-ac46-c7585007f7f5": {"__data__": {"id_": "e2245dea-0889-4d04-ac46-c7585007f7f5", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.  ", "original_text": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9453aec-ec42-4db1-9c12-4bc3b73578e4", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n", "original_text": "Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.  "}, "hash": "3aa7b4ab24e5fe653a61e4245fdaf96c21e7fa20fed8ff69d43f984eb5d321f3", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9453aec-ec42-4db1-9c12-4bc3b73578e4": {"__data__": {"id_": "a9453aec-ec42-4db1-9c12-4bc3b73578e4", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n", "original_text": "Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2245dea-0889-4d04-ac46-c7585007f7f5", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.  ", "original_text": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f24b3c92fdc1dc9a225799bc988ea6261dc274d8c7a1418852cc1e5ef1e09c27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb93c1ae-3395-4d62-aafb-f49c08500db9", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.  ", "original_text": "Today's conference is being recorded. "}, "hash": "58d00397762a75ed262328e8f3ee7357dcec8d45d2dabd2a786db628335256f9", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.  ", "start_char_idx": 48, "end_char_idx": 243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb93c1ae-3395-4d62-aafb-f49c08500db9": {"__data__": {"id_": "eb93c1ae-3395-4d62-aafb-f49c08500db9", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.  ", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9453aec-ec42-4db1-9c12-4bc3b73578e4", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n", "original_text": "Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f66ba805eebd5b398e909b42a00cea74402c5eb137c25c212bf8d8dd5f184d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b24bc4d2-9504-412e-a1ad-31ea9aebfcd9", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 . ", "original_text": "At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.  "}, "hash": "9a4e90f63379b67228cfe08d8c6f85bb42d9343c5ecca8e9e9474dd57c8b8512", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 243, "end_char_idx": 281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b24bc4d2-9504-412e-a1ad-31ea9aebfcd9": {"__data__": {"id_": "b24bc4d2-9504-412e-a1ad-31ea9aebfcd9", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 . ", "original_text": "At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb93c1ae-3395-4d62-aafb-f49c08500db9", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.  ", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2b1bc296bca4efb6c910f1b3cf9b9be66f862262d8b43688696abd7e48a5eae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ebc3f9b-9abf-4b25-951c-219679a28bb4", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.  ", "original_text": "Please go ahead, sir.  \n"}, "hash": "bbb5132d20640007dd06afbcad44ae9bcf961bf96bb41f0771f27ab3f953743b", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.  ", "start_char_idx": 281, "end_char_idx": 392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ebc3f9b-9abf-4b25-951c-219679a28bb4": {"__data__": {"id_": "0ebc3f9b-9abf-4b25-951c-219679a28bb4", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.  ", "original_text": "Please go ahead, sir.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b24bc4d2-9504-412e-a1ad-31ea9aebfcd9", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 . ", "original_text": "At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "354d5f786ec6b543e6caaf207583ba2865afb32e04965ae3bc99386d04f4d75d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd2593d9-854c-4aa2-834e-c9452387be22", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n", "original_text": "Kevin Moran: Good morning, and welcome.  "}, "hash": "11118d9d8356d32682f3d398b6a50a6d561efbf1e17cd5d3021f78dd07efcdf0", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead, sir.  \n", "start_char_idx": 392, "end_char_idx": 416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd2593d9-854c-4aa2-834e-c9452387be22": {"__data__": {"id_": "bd2593d9-854c-4aa2-834e-c9452387be22", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n", "original_text": "Kevin Moran: Good morning, and welcome.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ebc3f9b-9abf-4b25-951c-219679a28bb4", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.  ", "original_text": "Please go ahead, sir.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a722c8a6d34e31190cdd65ec2bf21d0551b03ff5b2f1a8e0a464407bedcae056", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30a5a0f6-e5f6-449d-a73d-23ca7eb34d0d", "node_type": "1", "metadata": {"window": "At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.  ", "original_text": "Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 . "}, "hash": "13be9ccc016de390122acef9e9c4b67a89aa554e93103ccb3860433e25b08dc8", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran: Good morning, and welcome.  ", "start_char_idx": 416, "end_char_idx": 457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30a5a0f6-e5f6-449d-a73d-23ca7eb34d0d": {"__data__": {"id_": "30a5a0f6-e5f6-449d-a73d-23ca7eb34d0d", "embedding": null, "metadata": {"window": "At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.  ", "original_text": "Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 . ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd2593d9-854c-4aa2-834e-c9452387be22", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n", "original_text": "Kevin Moran: Good morning, and welcome.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7e2c7a4bdb35fb5e3c94c67e6a72fe2a9db3a7b9e7ecc3b4fdeafb6351f4bab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c8c0fe2-7003-4ad4-b5a6-78e05cb3cab4", "node_type": "1", "metadata": {"window": "Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.  ", "original_text": "Results along with guidance for fiscal year 2022.  "}, "hash": "4cb68a256d357788889d3cdd6bf865e55739f6de84048405742258bd24fa16fd", "class_name": "RelatedNodeInfo"}}, "text": "Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 . ", "start_char_idx": 457, "end_char_idx": 529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c8c0fe2-7003-4ad4-b5a6-78e05cb3cab4": {"__data__": {"id_": "2c8c0fe2-7003-4ad4-b5a6-78e05cb3cab4", "embedding": null, "metadata": {"window": "Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.  ", "original_text": "Results along with guidance for fiscal year 2022.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30a5a0f6-e5f6-449d-a73d-23ca7eb34d0d", "node_type": "1", "metadata": {"window": "At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.   Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.  ", "original_text": "Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 . ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6c70ef24bd7928e9238414058db6061871771bbfaf197fc0d8bd8f81fb32e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "add45d40-6923-4444-997a-dffac8f43dbd", "node_type": "1", "metadata": {"window": "Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.  ", "original_text": "You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n"}, "hash": "22bd5a031f060dc300544f7ed7e0a1e7741250a7be09488b21aa902ab391939a", "class_name": "RelatedNodeInfo"}}, "text": "Results along with guidance for fiscal year 2022.  ", "start_char_idx": 529, "end_char_idx": 580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "add45d40-6923-4444-997a-dffac8f43dbd": {"__data__": {"id_": "add45d40-6923-4444-997a-dffac8f43dbd", "embedding": null, "metadata": {"window": "Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.  ", "original_text": "You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c8c0fe2-7003-4ad4-b5a6-78e05cb3cab4", "node_type": "1", "metadata": {"window": "Please go ahead, sir.  \n Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.  ", "original_text": "Results along with guidance for fiscal year 2022.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7dff13788c353e1031e99906514e0b912dae22a2a8ec945e0370d272bc8ae8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "275a9792-138a-4601-b02a-9d634a558f84", "node_type": "1", "metadata": {"window": "Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n", "original_text": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.  "}, "hash": "4333111129c9d8c38fe0c25d9425394fb580b667500fa1de555663033e926b14", "class_name": "RelatedNodeInfo"}}, "text": "You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n", "start_char_idx": 580, "end_char_idx": 694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "275a9792-138a-4601-b02a-9d634a558f84": {"__data__": {"id_": "275a9792-138a-4601-b02a-9d634a558f84", "embedding": null, "metadata": {"window": "Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n", "original_text": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "add45d40-6923-4444-997a-dffac8f43dbd", "node_type": "1", "metadata": {"window": "Kevin Moran: Good morning, and welcome.   Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.  ", "original_text": "You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5fbe4bb2efb536344e5dbeb11273d58711164ab23082017f8eddd1a4f5a4c10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "301ab9c6-6937-418c-8c39-d72d4e0352fd", "node_type": "1", "metadata": {"window": "Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.  ", "original_text": "During the call, we will be making forward -looking statements.  "}, "hash": "d3ba24d61e43d016f13dbd2cfa8c53b0ccb2335789177d0c8a45175029a32cd2", "class_name": "RelatedNodeInfo"}}, "text": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.  ", "start_char_idx": 694, "end_char_idx": 801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "301ab9c6-6937-418c-8c39-d72d4e0352fd": {"__data__": {"id_": "301ab9c6-6937-418c-8c39-d72d4e0352fd", "embedding": null, "metadata": {"window": "Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.  ", "original_text": "During the call, we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "275a9792-138a-4601-b02a-9d634a558f84", "node_type": "1", "metadata": {"window": "Today, we will discuss Cardinal Health's Fourth Quart er \nFiscal 2021 .  Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n", "original_text": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85bda357cf049c33349415f37d13617ed294a94626bc67a3f7a7629386aaeba8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f720c0ee-4af9-4588-99b0-9097408f998f", "node_type": "1", "metadata": {"window": "You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.  "}, "hash": "6d061eae197e12a0d192a1ca63ea65bec5a9d4e067de19da4ec8d14748f82599", "class_name": "RelatedNodeInfo"}}, "text": "During the call, we will be making forward -looking statements.  ", "start_char_idx": 801, "end_char_idx": 866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f720c0ee-4af9-4588-99b0-9097408f998f": {"__data__": {"id_": "f720c0ee-4af9-4588-99b0-9097408f998f", "embedding": null, "metadata": {"window": "You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "301ab9c6-6937-418c-8c39-d72d4e0352fd", "node_type": "1", "metadata": {"window": "Results along with guidance for fiscal year 2022.   You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.  ", "original_text": "During the call, we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9caad4defd040e6373622d1ee3eaf7cd0b1291d1b4121ec3919abf7fd7c5ec3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffc7079b-26a7-464a-a8b9-bc21a906eeee", "node_type": "1", "metadata": {"window": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n"}, "hash": "00660cb034b8585006498930d3ad69d5f62819d1b8a680776f9a151a41499eec", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.  ", "start_char_idx": 866, "end_char_idx": 1039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffc7079b-26a7-464a-a8b9-bc21a906eeee": {"__data__": {"id_": "ffc7079b-26a7-464a-a8b9-bc21a906eeee", "embedding": null, "metadata": {"window": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f720c0ee-4af9-4588-99b0-9097408f998f", "node_type": "1", "metadata": {"window": "You can find today's press release and \npresentation on the IR section of our Website at ir.cardinalhealth.com.  \n Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1aa1e9341fc7b49378074a5d4591e1d2f850552e59060e2e9d156d5f5896c355", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3472492-ce47-4337-8e75-a46c618ec3b7", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.  "}, "hash": "8c9c1fa8ca9e32459671906ab3478df36ebc37d448d900f9141d6105241c30f5", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n", "start_char_idx": 1039, "end_char_idx": 1204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3472492-ce47-4337-8e75-a46c618ec3b7": {"__data__": {"id_": "e3472492-ce47-4337-8e75-a46c618ec3b7", "embedding": null, "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffc7079b-26a7-464a-a8b9-bc21a906eeee", "node_type": "1", "metadata": {"window": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar,  Chief Financial \nOfficer.   During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f88f1f299c51e85d705d16d2669adc4745aa0779eb3ad81413fa23e01206586", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eabbdb28-f84a-4167-8299-8a16941ef2a8", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  ", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n"}, "hash": "fae673ab8781fa6a01d2e3e8f635ae6cefe430ebe1fcd34a28a9a01fc5b23867", "class_name": "RelatedNodeInfo"}}, "text": "Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.  ", "start_char_idx": 1204, "end_char_idx": 1344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eabbdb28-f84a-4167-8299-8a16941ef2a8": {"__data__": {"id_": "eabbdb28-f84a-4167-8299-8a16941ef2a8", "embedding": null, "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  ", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3472492-ce47-4337-8e75-a46c618ec3b7", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "737e9fa4764fa33756e04292868affa8aec7f76f0753039ea20f6052e709e922", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ec67509-d6ac-4051-a141-45806fc1fb77", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.  ", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.  "}, "hash": "f6bfd5da5316d9169c09bdd4a455d45c66646965d0d199f8c6ca9b751ce8e490", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n", "start_char_idx": 1344, "end_char_idx": 1466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ec67509-d6ac-4051-a141-45806fc1fb77": {"__data__": {"id_": "4ec67509-d6ac-4051-a141-45806fc1fb77", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.  ", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eabbdb28-f84a-4167-8299-8a16941ef2a8", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or impli ed.   Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  ", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc32a1cf3298a89484ac95f507077d261018634c1066ef428f655f51c144593f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce33a122-cbdc-457c-b0f0-b1b5af0dcee3", "node_type": "1", "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n", "original_text": "With that, I will now turn the call over to Mike.  \n"}, "hash": "0fb8ccd36befdc41c82d40d20d2de5aec07597a554c0fd85c02c5cfb2111f9a6", "class_name": "RelatedNodeInfo"}}, "text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.  ", "start_char_idx": 1466, "end_char_idx": 1624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce33a122-cbdc-457c-b0f0-b1b5af0dcee3": {"__data__": {"id_": "ce33a122-cbdc-457c-b0f0-b1b5af0dcee3", "embedding": null, "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n", "original_text": "With that, I will now turn the call over to Mike.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ec67509-d6ac-4051-a141-45806fc1fb77", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.  ", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f264411f8dffd490327a26b970ebb8b69cfe6c06701b824943d379cfb90dd848", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "254efc82-4482-4dc2-b827-97522417557a", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.  ", "original_text": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  "}, "hash": "1fb6f36bd58ead47c6fe2d48755db7f40990f0c0014925d2c2693e16af49f866", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will now turn the call over to Mike.  \n", "start_char_idx": 1624, "end_char_idx": 1676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "254efc82-4482-4dc2-b827-97522417557a": {"__data__": {"id_": "254efc82-4482-4dc2-b827-97522417557a", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.  ", "original_text": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce33a122-cbdc-457c-b0f0-b1b5af0dcee3", "node_type": "1", "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis unl ess they \nare specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n", "original_text": "With that, I will now turn the call over to Mike.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36fab308ae55b291e934600a737dc45442097fe32a88986be302b86c1cd74324", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e977aaf6-4405-4149-af4e-ce40265ba4fd", "node_type": "1", "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n", "original_text": "I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.  "}, "hash": "e93fc9761b4a26c0226dda003550b3cb1b4cca95d73e5ef8d8a7f00dfc8d3cb2", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  ", "start_char_idx": 1676, "end_char_idx": 1739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e977aaf6-4405-4149-af4e-ce40265ba4fd": {"__data__": {"id_": "e977aaf6-4405-4149-af4e-ce40265ba4fd", "embedding": null, "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n", "original_text": "I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "254efc82-4482-4dc2-b827-97522417557a", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can \nbe found in the schedule attached to our press release.  \n During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.  ", "original_text": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5dd9444d3e5f8f858822c11fdfc64643928482e7bcb0336a0a68c0227af047d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfe047fe-3ba8-4b37-87d8-edb3ae4f9b3b", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.  ", "original_text": "This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n"}, "hash": "b71fdcf133fadca5f8337abe06670b1f241e52c7330f971eb37cb3745cf0203a", "class_name": "RelatedNodeInfo"}}, "text": "I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.  ", "start_char_idx": 1739, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfe047fe-3ba8-4b37-87d8-edb3ae4f9b3b": {"__data__": {"id_": "bfe047fe-3ba8-4b37-87d8-edb3ae4f9b3b", "embedding": null, "metadata": {"window": "With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.  ", "original_text": "This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e977aaf6-4405-4149-af4e-ce40265ba4fd", "node_type": "1", "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to on e question \nso that we can try and give everyone an opportunity.   With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n", "original_text": "I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd2511a176b488dffa497f1f141a1406850206eddb27914996ba61baa1856988", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a349f2b2-8a87-43e8-98d9-398073c5895d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.  ", "original_text": "To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.  "}, "hash": "3449b5e9ed14272f31d13c0edf93f429cec84bd8cf2cc1c9dba1447abeb6dfa0", "class_name": "RelatedNodeInfo"}}, "text": "This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n", "start_char_idx": 1927, "end_char_idx": 2061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a349f2b2-8a87-43e8-98d9-398073c5895d": {"__data__": {"id_": "a349f2b2-8a87-43e8-98d9-398073c5895d", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.  ", "original_text": "To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfe047fe-3ba8-4b37-87d8-edb3ae4f9b3b", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over to Mike.  \n Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.  ", "original_text": "This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24289b2bb39faaaf4039c5fc02d1edaec24720449be4663c7e8d49b6f40d0e5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9964c598-1ddf-4f96-90a0-24721423a22a", "node_type": "1", "metadata": {"window": "I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.  ", "original_text": "Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n"}, "hash": "7d16dee5f1101513a63168e1e6595269c5cdba17e0df301c579a919e6bc2bc39", "class_name": "RelatedNodeInfo"}}, "text": "To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.  ", "start_char_idx": 2061, "end_char_idx": 2287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9964c598-1ddf-4f96-90a0-24721423a22a": {"__data__": {"id_": "9964c598-1ddf-4f96-90a0-24721423a22a", "embedding": null, "metadata": {"window": "I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.  ", "original_text": "Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a349f2b2-8a87-43e8-98d9-398073c5895d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thank you, Kevin, and good morning, everyone.   I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.  ", "original_text": "To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ad93f7e67f8c5e2128e26a1c200e8d7f185d6ef1dae4862899f0752fa194515", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07656d67-f11d-487b-adc2-435a456c7c1c", "node_type": "1", "metadata": {"window": "This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.   We are continually reviewing our business and seeking areas to improve.  \n ", "original_text": "In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.  "}, "hash": "45478da61c7dcd9ff42d6918273c58a0601c6d52156941d92809cd5a86a227dd", "class_name": "RelatedNodeInfo"}}, "text": "Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n", "start_char_idx": 2287, "end_char_idx": 2514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07656d67-f11d-487b-adc2-435a456c7c1c": {"__data__": {"id_": "07656d67-f11d-487b-adc2-435a456c7c1c", "embedding": null, "metadata": {"window": "This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.   We are continually reviewing our business and seeking areas to improve.  \n ", "original_text": "In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9964c598-1ddf-4f96-90a0-24721423a22a", "node_type": "1", "metadata": {"window": "I will start my comments today by \nacknowledging that our fourth quarter result s were below our expectations and yours primarily due to \nan inventory reserve adjustment of $197 million.   This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.  ", "original_text": "Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcc03843f370582d65396a92ad599bfd6a381916f1e0651aefd0f413283ffa7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b3cd265-71cb-4531-b300-2784bd55ec8e", "node_type": "1", "metadata": {"window": "To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.   We are continually reviewing our business and seeking areas to improve.  \n ", "original_text": "Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.  "}, "hash": "572a1371dc6ab3094154209cd0fd45cc5635059bb7d0fbd12c43a23b70583e6b", "class_name": "RelatedNodeInfo"}}, "text": "In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.  ", "start_char_idx": 2514, "end_char_idx": 2636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b3cd265-71cb-4531-b300-2784bd55ec8e": {"__data__": {"id_": "2b3cd265-71cb-4531-b300-2784bd55ec8e", "embedding": null, "metadata": {"window": "To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.   We are continually reviewing our business and seeking areas to improve.  \n ", "original_text": "Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07656d67-f11d-487b-adc2-435a456c7c1c", "node_type": "1", "metadata": {"window": "This reserve adjustment was driven by changing \nmarket conditions related to COVID -19 on certain highly commoditized PPE products.  \n To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.   We are continually reviewing our business and seeking areas to improve.  \n ", "original_text": "In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2511c4b009791c5069b8cb1db38137986aaff18a10e781636401c4087b43ba8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97eb211c-459e-4d85-b795-8f779e400600", "node_type": "1", "metadata": {"window": "Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.   We are continually reviewing our business and seeking areas to improve.  \n ", "original_text": "For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.  "}, "hash": "8d9173ce3e820427f75955a812992c6f0cece3feb6775040c44e9b19fa0713ba", "class_name": "RelatedNodeInfo"}}, "text": "Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.  ", "start_char_idx": 2636, "end_char_idx": 2764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97eb211c-459e-4d85-b795-8f779e400600": {"__data__": {"id_": "97eb211c-459e-4d85-b795-8f779e400600", "embedding": null, "metadata": {"window": "Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.   We are continually reviewing our business and seeking areas to improve.  \n ", "original_text": "For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b3cd265-71cb-4531-b300-2784bd55ec8e", "node_type": "1", "metadata": {"window": "To meet our custome r commitments during the pandemic, we carried higher levels of inventory in \ncertain PPE categories during a period of significantly increased demand, higher prices and longer -\nthan-normal supply chains.   Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.   We are continually reviewing our business and seeking areas to improve.  \n ", "original_text": "Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a5ccdab4e9bc78ae11a29b99e04edeccdc87b70ae69b16bfe90b2b50c69f8fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2aa092f-f798-42f2-a0de-4a9fc150b5e3", "node_type": "1", "metadata": {"window": "In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.   We are continually reviewing our business and seeking areas to improve.  \n ", "original_text": "We are continually reviewing our business and seeking areas to improve.  \n "}, "hash": "b40cb7b65b2198e6298aa7f6d0b2d76335b82ec5152bb3e254cec45d11e6e0a3", "class_name": "RelatedNodeInfo"}}, "text": "For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.  ", "start_char_idx": 2764, "end_char_idx": 3043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2aa092f-f798-42f2-a0de-4a9fc150b5e3": {"__data__": {"id_": "d2aa092f-f798-42f2-a0de-4a9fc150b5e3", "embedding": null, "metadata": {"window": "In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.   We are continually reviewing our business and seeking areas to improve.  \n ", "original_text": "We are continually reviewing our business and seeking areas to improve.  \n ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd9538092febc28704b880664b6f2c5a2a2f2b627547c3e5e3fd1b120ccb611", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97eb211c-459e-4d85-b795-8f779e400600", "node_type": "1", "metadata": {"window": "Our analysis at the quarter end of both the anticipat ed customer demand \nand projected future sale prices for these products resulted in a sizable inventory reserve that \naffected a subset of our medical products inventory.  \n In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.   We are continually reviewing our business and seeking areas to improve.  \n ", "original_text": "For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.  ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c5167f07942074dd8019da190bf4e6dbe9049759f7a40e1d613b4fee7cac7eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90ad4290-cfab-49b1-8c00-ea279524b958", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n", "original_text": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n"}, "hash": "75a717b995cd4b6afed97fc443e0f0ae0b90744c9cff9587b99362989373a8fc", "class_name": "RelatedNodeInfo"}}, "text": "We are continually reviewing our business and seeking areas to improve.  \n ", "start_char_idx": 3043, "end_char_idx": 3118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90ad4290-cfab-49b1-8c00-ea279524b958": {"__data__": {"id_": "90ad4290-cfab-49b1-8c00-ea279524b958", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n", "original_text": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2aa092f-f798-42f2-a0de-4a9fc150b5e3", "node_type": "1", "metadata": {"window": "In addition, there were a few other unexpected items that affected our results, which J ason will cover \nin his remarks.   Throughout the past year, we have been taking action to drive performance, and we \nwill continue to move forward with urgency.   For example, we divested the Cordis business, extended \nour Red Oak Sourcing agreement with CVS H ealth, identified $250 million of additional cost savings \nopportunities, restructured parts of our organization to increase accountability and made important \nleadership changes.   We are continually reviewing our business and seeking areas to improve.  \n ", "original_text": "We are continually reviewing our business and seeking areas to improve.  \n ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1f680de6e04354332a7b84c8a3d9eb4f91b6d055d490e037cb37594d305a7d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54152de9-c381-4183-8bae-6bc46ce77f8b", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n", "original_text": "In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.  "}, "hash": "723cbcaa8bdf81714455e18b154e31fe73df9aa6c2b7b0796a9ccef0cae62ce1", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n", "start_char_idx": 0, "end_char_idx": 211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54152de9-c381-4183-8bae-6bc46ce77f8b": {"__data__": {"id_": "54152de9-c381-4183-8bae-6bc46ce77f8b", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n", "original_text": "In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90ad4290-cfab-49b1-8c00-ea279524b958", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n", "original_text": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b1be87a9a4690347fb5d138fb0702e7742dc10cd0b9ea89930363f306a66f6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aff01caa-4f2f-430e-89d2-d4392d70086d", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.  ", "original_text": "We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.  "}, "hash": "d1cdce1c321774edae1ecea27e600d2dd630b4f26c51c17203e623c58588f1e3", "class_name": "RelatedNodeInfo"}}, "text": "In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.  ", "start_char_idx": 211, "end_char_idx": 382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aff01caa-4f2f-430e-89d2-d4392d70086d": {"__data__": {"id_": "aff01caa-4f2f-430e-89d2-d4392d70086d", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.  ", "original_text": "We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54152de9-c381-4183-8bae-6bc46ce77f8b", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n", "original_text": "In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b44b99f8b4adb5549527fd67c55b221c93847664c4d85edf573797605ef97702", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "533e460f-0585-4e89-be96-f896ba07c55d", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.  ", "original_text": "We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n"}, "hash": "71736538f2a9320686b20deba05d350725aba2e69d0d363ddb59626faa031a11", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.  ", "start_char_idx": 382, "end_char_idx": 524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "533e460f-0585-4e89-be96-f896ba07c55d": {"__data__": {"id_": "533e460f-0585-4e89-be96-f896ba07c55d", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.  ", "original_text": "We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aff01caa-4f2f-430e-89d2-d4392d70086d", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.  ", "original_text": "We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90566cdb5d7830e3f086dd270b0f740441a3ef49bc5863b2b71be092d1963667", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8986fbc-edf7-4849-a126-2de35b42c199", "node_type": "1", "metadata": {"window": "In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n", "original_text": "As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n"}, "hash": "87aa4a84692e2d88087541c50a80228a27c030ad642c4c7103fb9797d2d92e2e", "class_name": "RelatedNodeInfo"}}, "text": "We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n", "start_char_idx": 524, "end_char_idx": 711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8986fbc-edf7-4849-a126-2de35b42c199": {"__data__": {"id_": "f8986fbc-edf7-4849-a126-2de35b42c199", "embedding": null, "metadata": {"window": "In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n", "original_text": "As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "533e460f-0585-4e89-be96-f896ba07c55d", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.  ", "original_text": "We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0993b8d817903ac3a32fbc157ee96d4906d7edc62d346eda631f20286c640a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8712cf6-77f3-45ff-bbc6-7568ff438187", "node_type": "1", "metadata": {"window": "We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S. ", "original_text": "Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.  "}, "hash": "bf37fc0a4514e573dc5acda76b16ba3deade44a012e7c43a7422e50bc9fc4fa1", "class_name": "RelatedNodeInfo"}}, "text": "As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n", "start_char_idx": 711, "end_char_idx": 1005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8712cf6-77f3-45ff-bbc6-7568ff438187": {"__data__": {"id_": "c8712cf6-77f3-45ff-bbc6-7568ff438187", "embedding": null, "metadata": {"window": "We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S. ", "original_text": "Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8986fbc-edf7-4849-a126-2de35b42c199", "node_type": "1", "metadata": {"window": "In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n", "original_text": "As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29f224fc0b6754d8a1c5ee2f0edb1dd32e49aff65e253b58ec32cd9b5f28aeb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "309df031-5f52-4058-af3b-20eb5a682624", "node_type": "1", "metadata": {"window": "We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n", "original_text": "If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.  "}, "hash": "1f7154a8a102eaa6b308f81cc44f6289e77bc4905f547a3adeba484272b87bb4", "class_name": "RelatedNodeInfo"}}, "text": "Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.  ", "start_char_idx": 1005, "end_char_idx": 1247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "309df031-5f52-4058-af3b-20eb5a682624": {"__data__": {"id_": "309df031-5f52-4058-af3b-20eb5a682624", "embedding": null, "metadata": {"window": "We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n", "original_text": "If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8712cf6-77f3-45ff-bbc6-7568ff438187", "node_type": "1", "metadata": {"window": "We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S. ", "original_text": "Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c037dfbd2682014091b016fa7060f09d165e5e616bb811b17cb5216ca5af641", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8a3eefe-abb1-429c-8eb5-940765393a0c", "node_type": "1", "metadata": {"window": "As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n", "original_text": "This is an important step forward for our c ompany.   \n"}, "hash": "4f1b4bfa1a015fbf9eeaa0dcda777c3be3fd369a63c67199ef6e8fd9a91b72bc", "class_name": "RelatedNodeInfo"}}, "text": "If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.  ", "start_char_idx": 1247, "end_char_idx": 1538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8a3eefe-abb1-429c-8eb5-940765393a0c": {"__data__": {"id_": "a8a3eefe-abb1-429c-8eb5-940765393a0c", "embedding": null, "metadata": {"window": "As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n", "original_text": "This is an important step forward for our c ompany.   \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "309df031-5f52-4058-af3b-20eb5a682624", "node_type": "1", "metadata": {"window": "We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n", "original_text": "If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a091963e32154ff25aead8aaf049a54428b6faea0dbbac3354fb335743629159", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dd401b5-151f-44ba-94e6-15af816cb305", "node_type": "1", "metadata": {"window": "Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  ", "original_text": "As we've consistently said, we remain committed to being part of the solution for the U.S. "}, "hash": "43a97ed32b99c683afc6eed030688cb8a2ade6bd60e6238ac603435b428e715f", "class_name": "RelatedNodeInfo"}}, "text": "This is an important step forward for our c ompany.   \n", "start_char_idx": 1538, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dd401b5-151f-44ba-94e6-15af816cb305": {"__data__": {"id_": "3dd401b5-151f-44ba-94e6-15af816cb305", "embedding": null, "metadata": {"window": "Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  ", "original_text": "As we've consistently said, we remain committed to being part of the solution for the U.S. ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8a3eefe-abb1-429c-8eb5-940765393a0c", "node_type": "1", "metadata": {"window": "As I reflect on the unprecedented events of the past year, our team has prioritized our c ustomers, \nmaintained continuous operations, partnered with governmental agencies to support vaccine \nadministration and protect patients , and  has further improved the resiliency of our supply chain.  \n Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n", "original_text": "This is an important step forward for our c ompany.   \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36e6cdab5882b30fe03abe9ea0ed07794a29138366a746633056d3a10defdfd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0e1b0c8-837b-4862-bbdb-0030f79a2be3", "node_type": "1", "metadata": {"window": "If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n", "original_text": "opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n"}, "hash": "56ac0b953b0bf012f8f351f3bc3db5741579ee7ae633bf5aa678e4093a989069", "class_name": "RelatedNodeInfo"}}, "text": "As we've consistently said, we remain committed to being part of the solution for the U.S. ", "start_char_idx": 1593, "end_char_idx": 1684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0e1b0c8-837b-4862-bbdb-0030f79a2be3": {"__data__": {"id_": "a0e1b0c8-837b-4862-bbdb-0030f79a2be3", "embedding": null, "metadata": {"window": "If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n", "original_text": "opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dd401b5-151f-44ba-94e6-15af816cb305", "node_type": "1", "metadata": {"window": "Before turning it over to Jason, I want to highlight last week's announcement that we have negotiated \na comprehensive proposed settlement agreement and settlement process designed to achieve broad \nresolution of governmental opioid claims.   If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  ", "original_text": "As we've consistently said, we remain committed to being part of the solution for the U.S. ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ccce8273ff9eef2b3b72f83737af2e86edffcdec2c5b427a4e1c7b65d4beec2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "713247e5-0efe-43d9-96db-2ff58f3dbb9c", "node_type": "1", "metadata": {"window": "This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.  ", "original_text": "With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n"}, "hash": "84a0e7f213ae876200613bc34e8058c6a4f93bbd3523a3a6453e8b3bcbd0057c", "class_name": "RelatedNodeInfo"}}, "text": "opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n", "start_char_idx": 1684, "end_char_idx": 1838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "713247e5-0efe-43d9-96db-2ff58f3dbb9c": {"__data__": {"id_": "713247e5-0efe-43d9-96db-2ff58f3dbb9c", "embedding": null, "metadata": {"window": "This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.  ", "original_text": "With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0e1b0c8-837b-4862-bbdb-0030f79a2be3", "node_type": "1", "metadata": {"window": "If all conditions are satisfied, this agreement would result in \nthe settle ment of a substantial majority of opioid lawsuits filed by state and local governmental \nentities, and depending on the level of state and subdivision participation, we would pay up to $6.4 \nbillion over 18 years.   This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n", "original_text": "opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9182c52037be69349b161d95e21df5db7bc9cfc83ef0d6ca1226d5d4f500bdf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b60b9851-ffb5-4de5-8c39-6e66255aec5a", "node_type": "1", "metadata": {"window": "As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.  ", "original_text": "Jason Hollar:  Thanks, Mike, and good morning, everyone.  "}, "hash": "386d42411108ccc703327922d048c1cc2c1aff55e1308c34411bcd847d28e68c", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n", "start_char_idx": 1838, "end_char_idx": 1930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b60b9851-ffb5-4de5-8c39-6e66255aec5a": {"__data__": {"id_": "b60b9851-ffb5-4de5-8c39-6e66255aec5a", "embedding": null, "metadata": {"window": "As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.  ", "original_text": "Jason Hollar:  Thanks, Mike, and good morning, everyone.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "713247e5-0efe-43d9-96db-2ff58f3dbb9c", "node_type": "1", "metadata": {"window": "This is an important step forward for our c ompany.   \n As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.  ", "original_text": "With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cdfd512c9165376886d515cb8f54ff794f3dc804373a34e8aca8a760c64d630", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "725ee96c-b8b3-4432-8915-7ae04ca44928", "node_type": "1", "metadata": {"window": "opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n", "original_text": "In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n"}, "hash": "0f506736ae0744f744386f2c6ffc9f4193eb2ea505dcc98ca4dd65034bbbd66a", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Thanks, Mike, and good morning, everyone.  ", "start_char_idx": 1930, "end_char_idx": 1988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "725ee96c-b8b3-4432-8915-7ae04ca44928": {"__data__": {"id_": "725ee96c-b8b3-4432-8915-7ae04ca44928", "embedding": null, "metadata": {"window": "opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n", "original_text": "In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b60b9851-ffb5-4de5-8c39-6e66255aec5a", "node_type": "1", "metadata": {"window": "As we've consistently said, we remain committed to being part of the solution for the U.S.  opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.  ", "original_text": "Jason Hollar:  Thanks, Mike, and good morning, everyone.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6d16bd88507060d4074e442378c7e40c0c1a6206ef81cd7fc9f33215c3f2cbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49e3837c-77ce-40c4-b845-881f183a4043", "node_type": "1", "metadata": {"window": "With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.  ", "original_text": "Turning to the Pharma segment on slide six.  "}, "hash": "f90aea1abf153f5138368763ee897531d060b28bbc8362486f84b42637a18449", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n", "start_char_idx": 1988, "end_char_idx": 2148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49e3837c-77ce-40c4-b845-881f183a4043": {"__data__": {"id_": "49e3837c-77ce-40c4-b845-881f183a4043", "embedding": null, "metadata": {"window": "With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.  ", "original_text": "Turning to the Pharma segment on slide six.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "725ee96c-b8b3-4432-8915-7ae04ca44928", "node_type": "1", "metadata": {"window": "opioid \nepidemic and believe the settlement would be a prudent way to provide necessary relief  to our \ncommunities and certainty for our shareholders.  \n With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n", "original_text": "In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30c87dfa53aae6027a33ccb9a83b00702283eba8159723f07ad3889378c4a8d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a091da2c-fb59-43d3-bf7f-90ecb8b22fe3", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.  ", "original_text": "Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.  "}, "hash": "898727922a6969cf25c4aa5e0796c13cc00a003cbfe41e56bdbf9f3d72c2f441", "class_name": "RelatedNodeInfo"}}, "text": "Turning to the Pharma segment on slide six.  ", "start_char_idx": 2148, "end_char_idx": 2193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a091da2c-fb59-43d3-bf7f-90ecb8b22fe3": {"__data__": {"id_": "a091da2c-fb59-43d3-bf7f-90ecb8b22fe3", "embedding": null, "metadata": {"window": "Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.  ", "original_text": "Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49e3837c-77ce-40c4-b845-881f183a4043", "node_type": "1", "metadata": {"window": "With that, I'll turn it over to Jason to further discuss our results and FY '22 guidance.  \n Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.  ", "original_text": "Turning to the Pharma segment on slide six.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39698dfb1de6c8303d2ca0beef7ac525c37fef4fed16192cf2036a0cba268645", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4f5202a-67e9-4494-ab7a-8638bcae458f", "node_type": "1", "metadata": {"window": "In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.  ", "original_text": "As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n"}, "hash": "405bc9e099c0546063176584da92199d534332518f2e64d038c290637ce0303b", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.  ", "start_char_idx": 2193, "end_char_idx": 2356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4f5202a-67e9-4494-ab7a-8638bcae458f": {"__data__": {"id_": "f4f5202a-67e9-4494-ab7a-8638bcae458f", "embedding": null, "metadata": {"window": "In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.  ", "original_text": "As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a091da2c-fb59-43d3-bf7f-90ecb8b22fe3", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Mike, and good morning, everyone.   In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.  ", "original_text": "Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5460a36703275d8d1ba4208b6358c63075a6d6e2455982cb36ce767f7783fdcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68d7f5c3-53ed-40b4-9f92-3c5feb819a9f", "node_type": "1", "metadata": {"window": "Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n", "original_text": "Pharma segment profit was flat in the fourth quarter at $358 million.  "}, "hash": "287d173cdf546c9f0992308eeeb6751e73dc2bd965790f4363cf5798c8f1d2b7", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n", "start_char_idx": 2356, "end_char_idx": 2537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68d7f5c3-53ed-40b4-9f92-3c5feb819a9f": {"__data__": {"id_": "68d7f5c3-53ed-40b4-9f92-3c5feb819a9f", "embedding": null, "metadata": {"window": "Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n", "original_text": "Pharma segment profit was flat in the fourth quarter at $358 million.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4f5202a-67e9-4494-ab7a-8638bcae458f", "node_type": "1", "metadata": {"window": "In the fourth quarter, we delivered EPS of \n$0.77, which as Mike mentioned, included a $197 million inventory reserve on certain PPE in the \nMedical segment.  \n Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.  ", "original_text": "As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "012f37adc15a5ac5ec31cad3b7bd0d5a4521df78c37caf85f4d0317cc2f16db6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21b94426-9903-442a-b71a-ca8b79ec6a23", "node_type": "1", "metadata": {"window": "Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n", "original_text": "This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.  "}, "hash": "0cc72cf33fe0208305b9e9b1c6188b82fc4ddfa02d9110e39d2bcb4c8970f267", "class_name": "RelatedNodeInfo"}}, "text": "Pharma segment profit was flat in the fourth quarter at $358 million.  ", "start_char_idx": 2537, "end_char_idx": 2608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21b94426-9903-442a-b71a-ca8b79ec6a23": {"__data__": {"id_": "21b94426-9903-442a-b71a-ca8b79ec6a23", "embedding": null, "metadata": {"window": "Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n", "original_text": "This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68d7f5c3-53ed-40b4-9f92-3c5feb819a9f", "node_type": "1", "metadata": {"window": "Turning to the Pharma segment on slide six.   Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n", "original_text": "Pharma segment profit was flat in the fourth quarter at $358 million.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "186dd9eed65024af98cd7785fbbeaf262e5339d9b2d515a2ff9e6800a09efe27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec75cb56-4e07-4d2a-8e2d-3f7f0ed28657", "node_type": "1", "metadata": {"window": "As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n", "original_text": "This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.  "}, "hash": "b3167abd2212c2b91eff5d04a964c23972d7e6cb5ebe6d17dc938af4869bf84b", "class_name": "RelatedNodeInfo"}}, "text": "This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.  ", "start_char_idx": 2608, "end_char_idx": 2751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec75cb56-4e07-4d2a-8e2d-3f7f0ed28657": {"__data__": {"id_": "ec75cb56-4e07-4d2a-8e2d-3f7f0ed28657", "embedding": null, "metadata": {"window": "As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n", "original_text": "This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21b94426-9903-442a-b71a-ca8b79ec6a23", "node_type": "1", "metadata": {"window": "Fourth quarter revenue increased 15% to $38 billion, \ndriven primarily by sales growth from large Pharmaceutical Distribution and Specialty Solutions \ncustomers.   As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n", "original_text": "This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db7f8d91e3e9acd651bafd63aa21cbeffdde304054a0e4ea558c52c5138cf5cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e4e3465-3e02-4b3e-97e5-c27da80ec5f4", "node_type": "1", "metadata": {"window": "Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n I will further discuss our investments as we look to fiscal year '22.  ", "original_text": "However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n"}, "hash": "c305bcafe31d9f70b36b8730c344bda9f96b5c76c9a20b15d746d3f06246267a", "class_name": "RelatedNodeInfo"}}, "text": "This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.  ", "start_char_idx": 2751, "end_char_idx": 2859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e4e3465-3e02-4b3e-97e5-c27da80ec5f4": {"__data__": {"id_": "9e4e3465-3e02-4b3e-97e5-c27da80ec5f4", "embedding": null, "metadata": {"window": "Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n I will further discuss our investments as we look to fiscal year '22.  ", "original_text": "However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec75cb56-4e07-4d2a-8e2d-3f7f0ed28657", "node_type": "1", "metadata": {"window": "As a reminder, the fourth quarter of fiscal '20 included reduced pharmaceutical demand \nrelated to COVID -19, which, to a lesser extent, contributed to the growth in the quarter.  \n Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n", "original_text": "This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9dca274b28ee232a285966c8f30268f59d5e4e54565d5efc778879c051a8913", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a74bbc4b-5866-45b0-9f8d-c6a04ff21cbc", "node_type": "1", "metadata": {"window": "This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n I will further discuss our investments as we look to fiscal year '22.  ", "original_text": "As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n"}, "hash": "646374ad09e52bd89ba53331d97f932856bbb763c1202fc8620706d224414acd", "class_name": "RelatedNodeInfo"}}, "text": "However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n", "start_char_idx": 2859, "end_char_idx": 3007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a74bbc4b-5866-45b0-9f8d-c6a04ff21cbc": {"__data__": {"id_": "a74bbc4b-5866-45b0-9f8d-c6a04ff21cbc", "embedding": null, "metadata": {"window": "This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n I will further discuss our investments as we look to fiscal year '22.  ", "original_text": "As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e4e3465-3e02-4b3e-97e5-c27da80ec5f4", "node_type": "1", "metadata": {"window": "Pharma segment profit was flat in the fourth quarter at $358 million.   This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n I will further discuss our investments as we look to fiscal year '22.  ", "original_text": "However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2907f4641a50011b88456dc0708e1500ae1497c807aa3b12a462afda1101cb60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38ac468c-edde-4297-8a5e-bcc74ea72323", "node_type": "1", "metadata": {"window": "This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n I will further discuss our investments as we look to fiscal year '22.  ", "original_text": "In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n"}, "hash": "ffd310cb5bdbc98045fc8f65eab1257fda349c251c93661d50da746ad6a7f316", "class_name": "RelatedNodeInfo"}}, "text": "As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n", "start_char_idx": 3007, "end_char_idx": 3112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38ac468c-edde-4297-8a5e-bcc74ea72323": {"__data__": {"id_": "38ac468c-edde-4297-8a5e-bcc74ea72323", "embedding": null, "metadata": {"window": "This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n I will further discuss our investments as we look to fiscal year '22.  ", "original_text": "In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a74bbc4b-5866-45b0-9f8d-c6a04ff21cbc", "node_type": "1", "metadata": {"window": "This reflec ts COVID -19-related \nvolume recovery in our Nuclear business, offset by Pharmaceutical Distribution customer contract \nrenewals.   This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n I will further discuss our investments as we look to fiscal year '22.  ", "original_text": "As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b834312f88884c9f82ddfb60e1279fb8a3e689c64623f12a61ddc021b01ea58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35fb7340-7544-4ebe-aa8a-20b59eedf20b", "node_type": "1", "metadata": {"window": "However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n I will further discuss our investments as we look to fiscal year '22.  ", "original_text": "I will further discuss our investments as we look to fiscal year '22.  "}, "hash": "2f77944315a7b5e23b3f957d773cd3050c10447b54a96a2cb6455121a627099b", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n", "start_char_idx": 3112, "end_char_idx": 3353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35fb7340-7544-4ebe-aa8a-20b59eedf20b": {"__data__": {"id_": "35fb7340-7544-4ebe-aa8a-20b59eedf20b", "embedding": null, "metadata": {"window": "However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n I will further discuss our investments as we look to fiscal year '22.  ", "original_text": "I will further discuss our investments as we look to fiscal year '22.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1da89e7ab39432b0f0373364d36546ac579c4aa242784f0f63a1e866f9ee4b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38ac468c-edde-4297-8a5e-bcc74ea72323", "node_type": "1", "metadata": {"window": "This impact from renewals was in line with our expectations and generally consistent with \nprior quarters.   However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n I will further discuss our investments as we look to fiscal year '22.  ", "original_text": "In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2220d1d04209fc0762e77b025bedac19fcf2f330c67f5c2ae3b8200e613842f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5db360a-1a0c-4219-86c8-532af07c21f4", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.  ", "original_text": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.  "}, "hash": "0ae0ee9f1d291dd544928eae7620949389bbd3bc5d714724c04ac913d5b72b3f", "class_name": "RelatedNodeInfo"}}, "text": "I will further discuss our investments as we look to fiscal year '22.  ", "start_char_idx": 3353, "end_char_idx": 3424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5db360a-1a0c-4219-86c8-532af07c21f4": {"__data__": {"id_": "a5db360a-1a0c-4219-86c8-532af07c21f4", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.  ", "original_text": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35fb7340-7544-4ebe-aa8a-20b59eedf20b", "node_type": "1", "metadata": {"window": "However, there were s ome other items, including inventory adjustments and opioid -\nrelated legal costs that were higher than previously assumed.  \n As we've mentioned, we continue to prioritize investing for growth and optimizing our core operations.  \n In the fourth quarter, the dep loyment of some of these technology enhancements resulted in \nincremental costs for implementation and depreciation, which we also expect the next several \nquarters as we continue to deploy new capabilities.  \n I will further discuss our investments as we look to fiscal year '22.  ", "original_text": "I will further discuss our investments as we look to fiscal year '22.  ", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b9a948ced6149c695b84fc620d2d6f9b266635e0ba63fc4c21370b497a1ec91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e2d5108-81bd-4b34-b4fe-110ac67b84d0", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.  ", "original_text": "Our generics program continued to see generally consistent \nmarket dynamics.  "}, "hash": "9c88f15571989f4f3a29285d090dc6930c08ab1cbd5f21ecbd96e09929ddb059", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.  ", "start_char_idx": 0, "end_char_idx": 154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e2d5108-81bd-4b34-b4fe-110ac67b84d0": {"__data__": {"id_": "1e2d5108-81bd-4b34-b4fe-110ac67b84d0", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.  ", "original_text": "Our generics program continued to see generally consistent \nmarket dynamics.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5db360a-1a0c-4219-86c8-532af07c21f4", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.  ", "original_text": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a84116a1aa4688a15935f83b7558de4441e09751eb67532455fce08646ec6408", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cfd16f1-1369-4c65-8320-be38633045a9", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.  ", "original_text": "With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n"}, "hash": "034a7ba6d84c78d3e06153bfeec12d09ccf29ff994c0b8dec8a1889dc3933de3", "class_name": "RelatedNodeInfo"}}, "text": "Our generics program continued to see generally consistent \nmarket dynamics.  ", "start_char_idx": 154, "end_char_idx": 232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cfd16f1-1369-4c65-8320-be38633045a9": {"__data__": {"id_": "7cfd16f1-1369-4c65-8320-be38633045a9", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.  ", "original_text": "With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e2d5108-81bd-4b34-b4fe-110ac67b84d0", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.  ", "original_text": "Our generics program continued to see generally consistent \nmarket dynamics.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "583f4a1e95342ce6269e7b80bdabcf95bfb92f3f15973e5a76b187694e96cc11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98759a3f-dd77-42ec-a3ff-b1db1e113eb4", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n", "original_text": "In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.  "}, "hash": "c623f44847b39fd28cf9ccd5544e33d82c424d45147da371bf1cab125f052f10", "class_name": "RelatedNodeInfo"}}, "text": "With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n", "start_char_idx": 232, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98759a3f-dd77-42ec-a3ff-b1db1e113eb4": {"__data__": {"id_": "98759a3f-dd77-42ec-a3ff-b1db1e113eb4", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n", "original_text": "In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cfd16f1-1369-4c65-8320-be38633045a9", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.  ", "original_text": "With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8932f292141666ab853b7504dc4b5af7d60f6318c55d599f3724de20fee98bf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98b5aef8-1755-4bd3-a08b-f3a76dbbd0ca", "node_type": "1", "metadata": {"window": "Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.  ", "original_text": "This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.  "}, "hash": "2bfcc597028004a057166088a0fa74ced50ffd7a20a201281f5e8b6f2f58acaa", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.  ", "start_char_idx": 404, "end_char_idx": 503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98b5aef8-1755-4bd3-a08b-f3a76dbbd0ca": {"__data__": {"id_": "98b5aef8-1755-4bd3-a08b-f3a76dbbd0ca", "embedding": null, "metadata": {"window": "Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.  ", "original_text": "This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98759a3f-dd77-42ec-a3ff-b1db1e113eb4", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n", "original_text": "In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83d0b40d61c10e6af22c1c1977ea5721a52cf2fa2936b9f99f133c328ea3da99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc671572-46a2-42b1-80f0-886dcc561f61", "node_type": "1", "metadata": {"window": "With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.  ", "original_text": "Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.  "}, "hash": "6e3e8272ee178239e0b4b9b2e6dbd4474fbef79b82eb5b54854fb28838406da0", "class_name": "RelatedNodeInfo"}}, "text": "This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.  ", "start_char_idx": 503, "end_char_idx": 703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc671572-46a2-42b1-80f0-886dcc561f61": {"__data__": {"id_": "cc671572-46a2-42b1-80f0-886dcc561f61", "embedding": null, "metadata": {"window": "With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.  ", "original_text": "Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98b5aef8-1755-4bd3-a08b-f3a76dbbd0ca", "node_type": "1", "metadata": {"window": "Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.  ", "original_text": "This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f801a74f08e2cd00de2880370550f0f9964e30a6428386105d757dbd9b373e4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3240b546-e333-4b72-96be-c2aa262aee51", "node_type": "1", "metadata": {"window": "In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.  ", "original_text": "Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n"}, "hash": "45eb5cbc455c1f4fd46ac159eb88f6c82fbd7820831ee440bb06e92294f88dba", "class_name": "RelatedNodeInfo"}}, "text": "Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.  ", "start_char_idx": 703, "end_char_idx": 934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3240b546-e333-4b72-96be-c2aa262aee51": {"__data__": {"id_": "3240b546-e333-4b72-96be-c2aa262aee51", "embedding": null, "metadata": {"window": "In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.  ", "original_text": "Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc671572-46a2-42b1-80f0-886dcc561f61", "node_type": "1", "metadata": {"window": "With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.  ", "original_text": "Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d00726288e6fe0fa80cae80e0b1ebfd2da30d7f62b7da5db97581bff404fcbee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d155e7d3-a0d5-455b-8ade-6fbfa0ad310a", "node_type": "1", "metadata": {"window": "This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n", "original_text": "During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.  "}, "hash": "efec99afd29ed4c8187a743a1004948a634bf8835e1be2b8b9ef84fac2879ed2", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n", "start_char_idx": 934, "end_char_idx": 1034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d155e7d3-a0d5-455b-8ade-6fbfa0ad310a": {"__data__": {"id_": "d155e7d3-a0d5-455b-8ade-6fbfa0ad310a", "embedding": null, "metadata": {"window": "This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n", "original_text": "During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3240b546-e333-4b72-96be-c2aa262aee51", "node_type": "1", "metadata": {"window": "In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.   This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.  ", "original_text": "Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f6fe6be951d9cb3933add8edabef18b2e532ad8e36e22d63d73d6aa1e65b964", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9052854-53cb-44a5-95e8-cc40b5ae10e4", "node_type": "1", "metadata": {"window": "Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.  ", "original_text": "While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.  "}, "hash": "dc6a5735283cd98f2d15c113ff39f05cef5b12f855b5ed9735ff6105fcab0872", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.  ", "start_char_idx": 1034, "end_char_idx": 1158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9052854-53cb-44a5-95e8-cc40b5ae10e4": {"__data__": {"id_": "d9052854-53cb-44a5-95e8-cc40b5ae10e4", "embedding": null, "metadata": {"window": "Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.  ", "original_text": "While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d155e7d3-a0d5-455b-8ade-6fbfa0ad310a", "node_type": "1", "metadata": {"window": "This \nrevenue i ncrease was driven by a net positive impact from COVID -19 on products and distribution, \nprimarily due to a recovery in elective procedure volumes and a positive PPE pricing impact.   Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n", "original_text": "During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdf38b07afde932556eadf75ee3e407febbd2f89699cfd38ed8dbfd64841593e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "852b85c9-742c-40c9-9273-daca186e9c53", "node_type": "1", "metadata": {"window": "Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.  ", "original_text": "We are taking actions to help \nmitigate these impacts.  "}, "hash": "5796408e171828cdb197d2a67c7d02c6a17a900a9ad56bce37ee23f1cbf4fd03", "class_name": "RelatedNodeInfo"}}, "text": "While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.  ", "start_char_idx": 1158, "end_char_idx": 1403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "852b85c9-742c-40c9-9273-daca186e9c53": {"__data__": {"id_": "852b85c9-742c-40c9-9273-daca186e9c53", "embedding": null, "metadata": {"window": "Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.  ", "original_text": "We are taking actions to help \nmitigate these impacts.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9052854-53cb-44a5-95e8-cc40b5ae10e4", "node_type": "1", "metadata": {"window": "Medical \nsegment loss of $63 million in the fourth quarter was due to an ad verse impact from COVID -19, \nprimarily due to the previously mentioned inventory reserve, partially offset by a recovery in elective \nprocedure volumes.   Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.  ", "original_text": "While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5acacf46a866f71729c694b582d7131b3d04952efcb1066034e29167f6427d0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdff825a-32b1-46a5-b501-5fa52a264db8", "node_type": "1", "metadata": {"window": "During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.  ", "original_text": "But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n"}, "hash": "6890eaaeea2e77260cad93693d75d57eaf4de534ace17a69152c4199fc3696e9", "class_name": "RelatedNodeInfo"}}, "text": "We are taking actions to help \nmitigate these impacts.  ", "start_char_idx": 1403, "end_char_idx": 1459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdff825a-32b1-46a5-b501-5fa52a264db8": {"__data__": {"id_": "bdff825a-32b1-46a5-b501-5fa52a264db8", "embedding": null, "metadata": {"window": "During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.  ", "original_text": "But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "852b85c9-742c-40c9-9273-daca186e9c53", "node_type": "1", "metadata": {"window": "Additionally, benefits from cost savings initiatives were offset by elevated supply \nchain costs.  \n During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.  ", "original_text": "We are taking actions to help \nmitigate these impacts.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "737e7e345f4bedafde05777887452fa066d269a19732dc5f57e5999c81a515f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dabf534-8ab3-4689-a5d6-b4f08faba5a5", "node_type": "1", "metadata": {"window": "While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.  ", "original_text": "Now I'll  transition to full year results, beginning with the enterprise.  "}, "hash": "9f2f4fac2bbb9d5d2ebbd24456bd2e4a5cb55269386b72344c589af91a50ce98", "class_name": "RelatedNodeInfo"}}, "text": "But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n", "start_char_idx": 1459, "end_char_idx": 1554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dabf534-8ab3-4689-a5d6-b4f08faba5a5": {"__data__": {"id_": "4dabf534-8ab3-4689-a5d6-b4f08faba5a5", "embedding": null, "metadata": {"window": "While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.  ", "original_text": "Now I'll  transition to full year results, beginning with the enterprise.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdff825a-32b1-46a5-b501-5fa52a264db8", "node_type": "1", "metadata": {"window": "During the quarter, we were encouraged to see elective procedure volumes effectively return to near \npre-COVID -19 levels.   While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.  ", "original_text": "But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3f3749c0a925b68f6065da0b0d23f7b2272a6f6afca59fd54ab3b28bc1541c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6593d985-cf2e-4a3a-9b48-92e419e7ad4b", "node_type": "1", "metadata": {"window": "We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.  ", "original_text": "Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.  "}, "hash": "ec07c4da2a5a73faad0cc53696a31cd5a6c047708bea98e04c5565efd098834c", "class_name": "RelatedNodeInfo"}}, "text": "Now I'll  transition to full year results, beginning with the enterprise.  ", "start_char_idx": 1554, "end_char_idx": 1629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6593d985-cf2e-4a3a-9b48-92e419e7ad4b": {"__data__": {"id_": "6593d985-cf2e-4a3a-9b48-92e419e7ad4b", "embedding": null, "metadata": {"window": "We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.  ", "original_text": "Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dabf534-8ab3-4689-a5d6-b4f08faba5a5", "node_type": "1", "metadata": {"window": "While our team continued to execute on our cost savings and efficiency \ninitiatives within our global manufacturing and supply chain, we did e xperience elevated supply chain \ncosts, particularly in the areas of freight, labor and commodities.   We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.  ", "original_text": "Now I'll  transition to full year results, beginning with the enterprise.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6f2570795c0ead55b9831f88d3d7095a21db34e6aa9a7c936712acfdeea4e1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55580760-d6c0-4306-8157-868aa5f4cb73", "node_type": "1", "metadata": {"window": "But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n", "original_text": "Consolidated gross margin \ndecreased 2% to $6.8 billion.  "}, "hash": "fec93d64dc6181f7849dd509f9df99e6f36498681e7a02a6aaf380feb467207a", "class_name": "RelatedNodeInfo"}}, "text": "Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.  ", "start_char_idx": 1629, "end_char_idx": 1728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55580760-d6c0-4306-8157-868aa5f4cb73": {"__data__": {"id_": "55580760-d6c0-4306-8157-868aa5f4cb73", "embedding": null, "metadata": {"window": "But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n", "original_text": "Consolidated gross margin \ndecreased 2% to $6.8 billion.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6593d985-cf2e-4a3a-9b48-92e419e7ad4b", "node_type": "1", "metadata": {"window": "We are taking actions to help \nmitigate these impacts.   But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.  ", "original_text": "Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bfcea06e81598d081f9b8846f2cdbe1d6bbec1a2da819acb6eaf368132cead58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35545e8b-b3b5-4c21-8354-3322959ee8b6", "node_type": "1", "metadata": {"window": "Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.  ", "original_text": "Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.  "}, "hash": "9786f57d61c3dc61d059b1cbfd6f1550107896562a9bea35a7dff41077b02be3", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated gross margin \ndecreased 2% to $6.8 billion.  ", "start_char_idx": 1728, "end_char_idx": 1786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35545e8b-b3b5-4c21-8354-3322959ee8b6": {"__data__": {"id_": "35545e8b-b3b5-4c21-8354-3322959ee8b6", "embedding": null, "metadata": {"window": "Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.  ", "original_text": "Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55580760-d6c0-4306-8157-868aa5f4cb73", "node_type": "1", "metadata": {"window": "But as we look forward, we do expect some of these higher costs to continue \ninto next year.  \n Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n", "original_text": "Consolidated gross margin \ndecreased 2% to $6.8 billion.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28c12b1eb9281db0845737277e89f3b601ec9df7153e32bf088b30096aad5f87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a28cbbbf-aae3-45d2-a807-ce37eecd5e8b", "node_type": "1", "metadata": {"window": "Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n", "original_text": "Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.  "}, "hash": "cf76cf79083746806d95a1cb7ad0b13724aa036dd543c2e2b28ca9f035fcf565", "class_name": "RelatedNodeInfo"}}, "text": "Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.  ", "start_char_idx": 1786, "end_char_idx": 1901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a28cbbbf-aae3-45d2-a807-ce37eecd5e8b": {"__data__": {"id_": "a28cbbbf-aae3-45d2-a807-ce37eecd5e8b", "embedding": null, "metadata": {"window": "Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n", "original_text": "Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35545e8b-b3b5-4c21-8354-3322959ee8b6", "node_type": "1", "metadata": {"window": "Now I'll  transition to full year results, beginning with the enterprise.   Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.  ", "original_text": "Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f6d4551ec5223446608abbb202f4b0f1cec5dc52be512a96d81d1e6731f1db1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d41c212-4abb-485d-92a6-199616f528c9", "node_type": "1", "metadata": {"window": "Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.  ", "original_text": "Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n"}, "hash": "dcf5df2ddd1cd22566b700f20c3592cda7d6a7e3432ef3a62a1c4b8dd13cbfe4", "class_name": "RelatedNodeInfo"}}, "text": "Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.  ", "start_char_idx": 1901, "end_char_idx": 2079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d41c212-4abb-485d-92a6-199616f528c9": {"__data__": {"id_": "9d41c212-4abb-485d-92a6-199616f528c9", "embedding": null, "metadata": {"window": "Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.  ", "original_text": "Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a28cbbbf-aae3-45d2-a807-ce37eecd5e8b", "node_type": "1", "metadata": {"window": "Total company revenue increased \n6% to $162 billion with strong top line growth in both segments.   Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n", "original_text": "Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6db07c2e7b81d5e1c5f22b9a1c77b4cae84f2ed8726c75ca33e5b7afa9198ae2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c35226a6-9094-47b5-acd3-32c350d7b522", "node_type": "1", "metadata": {"window": "Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n", "original_text": "Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.  "}, "hash": "38a1525e9ebb5e46671c9be4a306ff16bbb8214f65bdef2e61baeb26fe38c4c2", "class_name": "RelatedNodeInfo"}}, "text": "Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n", "start_char_idx": 2079, "end_char_idx": 2180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c35226a6-9094-47b5-acd3-32c350d7b522": {"__data__": {"id_": "c35226a6-9094-47b5-acd3-32c350d7b522", "embedding": null, "metadata": {"window": "Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n", "original_text": "Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d41c212-4abb-485d-92a6-199616f528c9", "node_type": "1", "metadata": {"window": "Consolidated gross margin \ndecreased 2% to $6.8 billion.   Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.  ", "original_text": "Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2043f07a04e6d563d1d52aecc6426a75e806b5153d01208976583cb01bc60fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d37402cb-af87-4d50-a0db-f6e1b9387234", "node_type": "1", "metadata": {"window": "Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.  ", "original_text": "As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n"}, "hash": "84bbbb2988dbf9fc3841c4a0c7b9e4dc352d2853f8cacf8756f36b36db471d75", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.  ", "start_char_idx": 2180, "end_char_idx": 2436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d37402cb-af87-4d50-a0db-f6e1b9387234": {"__data__": {"id_": "d37402cb-af87-4d50-a0db-f6e1b9387234", "embedding": null, "metadata": {"window": "Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.  ", "original_text": "As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c35226a6-9094-47b5-acd3-32c350d7b522", "node_type": "1", "metadata": {"window": "Despite sales growth, SG&A decrease d 1%, reflecting the benefits of \nour enterprise -wide cost savings measures.   Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n", "original_text": "Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9946537e94b5372ec6487cfa1378a3719651c0993e000f77446b213eb967f175", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1507b76-1373-40bb-987e-61198e7800aa", "node_type": "1", "metadata": {"window": "Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.  ", "original_text": "Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.  "}, "hash": "8ef414a7f99921041244451761ec567d2bec250755595b63d485bc189e3ddee9", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n", "start_char_idx": 2436, "end_char_idx": 2594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1507b76-1373-40bb-987e-61198e7800aa": {"__data__": {"id_": "a1507b76-1373-40bb-987e-61198e7800aa", "embedding": null, "metadata": {"window": "Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.  ", "original_text": "Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d37402cb-af87-4d50-a0db-f6e1b9387234", "node_type": "1", "metadata": {"window": "Operating earnings decreased 5%, reflecting a \nheadwind of approximately $200 million year -over-year related to COVID -19, which was split fairly \nevenly between the segments.   Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.  ", "original_text": "As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b3599cc8240ce00145a81b8c590bce04c16f52d6fd18568d020edb11a4ce966", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b22d0d4-257a-4212-996b-26f9ce7731b0", "node_type": "1", "metadata": {"window": "Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n", "original_text": "We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n"}, "hash": "fe48a1de06650d36eb505fbee1c9e5f2f3a5af52cb73c9cf9eb3b1d38ab73880", "class_name": "RelatedNodeInfo"}}, "text": "Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.  ", "start_char_idx": 2594, "end_char_idx": 2677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b22d0d4-257a-4212-996b-26f9ce7731b0": {"__data__": {"id_": "3b22d0d4-257a-4212-996b-26f9ce7731b0", "embedding": null, "metadata": {"window": "Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n", "original_text": "We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1507b76-1373-40bb-987e-61198e7800aa", "node_type": "1", "metadata": {"window": "Exclu ding COVID -19, operating earnings would have grown in the low \nsingle digits in fiscal '21.  \n Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.  ", "original_text": "Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9847179d99ff6ffa1cee2ff9e7f9e2c2bd84ff24e9abb83415abc4b52ee8e8f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dd6cf46-d7f0-4a28-ae4f-2eab544cf835", "node_type": "1", "metadata": {"window": "As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.  ", "original_text": "Turning to the balance sheet.  "}, "hash": "fc33fac2b833c649014122d81433aeaecf17b1090ee7d404c971090d33e4e791", "class_name": "RelatedNodeInfo"}}, "text": "We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n", "start_char_idx": 2677, "end_char_idx": 2780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dd6cf46-d7f0-4a28-ae4f-2eab544cf835": {"__data__": {"id_": "9dd6cf46-d7f0-4a28-ae4f-2eab544cf835", "embedding": null, "metadata": {"window": "As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.  ", "original_text": "Turning to the balance sheet.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b22d0d4-257a-4212-996b-26f9ce7731b0", "node_type": "1", "metadata": {"window": "Moving below the line, interest and other decreased 44% to $133 million, driven by multiple items, \nincluding lower interest expense from debt reduction actions , an increase in the value of our deferred \ncompensation plan and one -time investment gains.   As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n", "original_text": "We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cd127bc5645ac3e1e036100667efc42a943c557f26d9c492efae72c9df5b30d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d725e47-ac3f-4651-b85b-b08fe8a91e69", "node_type": "1", "metadata": {"window": "Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.   We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "original_text": "We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.  "}, "hash": "3aef0eaab803bc3f16a2536ace859959c5190f24998c9d8de4562d9a0b2201d8", "class_name": "RelatedNodeInfo"}}, "text": "Turning to the balance sheet.  ", "start_char_idx": 2780, "end_char_idx": 2811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d725e47-ac3f-4651-b85b-b08fe8a91e69": {"__data__": {"id_": "5d725e47-ac3f-4651-b85b-b08fe8a91e69", "embedding": null, "metadata": {"window": "Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.   We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "original_text": "We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dd6cf46-d7f0-4a28-ae4f-2eab544cf835", "node_type": "1", "metadata": {"window": "As a reminder, deferred compensation gains or \nlosses reported in interest and other are fully offset in corporate SG&A and net neutral to our bottom \nline. \n Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.  ", "original_text": "Turning to the balance sheet.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17a0a33e13d72db7f53af060a63bf09a37ae6514c409795adc32cec158ecb8df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "092b1f43-fd76-4a33-9e6e-7d48542902ed", "node_type": "1", "metadata": {"window": "We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.   We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "original_text": "We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n"}, "hash": "b867438de369b5ae77c03d480f04b589a0c29fc05acb7539a7e1aa91e3b0cf94", "class_name": "RelatedNodeInfo"}}, "text": "We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.  ", "start_char_idx": 2811, "end_char_idx": 2952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "092b1f43-fd76-4a33-9e6e-7d48542902ed": {"__data__": {"id_": "092b1f43-fd76-4a33-9e6e-7d48542902ed", "embedding": null, "metadata": {"window": "We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.   We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "original_text": "We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d725e47-ac3f-4651-b85b-b08fe8a91e69", "node_type": "1", "metadata": {"window": "Our annu al effective tax rate finished at 22.8%, benefiting from discrete items.   We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.   We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "original_text": "We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d969d1a0261d7dfc6436b1c08946fcd19adcf0182dc56777f11eecba2ab83f73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c59b699e-5af5-466e-9e01-042fee01a86c", "node_type": "1", "metadata": {"window": "Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.   We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "original_text": "As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.  "}, "hash": "430fdfe7de0c5772dbba9c63aaf8c8952229d3df4dce096634f4b3e4be122394", "class_name": "RelatedNodeInfo"}}, "text": "We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n", "start_char_idx": 2952, "end_char_idx": 3078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c59b699e-5af5-466e-9e01-042fee01a86c": {"__data__": {"id_": "c59b699e-5af5-466e-9e01-042fee01a86c", "embedding": null, "metadata": {"window": "Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.   We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "original_text": "As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "092b1f43-fd76-4a33-9e6e-7d48542902ed", "node_type": "1", "metadata": {"window": "We finished the year \nwith EPS of $5.57, reflecting growth of 2% despite the net COVID -19 headwind.  \n Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.   We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "original_text": "We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61c4f6695420b4a4b972cf414cc56af59c9b729bc18f5d0e1f76e3764f5e45b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ddfdbd3-24ac-45f4-a9be-c1c5a9367fbf", "node_type": "1", "metadata": {"window": "We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.   We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "original_text": "We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  "}, "hash": "8e154cd7f48f9e980c5266fe037d8944a40fac2c8b8c2ebe1a0e114c6935972a", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.  ", "start_char_idx": 3078, "end_char_idx": 3176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ddfdbd3-24ac-45f4-a9be-c1c5a9367fbf": {"__data__": {"id_": "6ddfdbd3-24ac-45f4-a9be-c1c5a9367fbf", "embedding": null, "metadata": {"window": "We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.   We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "original_text": "We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd47821b-39f2-4b22-b3cb-1979088901de", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff3f81975076d000b37830b2e9f20926b8585e04d2dca0d0230d2216c5204d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c59b699e-5af5-466e-9e01-042fee01a86c", "node_type": "1", "metadata": {"window": "Turning to the balance sheet.   We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.   We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "original_text": "As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88f035030364a54e708ec7869f85a63f281d4c4d0fe0b492e25d57736e1df43a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "730404e6-0f63-4cb6-b84c-70432b82bb80", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n", "original_text": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.  "}, "hash": "1bdea9bd871fc292073ef5cbd5794ee3e3b6c0040b60d78575e73d4d233bc055", "class_name": "RelatedNodeInfo"}}, "text": "We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "start_char_idx": 3176, "end_char_idx": 3545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "730404e6-0f63-4cb6-b84c-70432b82bb80": {"__data__": {"id_": "730404e6-0f63-4cb6-b84c-70432b82bb80", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n", "original_text": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ddfdbd3-24ac-45f4-a9be-c1c5a9367fbf", "node_type": "1", "metadata": {"window": "We continue to operate with high net working capital  efficiency, \ngenerating robust operating cash flow of $2.4 billion for the full year.   We finished the year with a \nstrong cash position of $3.4 billion, with no outstanding borrowings on our credit facilities.  \n As a reminder, the day of the week in which th e quarter ends affects point -in-time cash flows.   We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "original_text": "We \ncontinue to deploy capital according to our priorities, investing $400 million back into the business in \ncapex to drive organic growth, strengthening our balance sheet t hrough  approximately $550 million  in \ndebt paydown, which occurred primarily in the fourth quarter and returning nearly $800 million to \nshareholders through dividends and share repurchases.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9b039b272fb7bd7a558e23802f860da3ec5c11a90dafe6638079ec7dfcb7243", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c20fbd52-519f-47e1-93cc-fd3f63605f8e", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.  ", "original_text": "Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.  "}, "hash": "b3dc54a58f869c2973aedf81aab00df1276d99141d58e5ad18135cd278924dc6", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.  ", "start_char_idx": 0, "end_char_idx": 236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c20fbd52-519f-47e1-93cc-fd3f63605f8e": {"__data__": {"id_": "c20fbd52-519f-47e1-93cc-fd3f63605f8e", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.  ", "original_text": "Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "730404e6-0f63-4cb6-b84c-70432b82bb80", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n", "original_text": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9d3957f68674e2f102b5363cc59743b23fd612e3ccbfda4dc11ebe75ddd5231", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af293b42-f610-41e1-82ca-24f17f82c3a8", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n", "original_text": "This was partially offset by \nfavorable brand sales mix.  "}, "hash": "fb69d5cb43cbdd348ed6b27a6903973cb983594e077d1729e58853dff3590d03", "class_name": "RelatedNodeInfo"}}, "text": "Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.  ", "start_char_idx": 236, "end_char_idx": 382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af293b42-f610-41e1-82ca-24f17f82c3a8": {"__data__": {"id_": "af293b42-f610-41e1-82ca-24f17f82c3a8", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n", "original_text": "This was partially offset by \nfavorable brand sales mix.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c20fbd52-519f-47e1-93cc-fd3f63605f8e", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.  ", "original_text": "Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3edb4ab8ed6af92258f473d9a6fc9503972bba426cf6803af12635eb8617cc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e4ebb2b-a433-4574-b07f-4d517eb2e34c", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.  ", "original_text": "Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n"}, "hash": "6ec2d2cb2e55e8f5cf2b1d7287fb3f47b9c49584955c36da2077b09840a0cc40", "class_name": "RelatedNodeInfo"}}, "text": "This was partially offset by \nfavorable brand sales mix.  ", "start_char_idx": 382, "end_char_idx": 440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e4ebb2b-a433-4574-b07f-4d517eb2e34c": {"__data__": {"id_": "9e4ebb2b-a433-4574-b07f-4d517eb2e34c", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.  ", "original_text": "Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af293b42-f610-41e1-82ca-24f17f82c3a8", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n", "original_text": "This was partially offset by \nfavorable brand sales mix.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfa5cc1e5aa715d1b55ef6970af13549336920f9adae153a9fdefc70966e40d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2e7bc3a-7cd8-4597-b71a-3a205189bf00", "node_type": "1", "metadata": {"window": "Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.  ", "original_text": "Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.  "}, "hash": "30b754e214aac25423ec676ebafc5bb918c6a92ab20a15ab740cd66bb2fc38b9", "class_name": "RelatedNodeInfo"}}, "text": "Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n", "start_char_idx": 440, "end_char_idx": 545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2e7bc3a-7cd8-4597-b71a-3a205189bf00": {"__data__": {"id_": "d2e7bc3a-7cd8-4597-b71a-3a205189bf00", "embedding": null, "metadata": {"window": "Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.  ", "original_text": "Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e4ebb2b-a433-4574-b07f-4d517eb2e34c", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.  ", "original_text": "Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9afdc59d4ab9dfb65889d973b8080560dd3066fea48b4098718a0fd18d98beeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5a46872-16b8-464b-9d97-a9fee53ca7e2", "node_type": "1", "metadata": {"window": "This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n", "original_text": "As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n"}, "hash": "842b740539e17e3e727342c53b1a379a7818d946a87189f06fde2d54d71d4561", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.  ", "start_char_idx": 545, "end_char_idx": 717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5a46872-16b8-464b-9d97-a9fee53ca7e2": {"__data__": {"id_": "f5a46872-16b8-464b-9d97-a9fee53ca7e2", "embedding": null, "metadata": {"window": "This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n", "original_text": "As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2e7bc3a-7cd8-4597-b71a-3a205189bf00", "node_type": "1", "metadata": {"window": "Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.  ", "original_text": "Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54adc25e74618285353654bf8793f0506d58a0dba28308d6140becc43b642ccc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62a03091-2ca0-4c5b-81ef-714dca1374f9", "node_type": "1", "metadata": {"window": "Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.  ", "original_text": "Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.  "}, "hash": "c9c9d78c621a28d7d33d2664b41dc740c0759f5694dcc3eb0dc5e15d1f2db7a2", "class_name": "RelatedNodeInfo"}}, "text": "As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n", "start_char_idx": 717, "end_char_idx": 850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62a03091-2ca0-4c5b-81ef-714dca1374f9": {"__data__": {"id_": "62a03091-2ca0-4c5b-81ef-714dca1374f9", "embedding": null, "metadata": {"window": "Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.  ", "original_text": "Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5a46872-16b8-464b-9d97-a9fee53ca7e2", "node_type": "1", "metadata": {"window": "This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n", "original_text": "As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e99fdc84b8218ca2c4a502a9c233631835f3c7c873a1d35525287b1fd9cf452b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "135a01be-1d7f-40e7-b669-592aed9b9d9a", "node_type": "1", "metadata": {"window": "Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n", "original_text": "This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.  "}, "hash": "cbb304c2c88d9088d0213235bc3cccf38e754068cfc7bf1cbcb9e0b402256f9e", "class_name": "RelatedNodeInfo"}}, "text": "Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.  ", "start_char_idx": 850, "end_char_idx": 976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "135a01be-1d7f-40e7-b669-592aed9b9d9a": {"__data__": {"id_": "135a01be-1d7f-40e7-b669-592aed9b9d9a", "embedding": null, "metadata": {"window": "Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n", "original_text": "This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62a03091-2ca0-4c5b-81ef-714dca1374f9", "node_type": "1", "metadata": {"window": "Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.  ", "original_text": "Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e9fde1d83094e84680d4b24455f637689d8c6b49df461dc1e4cfc3d777f01ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31e1d917-4860-4a5f-b770-226496d24a2b", "node_type": "1", "metadata": {"window": "As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.  ", "original_text": "Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n"}, "hash": "2f3dab858263f7f9b1d05f196a1f7eddf9198a151b5d60d882ecaaafd14735a6", "class_name": "RelatedNodeInfo"}}, "text": "This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.  ", "start_char_idx": 976, "end_char_idx": 1122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31e1d917-4860-4a5f-b770-226496d24a2b": {"__data__": {"id_": "31e1d917-4860-4a5f-b770-226496d24a2b", "embedding": null, "metadata": {"window": "As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.  ", "original_text": "Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "135a01be-1d7f-40e7-b669-592aed9b9d9a", "node_type": "1", "metadata": {"window": "Turning to Medical on slide 11...  Full year Medical revenue increased 8% to $16.7 billion, dri ven by a \nnet positive impact from COVID -19 on products and distribution.   As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n", "original_text": "This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c610e000c63ccd12f6b0d27d46c15effc6e1e07904edaad4ef5b525ed27367a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f56f0e18-58cd-433a-8e0c-1219fba92147", "node_type": "1", "metadata": {"window": "Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.  ", "original_text": "When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.  "}, "hash": "4c95a1ca109af655e72513acb1cf248410923561de0a0cb323e1ab9d8e4056ee", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n", "start_char_idx": 1122, "end_char_idx": 1237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f56f0e18-58cd-433a-8e0c-1219fba92147": {"__data__": {"id_": "f56f0e18-58cd-433a-8e0c-1219fba92147", "embedding": null, "metadata": {"window": "Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.  ", "original_text": "When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31e1d917-4860-4a5f-b770-226496d24a2b", "node_type": "1", "metadata": {"window": "As we saw throughout the year, this \nincrease was primarily due to the impact of PPE sales and higher volumes in our Lab business.  \n Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.  ", "original_text": "Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acf82e27891da5a4b0b6ad11b0788d4a367902b691480067a49ed693c4f75ff5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ccc8044-3ecb-428a-881b-c43951c1e2ac", "node_type": "1", "metadata": {"window": "This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n", "original_text": "While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n"}, "hash": "3282c198b29692be62a307293027b5a3cd76b63b4562b21fb282a40e899fee9f", "class_name": "RelatedNodeInfo"}}, "text": "When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.  ", "start_char_idx": 1237, "end_char_idx": 1375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ccc8044-3ecb-428a-881b-c43951c1e2ac": {"__data__": {"id_": "3ccc8044-3ecb-428a-881b-c43951c1e2ac", "embedding": null, "metadata": {"window": "This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n", "original_text": "While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f56f0e18-58cd-433a-8e0c-1219fba92147", "node_type": "1", "metadata": {"window": "Medical segment profit decreased 13% to $577 millio n due to an adverse impact from COVID -19 on \nproducts and distribution.   This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.  ", "original_text": "When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acab569fc0ffbc603be9efce90e32b97417ea9db9fa4272110ebcbf78a764d71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9705d73b-a692-42c2-a180-f30578d43b13", "node_type": "1", "metadata": {"window": "Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n", "original_text": "Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.  "}, "hash": "d9240e09df988ac44f503bfcb9b3aafed78b6067dad9ff6f93a7be15a811d571", "class_name": "RelatedNodeInfo"}}, "text": "While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n", "start_char_idx": 1375, "end_char_idx": 1623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9705d73b-a692-42c2-a180-f30578d43b13": {"__data__": {"id_": "9705d73b-a692-42c2-a180-f30578d43b13", "embedding": null, "metadata": {"window": "Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n", "original_text": "Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ccc8044-3ecb-428a-881b-c43951c1e2ac", "node_type": "1", "metadata": {"window": "This was primarily due to the fourth quarter inventory reserve on certain \nPPE products, partially offset by higher volumes in our Lab business.   Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n", "original_text": "While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d6e323063ed092091ae44c15756d4c478f023c9b6c8366e966cb899bc077089", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56cb433d-92db-417e-aa92-275632629c4f", "node_type": "1", "metadata": {"window": "When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.  ", "original_text": "This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.  "}, "hash": "32ee894ecbe39aafca89860ebf611d585843e9865126c9f5a297efc7fccc3eb7", "class_name": "RelatedNodeInfo"}}, "text": "Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.  ", "start_char_idx": 1623, "end_char_idx": 1742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56cb433d-92db-417e-aa92-275632629c4f": {"__data__": {"id_": "56cb433d-92db-417e-aa92-275632629c4f", "embedding": null, "metadata": {"window": "When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.  ", "original_text": "This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9705d73b-a692-42c2-a180-f30578d43b13", "node_type": "1", "metadata": {"window": "Additionally, the team delivered \nstrong  cost savings, including global manufacturing efficiencies on the year.  \n When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n", "original_text": "Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "082db3b05982f588a528b94f5618362695c88d04615a9ba9813b2383a4b99321", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbc4e744-8e1c-4939-bafc-95f4a2badb44", "node_type": "1", "metadata": {"window": "While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n", "original_text": "We expect interest and other in the range of $150 million to $180 million.  \n"}, "hash": "0647becb7c588343a73335958b3907e7e6b59565dfc1abeb435b00b57d4a23dc", "class_name": "RelatedNodeInfo"}}, "text": "This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.  ", "start_char_idx": 1742, "end_char_idx": 1959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbc4e744-8e1c-4939-bafc-95f4a2badb44": {"__data__": {"id_": "cbc4e744-8e1c-4939-bafc-95f4a2badb44", "embedding": null, "metadata": {"window": "While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n", "original_text": "We expect interest and other in the range of $150 million to $180 million.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56cb433d-92db-417e-aa92-275632629c4f", "node_type": "1", "metadata": {"window": "When adjusting for COVID -19-related impacts in Medical, we estimate the segment would have \ngrown mid -single digits for the full year.   While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.  ", "original_text": "This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f2a4251eb5c59de1dde5b7f54d05a03d98ce3ff44e0e460b716513f4fc9f77f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5524fe0a-ef89-4369-b0d5-1bdd53ff06bd", "node_type": "1", "metadata": {"window": "Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.  ", "original_text": "We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n"}, "hash": "29300f201ce290d3d771c7dd8b7c80829a56d691c6365ef830ccc27fa7c9d5d1", "class_name": "RelatedNodeInfo"}}, "text": "We expect interest and other in the range of $150 million to $180 million.  \n", "start_char_idx": 1959, "end_char_idx": 2036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5524fe0a-ef89-4369-b0d5-1bdd53ff06bd": {"__data__": {"id_": "5524fe0a-ef89-4369-b0d5-1bdd53ff06bd", "embedding": null, "metadata": {"window": "Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.  ", "original_text": "We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbc4e744-8e1c-4939-bafc-95f4a2badb44", "node_type": "1", "metadata": {"window": "While our fiscal '21 results fell short of our ex pectations, the \nunderlying growth we saw in both segments, excluding COVID -19, gives us confidence as we move \ninto next year and the pandemic s effects on our businesses continue to dissipate.  \n Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n", "original_text": "We expect interest and other in the range of $150 million to $180 million.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5372ceb652bf489d38dc0be18ad534a46a98635b14248f9ce6e13416f1c500b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97424113-9a7c-4cb5-83b6-f993e4556b9b", "node_type": "1", "metadata": {"window": "This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.  ", "original_text": "We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.  "}, "hash": "ab68456162d0abb46644295a1416240323ba3d9a80b14644238ca6364130212d", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n", "start_char_idx": 2036, "end_char_idx": 2232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97424113-9a7c-4cb5-83b6-f993e4556b9b": {"__data__": {"id_": "97424113-9a7c-4cb5-83b6-f993e4556b9b", "embedding": null, "metadata": {"window": "This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.  ", "original_text": "We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5524fe0a-ef89-4369-b0d5-1bdd53ff06bd", "node_type": "1", "metadata": {"window": "Turning to our guidance for fiscal '22 on slide 13...  We expec t earnings per share in the range of \n$5.60 to $5.90.   This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.  ", "original_text": "We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1acad7c18244f848f9f68f62fe02de91bac2cf81fc1f7e10e0c61a4e12dc16e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f386aa7e-6b6a-42b1-b33a-68cfb4dc6eae", "node_type": "1", "metadata": {"window": "We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n", "original_text": "We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n"}, "hash": "26efd98351a0f412d0b66e7729783a60d07de4583c50847eb8676552fc89e938", "class_name": "RelatedNodeInfo"}}, "text": "We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.  ", "start_char_idx": 2232, "end_char_idx": 2312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f386aa7e-6b6a-42b1-b33a-68cfb4dc6eae": {"__data__": {"id_": "f386aa7e-6b6a-42b1-b33a-68cfb4dc6eae", "embedding": null, "metadata": {"window": "We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n", "original_text": "We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97424113-9a7c-4cb5-83b6-f993e4556b9b", "node_type": "1", "metadata": {"window": "This reflects incremental technology investments of approximately $120 million to \ndrive growth and efficiencies across the enterprise, the Cordis divestiture and other assumptions that \nwe will detail mo mentarily.   We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.  ", "original_text": "We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dc064a85e5636f80592da3423e0585fcec188e2970af208fd086a9b33105025", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b60bd30e-9ce1-48f3-8eaf-cfd6147cc009", "node_type": "1", "metadata": {"window": "We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n", "original_text": "Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.  "}, "hash": "4e63f35554545277658961f8c9ef87cc061d5c7b889011d033df080b07ff81d5", "class_name": "RelatedNodeInfo"}}, "text": "We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n", "start_char_idx": 2312, "end_char_idx": 2459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b60bd30e-9ce1-48f3-8eaf-cfd6147cc009": {"__data__": {"id_": "b60bd30e-9ce1-48f3-8eaf-cfd6147cc009", "embedding": null, "metadata": {"window": "We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n", "original_text": "Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f386aa7e-6b6a-42b1-b33a-68cfb4dc6eae", "node_type": "1", "metadata": {"window": "We expect interest and other in the range of $150 million to $180 million.  \n We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n", "original_text": "We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e190c3e3590efc41942c0fcaf15d66954bccfacc50158b76447e47fa34ae6f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4252d548-ba0d-491d-990d-b4f58cd3ba47", "node_type": "1", "metadata": {"window": "We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.  ", "original_text": "We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.  "}, "hash": "b1710cde1efdd04cceb2342b3c9b8b266e0b360f375e02ae7fec9091409781fc", "class_name": "RelatedNodeInfo"}}, "text": "Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.  ", "start_char_idx": 2459, "end_char_idx": 2693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4252d548-ba0d-491d-990d-b4f58cd3ba47": {"__data__": {"id_": "4252d548-ba0d-491d-990d-b4f58cd3ba47", "embedding": null, "metadata": {"window": "We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.  ", "original_text": "We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b60bd30e-9ce1-48f3-8eaf-cfd6147cc009", "node_type": "1", "metadata": {"window": "We anticipate continued reduction in interest expense , with the increase over the prior year  primarily \na result of the fiscal '21 capability in deferred compensation n ot expected to repeat.  \n We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n", "original_text": "Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e8e6df376042fe0a281dda4abad3fa1b762b12f5d9d3b7d15af099c7d385a25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd50d670-40c5-43e9-8240-1464a197e401", "node_type": "1", "metadata": {"window": "We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n", "original_text": "While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n"}, "hash": "dd31b042ca9ff0fa04208eaaf079d210afa86673666b1d5fbbb9bd979c9218b5", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.  ", "start_char_idx": 2693, "end_char_idx": 2831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd50d670-40c5-43e9-8240-1464a197e401": {"__data__": {"id_": "dd50d670-40c5-43e9-8240-1464a197e401", "embedding": null, "metadata": {"window": "We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n", "original_text": "While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4252d548-ba0d-491d-990d-b4f58cd3ba47", "node_type": "1", "metadata": {"window": "We are assuming a non -GAAP effective tax rate in the range of 23.5% to 25.5%.   We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.  ", "original_text": "We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "203802f4048c541c19e5255ff262c6f3948ac03901980b81f7e59297990f807f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0842ab8-82ed-44bd-bbcd-4695cfb90090", "node_type": "1", "metadata": {"window": "Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.  ", "original_text": "As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n"}, "hash": "e69eeecc0db0675979e56e6db7d58abf426fbada771f17953e6707504a0c19bd", "class_name": "RelatedNodeInfo"}}, "text": "While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n", "start_char_idx": 2831, "end_char_idx": 2988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0842ab8-82ed-44bd-bbcd-4695cfb90090": {"__data__": {"id_": "b0842ab8-82ed-44bd-bbcd-4695cfb90090", "embedding": null, "metadata": {"window": "Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.  ", "original_text": "As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd50d670-40c5-43e9-8240-1464a197e401", "node_type": "1", "metadata": {"window": "We expect diluted \nweighted average shares outstanding in the range of $287 million to $292 million, and capex of $400 \nmillion to $450 million.  \n Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n", "original_text": "While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4104f2e23043c7114d02ae93b4cbc14dc92adb081920c7079dc6e06891d319e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d770dcf6-8654-49be-ae4f-f919eb43a8d3", "node_type": "1", "metadata": {"window": "We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.   We expect increased contributions from our growth areas, specialty, including biosimilars, ", "original_text": "Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.  "}, "hash": "6fbc83261e06f97ba6ff28759dc5a68366617ebc340e0cb9e29cc3517fa03f8d", "class_name": "RelatedNodeInfo"}}, "text": "As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n", "start_char_idx": 2988, "end_char_idx": 3243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d770dcf6-8654-49be-ae4f-f919eb43a8d3": {"__data__": {"id_": "d770dcf6-8654-49be-ae4f-f919eb43a8d3", "embedding": null, "metadata": {"window": "We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.   We expect increased contributions from our growth areas, specialty, including biosimilars, ", "original_text": "Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0842ab8-82ed-44bd-bbcd-4695cfb90090", "node_type": "1", "metadata": {"window": "Transitioni ng to the segments, beginning with Pharma on slide 14...  We expect high single -digit \nrevenue growth driven by growth from large customers and continued COVID -19 recovery and mid -\nsingle -digit segment profit growth.   We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.  ", "original_text": "As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4d6e6fb81dba3fd4b2cf9b222d0f141ed943e66cca26caefeb436298ddb2130", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6112ac99-1e1b-46d1-9edb-4777a5a3fb0a", "node_type": "1", "metadata": {"window": "While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.   We expect increased contributions from our growth areas, specialty, including biosimilars, ", "original_text": "We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n"}, "hash": "5c37cc56158262eee19532df5891f31b17326049637ef6ed19d6427d15761bdc", "class_name": "RelatedNodeInfo"}}, "text": "Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.  ", "start_char_idx": 3243, "end_char_idx": 3406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6112ac99-1e1b-46d1-9edb-4777a5a3fb0a": {"__data__": {"id_": "6112ac99-1e1b-46d1-9edb-4777a5a3fb0a", "embedding": null, "metadata": {"window": "While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.   We expect increased contributions from our growth areas, specialty, including biosimilars, ", "original_text": "We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d770dcf6-8654-49be-ae4f-f919eb43a8d3", "node_type": "1", "metadata": {"window": "We anticipate COVID -19 will be an overal l tailwind of \napproximately $100 million to Pharma segment profit compared to the prior year.   While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.   We expect increased contributions from our growth areas, specialty, including biosimilars, ", "original_text": "Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b790531755e249b29662d16b9950f1418b6dbdd91b5985fc7345a16e2002f4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf138164-7279-4d18-aea5-15aebebdfb7c", "node_type": "1", "metadata": {"window": "As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.   We expect increased contributions from our growth areas, specialty, including biosimilars, ", "original_text": "As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.  "}, "hash": "d4c92364acfa7b3a82e1821a2e5e12f127d76e589f82c3b0683e41e638431584", "class_name": "RelatedNodeInfo"}}, "text": "We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n", "start_char_idx": 3406, "end_char_idx": 3538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf138164-7279-4d18-aea5-15aebebdfb7c": {"__data__": {"id_": "cf138164-7279-4d18-aea5-15aebebdfb7c", "embedding": null, "metadata": {"window": "As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.   We expect increased contributions from our growth areas, specialty, including biosimilars, ", "original_text": "As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6112ac99-1e1b-46d1-9edb-4777a5a3fb0a", "node_type": "1", "metadata": {"window": "While we will likely \ncontinue to see some choppiness, we expect volume recovery in certain generic therapeutic classes \nby the end of the calendar year.   \n As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.   We expect increased contributions from our growth areas, specialty, including biosimilars, ", "original_text": "We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2f8650e47aeb6c0326741495dbd5661411803375e12004d7e2b455de49ef446", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9412bd8-5d07-4242-8183-e24b7ab4a8d8", "node_type": "1", "metadata": {"window": "Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.   We expect increased contributions from our growth areas, specialty, including biosimilars, ", "original_text": "We expect increased contributions from our growth areas, specialty, including biosimilars, "}, "hash": "0d6edfddfdab6d5ad0aff9642cb8469427c1846afb48723248e06127359ff050", "class_name": "RelatedNodeInfo"}}, "text": "As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.  ", "start_char_idx": 3538, "end_char_idx": 3640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9412bd8-5d07-4242-8183-e24b7ab4a8d8": {"__data__": {"id_": "d9412bd8-5d07-4242-8183-e24b7ab4a8d8", "embedding": null, "metadata": {"window": "Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.   We expect increased contributions from our growth areas, specialty, including biosimilars, ", "original_text": "We expect increased contributions from our growth areas, specialty, including biosimilars, ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718c25174f4488b65ded6581c90518ba52a1e27048bd828bf32e338c053fa00b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf138164-7279-4d18-aea5-15aebebdfb7c", "node_type": "1", "metadata": {"window": "As ment ioned, we are investing in technology enhancements to drive growth and efficiencies, which \nwe expect will lead to an $80 million segment profit headwind in fiscal '22, including the annualization \nof the investments made in the fourth quarter.  \n Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.   We expect increased contributions from our growth areas, specialty, including biosimilars, ", "original_text": "As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fdda7d723bcaa7a51d025baea4cd6c4249cb48aebe4d52846babf95b47ebfaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbc0688e-7f23-4469-82bf-96bebf9b99e9", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.  ", "original_text": " \nPage 5 of 15 \n \nnuclear and outcomes.  "}, "hash": "66f8ae43e8f6f2c709d929acb4efc5c01e22b424873a53c24d0ce04f6e6b8572", "class_name": "RelatedNodeInfo"}}, "text": "We expect increased contributions from our growth areas, specialty, including biosimilars, ", "start_char_idx": 3640, "end_char_idx": 3731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbc0688e-7f23-4469-82bf-96bebf9b99e9": {"__data__": {"id_": "dbc0688e-7f23-4469-82bf-96bebf9b99e9", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.  ", "original_text": " \nPage 5 of 15 \n \nnuclear and outcomes.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9412bd8-5d07-4242-8183-e24b7ab4a8d8", "node_type": "1", "metadata": {"window": "Adjusting for  the COVID -19-related impacts and the incremental technology investments, we see \nPharma normalized growth in the low to mid -single -digit range.   We believe normalizing for these \nimpacts provides a better approximation for the long -range growth trajectory o f the business.  \n As for other assumptions, we continue to expect consistent market dynamics in our generics \nprogram.   We expect increased contributions from our growth areas, specialty, including biosimilars, ", "original_text": "We expect increased contributions from our growth areas, specialty, including biosimilars, ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bacc5971f47d2ec005816ae2e845965fda18f982c9de59004c16e8d1918fc2b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69b374eb-40ac-4266-b78e-5a934a0ee6f3", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n", "original_text": "We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.  "}, "hash": "bc30bdfda0251a49d01d06eb69094d3026d81ab97aa6af249091bd9cd9e66cf7", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 15 \n \nnuclear and outcomes.  ", "start_char_idx": 0, "end_char_idx": 41, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69b374eb-40ac-4266-b78e-5a934a0ee6f3": {"__data__": {"id_": "69b374eb-40ac-4266-b78e-5a934a0ee6f3", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n", "original_text": "We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbc0688e-7f23-4469-82bf-96bebf9b99e9", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.  ", "original_text": " \nPage 5 of 15 \n \nnuclear and outcomes.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e49e2c35e9874856e6b504914e4715dec6a99c03ac0b5672d21dd9abdfe5d17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "849c7f7e-1bf3-4677-8926-b6d1a9b10895", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.  ", "original_text": "And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n"}, "hash": "c96ddda1aadf34d120f7d8670a102672d4de0e90cd2ef49ba1bd61146c26c944", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.  ", "start_char_idx": 41, "end_char_idx": 168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "849c7f7e-1bf3-4677-8926-b6d1a9b10895": {"__data__": {"id_": "849c7f7e-1bf3-4677-8926-b6d1a9b10895", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.  ", "original_text": "And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69b374eb-40ac-4266-b78e-5a934a0ee6f3", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n", "original_text": "We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0752bd4ab743fc6f2c284df0e485da411f8da208ce28da898ef1bfbcd0af4e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27057e26-88c9-4d0a-831d-48b839236e70", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.  ", "original_text": "For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.  "}, "hash": "3c218b5733dfa27a0972c2c1c613c8b4c34584ec7f58bdcb096f247760a1f922", "class_name": "RelatedNodeInfo"}}, "text": "And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n", "start_char_idx": 168, "end_char_idx": 290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27057e26-88c9-4d0a-831d-48b839236e70": {"__data__": {"id_": "27057e26-88c9-4d0a-831d-48b839236e70", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.  ", "original_text": "For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "849c7f7e-1bf3-4677-8926-b6d1a9b10895", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.  ", "original_text": "And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c05a2fede92f07257902048509e819db219f32bf79809a38e4e38693e9d510c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55cd0d4e-271e-4324-8e4a-cf265d7fdacd", "node_type": "1", "metadata": {"window": "We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n", "original_text": "With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n"}, "hash": "64292e3a59bef12c820fb7592eaa4304133d07d6d6c594450699b407c4ab2ab9", "class_name": "RelatedNodeInfo"}}, "text": "For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.  ", "start_char_idx": 290, "end_char_idx": 477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55cd0d4e-271e-4324-8e4a-cf265d7fdacd": {"__data__": {"id_": "55cd0d4e-271e-4324-8e4a-cf265d7fdacd", "embedding": null, "metadata": {"window": "We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n", "original_text": "With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27057e26-88c9-4d0a-831d-48b839236e70", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.  ", "original_text": "For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da07a3fa9fb53e0f6870812a466222a7bf86290e2f3fec0585f5fd0daa5a1314", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7f47851-4562-44fd-94f2-dc57f9dbf115", "node_type": "1", "metadata": {"window": "And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.  ", "original_text": "We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.  "}, "hash": "60fc8e4deb0a09dd741251ecd38dc0f0e6a05f3aa1b594213fd21934f4f5d671", "class_name": "RelatedNodeInfo"}}, "text": "With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n", "start_char_idx": 477, "end_char_idx": 598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7f47851-4562-44fd-94f2-dc57f9dbf115": {"__data__": {"id_": "d7f47851-4562-44fd-94f2-dc57f9dbf115", "embedding": null, "metadata": {"window": "And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.  ", "original_text": "We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55cd0d4e-271e-4324-8e4a-cf265d7fdacd", "node_type": "1", "metadata": {"window": "We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n", "original_text": "With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13c0b8cf9317c9c1c350242a417122b843e4c899ea3655f8ef5c617aa5f8ec81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5858a507-a87f-496a-bcb0-1f6ccdd2e394", "node_type": "1", "metadata": {"window": "For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.  ", "original_text": "We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.  "}, "hash": "6b4e5f923c69923b227ce2c68deb761b1a5909813165209a99548469acf93463", "class_name": "RelatedNodeInfo"}}, "text": "We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.  ", "start_char_idx": 598, "end_char_idx": 705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5858a507-a87f-496a-bcb0-1f6ccdd2e394": {"__data__": {"id_": "5858a507-a87f-496a-bcb0-1f6ccdd2e394", "embedding": null, "metadata": {"window": "For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.  ", "original_text": "We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7f47851-4562-44fd-94f2-dc57f9dbf115", "node_type": "1", "metadata": {"window": "And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.  ", "original_text": "We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "450382f904cfdeec63256fb5e6a90430d7f425865e04ffb79cb053316c72b970", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3bf20f2-9a90-48da-a943-7939756d76c0", "node_type": "1", "metadata": {"window": "With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.  ", "original_text": "And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n"}, "hash": "651a4918e8b7d2764a63fc4ecdf46cd14d976f06ef73115e82d05dd397d69e9d", "class_name": "RelatedNodeInfo"}}, "text": "We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.  ", "start_char_idx": 705, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3bf20f2-9a90-48da-a943-7939756d76c0": {"__data__": {"id_": "e3bf20f2-9a90-48da-a943-7939756d76c0", "embedding": null, "metadata": {"window": "With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.  ", "original_text": "And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5858a507-a87f-496a-bcb0-1f6ccdd2e394", "node_type": "1", "metadata": {"window": "For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.   With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.  ", "original_text": "We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c597e2a2042493f19b5a7afe310598939c921cfc420b5f6af351987fd081c4fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f8ea981-2a25-4dae-942f-b35070d1311d", "node_type": "1", "metadata": {"window": "We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n", "original_text": "Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.  "}, "hash": "c0aa5a666b3f8a51fc2769012abbf696f3beba0f489abebbdc74d13cbfdd5d97", "class_name": "RelatedNodeInfo"}}, "text": "And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n", "start_char_idx": 863, "end_char_idx": 959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f8ea981-2a25-4dae-942f-b35070d1311d": {"__data__": {"id_": "2f8ea981-2a25-4dae-942f-b35070d1311d", "embedding": null, "metadata": {"window": "We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n", "original_text": "Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3bf20f2-9a90-48da-a943-7939756d76c0", "node_type": "1", "metadata": {"window": "With respect to \nCOVID -19, we expect an approximate $100 million year -over-year tailwind to Medical segment pro fit.  \n We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.  ", "original_text": "And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "178c6b75c77c78451717641e137def0ce6d48c45e97a761a7ff817fec5d640d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "355faad5-e4a7-451a-844f-70321a94e959", "node_type": "1", "metadata": {"window": "We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.  ", "original_text": "Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.  "}, "hash": "e5ba5837127969fd2b1416c5cfc7bf6066663660779d33c308c01a1f72cfe2b2", "class_name": "RelatedNodeInfo"}}, "text": "Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.  ", "start_char_idx": 959, "end_char_idx": 1076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "355faad5-e4a7-451a-844f-70321a94e959": {"__data__": {"id_": "355faad5-e4a7-451a-844f-70321a94e959", "embedding": null, "metadata": {"window": "We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.  ", "original_text": "Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f8ea981-2a25-4dae-942f-b35070d1311d", "node_type": "1", "metadata": {"window": "We are assuming elective procedures to remain at or near pre -COVID levels for the duration of the \nyear.   We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n", "original_text": "Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb02f6028c71b3b022d7704ee085e551c0ba4bb69c87fa2bd2c9c91c5d028d8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a68c8237-1b2a-4cf3-a163-82b94b7fdd24", "node_type": "1", "metadata": {"window": "And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n", "original_text": "Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.  "}, "hash": "6e0c7c18c7f9b62d98d1a61ac1f4dd51549518562474118c74ca84310b36bb1d", "class_name": "RelatedNodeInfo"}}, "text": "Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.  ", "start_char_idx": 1076, "end_char_idx": 1289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a68c8237-1b2a-4cf3-a163-82b94b7fdd24": {"__data__": {"id_": "a68c8237-1b2a-4cf3-a163-82b94b7fdd24", "embedding": null, "metadata": {"window": "And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n", "original_text": "Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "355faad5-e4a7-451a-844f-70321a94e959", "node_type": "1", "metadata": {"window": "We expect moderate headwinds in fiscal '22 related to timing of selling higher -cost PPE \nproducts and lower lab testing utilization versus the pri or year.   And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.  ", "original_text": "Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d12fca6f1a935b90596179eb88531b5dc18f69ed617447464cbd9aab3309edd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c3e9391-6ed7-4f55-8baa-8087bd0b7bc3", "node_type": "1", "metadata": {"window": "Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.  ", "original_text": "Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n"}, "hash": "c46eea90cc6a4e03ae72f366d93e5ea8503cdf196ff8e48522401995c25706e9", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.  ", "start_char_idx": 1289, "end_char_idx": 1439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c3e9391-6ed7-4f55-8baa-8087bd0b7bc3": {"__data__": {"id_": "9c3e9391-6ed7-4f55-8baa-8087bd0b7bc3", "embedding": null, "metadata": {"window": "Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.  ", "original_text": "Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a68c8237-1b2a-4cf3-a163-82b94b7fdd24", "node_type": "1", "metadata": {"window": "And we anticipate a year -over-year \ncomparison benefit related to the PPE inventory reserve.  \n Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n", "original_text": "Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99ff12fa4b45afe10dfbe6b3f406e620907d571c965f027fc0911bdddfa6af71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d87aa1cf-b431-40e4-bae3-b14229d71f83", "node_type": "1", "metadata": {"window": "Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.  ", "original_text": "Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.  "}, "hash": "0b61a32a06d8833dc09e6b132ec89e4d14bb7243a41457cbe69e139ec38070dc", "class_name": "RelatedNodeInfo"}}, "text": "Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n", "start_char_idx": 1439, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d87aa1cf-b431-40e4-bae3-b14229d71f83": {"__data__": {"id_": "d87aa1cf-b431-40e4-bae3-b14229d71f83", "embedding": null, "metadata": {"window": "Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.  ", "original_text": "Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c3e9391-6ed7-4f55-8baa-8087bd0b7bc3", "node_type": "1", "metadata": {"window": "Outside of COVID -19, we expect an approximate $80 million impact to segment profit due to the \nCordis divestiture.   Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.  ", "original_text": "Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce47750d6cf44239b5ac1b4cd2b11af41ea493f99d70a20ebb4e21e52a8998fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f817ad04-f866-4339-82f5-2689d337f6db", "node_type": "1", "metadata": {"window": "Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n", "original_text": "We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n"}, "hash": "2920c028bde127622bd2f154c66ff5270acd022b0d7c842f8e6fde205baacb35", "class_name": "RelatedNodeInfo"}}, "text": "Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.  ", "start_char_idx": 1562, "end_char_idx": 1697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f817ad04-f866-4339-82f5-2689d337f6db": {"__data__": {"id_": "f817ad04-f866-4339-82f5-2689d337f6db", "embedding": null, "metadata": {"window": "Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n", "original_text": "We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d87aa1cf-b431-40e4-bae3-b14229d71f83", "node_type": "1", "metadata": {"window": "Note, the anticipated reported impact f or fiscal '22 is higher than previously \ncommunicated, primarily due to exchange rate favorability and other operating improvements within \nthe business in the prior year.   Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.  ", "original_text": "Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fa4713aaead56e74b5032bb310e59697e8ec6d52852afd98f8cdba071e20d03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a8e58bf-637e-4dad-8578-8f41b147afee", "node_type": "1", "metadata": {"window": "Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n", "original_text": "Now a few additional comments on the expected cadence next year.  "}, "hash": "02f0f2d0e53aee24b778f1ba2db7edbc96c96f47fe6debb98a5c5e8b6756ba8d", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n", "start_char_idx": 1697, "end_char_idx": 1890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a8e58bf-637e-4dad-8578-8f41b147afee": {"__data__": {"id_": "1a8e58bf-637e-4dad-8578-8f41b147afee", "embedding": null, "metadata": {"window": "Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n", "original_text": "Now a few additional comments on the expected cadence next year.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f817ad04-f866-4339-82f5-2689d337f6db", "node_type": "1", "metadata": {"window": "Additionally, we expect to invest an incremental $20 million in \ntechnology enhancemen ts in our at -Home business to drive growth and efficiencies.   Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n", "original_text": "We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9de47177a6d6114f681ae3bf2a66c9d24405cc7a0b1347cb30df0498eae5616c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75878e77-0b6d-454c-8bda-9ccc199091f1", "node_type": "1", "metadata": {"window": "Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n", "original_text": "We expect profit growth to be \nsignificantly back -half weighted in both segments.  "}, "hash": "e862ea18c0146dc4c16c3466d4854aba3d38f7696c267e6fb253b51523ad961b", "class_name": "RelatedNodeInfo"}}, "text": "Now a few additional comments on the expected cadence next year.  ", "start_char_idx": 1890, "end_char_idx": 1956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75878e77-0b6d-454c-8bda-9ccc199091f1": {"__data__": {"id_": "75878e77-0b6d-454c-8bda-9ccc199091f1", "embedding": null, "metadata": {"window": "Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n", "original_text": "We expect profit growth to be \nsignificantly back -half weighted in both segments.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a8e58bf-637e-4dad-8578-8f41b147afee", "node_type": "1", "metadata": {"window": "Adjusting for \nthese items, we see normalized Medical segment profit growth of mid to high -single digits in fiscal '22.  \n Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n", "original_text": "Now a few additional comments on the expected cadence next year.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f88df275403072328a0e32d7abb7c509bd443ea2026fb699f17cbcbc39eb4c67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18196012-223e-4e7b-a7ce-274bc1d1e276", "node_type": "1", "metadata": {"window": "We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.  ", "original_text": "In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n"}, "hash": "7b896f29a4e9a0c90aeb07f2c4e85fc8465a60a765bad62185a94879d8e9ff1e", "class_name": "RelatedNodeInfo"}}, "text": "We expect profit growth to be \nsignificantly back -half weighted in both segments.  ", "start_char_idx": 1956, "end_char_idx": 2040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18196012-223e-4e7b-a7ce-274bc1d1e276": {"__data__": {"id_": "18196012-223e-4e7b-a7ce-274bc1d1e276", "embedding": null, "metadata": {"window": "We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.  ", "original_text": "In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75878e77-0b6d-454c-8bda-9ccc199091f1", "node_type": "1", "metadata": {"window": "Finally, as seen in the fourth quarter, we expect elevated supply chain cost to persist, particularly in \nthe first half of the year.   We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n", "original_text": "We expect profit growth to be \nsignificantly back -half weighted in both segments.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "441d17262a046618e2a8096a8b3353b1d48eb684c6dfa373cbec3e9a53d8704a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b820bec-5ade-4b3a-95e6-77386d7e07b0", "node_type": "1", "metadata": {"window": "Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n", "original_text": "In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n"}, "hash": "94ad4ea63946c9535c3af2d0807114ab758691bf155371b684a594fd6756294b", "class_name": "RelatedNodeInfo"}}, "text": "In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n", "start_char_idx": 2040, "end_char_idx": 2314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b820bec-5ade-4b3a-95e6-77386d7e07b0": {"__data__": {"id_": "0b820bec-5ade-4b3a-95e6-77386d7e07b0", "embedding": null, "metadata": {"window": "Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n", "original_text": "In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18196012-223e-4e7b-a7ce-274bc1d1e276", "node_type": "1", "metadata": {"window": "We anticipate these elevated costs will be partially offset by the continued \nbenefits from our global manufacturing and supply chain transformation, which will ramp up \nthroughout the year.  \n Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.  ", "original_text": "In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "494e3a755dd65ded7fd7ec5a831d9ba4ee3e63bde278c909c5f93f4cb5d2c59a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02e31643-affd-499c-8b00-4af7a1410b2b", "node_type": "1", "metadata": {"window": "We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.  ", "original_text": "As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n"}, "hash": "a87065da3e3c9e7c98f042388b52b47a0198491615f9ae2ea73143ca16576fc9", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n", "start_char_idx": 2314, "end_char_idx": 2526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02e31643-affd-499c-8b00-4af7a1410b2b": {"__data__": {"id_": "02e31643-affd-499c-8b00-4af7a1410b2b", "embedding": null, "metadata": {"window": "We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.  ", "original_text": "As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b820bec-5ade-4b3a-95e6-77386d7e07b0", "node_type": "1", "metadata": {"window": "Now a few additional comments on the expected cadence next year.   We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n", "original_text": "In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d52ce92fe173975cad4101d5eac09d793af5ae1a9c337781bcad525ee6cbf9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55c825be-2d54-4ebe-bf25-8c3f274329ad", "node_type": "1", "metadata": {"window": "In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.  ", "original_text": "Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.  "}, "hash": "b270aea3f4b7f72cd39a68a82f108e503fbac9d0712e0def2a5284040299a72e", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n", "start_char_idx": 2526, "end_char_idx": 2658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55c825be-2d54-4ebe-bf25-8c3f274329ad": {"__data__": {"id_": "55c825be-2d54-4ebe-bf25-8c3f274329ad", "embedding": null, "metadata": {"window": "In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.  ", "original_text": "Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02e31643-affd-499c-8b00-4af7a1410b2b", "node_type": "1", "metadata": {"window": "We expect profit growth to be \nsignificantly back -half weighted in both segments.   In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.  ", "original_text": "As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad00f6f4c3c3465be2ab6e7ec431a512cf22f9b7a39376c553bc077eb671fbfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68e215a6-1cf2-473a-b1ff-9220b7d7dc14", "node_type": "1", "metadata": {"window": "In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n", "original_text": "Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n"}, "hash": "18792f45104ec9f5a42f614dcb9cb5956d45d375a650bbc7cf54e3e6a00982fc", "class_name": "RelatedNodeInfo"}}, "text": "Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.  ", "start_char_idx": 2658, "end_char_idx": 2838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68e215a6-1cf2-473a-b1ff-9220b7d7dc14": {"__data__": {"id_": "68e215a6-1cf2-473a-b1ff-9220b7d7dc14", "embedding": null, "metadata": {"window": "In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n", "original_text": "Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55c825be-2d54-4ebe-bf25-8c3f274329ad", "node_type": "1", "metadata": {"window": "In Pharma, this is primarily driven by the timing of \nthe previously mentioned incremental technology invest ments being more weighted towards the front \nhalf as well as stronger expected second half performance in our generics program, including the \nimpact of COVID -19. \n In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.  ", "original_text": "Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76924058d212210c385ee4ae7f8819506b64051dab31345692f79ea056538642", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "285d875f-067a-4e98-aab8-2b4a948757dd", "node_type": "1", "metadata": {"window": "As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n With that, I'll now turn it over to Mike.  ", "original_text": "Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.  "}, "hash": "29cadc1b949b22b04241faa2cce2cba2580e54f7fd453c37e63c1868dfe68c55", "class_name": "RelatedNodeInfo"}}, "text": "Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n", "start_char_idx": 2838, "end_char_idx": 3079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "285d875f-067a-4e98-aab8-2b4a948757dd": {"__data__": {"id_": "285d875f-067a-4e98-aab8-2b4a948757dd", "embedding": null, "metadata": {"window": "As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n With that, I'll now turn it over to Mike.  ", "original_text": "Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68e215a6-1cf2-473a-b1ff-9220b7d7dc14", "node_type": "1", "metadata": {"window": "In Medical, in addition to the elevated supply chain costs, we also anticipate the total unfavo rable \nfiscal '22 COVID -19 impact of approximately $50 million to occur primarily in the first half of the year.  \n As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n", "original_text": "Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab8f5071351cfe230509eab0588e40a1c5c77b3088909b0055b9c4fab47c6cff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5df697bd-04ad-444b-99a4-1dd987629a77", "node_type": "1", "metadata": {"window": "Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n With that, I'll now turn it over to Mike.  ", "original_text": "We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.  "}, "hash": "2af0bdf02137265934e78648e1fa169c16dc056f7945c80215f06e69a3c56ace", "class_name": "RelatedNodeInfo"}}, "text": "Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.  ", "start_char_idx": 3079, "end_char_idx": 3278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5df697bd-04ad-444b-99a4-1dd987629a77": {"__data__": {"id_": "5df697bd-04ad-444b-99a4-1dd987629a77", "embedding": null, "metadata": {"window": "Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n With that, I'll now turn it over to Mike.  ", "original_text": "We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "285d875f-067a-4e98-aab8-2b4a948757dd", "node_type": "1", "metadata": {"window": "As a reminder, we also experienced favorable COVID -19 impact in the first half of fiscal '21, which \nwas of a similar magnitude.  \n Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n With that, I'll now turn it over to Mike.  ", "original_text": "Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5b87ac8c420cf70c00bda04b9b7d98589b21bcffb92c6be5f0b876579c35e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f466fa7-7409-4ad3-91fa-2e92a2f1482e", "node_type": "1", "metadata": {"window": "Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n With that, I'll now turn it over to Mike.  ", "original_text": "In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n"}, "hash": "f590c1f45445f6c6cf62709b7611b5a5e387cdf5cc1fdf9ce4b0ffd573ee1d24", "class_name": "RelatedNodeInfo"}}, "text": "We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.  ", "start_char_idx": 3278, "end_char_idx": 3365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f466fa7-7409-4ad3-91fa-2e92a2f1482e": {"__data__": {"id_": "7f466fa7-7409-4ad3-91fa-2e92a2f1482e", "embedding": null, "metadata": {"window": "Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n With that, I'll now turn it over to Mike.  ", "original_text": "In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5df697bd-04ad-444b-99a4-1dd987629a77", "node_type": "1", "metadata": {"window": "Across the orga nization, we continue to place a high priority on cash flow generation as well as \nallocating capital in a balanced, disciplined and shareholder -friendly manner.   Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n With that, I'll now turn it over to Mike.  ", "original_text": "We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ee863e5f9dd69174e707d3002b93faf2a84be298a309951f3e1fe973e59ded0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49fc8353-d490-4847-bf0f-fc3788d1553f", "node_type": "1", "metadata": {"window": "Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n With that, I'll now turn it over to Mike.  ", "original_text": "With that, I'll now turn it over to Mike.  "}, "hash": "4f017116e27073dc20b73b07a9792ae9fb68a418212308c2b1aff4e4e8151e39", "class_name": "RelatedNodeInfo"}}, "text": "In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n", "start_char_idx": 3365, "end_char_idx": 3530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49fc8353-d490-4847-bf0f-fc3788d1553f": {"__data__": {"id_": "49fc8353-d490-4847-bf0f-fc3788d1553f", "embedding": null, "metadata": {"window": "Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n With that, I'll now turn it over to Mike.  ", "original_text": "With that, I'll now turn it over to Mike.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "63991299-8af0-42fb-9c98-6c628d1be1f9", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a953b95668222dbdc324e1b137f0cbe1a8e35f0f8cc288e2930945a86d67550c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f466fa7-7409-4ad3-91fa-2e92a2f1482e", "node_type": "1", "metadata": {"window": "Our strong cash flow \nand improving capital position will enable our capital allocation priorit ies, support our company's \nobligations and provide increased flexibility and the ability to be more opportunistic in our capital \ndeployment.  \n Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n With that, I'll now turn it over to Mike.  ", "original_text": "In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94b655d79596bcb545fb4138d7eaec0ebd94b79ff4f33aadc01554092667868f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cabf8c3-39df-4945-9dbe-e4ae7a1f0a0d", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.  ", "original_text": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.  "}, "hash": "73445b581c7211a9f08a8aca5e6c2bbfc77415a7b3b8bd927cbe54de305fd7cd", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll now turn it over to Mike.  ", "start_char_idx": 3530, "end_char_idx": 3573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cabf8c3-39df-4945-9dbe-e4ae7a1f0a0d": {"__data__": {"id_": "6cabf8c3-39df-4945-9dbe-e4ae7a1f0a0d", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.  ", "original_text": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49fc8353-d490-4847-bf0f-fc3788d1553f", "node_type": "1", "metadata": {"window": "Along those lines, we anticipate deploying the Cordis proceeds through a combination of share \nrepurchases and debt paydown, which is expected to offset the earnings dilution on a pro forma \nbasis.   We expect share repurchases in the range of $500 million to $1 billion in fiscal '22.   In addition, \nwe expect total debt paydown of approximately $850 million, reflecting the  completion of the \nremaining June 2022 debt tower at or before maturity.  \n With that, I'll now turn it over to Mike.  ", "original_text": "With that, I'll now turn it over to Mike.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "348a5fd7acde8f8c22e2a849ac35ef21e882b250514651f198933a7587a83a8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fa2ad87-25df-4ea9-962a-d9ab2d393269", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n", "original_text": "To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.  "}, "hash": "38589901feaf9fde30a7c08958eae3af8409f7e5306720607edd1dc4713dd26f", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.  ", "start_char_idx": 0, "end_char_idx": 50, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fa2ad87-25df-4ea9-962a-d9ab2d393269": {"__data__": {"id_": "8fa2ad87-25df-4ea9-962a-d9ab2d393269", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n", "original_text": "To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cabf8c3-39df-4945-9dbe-e4ae7a1f0a0d", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.  ", "original_text": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "485dc85087f53702a00d0720a0a1918e9e45744d6fd81aa52ce9890c218f53f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0173b9c1-f15e-4dbe-8701-a5b8545d4d68", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n", "original_text": "We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.  "}, "hash": "62570edc7eee7c0cc7b0ade7577616bab5b1e0b0bd3e11dcfc711fa163f98a11", "class_name": "RelatedNodeInfo"}}, "text": "To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.  ", "start_char_idx": 50, "end_char_idx": 214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0173b9c1-f15e-4dbe-8701-a5b8545d4d68": {"__data__": {"id_": "0173b9c1-f15e-4dbe-8701-a5b8545d4d68", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n", "original_text": "We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fa2ad87-25df-4ea9-962a-d9ab2d393269", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n", "original_text": "To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc592c7f6014004dcfdcce3e7ccc94ef69d760bac4eb0b9bffbffe49590742e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a99e9348-72a9-4b5f-aa82-dea758f9188d", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.  ", "original_text": "And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.  "}, "hash": "3f7ece7385796e4abfe00e6a0e370a3a3781f1128b5501fb3fefc57d3fd692eb", "class_name": "RelatedNodeInfo"}}, "text": "We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.  ", "start_char_idx": 214, "end_char_idx": 361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a99e9348-72a9-4b5f-aa82-dea758f9188d": {"__data__": {"id_": "a99e9348-72a9-4b5f-aa82-dea758f9188d", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.  ", "original_text": "And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0173b9c1-f15e-4dbe-8701-a5b8545d4d68", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n", "original_text": "We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cca891c1875130f5c0727c790eb3849377ab6a85a921c8a8e778f957e4f95a1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca3f7a5a-8df2-41a9-a8dd-f43f3470e92c", "node_type": "1", "metadata": {"window": "To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.  ", "original_text": "While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n"}, "hash": "f860b2481ecc12886ea765145696772d022259b72c116b5d59338ce40b8ac746", "class_name": "RelatedNodeInfo"}}, "text": "And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.  ", "start_char_idx": 361, "end_char_idx": 542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca3f7a5a-8df2-41a9-a8dd-f43f3470e92c": {"__data__": {"id_": "ca3f7a5a-8df2-41a9-a8dd-f43f3470e92c", "embedding": null, "metadata": {"window": "To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.  ", "original_text": "While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a99e9348-72a9-4b5f-aa82-dea758f9188d", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.  ", "original_text": "And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a884c7dc93877c1a9d3fc62b3900dfd5dfea47c19975808e94e207e65226533c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24f6e02d-6693-4098-bb62-e03d17e049d8", "node_type": "1", "metadata": {"window": "We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.  ", "original_text": "In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n"}, "hash": "0f633bd8ec9bb0969693e3cd371eb95523e00a681c54b2a95aec18628088df25", "class_name": "RelatedNodeInfo"}}, "text": "While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n", "start_char_idx": 542, "end_char_idx": 683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24f6e02d-6693-4098-bb62-e03d17e049d8": {"__data__": {"id_": "24f6e02d-6693-4098-bb62-e03d17e049d8", "embedding": null, "metadata": {"window": "We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.  ", "original_text": "In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca3f7a5a-8df2-41a9-a8dd-f43f3470e92c", "node_type": "1", "metadata": {"window": "To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.  ", "original_text": "While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d615009e2b7e3615f7c7c52beee8993daca9ba2b462ebcd5ef2cd3d11c8a2cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79dd1b5e-c675-4662-acbb-90b8cd7d9c49", "node_type": "1", "metadata": {"window": "And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n", "original_text": "Our generics program remains a critical priority.  "}, "hash": "1190f59734ac46d18b66118fabe671d9b00b6db1c216066445024f6f31f4a4d5", "class_name": "RelatedNodeInfo"}}, "text": "In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n", "start_char_idx": 683, "end_char_idx": 942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79dd1b5e-c675-4662-acbb-90b8cd7d9c49": {"__data__": {"id_": "79dd1b5e-c675-4662-acbb-90b8cd7d9c49", "embedding": null, "metadata": {"window": "And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n", "original_text": "Our generics program remains a critical priority.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24f6e02d-6693-4098-bb62-e03d17e049d8", "node_type": "1", "metadata": {"window": "We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.  ", "original_text": "In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8fe0e4e54db7def233d9303cd91ac81c2590d42aa25858fa4c9c7a31e3d6eb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43040cd7-3e00-496b-b492-a7b79af82fda", "node_type": "1", "metadata": {"window": "While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.  ", "original_text": "This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.  "}, "hash": "7a7e8bbffb792460cbf61438f8bfd3497234d18c4fadc941b8ee3b84e92324aa", "class_name": "RelatedNodeInfo"}}, "text": "Our generics program remains a critical priority.  ", "start_char_idx": 942, "end_char_idx": 993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43040cd7-3e00-496b-b492-a7b79af82fda": {"__data__": {"id_": "43040cd7-3e00-496b-b492-a7b79af82fda", "embedding": null, "metadata": {"window": "While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.  ", "original_text": "This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79dd1b5e-c675-4662-acbb-90b8cd7d9c49", "node_type": "1", "metadata": {"window": "And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.   While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n", "original_text": "Our generics program remains a critical priority.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05c0d10cff97434fb740d55900adde61a37ebd49c487e747a6ea69d10b2b8b2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d533a742-f7ba-4be1-9bc1-e42648900761", "node_type": "1", "metadata": {"window": "In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n", "original_text": "This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.  "}, "hash": "fd8e6f80f4ce8471cce28cb0cc535ea06ce6f2be01bf9332e5c9b99c83ac9a13", "class_name": "RelatedNodeInfo"}}, "text": "This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.  ", "start_char_idx": 993, "end_char_idx": 1169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d533a742-f7ba-4be1-9bc1-e42648900761": {"__data__": {"id_": "d533a742-f7ba-4be1-9bc1-e42648900761", "embedding": null, "metadata": {"window": "In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n", "original_text": "This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43040cd7-3e00-496b-b492-a7b79af82fda", "node_type": "1", "metadata": {"window": "While we expect to benefit from these investments this fiscal year, the majority of these \nbenefits will materialize in FY '23 and beyond.  \n In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.  ", "original_text": "This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "780be9e21d72b0541836aa5a9ba44f35c82caf664f50d1e32b20939b4346a2e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64ac07a0-f625-4adf-a309-62d75aba5e87", "node_type": "1", "metadata": {"window": "Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.  ", "original_text": "We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n"}, "hash": "46b206606f337c091fa2e7c798679bfe9a9a25b0bb58f9dea508f76008393120", "class_name": "RelatedNodeInfo"}}, "text": "This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.  ", "start_char_idx": 1169, "end_char_idx": 1294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64ac07a0-f625-4adf-a309-62d75aba5e87": {"__data__": {"id_": "64ac07a0-f625-4adf-a309-62d75aba5e87", "embedding": null, "metadata": {"window": "Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.  ", "original_text": "We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d533a742-f7ba-4be1-9bc1-e42648900761", "node_type": "1", "metadata": {"window": "In Pharma, we're investing an additional $80 million in technology infrastructure to create additional \noperational efficiencies, improve data insights and drive cost synergies to enhance our ability to grow \nand generate better outcomes for our customers.  \n Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n", "original_text": "This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec63944df4286483ce36d14b146623628f1aef98bd3d41054d82e334ccd42f8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8b11fc9-a169-4786-a6f4-a3ae79437030", "node_type": "1", "metadata": {"window": "This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n", "original_text": "We remain committed to supporting the retail pharmacy community.  "}, "hash": "5b9360160b66839eb1af9b1a9eeafc622a4bea25a7d8119dc9f1d26d0c42453b", "class_name": "RelatedNodeInfo"}}, "text": "We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n", "start_char_idx": 1294, "end_char_idx": 1518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8b11fc9-a169-4786-a6f4-a3ae79437030": {"__data__": {"id_": "a8b11fc9-a169-4786-a6f4-a3ae79437030", "embedding": null, "metadata": {"window": "This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n", "original_text": "We remain committed to supporting the retail pharmacy community.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64ac07a0-f625-4adf-a309-62d75aba5e87", "node_type": "1", "metadata": {"window": "Our generics program remains a critical priority.   This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.  ", "original_text": "We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94ec27a4bb93121cc0fd3dd4e21c940187a3c4a221345b34544b7bdf70032886", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43cf2c62-6f8b-44da-ab2e-b50bb592fed9", "node_type": "1", "metadata": {"window": "This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.  ", "original_text": "At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n"}, "hash": "37c05afe16033284836c7311b3b6755e6eb1e0daba1c675d5f1226573287d188", "class_name": "RelatedNodeInfo"}}, "text": "We remain committed to supporting the retail pharmacy community.  ", "start_char_idx": 1518, "end_char_idx": 1584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43cf2c62-6f8b-44da-ab2e-b50bb592fed9": {"__data__": {"id_": "43cf2c62-6f8b-44da-ab2e-b50bb592fed9", "embedding": null, "metadata": {"window": "This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.  ", "original_text": "At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8b11fc9-a169-4786-a6f4-a3ae79437030", "node_type": "1", "metadata": {"window": "This week, we extended our Red Oak agreement \nwith CVS Health for an additional five years, which takes the term of our generic sourcing joint \nventure through June 30, 2029.   This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n", "original_text": "We remain committed to supporting the retail pharmacy community.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a34055816e02cc0fd89755581ed04f9a516c200e564cf55258fc8a514c1c647c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99e6a32e-b62b-431c-ae6e-462faaa92c07", "node_type": "1", "metadata": {"window": "We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.  ", "original_text": "In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.  "}, "hash": "82c1893649e2ad5c6fa4148b921dee99693677525a2bda7461b0fd1cad07b910", "class_name": "RelatedNodeInfo"}}, "text": "At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n", "start_char_idx": 1584, "end_char_idx": 1878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99e6a32e-b62b-431c-ae6e-462faaa92c07": {"__data__": {"id_": "99e6a32e-b62b-431c-ae6e-462faaa92c07", "embedding": null, "metadata": {"window": "We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.  ", "original_text": "In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43cf2c62-6f8b-44da-ab2e-b50bb592fed9", "node_type": "1", "metadata": {"window": "This ensures that we can contin ue to deliver best -in-class sourcing \ncapabilities for our customers well into the future.   We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.  ", "original_text": "At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea49d8665a4e4de967640bcb78bcdbde450c2004a456323e9a36751d07ac157e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e66fc7c0-52c5-42e2-a231-a096e8f4f4b8", "node_type": "1", "metadata": {"window": "We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.  ", "original_text": "In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n"}, "hash": "96690a15169a357c40d127a5e62b8c6eb132c19188a927316eed9b68c3aaff11", "class_name": "RelatedNodeInfo"}}, "text": "In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.  ", "start_char_idx": 1878, "end_char_idx": 2028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e66fc7c0-52c5-42e2-a231-a096e8f4f4b8": {"__data__": {"id_": "e66fc7c0-52c5-42e2-a231-a096e8f4f4b8", "embedding": null, "metadata": {"window": "We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.  ", "original_text": "In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99e6a32e-b62b-431c-ae6e-462faaa92c07", "node_type": "1", "metadata": {"window": "We are also investing in data and analytics, \nincluding our pricing capabilities, as we continue to focus on managing all components of our \ngenerics program and expec t market dynamics consistent with the last few years.  \n We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.  ", "original_text": "In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62e10684368890e3c415843e21dc3030fef51c97314227d38fc3b9a5b2ac72f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c280d6f-8244-4e83-a00d-64469b64f04d", "node_type": "1", "metadata": {"window": "At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.  ", "original_text": "In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.  "}, "hash": "227ecb2917841ffce993775effc115f267466f837b950dedcf2e23e9149b7968", "class_name": "RelatedNodeInfo"}}, "text": "In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n", "start_char_idx": 2028, "end_char_idx": 2234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c280d6f-8244-4e83-a00d-64469b64f04d": {"__data__": {"id_": "8c280d6f-8244-4e83-a00d-64469b64f04d", "embedding": null, "metadata": {"window": "At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.  ", "original_text": "In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e66fc7c0-52c5-42e2-a231-a096e8f4f4b8", "node_type": "1", "metadata": {"window": "We remain committed to supporting the retail pharmacy community.   At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.  ", "original_text": "In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc6a18876eba6bbef76c12498704b4905314900b8ab30224be045e89a27633ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03bf5325-9dcc-4740-8bcb-9a8a50fc625b", "node_type": "1", "metadata": {"window": "In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.  ", "original_text": "We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.  "}, "hash": "5ad367929de66f67dc210b161406defdfc8eb2fc9d2f6b264e0578eb99fc468d", "class_name": "RelatedNodeInfo"}}, "text": "In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.  ", "start_char_idx": 2234, "end_char_idx": 2370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03bf5325-9dcc-4740-8bcb-9a8a50fc625b": {"__data__": {"id_": "03bf5325-9dcc-4740-8bcb-9a8a50fc625b", "embedding": null, "metadata": {"window": "In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.  ", "original_text": "We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c280d6f-8244-4e83-a00d-64469b64f04d", "node_type": "1", "metadata": {"window": "At our recent Annual Retail \nBusiness conference, we connected virtually with over 4,000 retail independent pharmacy customers \nand launch ed two new digital offerings, NavixRx and e -commerce storefront to help independent \npharmacies expand their services and improve health care outcomes.  \n In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.  ", "original_text": "In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b67553beec41fc8e6df5187bf43b82b439355476109853517b44e673270cecd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23d2b9a4-f12e-4485-b702-a009a8cc1e8d", "node_type": "1", "metadata": {"window": "In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S. ", "original_text": "We \nexpect double -digit profit growth in Nuclear over the next several years.  "}, "hash": "df181df66c03ba2ea130edb1d57f859b6127365e665b400dc9fc4daa3e8b7552", "class_name": "RelatedNodeInfo"}}, "text": "We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.  ", "start_char_idx": 2370, "end_char_idx": 2531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23d2b9a4-f12e-4485-b702-a009a8cc1e8d": {"__data__": {"id_": "23d2b9a4-f12e-4485-b702-a009a8cc1e8d", "embedding": null, "metadata": {"window": "In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S. ", "original_text": "We \nexpect double -digit profit growth in Nuclear over the next several years.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03bf5325-9dcc-4740-8bcb-9a8a50fc625b", "node_type": "1", "metadata": {"window": "In Specialty, we're investing in our Sonexus\u2122 patient hub where our technology solutions help \nbiopharma c ustomers remove barriers to patient care.   In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.  ", "original_text": "We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4419e9f47010c2b0b0c6e04a33034619eedc31d1a1289383c78d536111b448b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75a0c5f8-dd92-4cd9-80e9-d2f8d92dcc56", "node_type": "1", "metadata": {"window": "In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n", "original_text": "And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.  "}, "hash": "af61b3c95e551a7e4570cdf12d2414a6ca5b16d6b0f471270d331815cf7ff0f6", "class_name": "RelatedNodeInfo"}}, "text": "We \nexpect double -digit profit growth in Nuclear over the next several years.  ", "start_char_idx": 2531, "end_char_idx": 2611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75a0c5f8-dd92-4cd9-80e9-d2f8d92dcc56": {"__data__": {"id_": "75a0c5f8-dd92-4cd9-80e9-d2f8d92dcc56", "embedding": null, "metadata": {"window": "In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n", "original_text": "And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23d2b9a4-f12e-4485-b702-a009a8cc1e8d", "node_type": "1", "metadata": {"window": "In our third -party logistics business, we're \nexpanding our cold chain storage space to accommodate the growing number of temperature \ntemperature -sensitive products, including cell and gene therapies.  \n In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S. ", "original_text": "We \nexpect double -digit profit growth in Nuclear over the next several years.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "026f2785c4a56caf1d6552363b9e361ceed8704b2ac73c58b434176195678abd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b1b564c-8117-46f4-a0fc-7dd9b0434589", "node_type": "1", "metadata": {"window": "We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "original_text": "We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.  "}, "hash": "bad5365871fb345957dc1d3f27c4927656c506cd864493d34faac8fb914ddfa1", "class_name": "RelatedNodeInfo"}}, "text": "And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.  ", "start_char_idx": 2611, "end_char_idx": 2796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b1b564c-8117-46f4-a0fc-7dd9b0434589": {"__data__": {"id_": "4b1b564c-8117-46f4-a0fc-7dd9b0434589", "embedding": null, "metadata": {"window": "We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "original_text": "We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75a0c5f8-dd92-4cd9-80e9-d2f8d92dcc56", "node_type": "1", "metadata": {"window": "In Nuclear, w e received FDA approval to use our radioactive diagnostic agent LYMPHOSEEK\u00ae, in \npediatric patients one month and older.   We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n", "original_text": "And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9d042a21db2260b19139545ff20caf7acfdc5df081b8a845264a0c3ce67120e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eef38633-9903-445c-9d3d-a6ab65ea5ed9", "node_type": "1", "metadata": {"window": "We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "original_text": "We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S. "}, "hash": "9568b1c5f3105f9064f2cbd3da881e3d83d8a8654a7dada483415f72462fdf63", "class_name": "RelatedNodeInfo"}}, "text": "We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.  ", "start_char_idx": 2796, "end_char_idx": 2978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eef38633-9903-445c-9d3d-a6ab65ea5ed9": {"__data__": {"id_": "eef38633-9903-445c-9d3d-a6ab65ea5ed9", "embedding": null, "metadata": {"window": "We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "original_text": "We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S. ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b1b564c-8117-46f4-a0fc-7dd9b0434589", "node_type": "1", "metadata": {"window": "We continue to build out our multi -million -dollar center for \nTheranostics advancement in Indianapolis and are also investing to expand our PET capabilities.   We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "original_text": "We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d298557551aea0281208f6102caa76b56354821ceb166d4b791a1fdfd9e921e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9008ed4-35e7-47e4-80cd-d38b88618011", "node_type": "1", "metadata": {"window": "And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "original_text": "medical products and distribution as well as a single leader to manage international.  \n"}, "hash": "9668b297923e860484e8981792f8d02c1e68300d64d282a8bb39aae7aed68f6a", "class_name": "RelatedNodeInfo"}}, "text": "We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S. ", "start_char_idx": 2978, "end_char_idx": 3174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9008ed4-35e7-47e4-80cd-d38b88618011": {"__data__": {"id_": "d9008ed4-35e7-47e4-80cd-d38b88618011", "embedding": null, "metadata": {"window": "And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "original_text": "medical products and distribution as well as a single leader to manage international.  \n", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eef38633-9903-445c-9d3d-a6ab65ea5ed9", "node_type": "1", "metadata": {"window": "We \nexpect double -digit profit growth in Nuclear over the next several years.   And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "original_text": "We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S. ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31be1490b49177efb333bee6d433a51802420dbae6314001017d2f95de681a22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcf88c7a-328d-44ef-b997-e3b3477aea24", "node_type": "1", "metadata": {"window": "We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "original_text": "With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  "}, "hash": "5327c4cb70fa59089a2719f3e7ae75219cd667bc7f0c2623dc68f933a53bc50a", "class_name": "RelatedNodeInfo"}}, "text": "medical products and distribution as well as a single leader to manage international.  \n", "start_char_idx": 3174, "end_char_idx": 3262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcf88c7a-328d-44ef-b997-e3b3477aea24": {"__data__": {"id_": "fcf88c7a-328d-44ef-b997-e3b3477aea24", "embedding": null, "metadata": {"window": "We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "original_text": "With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db456ec4f171087ef6d300c75250737c7d11c7d6201acbf99a8c3be3e99895d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9008ed4-35e7-47e4-80cd-d38b88618011", "node_type": "1", "metadata": {"window": "And in outcomes, we also \nexpect double -digit profit growth as we expand our direct -to-patient digital footprint and implement \nnew patient adherence program s. \nTurning to Medical.   We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "original_text": "medical products and distribution as well as a single leader to manage international.  \n", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4486d393e071dc546e4528a4d6aad0e2bfd3f6b8c5acd6f16c5f57922ce2ba80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa4d9b2b-cfc3-4b25-9174-9c475a971c0f", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n", "original_text": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n"}, "hash": "d6d2b6aad3ea94dcf5d769a18b9b276384837113ff5038ed232a6148dc42f6e4", "class_name": "RelatedNodeInfo"}}, "text": "With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "start_char_idx": 3262, "end_char_idx": 3546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa4d9b2b-cfc3-4b25-9174-9c475a971c0f": {"__data__": {"id_": "fa4d9b2b-cfc3-4b25-9174-9c475a971c0f", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n", "original_text": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcf88c7a-328d-44ef-b997-e3b3477aea24", "node_type": "1", "metadata": {"window": "We have been taking quick , decisive action  throughout the fiscal year to \nstreamline and simplify our Medical business, and this work remains a top priority heading into FY \n'22.   We've recently restructured our organization to estab lish clearer lines of ownership  and \naccountability,  and made some management changes, including appointing a single leader to \nmanage U.S.  medical products and distribution as well as a single leader to manage international.  \n With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "original_text": "With the divestiture of Cor dis, we plan to significantly reduce our international commercial footprint \nand have initially identified 36 markets we intend to exit, so we can focus on the locations where we \nhave a competitive advantage and can generate sustained long -term growth.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ccb63b3ec4b95e9bdf79782bd0a253cfa651f25ed8da7ffe05e1ca814a91acba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1baaf3cf-4d04-48bd-a1bb-a01ced51b8bf", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n", "original_text": "In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.  "}, "hash": "e0b8394729eebab9d0220df4707f05c310da825405547409744e4d3348754bd9", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n", "start_char_idx": 0, "end_char_idx": 244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1baaf3cf-4d04-48bd-a1bb-a01ced51b8bf": {"__data__": {"id_": "1baaf3cf-4d04-48bd-a1bb-a01ced51b8bf", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n", "original_text": "In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa4d9b2b-cfc3-4b25-9174-9c475a971c0f", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n", "original_text": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0608915843d13987db065832119511c67c67c2dac7d9d3289c86cecd1493050e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2a106f3-01f1-44ab-9f26-1a3b4e75a8b7", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.  ", "original_text": "Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.  "}, "hash": "cd80fec5b824d1ee30b2f4b18d7d5ef31c07ab92f6a429e1470e7cb15fb606b4", "class_name": "RelatedNodeInfo"}}, "text": "In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.  ", "start_char_idx": 244, "end_char_idx": 409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2a106f3-01f1-44ab-9f26-1a3b4e75a8b7": {"__data__": {"id_": "e2a106f3-01f1-44ab-9f26-1a3b4e75a8b7", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.  ", "original_text": "Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1baaf3cf-4d04-48bd-a1bb-a01ced51b8bf", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n", "original_text": "In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a467a6cb2403422c7cb933f4643c69e0834cf36b2fb98a8212f98ce46ffc74b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c653496-af6a-4e20-93f4-9e1df47edf81", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n", "original_text": "We continue to see volume growth as care is rapidly shifting to the home.  \n"}, "hash": "220d897fbcc2c59ec52e34e6d261cc48428e47bffc76caf026843958caf43ccb", "class_name": "RelatedNodeInfo"}}, "text": "Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.  ", "start_char_idx": 409, "end_char_idx": 557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c653496-af6a-4e20-93f4-9e1df47edf81": {"__data__": {"id_": "4c653496-af6a-4e20-93f4-9e1df47edf81", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n", "original_text": "We continue to see volume growth as care is rapidly shifting to the home.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2a106f3-01f1-44ab-9f26-1a3b4e75a8b7", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.  ", "original_text": "Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "222d3df69c1f2d6bc76d30da6b2d46cb06f34feb3f53ef95daf573cd84ec7b61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53b8aa27-d662-4d86-8d44-53edebb760c3", "node_type": "1", "metadata": {"window": "In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n", "original_text": "For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n"}, "hash": "cb732c3c40a3a73f414b7d8008febd1918d44c3335ec8bde8d8ce68b7b9518ac", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see volume growth as care is rapidly shifting to the home.  \n", "start_char_idx": 557, "end_char_idx": 633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53b8aa27-d662-4d86-8d44-53edebb760c3": {"__data__": {"id_": "53b8aa27-d662-4d86-8d44-53edebb760c3", "embedding": null, "metadata": {"window": "In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n", "original_text": "For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c653496-af6a-4e20-93f4-9e1df47edf81", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n", "original_text": "We continue to see volume growth as care is rapidly shifting to the home.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9770342e3f78ba63756b93586345e2eef666d17c8ac8a8f7065352296d169d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40c29df3-ec94-43c7-ad35-b392940a72cf", "node_type": "1", "metadata": {"window": "Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.  ", "original_text": "With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.  "}, "hash": "1e73823f205579570307d40fb3c3157313b46b89aea2e48a7cef22f7f10da8ed", "class_name": "RelatedNodeInfo"}}, "text": "For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n", "start_char_idx": 633, "end_char_idx": 782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40c29df3-ec94-43c7-ad35-b392940a72cf": {"__data__": {"id_": "40c29df3-ec94-43c7-ad35-b392940a72cf", "embedding": null, "metadata": {"window": "Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.  ", "original_text": "With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53b8aa27-d662-4d86-8d44-53edebb760c3", "node_type": "1", "metadata": {"window": "In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n", "original_text": "For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a210af4768d1a2614d0527ec5cf491c1a8a525a555ee0ef288f62b72ed932c1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "849fc05f-8722-4e4e-80c2-27d036dda022", "node_type": "1", "metadata": {"window": "We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n", "original_text": "In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n"}, "hash": "23ed55d0a721939c74e8343a360498312d736867c7de32925d167081b3b6aa9b", "class_name": "RelatedNodeInfo"}}, "text": "With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.  ", "start_char_idx": 782, "end_char_idx": 993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "849fc05f-8722-4e4e-80c2-27d036dda022": {"__data__": {"id_": "849fc05f-8722-4e4e-80c2-27d036dda022", "embedding": null, "metadata": {"window": "We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n", "original_text": "In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40c29df3-ec94-43c7-ad35-b392940a72cf", "node_type": "1", "metadata": {"window": "Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.  ", "original_text": "With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00a9a5769a305f6a48694ab654c3d153d1510a12bbf3857562c3995f1391a9e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52bf7572-de08-49f7-8585-cd6bd629e76d", "node_type": "1", "metadata": {"window": "For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.  ", "original_text": "As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n"}, "hash": "57768840f882eff70aa17d4aa8ed8f476c58a36a1b74e8708715ced6a2c8bcd8", "class_name": "RelatedNodeInfo"}}, "text": "In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n", "start_char_idx": 993, "end_char_idx": 1111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52bf7572-de08-49f7-8585-cd6bd629e76d": {"__data__": {"id_": "52bf7572-de08-49f7-8585-cd6bd629e76d", "embedding": null, "metadata": {"window": "For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.  ", "original_text": "As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "849fc05f-8722-4e4e-80c2-27d036dda022", "node_type": "1", "metadata": {"window": "We continue to see volume growth as care is rapidly shifting to the home.  \n For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n", "original_text": "In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09b0d31588ed30dec83c8dca20110cfa95c210301d7afa7683765f06e9551e89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67a6dfc5-e465-4d02-8fd6-114574a6e6c3", "node_type": "1", "metadata": {"window": "With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.  ", "original_text": "In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.  "}, "hash": "83287319affee184e98bef8c61592356f5d1d0309ecd780d8d19d1478f3fd704", "class_name": "RelatedNodeInfo"}}, "text": "As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n", "start_char_idx": 1111, "end_char_idx": 1347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67a6dfc5-e465-4d02-8fd6-114574a6e6c3": {"__data__": {"id_": "67a6dfc5-e465-4d02-8fd6-114574a6e6c3", "embedding": null, "metadata": {"window": "With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.  ", "original_text": "In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52bf7572-de08-49f7-8585-cd6bd629e76d", "node_type": "1", "metadata": {"window": "For FY '22, we're investing an additional $20 million in technology infrastructure to create operational \nefficiencies and better data visibility.  \n With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.  ", "original_text": "As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c8ffc4b41248b95e460d77d275fd863b7ad77a35e16bbff4d9419f744038399", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "203595ae-8777-48b4-af4f-3fba2468b8b5", "node_type": "1", "metadata": {"window": "In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  ", "original_text": "And now Jason and \nI will take your questions.  \n"}, "hash": "45a6fe0c5006a6b7c0cfa49a8d31bee1b29196d711dee567e86851d3dae720f3", "class_name": "RelatedNodeInfo"}}, "text": "In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.  ", "start_char_idx": 1347, "end_char_idx": 1538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "203595ae-8777-48b4-af4f-3fba2468b8b5": {"__data__": {"id_": "203595ae-8777-48b4-af4f-3fba2468b8b5", "embedding": null, "metadata": {"window": "In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  ", "original_text": "And now Jason and \nI will take your questions.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67a6dfc5-e465-4d02-8fd6-114574a6e6c3", "node_type": "1", "metadata": {"window": "With respect to the Enter prise, we're aggressively reviewing our cost structure to continue \nstreamlining our operations and processes and intend to reinvest a portion of these savings to fuel \nfuture growth.   In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.  ", "original_text": "In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a076e9ba88d901a371830c281b38d66f5bb50ff06c2accfed54099c809d6969f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38e479bf-a142-47ff-ae96-d4b58657826e", "node_type": "1", "metadata": {"window": "As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.  ", "original_text": "Opera tor:  Thank you.  "}, "hash": "d736cf049695b8a1aae9a645bc08c56d0f074abf891098c4365198746b250adf", "class_name": "RelatedNodeInfo"}}, "text": "And now Jason and \nI will take your questions.  \n", "start_char_idx": 1538, "end_char_idx": 1587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38e479bf-a142-47ff-ae96-d4b58657826e": {"__data__": {"id_": "38e479bf-a142-47ff-ae96-d4b58657826e", "embedding": null, "metadata": {"window": "As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.  ", "original_text": "Opera tor:  Thank you.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "203595ae-8777-48b4-af4f-3fba2468b8b5", "node_type": "1", "metadata": {"window": "In FY '22, we plan to launch initiatives that will deliver at least an ad ditional $250 \nmillion savings by FY '23.  \n As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  ", "original_text": "And now Jason and \nI will take your questions.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f441ee70042708e366c2f7acff32eb6d0b8a97c57d9e4ba20d5b608399338428", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c1c11cb-2e73-4e34-877d-8d24bbcaf875", "node_type": "1", "metadata": {"window": "In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n", "original_text": "And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.  "}, "hash": "04eb908139650090a645a576326577d86ce215cc3105bb39d987f8ecfbbd148d", "class_name": "RelatedNodeInfo"}}, "text": "Opera tor:  Thank you.  ", "start_char_idx": 1587, "end_char_idx": 1611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c1c11cb-2e73-4e34-877d-8d24bbcaf875": {"__data__": {"id_": "4c1c11cb-2e73-4e34-877d-8d24bbcaf875", "embedding": null, "metadata": {"window": "In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n", "original_text": "And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38e479bf-a142-47ff-ae96-d4b58657826e", "node_type": "1", "metadata": {"window": "As Jason discussed earlier, we take a balanced, disciplined and shareholder -friendly approach to \ncapital deployment with a focus on investing in the business, maintaining a strong balance sheet and \nreturning cash to  shareholders.  \n In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.  ", "original_text": "Opera tor:  Thank you.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fba872bd38fc0377d1428b03526425ed26a6ecf588d2bf00a3e188f51cab1df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ca73968-075f-4fa4-beb0-e7e12436590b", "node_type": "1", "metadata": {"window": "And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.  ", "original_text": "If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  "}, "hash": "dc2af4201a7781168f4aa8db27b84c962b64069e80d3fb97f7952c61a8427039", "class_name": "RelatedNodeInfo"}}, "text": "And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.  ", "start_char_idx": 1611, "end_char_idx": 1713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ca73968-075f-4fa4-beb0-e7e12436590b": {"__data__": {"id_": "5ca73968-075f-4fa4-beb0-e7e12436590b", "embedding": null, "metadata": {"window": "And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.  ", "original_text": "If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c1c11cb-2e73-4e34-877d-8d24bbcaf875", "node_type": "1", "metadata": {"window": "In closing, I want to thank our employees for their hard work and contributions that make it possible \nfor Cardinal Health to fulfill its mission of improving the lives of people every day.   And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n", "original_text": "And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da774aebcafff1aae55e76f5747296034a7161cfc87d5bec8a8d11c60faa08ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc5215a9-fb78-43ea-8e53-7f0f791694bf", "node_type": "1", "metadata": {"window": "Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n", "original_text": "Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.  "}, "hash": "dd96050066aad70ddcccc9b4e1deb57c270575c8f1a5db207421a09e92da734c", "class_name": "RelatedNodeInfo"}}, "text": "If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  ", "start_char_idx": 1713, "end_char_idx": 1843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc5215a9-fb78-43ea-8e53-7f0f791694bf": {"__data__": {"id_": "cc5215a9-fb78-43ea-8e53-7f0f791694bf", "embedding": null, "metadata": {"window": "Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n", "original_text": "Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ca73968-075f-4fa4-beb0-e7e12436590b", "node_type": "1", "metadata": {"window": "And now Jason and \nI will take your questions.  \n Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.  ", "original_text": "If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52ed7f9db9b10bef8fe523f06b36c028f95b4c910eb17e4a1ef1b0542340bdd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec139860-a790-4eba-b4a6-5d5383bfb5e6", "node_type": "1", "metadata": {"window": "And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.  ", "original_text": "We\u2019ll pause for a quick moment to assemble the \nqueue.   \n"}, "hash": "c86db56b9222d5ca20109b8ace2ced78cbea5510dab91306c6c85b74fea62771", "class_name": "RelatedNodeInfo"}}, "text": "Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.  ", "start_char_idx": 1843, "end_char_idx": 1933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec139860-a790-4eba-b4a6-5d5383bfb5e6": {"__data__": {"id_": "ec139860-a790-4eba-b4a6-5d5383bfb5e6", "embedding": null, "metadata": {"window": "And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.  ", "original_text": "We\u2019ll pause for a quick moment to assemble the \nqueue.   \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc5215a9-fb78-43ea-8e53-7f0f791694bf", "node_type": "1", "metadata": {"window": "Opera tor:  Thank you.   And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n", "original_text": "Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "114ace311fafc0e26fce87400f88f328f1d27a1df104201c20c5ba2c6eec2bc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29288c44-a569-4859-8d00-5eef00de66ba", "node_type": "1", "metadata": {"window": "If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.  ", "original_text": "And our first question will come from Michael Cherny with Bank of America.  "}, "hash": "846f48ea7a4a2f3acdb08dd099d122cb226591ee2aae9938997661d212ddadb6", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ll pause for a quick moment to assemble the \nqueue.   \n", "start_char_idx": 1933, "end_char_idx": 1991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29288c44-a569-4859-8d00-5eef00de66ba": {"__data__": {"id_": "29288c44-a569-4859-8d00-5eef00de66ba", "embedding": null, "metadata": {"window": "If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.  ", "original_text": "And our first question will come from Michael Cherny with Bank of America.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec139860-a790-4eba-b4a6-5d5383bfb5e6", "node_type": "1", "metadata": {"window": "And if you would like to ask a question, please signal by pressing star 1 on \nyour telephone keypad.   If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.  ", "original_text": "We\u2019ll pause for a quick moment to assemble the \nqueue.   \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15f95a4e1df82512279f59e2e92b1c7b678119f127529154851a53a69659524a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c3de4e1-3aab-477f-8ef2-9de739250a34", "node_type": "1", "metadata": {"window": "Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.  ", "original_text": "Please go ahead.  \n"}, "hash": "655a831251b0141ec023739eaf4bef6b1b03ff7ba0f7791a27585f96effd36ea", "class_name": "RelatedNodeInfo"}}, "text": "And our first question will come from Michael Cherny with Bank of America.  ", "start_char_idx": 1991, "end_char_idx": 2067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c3de4e1-3aab-477f-8ef2-9de739250a34": {"__data__": {"id_": "7c3de4e1-3aab-477f-8ef2-9de739250a34", "embedding": null, "metadata": {"window": "Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.  ", "original_text": "Please go ahead.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29288c44-a569-4859-8d00-5eef00de66ba", "node_type": "1", "metadata": {"window": "If you are using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.  ", "original_text": "And our first question will come from Michael Cherny with Bank of America.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86d4f6193e7990455cb43ce5da46fe36a0182c1b03592d7040b18d118d3e5947", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2f0f802-79a5-46a1-9822-fbc679f6da3b", "node_type": "1", "metadata": {"window": "We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.  ", "original_text": "Michael Cherny:  Good morn ing, thanks so much for the question.  "}, "hash": "00c9fccafe8da7821021c74fe08ab18991b953ed20f33970eaa62d96f61d2e3e", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n", "start_char_idx": 2067, "end_char_idx": 2086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2f0f802-79a5-46a1-9822-fbc679f6da3b": {"__data__": {"id_": "b2f0f802-79a5-46a1-9822-fbc679f6da3b", "embedding": null, "metadata": {"window": "We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.  ", "original_text": "Michael Cherny:  Good morn ing, thanks so much for the question.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c3de4e1-3aab-477f-8ef2-9de739250a34", "node_type": "1", "metadata": {"window": "Once aga in, everyone, to ask a question, \nplease press star 1 on your telephone keypad.   We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.  ", "original_text": "Please go ahead.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b18801ab145b00bac1d3b6c75e3a0836fa73d3e3ee9defbbe07b8233579a4f27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8fafddc-dc20-4e4f-b593-2f4f185d028f", "node_type": "1", "metadata": {"window": "And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?  ", "original_text": "I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.  "}, "hash": "bf94e83ffcc8ef1b6670185d07374c8a778b863f4aa7b7bd73f8c1f4538fc6e1", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny:  Good morn ing, thanks so much for the question.  ", "start_char_idx": 2086, "end_char_idx": 2152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8fafddc-dc20-4e4f-b593-2f4f185d028f": {"__data__": {"id_": "e8fafddc-dc20-4e4f-b593-2f4f185d028f", "embedding": null, "metadata": {"window": "And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?  ", "original_text": "I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2f0f802-79a5-46a1-9822-fbc679f6da3b", "node_type": "1", "metadata": {"window": "We\u2019ll pause for a quick moment to assemble the \nqueue.   \n And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.  ", "original_text": "Michael Cherny:  Good morn ing, thanks so much for the question.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c81bcc0835b118ed21e7eaf2f10297ab1fd613703e4a504bbdab24e1d234cb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46995194-7c84-42db-ac6e-8d41583e1d49", "node_type": "1", "metadata": {"window": "Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.  ", "original_text": "Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.  "}, "hash": "1b4b8d780152fab25a65df19733dcb31ed799d67194080cfc0ac57c448fbb8c8", "class_name": "RelatedNodeInfo"}}, "text": "I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.  ", "start_char_idx": 2152, "end_char_idx": 2255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46995194-7c84-42db-ac6e-8d41583e1d49": {"__data__": {"id_": "46995194-7c84-42db-ac6e-8d41583e1d49", "embedding": null, "metadata": {"window": "Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.  ", "original_text": "Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8fafddc-dc20-4e4f-b593-2f4f185d028f", "node_type": "1", "metadata": {"window": "And our first question will come from Michael Cherny with Bank of America.   Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?  ", "original_text": "I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48c75ac59e52a1879558064003a5f5a8cf95d7cc6605eb9fcd6e31a600638079", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43371d05-f106-409a-90ba-c10e3a25462e", "node_type": "1", "metadata": {"window": "Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n", "original_text": "The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.  "}, "hash": "4c4c71423c15250f59b3d08752faa41cb376de0605eece3c9cce05c8b0f8c895", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.  ", "start_char_idx": 2255, "end_char_idx": 2342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43371d05-f106-409a-90ba-c10e3a25462e": {"__data__": {"id_": "43371d05-f106-409a-90ba-c10e3a25462e", "embedding": null, "metadata": {"window": "Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n", "original_text": "The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46995194-7c84-42db-ac6e-8d41583e1d49", "node_type": "1", "metadata": {"window": "Please go ahead.  \n Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.  ", "original_text": "Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f735b57cae52ad6bfeb6ab3b8873cf2b5d94a8c871eac6b427c987cbf0e916a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fbb70c2-292f-4148-b2d7-5c4456fa5b71", "node_type": "1", "metadata": {"window": "I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.  ", "original_text": "When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?  "}, "hash": "12b760365d12d10f96488a25c832f67cafeac81976e162749a8c3e4058129c72", "class_name": "RelatedNodeInfo"}}, "text": "The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.  ", "start_char_idx": 2342, "end_char_idx": 2477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fbb70c2-292f-4148-b2d7-5c4456fa5b71": {"__data__": {"id_": "0fbb70c2-292f-4148-b2d7-5c4456fa5b71", "embedding": null, "metadata": {"window": "I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.  ", "original_text": "When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43371d05-f106-409a-90ba-c10e3a25462e", "node_type": "1", "metadata": {"window": "Michael Cherny:  Good morn ing, thanks so much for the question.   I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n", "original_text": "The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f0370f481ab87c82fee7b92ef02be5f68166d79373766116475f78bb67f6a17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89b2b6f6-ff58-44ec-a26a-08aeb0a01031", "node_type": "1", "metadata": {"window": "Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.  ", "original_text": "On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.  "}, "hash": "584f088909f28ea95b95852fcbaf9da1822d3f8dfefc0240b5a34cc74b2f7aea", "class_name": "RelatedNodeInfo"}}, "text": "When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?  ", "start_char_idx": 2477, "end_char_idx": 2790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89b2b6f6-ff58-44ec-a26a-08aeb0a01031": {"__data__": {"id_": "89b2b6f6-ff58-44ec-a26a-08aeb0a01031", "embedding": null, "metadata": {"window": "Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.  ", "original_text": "On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fbb70c2-292f-4148-b2d7-5c4456fa5b71", "node_type": "1", "metadata": {"window": "I want to dive a little bit more into \nthe capital deployment priorities as you think about into '22.   Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.  ", "original_text": "When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9b13ebb75b49697015215a0365854fa5dfe52dd20e3314209c1d9bf573ca20e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81bc229c-46fb-4813-bae7-8038604ef379", "node_type": "1", "metadata": {"window": "The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.  ", "original_text": "Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n"}, "hash": "a0412c2b3f48614770cfb87a4026233e64790a2839a985ed7dc25ca6abcc7613", "class_name": "RelatedNodeInfo"}}, "text": "On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.  ", "start_char_idx": 2790, "end_char_idx": 2910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81bc229c-46fb-4813-bae7-8038604ef379": {"__data__": {"id_": "81bc229c-46fb-4813-bae7-8038604ef379", "embedding": null, "metadata": {"window": "The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.  ", "original_text": "Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89b2b6f6-ff58-44ec-a26a-08aeb0a01031", "node_type": "1", "metadata": {"window": "Obviously, you have the Cordis proceeds \nthat are coming in at $1 billion, I believe.   The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.  ", "original_text": "On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0e761255e8f1d0aef3441e9407495fe9461e463b1aec90baa6f727f6e2b617d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b5dc645-47f3-4bd0-9eba-5017811d6ade", "node_type": "1", "metadata": {"window": "When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.   But I'm going to have Jason give you a little bit more color on it.  ", "original_text": "Mike Kaufmann:  Thanks, Mike.  "}, "hash": "f9561f44d3d5431e63e1abc284ba946f9fd13ed546e64ec12b9a73828e61d7b5", "class_name": "RelatedNodeInfo"}}, "text": "Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n", "start_char_idx": 2910, "end_char_idx": 3066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b5dc645-47f3-4bd0-9eba-5017811d6ade": {"__data__": {"id_": "5b5dc645-47f3-4bd0-9eba-5017811d6ade", "embedding": null, "metadata": {"window": "When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.   But I'm going to have Jason give you a little bit more color on it.  ", "original_text": "Mike Kaufmann:  Thanks, Mike.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81bc229c-46fb-4813-bae7-8038604ef379", "node_type": "1", "metadata": {"window": "The tax receivable agreement,  if I recall, is about $1 billion \nor so, and I can double check that in the last quarter's transcript.   When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.  ", "original_text": "Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ae65c90e5a90e006dd7ae54bb73aa30ee20074011d4543082be328dce0a0c64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c3f0b33-e101-4197-9145-56315b5c8a83", "node_type": "1", "metadata": {"window": "On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.   But I'm going to have Jason give you a little bit more color on it.  ", "original_text": "I appreciate the question.  "}, "hash": "60a25217ec35eed934630c86f6a0f3453dd71688b7d3f659a69678e2b4da2091", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks, Mike.  ", "start_char_idx": 3066, "end_char_idx": 3097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c3f0b33-e101-4197-9145-56315b5c8a83": {"__data__": {"id_": "4c3f0b33-e101-4197-9145-56315b5c8a83", "embedding": null, "metadata": {"window": "On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.   But I'm going to have Jason give you a little bit more color on it.  ", "original_text": "I appreciate the question.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b5dc645-47f3-4bd0-9eba-5017811d6ade", "node_type": "1", "metadata": {"window": "When you think about that, think \nabout your cash position as you sit now and the free cash that you're going to generate this year, \neven with the invest ments that you're making, do you think there's an opportunity to be a bit more \naggressive, either on the buyback given where your stock sits in the market?   On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.   But I'm going to have Jason give you a little bit more color on it.  ", "original_text": "Mike Kaufmann:  Thanks, Mike.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4ff8742e7254a9370aaa6dbd9d66db87ee340ded129675bb3317e367a6fa3f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "898e4a68-f735-43a7-8037-4d029e8a2120", "node_type": "1", "metadata": {"window": "Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.   But I'm going to have Jason give you a little bit more color on it.  ", "original_text": "And we are really excited about the work \nwe've done around that.  "}, "hash": "39e19c9e75963e56509a68623ed8dc10bce3890e98d2b8ea82842d9bd5931eda", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate the question.  ", "start_char_idx": 3097, "end_char_idx": 3125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "898e4a68-f735-43a7-8037-4d029e8a2120": {"__data__": {"id_": "898e4a68-f735-43a7-8037-4d029e8a2120", "embedding": null, "metadata": {"window": "Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.   But I'm going to have Jason give you a little bit more color on it.  ", "original_text": "And we are really excited about the work \nwe've done around that.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c3f0b33-e101-4197-9145-56315b5c8a83", "node_type": "1", "metadata": {"window": "On M&A, given that you \ntalked about a number of growth priorities of which, I assume with some bolt -on transactions.   Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.   But I'm going to have Jason give you a little bit more color on it.  ", "original_text": "I appreciate the question.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a55f36933fcb1d0ddd3edca0941b865bb8b7a9f94c3e38c34b624cb4542f13d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b170628a-6e6d-4b86-9849-ea39b6515135", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.   But I'm going to have Jason give you a little bit more color on it.  ", "original_text": "But I'm going to have Jason give you a little bit more color on it.  "}, "hash": "3690d09818ffcc7bfcf089ce3b24b79f2ddff74f8c08da6f21fb6e8b9572d92f", "class_name": "RelatedNodeInfo"}}, "text": "And we are really excited about the work \nwe've done around that.  ", "start_char_idx": 3125, "end_char_idx": 3192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b170628a-6e6d-4b86-9849-ea39b6515135": {"__data__": {"id_": "b170628a-6e6d-4b86-9849-ea39b6515135", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.   But I'm going to have Jason give you a little bit more color on it.  ", "original_text": "But I'm going to have Jason give you a little bit more color on it.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c87918aa-82a0-4625-9e1f-a71101645067", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4138d856449d266becd8223aaff004fd24d45fc164ea9ccda125d870f0e9e0e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "898e4a68-f735-43a7-8037-4d029e8a2120", "node_type": "1", "metadata": {"window": "Just \ncurious about that philosophy where you sit now given that the company is in a stronger balance \nsheet position, as I can recall seeing in a while?  \n Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.   But I'm going to have Jason give you a little bit more color on it.  ", "original_text": "And we are really excited about the work \nwe've done around that.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37a620addba093096f18d9a316c9ed7ff53e85dc750b6874061538d9bfe18b62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d00b91fd-2b19-40c1-b417-eac55830905d", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n", "original_text": " \nPage 8 of 15 \n \nJason Hollar:  Yes.  "}, "hash": "8ff46e1188ec78188d4985dfc1885397bd9131d0490ea0ab12d4c418b74be956", "class_name": "RelatedNodeInfo"}}, "text": "But I'm going to have Jason give you a little bit more color on it.  ", "start_char_idx": 3192, "end_char_idx": 3261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d00b91fd-2b19-40c1-b417-eac55830905d": {"__data__": {"id_": "d00b91fd-2b19-40c1-b417-eac55830905d", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n", "original_text": " \nPage 8 of 15 \n \nJason Hollar:  Yes.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b170628a-6e6d-4b86-9849-ea39b6515135", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Mike.   I appreciate the question.   And we are really excited about the work \nwe've done around that.   But I'm going to have Jason give you a little bit more color on it.  ", "original_text": "But I'm going to have Jason give you a little bit more color on it.  ", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba13f38926b28b5483b3971542e2ce2c1b59f6588a8d6b0bbd00953237e7ddda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d1a713a-3b29-4447-bce9-b37cb574e11a", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n", "original_text": "Thanks, Mike.  "}, "hash": "be63cc3e3767cad28fe14e1dd8bf83ef6e5de9561d1d44b766a56e0a0e69b829", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 15 \n \nJason Hollar:  Yes.  ", "start_char_idx": 0, "end_char_idx": 39, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d1a713a-3b29-4447-bce9-b37cb574e11a": {"__data__": {"id_": "8d1a713a-3b29-4447-bce9-b37cb574e11a", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n", "original_text": "Thanks, Mike.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d00b91fd-2b19-40c1-b417-eac55830905d", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n", "original_text": " \nPage 8 of 15 \n \nJason Hollar:  Yes.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1c46727115249e7f9baa51ebd0b2abd2a094229aed3dd2071fa70d827112ac3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "effc2daa-9252-40d1-8dfc-80cec472e5bb", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.  ", "original_text": "And first of all, yes, I think we had some really great cash flow this \nlast year.  "}, "hash": "74d31a324482e7653fd33dab6b3f687144d32138858fbc00c53e79e3dcbe8de2", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Mike.  ", "start_char_idx": 39, "end_char_idx": 54, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "effc2daa-9252-40d1-8dfc-80cec472e5bb": {"__data__": {"id_": "effc2daa-9252-40d1-8dfc-80cec472e5bb", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.  ", "original_text": "And first of all, yes, I think we had some really great cash flow this \nlast year.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d1a713a-3b29-4447-bce9-b37cb574e11a", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n", "original_text": "Thanks, Mike.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "afe5385ca0ee940b324106177e8e8ddb15b64b849e433395e1e8fe904dbe48f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fa5aba6-80c1-44c4-bea0-ede0ecb30ad3", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.  ", "original_text": "So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n"}, "hash": "028e3d4acce32a408e9f81db5fd8f90977b9b3f7804755e38b98a73cd09d6d79", "class_name": "RelatedNodeInfo"}}, "text": "And first of all, yes, I think we had some really great cash flow this \nlast year.  ", "start_char_idx": 54, "end_char_idx": 138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fa5aba6-80c1-44c4-bea0-ede0ecb30ad3": {"__data__": {"id_": "0fa5aba6-80c1-44c4-bea0-ede0ecb30ad3", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.  ", "original_text": "So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "effc2daa-9252-40d1-8dfc-80cec472e5bb", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.  ", "original_text": "And first of all, yes, I think we had some really great cash flow this \nlast year.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e8646cba5fc4053a2ae775a3b1d81530fea76734dfefbcd4ed5ec17be5e03a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d53d790c-cc12-453d-b848-71936ceda947", "node_type": "1", "metadata": {"window": "Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n", "original_text": "So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n"}, "hash": "fb2ff6dcb188c0819bc02326dfbc610b70952edc8cd8e0320f2716e92e92fd59", "class_name": "RelatedNodeInfo"}}, "text": "So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n", "start_char_idx": 138, "end_char_idx": 327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d53d790c-cc12-453d-b848-71936ceda947": {"__data__": {"id_": "d53d790c-cc12-453d-b848-71936ceda947", "embedding": null, "metadata": {"window": "Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n", "original_text": "So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fa5aba6-80c1-44c4-bea0-ede0ecb30ad3", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.  ", "original_text": "So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb250373101280be6b883633c248b97c19dce628e5d79768b5c271f710371ccd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e31b1500-3b97-4fb5-8dce-68b32ac21387", "node_type": "1", "metadata": {"window": "And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.  ", "original_text": "As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.  "}, "hash": "3da149f3899a6f56d0b6e86f011e2808bba3d7bbdc97ee81b65d6d23c3ef35ad", "class_name": "RelatedNodeInfo"}}, "text": "So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n", "start_char_idx": 327, "end_char_idx": 545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e31b1500-3b97-4fb5-8dce-68b32ac21387": {"__data__": {"id_": "e31b1500-3b97-4fb5-8dce-68b32ac21387", "embedding": null, "metadata": {"window": "And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.  ", "original_text": "As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d53d790c-cc12-453d-b848-71936ceda947", "node_type": "1", "metadata": {"window": "Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n", "original_text": "So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0786b03d594cdd6a6891d60092d59268c0665865358bc768ab602d080906ae38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64a84fda-561f-4c33-b427-9fb305a5ca6f", "node_type": "1", "metadata": {"window": "So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.  ", "original_text": "So that will be \none of those uses.  "}, "hash": "1d13d7fe77c1e30735c5fcff0cd4ec0612f25b92540e1adc49d0be18d585dee1", "class_name": "RelatedNodeInfo"}}, "text": "As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.  ", "start_char_idx": 545, "end_char_idx": 729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64a84fda-561f-4c33-b427-9fb305a5ca6f": {"__data__": {"id_": "64a84fda-561f-4c33-b427-9fb305a5ca6f", "embedding": null, "metadata": {"window": "So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.  ", "original_text": "So that will be \none of those uses.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e31b1500-3b97-4fb5-8dce-68b32ac21387", "node_type": "1", "metadata": {"window": "And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.  ", "original_text": "As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02285d19d1307507b3d42fc8a31d82b853ac850d553ed71fe25da04d9516d6b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b185f0d-a2a9-4dcb-81dc-030ab09656e6", "node_type": "1", "metadata": {"window": "So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n", "original_text": "And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n"}, "hash": "9da2d9d99b3b7d500d0cad2c55cd0ed5a60b9afe2bda9c9b22ab5112983cb608", "class_name": "RelatedNodeInfo"}}, "text": "So that will be \none of those uses.  ", "start_char_idx": 729, "end_char_idx": 766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b185f0d-a2a9-4dcb-81dc-030ab09656e6": {"__data__": {"id_": "5b185f0d-a2a9-4dcb-81dc-030ab09656e6", "embedding": null, "metadata": {"window": "So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n", "original_text": "And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64a84fda-561f-4c33-b427-9fb305a5ca6f", "node_type": "1", "metadata": {"window": "So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.  ", "original_text": "So that will be \none of those uses.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d81d6459b5d67bae74069b8c440033b9da45f071dc80bc4066837f757eaf6fb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef999eb8-bb70-45bc-91f0-5db70db79680", "node_type": "1", "metadata": {"window": "As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.  ", "original_text": "And as I think about the Cordis proceeds, of course, cash is somewhat fungible.  "}, "hash": "4adbef2bf223ce55d8e890f0f6564bac3f535af37152630b0ec6b388f863e525", "class_name": "RelatedNodeInfo"}}, "text": "And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n", "start_char_idx": 766, "end_char_idx": 955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef999eb8-bb70-45bc-91f0-5db70db79680": {"__data__": {"id_": "ef999eb8-bb70-45bc-91f0-5db70db79680", "embedding": null, "metadata": {"window": "As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.  ", "original_text": "And as I think about the Cordis proceeds, of course, cash is somewhat fungible.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b185f0d-a2a9-4dcb-81dc-030ab09656e6", "node_type": "1", "metadata": {"window": "So as you indicated perfectly, we are stepping into this year with a lot of flexibility even befor e the \nCordis transaction closed, which was just a few days ago, which does add another $1 billion to that \nbalance.  \n As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n", "original_text": "And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5a1027cd31527a1ac3bfd8cbf2cc0e9bbe2fa4db0be0a0b2ecfdf6f48ae014c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb323e65-8f05-43cd-b89a-e330e05ac1a8", "node_type": "1", "metadata": {"window": "So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n", "original_text": "But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.  "}, "hash": "828279f24632b9d3566c3e05f288550e9a55711dd8675069da150f84c5b1a76c", "class_name": "RelatedNodeInfo"}}, "text": "And as I think about the Cordis proceeds, of course, cash is somewhat fungible.  ", "start_char_idx": 955, "end_char_idx": 1036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb323e65-8f05-43cd-b89a-e330e05ac1a8": {"__data__": {"id_": "fb323e65-8f05-43cd-b89a-e330e05ac1a8", "embedding": null, "metadata": {"window": "So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n", "original_text": "But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef999eb8-bb70-45bc-91f0-5db70db79680", "node_type": "1", "metadata": {"window": "As we highlighted in some of those comments this morning, we do expect to paydown the $850 \nmillion that is coming due by the end of the fiscal year or before end of the fiscal year.   So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.  ", "original_text": "And as I think about the Cordis proceeds, of course, cash is somewhat fungible.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4734e941389308e23348b79e833a0384e36de1f2090d27adec9d97d1db467366", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f440b27f-3a59-46c9-b310-ae531541bd5e", "node_type": "1", "metadata": {"window": "And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.  ", "original_text": "So we feel real good about that as we entered into the first quarter here.  \n"}, "hash": "1a9cae5619ff1405439b147eddc239e41bab9029a43cdae6a46dae2f3fe91926", "class_name": "RelatedNodeInfo"}}, "text": "But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.  ", "start_char_idx": 1036, "end_char_idx": 1195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f440b27f-3a59-46c9-b310-ae531541bd5e": {"__data__": {"id_": "f440b27f-3a59-46c9-b310-ae531541bd5e", "embedding": null, "metadata": {"window": "And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.  ", "original_text": "So we feel real good about that as we entered into the first quarter here.  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb323e65-8f05-43cd-b89a-e330e05ac1a8", "node_type": "1", "metadata": {"window": "So that will be \none of those uses.   And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n", "original_text": "But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71b2c92736f3471f45637ab6edb10097bdb4b2193c265a8007117cd0c6a979af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea4daf27-2a3a-4997-9bd1-afa121864425", "node_type": "1", "metadata": {"window": "And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.  ", "original_text": "You referenced the tax receivable.  "}, "hash": "b2ebafbee91e3be3cafe93109f208be6ada432ad81aef8b0bf80e5aa9cd794d1", "class_name": "RelatedNodeInfo"}}, "text": "So we feel real good about that as we entered into the first quarter here.  \n", "start_char_idx": 1195, "end_char_idx": 1272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea4daf27-2a3a-4997-9bd1-afa121864425": {"__data__": {"id_": "ea4daf27-2a3a-4997-9bd1-afa121864425", "embedding": null, "metadata": {"window": "And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.  ", "original_text": "You referenced the tax receivable.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f440b27f-3a59-46c9-b310-ae531541bd5e", "node_type": "1", "metadata": {"window": "And then, of course, we guided towards the $500 million to $1 billion for the share \nrepurchases, which is a fairly wide range reflective of some of the flexibility that we talked about.  \n And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.  ", "original_text": "So we feel real good about that as we entered into the first quarter here.  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c4123a92ecfe5c44f31cf9d8f09f1730769c1fe59cf3589faaf1d3c00e17cc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6767039a-0b9e-4238-a711-35a5d90a496a", "node_type": "1", "metadata": {"window": "But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.  ", "original_text": "And I don't think we provided any updated comments on that so \nfar.   \n"}, "hash": "f23ab9d46a1a05003b29965e09799ab67154fd0ffa808b3d6d09ec9133987b2d", "class_name": "RelatedNodeInfo"}}, "text": "You referenced the tax receivable.  ", "start_char_idx": 1272, "end_char_idx": 1308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6767039a-0b9e-4238-a711-35a5d90a496a": {"__data__": {"id_": "6767039a-0b9e-4238-a711-35a5d90a496a", "embedding": null, "metadata": {"window": "But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.  ", "original_text": "And I don't think we provided any updated comments on that so \nfar.   \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea4daf27-2a3a-4997-9bd1-afa121864425", "node_type": "1", "metadata": {"window": "And as I think about the Cordis proceeds, of course, cash is somewhat fungible.   But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.  ", "original_text": "You referenced the tax receivable.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d401bc511ac4d57112f5640ad00996db71ae9d86e9ce122e0e8803c3a1049636", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6f2bbee-38c2-4401-b0db-8f5745ce097d", "node_type": "1", "metadata": {"window": "So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.  ", "original_text": "Last quarter, I referenced that we expected b y the end of the calendar year.  "}, "hash": "fca81a62f125da3fb690fc04a636164c5a8e23617ae402bf770e9258bceebb94", "class_name": "RelatedNodeInfo"}}, "text": "And I don't think we provided any updated comments on that so \nfar.   \n", "start_char_idx": 1308, "end_char_idx": 1379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6f2bbee-38c2-4401-b0db-8f5745ce097d": {"__data__": {"id_": "e6f2bbee-38c2-4401-b0db-8f5745ce097d", "embedding": null, "metadata": {"window": "So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.  ", "original_text": "Last quarter, I referenced that we expected b y the end of the calendar year.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6767039a-0b9e-4238-a711-35a5d90a496a", "node_type": "1", "metadata": {"window": "But essentially, that \n$1 billion, how we're thinking about it is accelerating some of that debt paydown and a portion of that,  \n$500 million to $1 billion.   So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.  ", "original_text": "And I don't think we provided any updated comments on that so \nfar.   \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2efbb4bf926cb9b05953cd9773d64263f4d7c1f527696ea997e4a33bee80b425", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6f44f98-cd38-4b55-a754-1ef435570036", "node_type": "1", "metadata": {"window": "You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.  ", "original_text": "That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.  "}, "hash": "a786f9c1623281d149f05dc56336bccb0f90e5de56b7e7a29494bda8608e5ba8", "class_name": "RelatedNodeInfo"}}, "text": "Last quarter, I referenced that we expected b y the end of the calendar year.  ", "start_char_idx": 1379, "end_char_idx": 1458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6f44f98-cd38-4b55-a754-1ef435570036": {"__data__": {"id_": "d6f44f98-cd38-4b55-a754-1ef435570036", "embedding": null, "metadata": {"window": "You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.  ", "original_text": "That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6f2bbee-38c2-4401-b0db-8f5745ce097d", "node_type": "1", "metadata": {"window": "So we feel real good about that as we entered into the first quarter here.  \n You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.  ", "original_text": "Last quarter, I referenced that we expected b y the end of the calendar year.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2146881a5e0dc2b0b88582c4df81c1de7f151c786fd342e9b9de91543adb3a14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb4ce76f-f78b-4c0b-b6d5-c1293e284468", "node_type": "1", "metadata": {"window": "And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.  ", "original_text": "I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.  "}, "hash": "9e1163bb89d77480d1caa37afdc4be5aea0a122915491d934d2d7f258a0d8027", "class_name": "RelatedNodeInfo"}}, "text": "That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.  ", "start_char_idx": 1458, "end_char_idx": 1570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb4ce76f-f78b-4c0b-b6d5-c1293e284468": {"__data__": {"id_": "cb4ce76f-f78b-4c0b-b6d5-c1293e284468", "embedding": null, "metadata": {"window": "And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.  ", "original_text": "I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6f44f98-cd38-4b55-a754-1ef435570036", "node_type": "1", "metadata": {"window": "You referenced the tax receivable.   And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.  ", "original_text": "That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "632d77bc184f344b621b141835e295c5a7b8cd15f663bc79be2c7f4a3c5c9641", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c537bbb2-9c7e-465f-84a0-5db1a7c8fda1", "node_type": "1", "metadata": {"window": "Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n", "original_text": "But we still \nfeel pretty good that's a good approximate time frame.  "}, "hash": "bae7e30f9a2f6737b085f91f8e0308c3b70df94df9bac97ee9b7ed94528ba67e", "class_name": "RelatedNodeInfo"}}, "text": "I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.  ", "start_char_idx": 1570, "end_char_idx": 1679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c537bbb2-9c7e-465f-84a0-5db1a7c8fda1": {"__data__": {"id_": "c537bbb2-9c7e-465f-84a0-5db1a7c8fda1", "embedding": null, "metadata": {"window": "Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n", "original_text": "But we still \nfeel pretty good that's a good approximate time frame.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb4ce76f-f78b-4c0b-b6d5-c1293e284468", "node_type": "1", "metadata": {"window": "And I don't think we provided any updated comments on that so \nfar.   \n Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.  ", "original_text": "I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d47ba383be14c2255391801705f09950494c2da15cd618278c4236f9ab73376b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f957d7f-9b1b-444a-8602-0c01558d9945", "node_type": "1", "metadata": {"window": "That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.  ", "original_text": "But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.  "}, "hash": "4afde7c6eb20d80aebca7aedb7eafc4cbda371a97c78ec007b54e37da84adc09", "class_name": "RelatedNodeInfo"}}, "text": "But we still \nfeel pretty good that's a good approximate time frame.  ", "start_char_idx": 1679, "end_char_idx": 1749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f957d7f-9b1b-444a-8602-0c01558d9945": {"__data__": {"id_": "6f957d7f-9b1b-444a-8602-0c01558d9945", "embedding": null, "metadata": {"window": "That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.  ", "original_text": "But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c537bbb2-9c7e-465f-84a0-5db1a7c8fda1", "node_type": "1", "metadata": {"window": "Last quarter, I referenced that we expected b y the end of the calendar year.   That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n", "original_text": "But we still \nfeel pretty good that's a good approximate time frame.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "775afb4ce2bb4a0ee87ec53927686cf3efdc5ee4a28d4d3d2dff30316d42efa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "491b67d4-ca22-43c9-8735-01d88e669d27", "node_type": "1", "metadata": {"window": "I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.  ", "original_text": "So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.  "}, "hash": "44696866c0dd4b24eb3d827c58b846a1ead74bfe31c2f2d9976a9989aa442cc0", "class_name": "RelatedNodeInfo"}}, "text": "But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.  ", "start_char_idx": 1749, "end_char_idx": 1915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "491b67d4-ca22-43c9-8735-01d88e669d27": {"__data__": {"id_": "491b67d4-ca22-43c9-8735-01d88e669d27", "embedding": null, "metadata": {"window": "I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.  ", "original_text": "So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f957d7f-9b1b-444a-8602-0c01558d9945", "node_type": "1", "metadata": {"window": "That's still our \nexpectation, like, I think, a lot of different organizations throughout the world right now.   I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.  ", "original_text": "But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bfc3ec09231878f5daad3d85fb8ae9cc532d2e7dab44967aa2acda11199e5387", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be27846c-5f8a-4f48-8a58-2995908d59fc", "node_type": "1", "metadata": {"window": "But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.  ", "original_text": "But nonetheless, there's a lot of flexibility that goes along with that.  \n"}, "hash": "6c206a83e64f266ac1876437dac79b49be416dd8199ba296a077e43ebada5753", "class_name": "RelatedNodeInfo"}}, "text": "So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.  ", "start_char_idx": 1915, "end_char_idx": 2026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be27846c-5f8a-4f48-8a58-2995908d59fc": {"__data__": {"id_": "be27846c-5f8a-4f48-8a58-2995908d59fc", "embedding": null, "metadata": {"window": "But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.  ", "original_text": "But nonetheless, there's a lot of flexibility that goes along with that.  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "491b67d4-ca22-43c9-8735-01d88e669d27", "node_type": "1", "metadata": {"window": "I think COVID \nhas impacted some of the processes and a little bit less certainty as to the precise timing.   But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.  ", "original_text": "So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7006d3d3ac7afbea6a292e0d79ce9883d7d2feb634e0dc6bc972a9b8752b046", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02e9905a-1dc6-4827-8775-a026c5f6bcf7", "node_type": "1", "metadata": {"window": "But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n", "original_text": "As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.  "}, "hash": "2d0a56008ff8bc895e225ef7cfece3f870caf08fd98f8e0786dc37b0d2720a3c", "class_name": "RelatedNodeInfo"}}, "text": "But nonetheless, there's a lot of flexibility that goes along with that.  \n", "start_char_idx": 2026, "end_char_idx": 2101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02e9905a-1dc6-4827-8775-a026c5f6bcf7": {"__data__": {"id_": "02e9905a-1dc6-4827-8775-a026c5f6bcf7", "embedding": null, "metadata": {"window": "But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n", "original_text": "As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be27846c-5f8a-4f48-8a58-2995908d59fc", "node_type": "1", "metadata": {"window": "But we still \nfeel pretty good that's a good approximate time frame.   But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.  ", "original_text": "But nonetheless, there's a lot of flexibility that goes along with that.  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c76068336a1ae9b22a7c81cc9344726c4b975cbb8b25b21bd56b799be6dab8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f550661-e410-4765-b6db-8eed7172125b", "node_type": "1", "metadata": {"window": "So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n", "original_text": "M&A is always on that list.  "}, "hash": "bc929ff8d2d8e483cc59454c4e5a0ef2e9b3151b97df5d77094b66f1658bfa22", "class_name": "RelatedNodeInfo"}}, "text": "As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.  ", "start_char_idx": 2101, "end_char_idx": 2214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f550661-e410-4765-b6db-8eed7172125b": {"__data__": {"id_": "0f550661-e410-4765-b6db-8eed7172125b", "embedding": null, "metadata": {"window": "So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n", "original_text": "M&A is always on that list.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02e9905a-1dc6-4827-8775-a026c5f6bcf7", "node_type": "1", "metadata": {"window": "But when you think about receiving those \nproceeds perhaps late in the calendar year, there will be less time to actually deploy those to the \nbalance of this year.   So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n", "original_text": "As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8073d12afd3af35dc3ebaf49db13a08ffd625043c111c9d3fc7b6286169b8e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "904c40b7-a1cf-4a2a-ad01-7c4b4dd883d9", "node_type": "1", "metadata": {"window": "But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.  ", "original_text": "And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.  "}, "hash": "7779ffc0b5099279cbef71bc66cecbeb3f3800076c97fcff34e4c603bcdfb0ec", "class_name": "RelatedNodeInfo"}}, "text": "M&A is always on that list.  ", "start_char_idx": 2214, "end_char_idx": 2243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "904c40b7-a1cf-4a2a-ad01-7c4b4dd883d9": {"__data__": {"id_": "904c40b7-a1cf-4a2a-ad01-7c4b4dd883d9", "embedding": null, "metadata": {"window": "But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.  ", "original_text": "And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f550661-e410-4765-b6db-8eed7172125b", "node_type": "1", "metadata": {"window": "So that's certainly still a  potential opportunity to get us maybe to some of the \nhigher ends of that range.   But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n", "original_text": "M&A is always on that list.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3606d71540cb56456983f5d4e4d451e0550139038a118b09b8f01863a7d2bca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7fc9d9b-d945-491a-9bb2-5096b998b651", "node_type": "1", "metadata": {"window": "As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n", "original_text": "And so that will be another thing that we evaluate along the year.  \n"}, "hash": "466028793018563c3ee5170b2e0a0b79db58b0df95afff5137c790ae5682f9f5", "class_name": "RelatedNodeInfo"}}, "text": "And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.  ", "start_char_idx": 2243, "end_char_idx": 2345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7fc9d9b-d945-491a-9bb2-5096b998b651": {"__data__": {"id_": "c7fc9d9b-d945-491a-9bb2-5096b998b651", "embedding": null, "metadata": {"window": "As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n", "original_text": "And so that will be another thing that we evaluate along the year.  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "904c40b7-a1cf-4a2a-ad01-7c4b4dd883d9", "node_type": "1", "metadata": {"window": "But nonetheless, there's a lot of flexibility that goes along with that.  \n As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.  ", "original_text": "And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae6c4fea4c37cd41b7f3b7a72594bedf892454a38b604ada0f611489b9ea3619", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "899f14de-aa3b-4052-8fa8-34a73ec6ab52", "node_type": "1", "metadata": {"window": "M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.  ", "original_text": "Thanks for the question.   \n"}, "hash": "5f89f1dbdadf738f7d593f90e307d4822553e504233f9345237e1f7f60583512", "class_name": "RelatedNodeInfo"}}, "text": "And so that will be another thing that we evaluate along the year.  \n", "start_char_idx": 2345, "end_char_idx": 2414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "899f14de-aa3b-4052-8fa8-34a73ec6ab52": {"__data__": {"id_": "899f14de-aa3b-4052-8fa8-34a73ec6ab52", "embedding": null, "metadata": {"window": "M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.  ", "original_text": "Thanks for the question.   \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7fc9d9b-d945-491a-9bb2-5096b998b651", "node_type": "1", "metadata": {"window": "As you indicated, when we talk about the opportunistic uses, essentially, we have increased flexibili ty \nhere.   M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n", "original_text": "And so that will be another thing that we evaluate along the year.  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74fcaadacb3a53fa4403dfb1606046c99e5498878524ec98550b98db8ab33077", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f308450b-9306-45c8-b2c3-0a94c569718a", "node_type": "1", "metadata": {"window": "And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.  ", "original_text": "Operator:  Up next, we'll hear from Kevin Caliendo with UBS.  "}, "hash": "6813624c119267334309768e93afc838ca57eee620f89f576661472327f46165", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question.   \n", "start_char_idx": 2414, "end_char_idx": 2442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f308450b-9306-45c8-b2c3-0a94c569718a": {"__data__": {"id_": "f308450b-9306-45c8-b2c3-0a94c569718a", "embedding": null, "metadata": {"window": "And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.  ", "original_text": "Operator:  Up next, we'll hear from Kevin Caliendo with UBS.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "899f14de-aa3b-4052-8fa8-34a73ec6ab52", "node_type": "1", "metadata": {"window": "M&A is always on that list.   And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.  ", "original_text": "Thanks for the question.   \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39545dedd6a8cdb13d7d5b5a68922477f8be49f16ee38f4f00dba02c38259820", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f4efe1d-0606-4825-9b6b-797a582bd12a", "node_type": "1", "metadata": {"window": "And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks. ", "original_text": "Please go ahead.   \n"}, "hash": "d133b9970d722603682df4cdb195423bdfa5ca8ffe5ceb369d4d99d91da1cfb6", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Up next, we'll hear from Kevin Caliendo with UBS.  ", "start_char_idx": 2442, "end_char_idx": 2504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f4efe1d-0606-4825-9b6b-797a582bd12a": {"__data__": {"id_": "8f4efe1d-0606-4825-9b6b-797a582bd12a", "embedding": null, "metadata": {"window": "And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks. ", "original_text": "Please go ahead.   \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f308450b-9306-45c8-b2c3-0a94c569718a", "node_type": "1", "metadata": {"window": "And it depends on the opportunity, the valuation and what we see is \ndelivering to us strategically.   And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.  ", "original_text": "Operator:  Up next, we'll hear from Kevin Caliendo with UBS.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1d2a2f86cce68fb34452fa1d3cd724f27cb65583ce348fd376c446f718af921", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a826f569-150b-43da-9ebb-225ed427d968", "node_type": "1", "metadata": {"window": "Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater. ", "original_text": "Kevin Caliendo:  Great, thanks.  "}, "hash": "ea6b06619bfc5ef816831bf549aec67e43bfe023cdf45a8c5e1a0f79b0c1ed0f", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.   \n", "start_char_idx": 2504, "end_char_idx": 2524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a826f569-150b-43da-9ebb-225ed427d968": {"__data__": {"id_": "a826f569-150b-43da-9ebb-225ed427d968", "embedding": null, "metadata": {"window": "Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater. ", "original_text": "Kevin Caliendo:  Great, thanks.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f4efe1d-0606-4825-9b6b-797a582bd12a", "node_type": "1", "metadata": {"window": "And so that will be another thing that we evaluate along the year.  \n Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks. ", "original_text": "Please go ahead.   \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d065f0a76c09f40b1266637720f7a52f3a83c3f48c07d7499b8d5ff2f485269", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8297610e-e4c0-4e85-835e-f3fc85b57af2", "node_type": "1", "metadata": {"window": "Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely. ", "original_text": "I just want to expand on that a little bit.  "}, "hash": "552ddb8ff0f5c20ce01fb017c7923cf428cecad62fdf043356661190ffae9b85", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo:  Great, thanks.  ", "start_char_idx": 2524, "end_char_idx": 2557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8297610e-e4c0-4e85-835e-f3fc85b57af2": {"__data__": {"id_": "8297610e-e4c0-4e85-835e-f3fc85b57af2", "embedding": null, "metadata": {"window": "Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely. ", "original_text": "I just want to expand on that a little bit.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a826f569-150b-43da-9ebb-225ed427d968", "node_type": "1", "metadata": {"window": "Thanks for the question.   \n Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater. ", "original_text": "Kevin Caliendo:  Great, thanks.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e718d775fb6266cdeb9f6efb7cb689ce9e69d5a82ca017190a97a691cc07819", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e517072-cc90-4c90-99c6-29a5c2fa5536", "node_type": "1", "metadata": {"window": "Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more. ", "original_text": "I guess I don't understand \nwhy you're not being more aggressive with the buybacks. "}, "hash": "ae3a6951500b1d326a880d305ce8cdc432fdf4a547bbab653f0968bf4cf969a0", "class_name": "RelatedNodeInfo"}}, "text": "I just want to expand on that a little bit.  ", "start_char_idx": 2557, "end_char_idx": 2602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e517072-cc90-4c90-99c6-29a5c2fa5536": {"__data__": {"id_": "7e517072-cc90-4c90-99c6-29a5c2fa5536", "embedding": null, "metadata": {"window": "Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more. ", "original_text": "I guess I don't understand \nwhy you're not being more aggressive with the buybacks. ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8297610e-e4c0-4e85-835e-f3fc85b57af2", "node_type": "1", "metadata": {"window": "Operator:  Up next, we'll hear from Kevin Caliendo with UBS.   Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely. ", "original_text": "I just want to expand on that a little bit.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37b7bf6a7948a65317fc4ab382b52c76d50f00f0d0d28526f41c7bc90d7d923d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ce28520-cc3e-45a0-913d-257a419901f6", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about? ", "original_text": "Given the sett lement looks like its largely \ndone, the cash on hand is greater. "}, "hash": "34d014b4e7ac7b860c2900e8238ca0de20cb954eff97e6173f114c37fc7b01f8", "class_name": "RelatedNodeInfo"}}, "text": "I guess I don't understand \nwhy you're not being more aggressive with the buybacks. ", "start_char_idx": 2602, "end_char_idx": 2686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ce28520-cc3e-45a0-913d-257a419901f6": {"__data__": {"id_": "1ce28520-cc3e-45a0-913d-257a419901f6", "embedding": null, "metadata": {"window": "Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about? ", "original_text": "Given the sett lement looks like its largely \ndone, the cash on hand is greater. ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e517072-cc90-4c90-99c6-29a5c2fa5536", "node_type": "1", "metadata": {"window": "Please go ahead.   \n Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more. ", "original_text": "I guess I don't understand \nwhy you're not being more aggressive with the buybacks. ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1aa8223d8c6dae747d8f7642fca0ccc69e52daa8b45fd42086209c9c6f696b92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ddf8e44-617b-45b5-953d-4796a85ebc85", "node_type": "1", "metadata": {"window": "I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.  ", "original_text": "The stock is going to come under pretty meaningful pressure \ntoday, most likely. "}, "hash": "659e480016e4b88a2825b307fdfa4167debe7d8403296f5fd6ce685c37fbe039", "class_name": "RelatedNodeInfo"}}, "text": "Given the sett lement looks like its largely \ndone, the cash on hand is greater. ", "start_char_idx": 2686, "end_char_idx": 2767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ddf8e44-617b-45b5-953d-4796a85ebc85": {"__data__": {"id_": "7ddf8e44-617b-45b5-953d-4796a85ebc85", "embedding": null, "metadata": {"window": "I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.  ", "original_text": "The stock is going to come under pretty meaningful pressure \ntoday, most likely. ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ce28520-cc3e-45a0-913d-257a419901f6", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  Great, thanks.   I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about? ", "original_text": "Given the sett lement looks like its largely \ndone, the cash on hand is greater. ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11da583dbdb2ee7b42fac3b46de35af2ba8d0e9fd142003726ea06e7a053c549", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b64125c0-1c76-421a-8152-a28a21a09a0c", "node_type": "1", "metadata": {"window": "I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?  ", "original_text": "What\u2019s stopping you from going out and buying $2 billion of stock or more. "}, "hash": "ab99d60d144bdf618cb311edb152763983bf6db4ca5c433da01ebe2719caf549", "class_name": "RelatedNodeInfo"}}, "text": "The stock is going to come under pretty meaningful pressure \ntoday, most likely. ", "start_char_idx": 2767, "end_char_idx": 2848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b64125c0-1c76-421a-8152-a28a21a09a0c": {"__data__": {"id_": "b64125c0-1c76-421a-8152-a28a21a09a0c", "embedding": null, "metadata": {"window": "I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?  ", "original_text": "What\u2019s stopping you from going out and buying $2 billion of stock or more. ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ddf8e44-617b-45b5-953d-4796a85ebc85", "node_type": "1", "metadata": {"window": "I just want to expand on that a little bit.   I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.  ", "original_text": "The stock is going to come under pretty meaningful pressure \ntoday, most likely. ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c551de1d35422520a3a7e4597ff539b365bd25c75ed2103f65e95c40e31429af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf5d61d2-cf60-493a-87c0-76720783f425", "node_type": "1", "metadata": {"window": "Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n", "original_text": "Are \nthere any credit issues or anyth ing else that you\u2019re concerned about? "}, "hash": "903aad5f49ab1b9a076e8155655ea82ee376c5f272dda49a5fd5ee60effa5f22", "class_name": "RelatedNodeInfo"}}, "text": "What\u2019s stopping you from going out and buying $2 billion of stock or more. ", "start_char_idx": 2848, "end_char_idx": 2923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf5d61d2-cf60-493a-87c0-76720783f425": {"__data__": {"id_": "cf5d61d2-cf60-493a-87c0-76720783f425", "embedding": null, "metadata": {"window": "Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n", "original_text": "Are \nthere any credit issues or anyth ing else that you\u2019re concerned about? ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b64125c0-1c76-421a-8152-a28a21a09a0c", "node_type": "1", "metadata": {"window": "I guess I don't understand \nwhy you're not being more aggressive with the buybacks.  Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?  ", "original_text": "What\u2019s stopping you from going out and buying $2 billion of stock or more. ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "622015d4be7bb6daee4884e7a84f2d8b0ebb1b83b2c4211b4e58e502d50d693f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4679fb83-2086-42a6-af48-1bd151773ab0", "node_type": "1", "metadata": {"window": "The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.  ", "original_text": "And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.  "}, "hash": "c8a3907f90a32677169c46badc2e09f579cfd4da8572ad77a8ad2a707486bd27", "class_name": "RelatedNodeInfo"}}, "text": "Are \nthere any credit issues or anyth ing else that you\u2019re concerned about? ", "start_char_idx": 2923, "end_char_idx": 2999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4679fb83-2086-42a6-af48-1bd151773ab0": {"__data__": {"id_": "4679fb83-2086-42a6-af48-1bd151773ab0", "embedding": null, "metadata": {"window": "The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.  ", "original_text": "And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf5d61d2-cf60-493a-87c0-76720783f425", "node_type": "1", "metadata": {"window": "Given the sett lement looks like its largely \ndone, the cash on hand is greater.  The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n", "original_text": "Are \nthere any credit issues or anyth ing else that you\u2019re concerned about? ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70aed17cc5e23a57f4cc520b33b0d515eb34fd68d44f0fe7bd8f7a0c40d13498", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cde3aca3-3a36-45bd-838a-0cda40251d70", "node_type": "1", "metadata": {"window": "What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.  ", "original_text": "Is \nthere -- is it just simply the timing that it would happen so late in the year ?  "}, "hash": "a1b74ea5eb194fc695fa53eb38d4fb91ab16ed6eb2e4d9cbccd22008583dfed9", "class_name": "RelatedNodeInfo"}}, "text": "And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.  ", "start_char_idx": 2999, "end_char_idx": 3137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cde3aca3-3a36-45bd-838a-0cda40251d70": {"__data__": {"id_": "cde3aca3-3a36-45bd-838a-0cda40251d70", "embedding": null, "metadata": {"window": "What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.  ", "original_text": "Is \nthere -- is it just simply the timing that it would happen so late in the year ?  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4679fb83-2086-42a6-af48-1bd151773ab0", "node_type": "1", "metadata": {"window": "The stock is going to come under pretty meaningful pressure \ntoday, most likely.  What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.  ", "original_text": "And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d133d6b19129c2642f3e24e726a31ebcd96dc7afc50e4a25d8a05b99dfd0ce7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6d04839-42f1-4757-8255-903a85c32a4c", "node_type": "1", "metadata": {"window": "Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.  ", "original_text": "Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n"}, "hash": "e645ede76b887189bda4357528fdf18121c10c35e7039b82e5ded69d475a61aa", "class_name": "RelatedNodeInfo"}}, "text": "Is \nthere -- is it just simply the timing that it would happen so late in the year ?  ", "start_char_idx": 3137, "end_char_idx": 3223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6d04839-42f1-4757-8255-903a85c32a4c": {"__data__": {"id_": "b6d04839-42f1-4757-8255-903a85c32a4c", "embedding": null, "metadata": {"window": "Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.  ", "original_text": "Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cde3aca3-3a36-45bd-838a-0cda40251d70", "node_type": "1", "metadata": {"window": "What\u2019s stopping you from going out and buying $2 billion of stock or more.  Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.  ", "original_text": "Is \nthere -- is it just simply the timing that it would happen so late in the year ?  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6b3bb3fc59b3e33f96fba3f27dd2041d36b382b5b411e6e266fcdaad792e5d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97ad77e0-56cc-45ba-a0de-80590e56ead7", "node_type": "1", "metadata": {"window": "And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "ad0a735e0e30606f4ed91489bd61901f48ceb89fc7e4eb42863f9039d07c6a0e", "class_name": "RelatedNodeInfo"}}, "text": "Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n", "start_char_idx": 3223, "end_char_idx": 3313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97ad77e0-56cc-45ba-a0de-80590e56ead7": {"__data__": {"id_": "97ad77e0-56cc-45ba-a0de-80590e56ead7", "embedding": null, "metadata": {"window": "And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6d04839-42f1-4757-8255-903a85c32a4c", "node_type": "1", "metadata": {"window": "Are \nthere any credit issues or anyth ing else that you\u2019re concerned about?  And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.  ", "original_text": "Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9602322c4ddc0f52f90a414b9fc3ec7848d9437b192b9b1c58472b30b272fbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "206e3f0f-8f19-4cfc-9541-f8ce5b73bd2b", "node_type": "1", "metadata": {"window": "Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.  ", "original_text": "Let me start, Kevin, and then I'll turn it back over to Jason.  "}, "hash": "648cad0430fa711d802874a6eec7b72e7ac4d125caf648acbd644e1786333e61", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 3313, "end_char_idx": 3335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "206e3f0f-8f19-4cfc-9541-f8ce5b73bd2b": {"__data__": {"id_": "206e3f0f-8f19-4cfc-9541-f8ce5b73bd2b", "embedding": null, "metadata": {"window": "Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.  ", "original_text": "Let me start, Kevin, and then I'll turn it back over to Jason.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97ad77e0-56cc-45ba-a0de-80590e56ead7", "node_type": "1", "metadata": {"window": "And also, on the buyback, if I'm \ndoing the math right, it feels like your -- like the numbers don't entirely jive to get to that $0.21.   Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5b536cb6088ca18d8a3e51bf1dc96ddf5cb906cac9319904834ed44986a9528", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edf551b9-8e43-4d00-befb-95c3b66f5db4", "node_type": "1", "metadata": {"window": "Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.   So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "original_text": "I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.  "}, "hash": "3426b819f994415a9e6f8e37db6f772be841f20a5edac213c98682eec83db530", "class_name": "RelatedNodeInfo"}}, "text": "Let me start, Kevin, and then I'll turn it back over to Jason.  ", "start_char_idx": 3335, "end_char_idx": 3399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edf551b9-8e43-4d00-befb-95c3b66f5db4": {"__data__": {"id_": "edf551b9-8e43-4d00-befb-95c3b66f5db4", "embedding": null, "metadata": {"window": "Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.   So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "original_text": "I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "206e3f0f-8f19-4cfc-9541-f8ce5b73bd2b", "node_type": "1", "metadata": {"window": "Is \nthere -- is it just simply the timing that it would happen so late in the year ?   Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.  ", "original_text": "Let me start, Kevin, and then I'll turn it back over to Jason.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64e15bffa502d80ea194d5e124869453e0f0bf89929295b63bea7edc0ef346f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7e52848-e9ec-4a85-bc8a-9226e32ca242", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.   So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "original_text": "The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.  "}, "hash": "c0f63f6d42a87654103fd8607fb5292b5493b74eeb8ffc0c9ce0b5b90e4df28b", "class_name": "RelatedNodeInfo"}}, "text": "I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.  ", "start_char_idx": 3399, "end_char_idx": 3511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7e52848-e9ec-4a85-bc8a-9226e32ca242": {"__data__": {"id_": "a7e52848-e9ec-4a85-bc8a-9226e32ca242", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.   So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "original_text": "The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edf551b9-8e43-4d00-befb-95c3b66f5db4", "node_type": "1", "metadata": {"window": "Is why the buyback s \nwould n\u2019t be cover ing the sort of $0.21 of dilution from Cordis?  \n Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.   So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "original_text": "I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c70fb157f665a5e7c967513c8d9a92707a8b9e7da87f57ac09e523cf1958709", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "769d7c32-314c-497d-8a4c-36d6f334372f", "node_type": "1", "metadata": {"window": "Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.   So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "original_text": "But it does have a few more steps left in it.  "}, "hash": "e42178ae136afdb231f48001dc85c35bb03bb6f92369a5f3e652c766b039d486", "class_name": "RelatedNodeInfo"}}, "text": "The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.  ", "start_char_idx": 3511, "end_char_idx": 3648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "769d7c32-314c-497d-8a4c-36d6f334372f": {"__data__": {"id_": "769d7c32-314c-497d-8a4c-36d6f334372f", "embedding": null, "metadata": {"window": "Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.   So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "original_text": "But it does have a few more steps left in it.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7e52848-e9ec-4a85-bc8a-9226e32ca242", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.   So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "original_text": "The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8414b63938a3e59af36f3d8a40f1aeec0bd72be8b6322ae8309797b1b5fe1851", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89c91f11-8c13-4b74-ba8a-7adbb7345883", "node_type": "1", "metadata": {"window": "I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.   So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "original_text": "So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in "}, "hash": "0c9a36de8c8b547bce788b2827be022bcfe60ee71493f0992576adfae34f3728", "class_name": "RelatedNodeInfo"}}, "text": "But it does have a few more steps left in it.  ", "start_char_idx": 3648, "end_char_idx": 3695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89c91f11-8c13-4b74-ba8a-7adbb7345883": {"__data__": {"id_": "89c91f11-8c13-4b74-ba8a-7adbb7345883", "embedding": null, "metadata": {"window": "I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.   So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "original_text": "So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edc7c708-05c8-4f38-8771-da87d6779c94", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8433762ae50be335850595ead5c2d8affde5de02927870a887d42881826662a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "769d7c32-314c-497d-8a4c-36d6f334372f", "node_type": "1", "metadata": {"window": "Let me start, Kevin, and then I'll turn it back over to Jason.   I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.   So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "original_text": "But it does have a few more steps left in it.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a070d4a1efa36541d14b2d5a5d9671ff2f913fb91f484490c262a26152f63bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b93994cd-96e9-44e3-82f0-2154b5551630", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n", "original_text": " \nPage 9 of 15 \n \norder to make a final decision.  "}, "hash": "89bf6d3b00f9257a0b1b544fc295ba43bfd65e21af47bf5802b746bd5fdadead", "class_name": "RelatedNodeInfo"}}, "text": "So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "start_char_idx": 3695, "end_char_idx": 3813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b93994cd-96e9-44e3-82f0-2154b5551630": {"__data__": {"id_": "b93994cd-96e9-44e3-82f0-2154b5551630", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n", "original_text": " \nPage 9 of 15 \n \norder to make a final decision.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89c91f11-8c13-4b74-ba8a-7adbb7345883", "node_type": "1", "metadata": {"window": "I'll just comment \nspecifically on the opioid piece and then let Jason give you a little bit more information.   The opioid, \nas we said, we're pleased to get to the point where we are right now, where we have a \ncomprehensive settlement out there.   But it does have a few more steps left in it.   So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "original_text": "So we do have to \nwait and see if we get the states and cities and counties to sign on to get enough critical mass in ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfaff6ea2e446af44f32fb07367c300adef0e2699acd91bd5aa710e388913361", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f12750c-6c5f-4511-88d3-0a87e3dcf924", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.  ", "original_text": "And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.  "}, "hash": "ada8066ac00a5f32cf532fa01f850aec1f4d658930451945bd1ffffe1e2ec931", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 15 \n \norder to make a final decision.  ", "start_char_idx": 0, "end_char_idx": 51, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f12750c-6c5f-4511-88d3-0a87e3dcf924": {"__data__": {"id_": "0f12750c-6c5f-4511-88d3-0a87e3dcf924", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.  ", "original_text": "And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b93994cd-96e9-44e3-82f0-2154b5551630", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n", "original_text": " \nPage 9 of 15 \n \norder to make a final decision.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cae789deb24b0a479425978ac0f6c9291e88761c8fd7066b99ee369bdf63195", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc1be5f7-7d91-43fb-91c7-b0523e2b83a1", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.  ", "original_text": "But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n"}, "hash": "4702534221003c97594f4b85d50a73c41fcbb479fdb97d04defad0860cb14546", "class_name": "RelatedNodeInfo"}}, "text": "And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.  ", "start_char_idx": 51, "end_char_idx": 173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc1be5f7-7d91-43fb-91c7-b0523e2b83a1": {"__data__": {"id_": "cc1be5f7-7d91-43fb-91c7-b0523e2b83a1", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.  ", "original_text": "But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f12750c-6c5f-4511-88d3-0a87e3dcf924", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.  ", "original_text": "And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d88909bfda2edf12d70d7130ddfcac02f5475c8640603332790cc89722e8903a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22405e1b-4d33-4b2d-920d-e85df60ec7c6", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.  ", "original_text": "And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n"}, "hash": "8467a45f99a0c8f60c12e351c863514b632deb8d5ba12ab1d7e72b7b4dc27aa5", "class_name": "RelatedNodeInfo"}}, "text": "But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n", "start_char_idx": 173, "end_char_idx": 301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22405e1b-4d33-4b2d-920d-e85df60ec7c6": {"__data__": {"id_": "22405e1b-4d33-4b2d-920d-e85df60ec7c6", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.  ", "original_text": "And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc1be5f7-7d91-43fb-91c7-b0523e2b83a1", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.  ", "original_text": "But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f213bff3da2ea953468332a02c26728da06ad29e83328e1c36ef2d955a1d896d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e50f05e-9e57-4e5c-b654-0c54add01804", "node_type": "1", "metadata": {"window": "And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.  ", "original_text": "Jason Hollar:  Yes.  "}, "hash": "52b3da7dcd656086a0d5695732f0f0a5f400163d62643cbd3f3566be4b7cde36", "class_name": "RelatedNodeInfo"}}, "text": "And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n", "start_char_idx": 301, "end_char_idx": 418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e50f05e-9e57-4e5c-b654-0c54add01804": {"__data__": {"id_": "8e50f05e-9e57-4e5c-b654-0c54add01804", "embedding": null, "metadata": {"window": "And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22405e1b-4d33-4b2d-920d-e85df60ec7c6", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.  ", "original_text": "And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adf159c114a1945f3989ed020a507a10b53f0bf1769e7ef5367352143bfec6ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d908a2b-6780-4827-a37f-106ef5f86f82", "node_type": "1", "metadata": {"window": "But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n", "original_text": "And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.  "}, "hash": "66e49d0bcec39e8cce811d00ca2bf9ea2d07ff185bc09223d8d1aaab9f46c7de", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes.  ", "start_char_idx": 418, "end_char_idx": 439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d908a2b-6780-4827-a37f-106ef5f86f82": {"__data__": {"id_": "3d908a2b-6780-4827-a37f-106ef5f86f82", "embedding": null, "metadata": {"window": "But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n", "original_text": "And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e50f05e-9e57-4e5c-b654-0c54add01804", "node_type": "1", "metadata": {"window": "And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20ff8e69e9cb7a8d954ced13aa9d1627ccae4f14ef94c396258737bd665c5dc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "284f5dc5-893c-40b1-b028-5fafeec44e95", "node_type": "1", "metadata": {"window": "And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.  ", "original_text": "And so there's an opportunity for that to have a reasonable \nrange.  "}, "hash": "3432889c8cd82de7dff5bddb4ca76037f6ca220f1e5c1fc767460186f32b5619", "class_name": "RelatedNodeInfo"}}, "text": "And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.  ", "start_char_idx": 439, "end_char_idx": 660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "284f5dc5-893c-40b1-b028-5fafeec44e95": {"__data__": {"id_": "284f5dc5-893c-40b1-b028-5fafeec44e95", "embedding": null, "metadata": {"window": "And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.  ", "original_text": "And so there's an opportunity for that to have a reasonable \nrange.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d908a2b-6780-4827-a37f-106ef5f86f82", "node_type": "1", "metadata": {"window": "But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n", "original_text": "And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b34d91e64fb2d8dda299a2343e5def3dd852dbabdfc21c6ca8c76479ddb6345", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38226411-e441-43d0-aff3-5642249add52", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.  ", "original_text": "And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.  "}, "hash": "63399e9df4a103850c078a9ac76650159f7acdf3070bb1b12a90f4935bb2fb48", "class_name": "RelatedNodeInfo"}}, "text": "And so there's an opportunity for that to have a reasonable \nrange.  ", "start_char_idx": 660, "end_char_idx": 729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38226411-e441-43d0-aff3-5642249add52": {"__data__": {"id_": "38226411-e441-43d0-aff3-5642249add52", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.  ", "original_text": "And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "284f5dc5-893c-40b1-b028-5fafeec44e95", "node_type": "1", "metadata": {"window": "And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.  ", "original_text": "And so there's an opportunity for that to have a reasonable \nrange.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abeec30de94d0d7d824fcf2b3a4795e33b46f012b2e89eac8bd30387768661e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a096722-c9e0-4084-8a59-18105d26414d", "node_type": "1", "metadata": {"window": "And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.  ", "original_text": "And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n"}, "hash": "506a9cb1887b6684c4959f31b28ec348c992a86b1253618c6f14274ac51caab3", "class_name": "RelatedNodeInfo"}}, "text": "And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.  ", "start_char_idx": 729, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a096722-c9e0-4084-8a59-18105d26414d": {"__data__": {"id_": "1a096722-c9e0-4084-8a59-18105d26414d", "embedding": null, "metadata": {"window": "And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.  ", "original_text": "And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38226411-e441-43d0-aff3-5642249add52", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.  ", "original_text": "And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b83bccd87e7c3a6a6185fbe5e7c7c4c3baace69dc6956712db06982decddf51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff961dbf-f124-4626-ab61-719adcaceac4", "node_type": "1", "metadata": {"window": "And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.  ", "original_text": "As it relates to y our other question, as it relates to credit issues.  "}, "hash": "f732862e319ae0d968f99c97a895e79db4cf983e685e4e734af4a608a1c78796", "class_name": "RelatedNodeInfo"}}, "text": "And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n", "start_char_idx": 914, "end_char_idx": 1038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff961dbf-f124-4626-ab61-719adcaceac4": {"__data__": {"id_": "ff961dbf-f124-4626-ab61-719adcaceac4", "embedding": null, "metadata": {"window": "And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.  ", "original_text": "As it relates to y our other question, as it relates to credit issues.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a096722-c9e0-4084-8a59-18105d26414d", "node_type": "1", "metadata": {"window": "And as it relates to the dilution on Cordis  that was implied , a reference within \nthere, it's just a matter of the timing of what you assume when we pay down the debt and when we \nwould complete the share repurchases.   And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.  ", "original_text": "And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33a13b2f9aaea5a54b7a92491a7eacb0c23e8ca37282d09b7c5adbf04b0266cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa2a8f47-2a7a-444b-b663-664d053fd016", "node_type": "1", "metadata": {"window": "And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.  ", "original_text": "There's nothing there.  "}, "hash": "15a9008f28d462312176a33851220735358f434b0aee75d8dd752fdbcab6d5b4", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to y our other question, as it relates to credit issues.  ", "start_char_idx": 1038, "end_char_idx": 1110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa2a8f47-2a7a-444b-b663-664d053fd016": {"__data__": {"id_": "aa2a8f47-2a7a-444b-b663-664d053fd016", "embedding": null, "metadata": {"window": "And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.  ", "original_text": "There's nothing there.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff961dbf-f124-4626-ab61-719adcaceac4", "node_type": "1", "metadata": {"window": "And so there's an opportunity for that to have a reasonable \nrange.   And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.  ", "original_text": "As it relates to y our other question, as it relates to credit issues.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbc9c09639b485cf722d67c3d9c3f18c280a81ff7c4c7ea5df9a5f4366bd6e38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9160c7fc-97f6-4371-87ea-fd33c348dda8", "node_type": "1", "metadata": {"window": "And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.  ", "original_text": "I mean we're \non a gliding path to getting to our targeted leverage ratio.  "}, "hash": "c8106bea2670ca284179394fdbfb616de4fb03688d57498de100c13e9be2781f", "class_name": "RelatedNodeInfo"}}, "text": "There's nothing there.  ", "start_char_idx": 1110, "end_char_idx": 1134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9160c7fc-97f6-4371-87ea-fd33c348dda8": {"__data__": {"id_": "9160c7fc-97f6-4371-87ea-fd33c348dda8", "embedding": null, "metadata": {"window": "And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.  ", "original_text": "I mean we're \non a gliding path to getting to our targeted leverage ratio.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa2a8f47-2a7a-444b-b663-664d053fd016", "node_type": "1", "metadata": {"window": "And that guidance range, we think, reflects what we think that possibility may be  -- but the key \nthing on a pro forma basis is that extra $1 billion will be deployed in some manner.   And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.  ", "original_text": "There's nothing there.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92b945b08a7f7999d2be0a11a7de745887b224b93267826e9da454ef33730a2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a2bd59d-7763-4f28-8932-36de6ae53083", "node_type": "1", "metadata": {"window": "As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n", "original_text": "A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.  "}, "hash": "2971191efbcf1b31c699300dd61b6eb02308c7470b490d21a9a5ce3a8a966f53", "class_name": "RelatedNodeInfo"}}, "text": "I mean we're \non a gliding path to getting to our targeted leverage ratio.  ", "start_char_idx": 1134, "end_char_idx": 1210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a2bd59d-7763-4f28-8932-36de6ae53083": {"__data__": {"id_": "4a2bd59d-7763-4f28-8932-36de6ae53083", "embedding": null, "metadata": {"window": "As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n", "original_text": "A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9160c7fc-97f6-4371-87ea-fd33c348dda8", "node_type": "1", "metadata": {"window": "And we will see -- \nand certainly, within  fiscal '23 run rate, there will not be dilution expected for that divestiture.  \n As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.  ", "original_text": "I mean we're \non a gliding path to getting to our targeted leverage ratio.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b440d26a02ebfb10b50f64906f2df13e95b65a0f7f3b56ee5a85b4e502867481", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e658415-3ef2-444e-9b42-4267e2176ae3", "node_type": "1", "metadata": {"window": "There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n", "original_text": "And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.  "}, "hash": "b5d27c819698e63d9af4995cbf2c710af030d4053100f56b09cc0a1150212146", "class_name": "RelatedNodeInfo"}}, "text": "A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.  ", "start_char_idx": 1210, "end_char_idx": 1383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e658415-3ef2-444e-9b42-4267e2176ae3": {"__data__": {"id_": "5e658415-3ef2-444e-9b42-4267e2176ae3", "embedding": null, "metadata": {"window": "There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n", "original_text": "And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a2bd59d-7763-4f28-8932-36de6ae53083", "node_type": "1", "metadata": {"window": "As it relates to y our other question, as it relates to credit issues.   There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n", "original_text": "A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d38e14ac3b89c4fd5f73399949397629a26e7215f8c2bed647fa3ac3dadb3d9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73f37080-b75a-4213-948f-e7a31abafd7a", "node_type": "1", "metadata": {"window": "I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.  ", "original_text": "That continues to be our expectation.  "}, "hash": "a4685281f0ae58fffca64e9d4ae0644db3db98fd41b0d7afcca273ecfb1aece0", "class_name": "RelatedNodeInfo"}}, "text": "And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.  ", "start_char_idx": 1383, "end_char_idx": 1510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73f37080-b75a-4213-948f-e7a31abafd7a": {"__data__": {"id_": "73f37080-b75a-4213-948f-e7a31abafd7a", "embedding": null, "metadata": {"window": "I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.  ", "original_text": "That continues to be our expectation.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e658415-3ef2-444e-9b42-4267e2176ae3", "node_type": "1", "metadata": {"window": "There's nothing there.   I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n", "original_text": "And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82b35e6d4e8eea0ab744e0cb547684cd1a07e3b03d3ddc08b2390d4e6a195316", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "233a737a-efc8-452c-9254-6ec1d856f801", "node_type": "1", "metadata": {"window": "A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n", "original_text": "There's a lot of factors, \nas Mike just referenced, that could play into that.   \n"}, "hash": "7c0f19d32fac686c5e6469f6ce7d9ac6dace318a27dae641c47a9ec78d2cc8ef", "class_name": "RelatedNodeInfo"}}, "text": "That continues to be our expectation.  ", "start_char_idx": 1510, "end_char_idx": 1549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "233a737a-efc8-452c-9254-6ec1d856f801": {"__data__": {"id_": "233a737a-efc8-452c-9254-6ec1d856f801", "embedding": null, "metadata": {"window": "A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n", "original_text": "There's a lot of factors, \nas Mike just referenced, that could play into that.   \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73f37080-b75a-4213-948f-e7a31abafd7a", "node_type": "1", "metadata": {"window": "I mean we're \non a gliding path to getting to our targeted leverage ratio.   A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.  ", "original_text": "That continues to be our expectation.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edc3fc69d448873c21169d9ece40b52a91ec01d005779c9f3a0a9dbb992c6330", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c70bac99-676e-45e1-ab75-18001952b176", "node_type": "1", "metadata": {"window": "And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.  ", "original_text": "But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n"}, "hash": "0efcba7e04039203060bab74d3941e7cbe5815c5f2821527c9c2ac4403e2c049", "class_name": "RelatedNodeInfo"}}, "text": "There's a lot of factors, \nas Mike just referenced, that could play into that.   \n", "start_char_idx": 1549, "end_char_idx": 1631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c70bac99-676e-45e1-ab75-18001952b176": {"__data__": {"id_": "c70bac99-676e-45e1-ab75-18001952b176", "embedding": null, "metadata": {"window": "And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.  ", "original_text": "But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "233a737a-efc8-452c-9254-6ec1d856f801", "node_type": "1", "metadata": {"window": "A key part that I referenced last quarter is \nthat this remaining debt that's coming due at the end of this fiscal year is a key part of getting us \ntowards those targets.   And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n", "original_text": "There's a lot of factors, \nas Mike just referenced, that could play into that.   \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3314935ddf6c8d4052a0993604ccbd46034cd1c6ae3f77340159a43ca82d0b0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bca89952-052d-4224-a694-29ae72ee7922", "node_type": "1", "metadata": {"window": "That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n", "original_text": "And we also need to see underlying performance and cash flow over the course of the year.  "}, "hash": "c4130468338abf9036a2a7dfd9d714d59d14f5d7407d9cf51e68e52790a2385b", "class_name": "RelatedNodeInfo"}}, "text": "But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n", "start_char_idx": 1631, "end_char_idx": 1847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bca89952-052d-4224-a694-29ae72ee7922": {"__data__": {"id_": "bca89952-052d-4224-a694-29ae72ee7922", "embedding": null, "metadata": {"window": "That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n", "original_text": "And we also need to see underlying performance and cash flow over the course of the year.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c70bac99-676e-45e1-ab75-18001952b176", "node_type": "1", "metadata": {"window": "And I indicated last quarter that I would anticipate the level of debt paydow n to \nbegin to diminish after this fiscal year.   That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.  ", "original_text": "But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a7f1516c816a55dc33b1829847f208821cc7f60aa7e87921246514bc6ee5032", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ac9cfc2-4286-4986-8bd3-f2833160b29f", "node_type": "1", "metadata": {"window": "There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.  ", "original_text": "And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n"}, "hash": "0decbd7cdbb5893bbc24089608821b7b644fd0b89d5a399e1d9306636cf86727", "class_name": "RelatedNodeInfo"}}, "text": "And we also need to see underlying performance and cash flow over the course of the year.  ", "start_char_idx": 1847, "end_char_idx": 1938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ac9cfc2-4286-4986-8bd3-f2833160b29f": {"__data__": {"id_": "0ac9cfc2-4286-4986-8bd3-f2833160b29f", "embedding": null, "metadata": {"window": "There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.  ", "original_text": "And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bca89952-052d-4224-a694-29ae72ee7922", "node_type": "1", "metadata": {"window": "That continues to be our expectation.   There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n", "original_text": "And we also need to see underlying performance and cash flow over the course of the year.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbe732eac8e129ffbe36a22677a98fcb568df748a692d6c20ff7217d65ca6c51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "598733c1-304d-4325-9333-70dccc418ee0", "node_type": "1", "metadata": {"window": "But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.  ", "original_text": "Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.  "}, "hash": "62b68c73344c40738634ad812a98d76d045104205450fe4c0e0edd6676eae59c", "class_name": "RelatedNodeInfo"}}, "text": "And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n", "start_char_idx": 1938, "end_char_idx": 2073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "598733c1-304d-4325-9333-70dccc418ee0": {"__data__": {"id_": "598733c1-304d-4325-9333-70dccc418ee0", "embedding": null, "metadata": {"window": "But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.  ", "original_text": "Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ac9cfc2-4286-4986-8bd3-f2833160b29f", "node_type": "1", "metadata": {"window": "There's a lot of factors, \nas Mike just referenced, that could play into that.   \n But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.  ", "original_text": "And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b806cbe3eb3200efce117f9f9f46158e49f802b566f9b546448a841f4dcdf42a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13086624-1ee4-4e4a-9f47-bf37d2f28eac", "node_type": "1", "metadata": {"window": "And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n", "original_text": "Please go \nahead.   \n"}, "hash": "9cda042b162768bb6a22306de41eba9b018355d7cffef28dddd122a215a23513", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.  ", "start_char_idx": 2073, "end_char_idx": 2163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13086624-1ee4-4e4a-9f47-bf37d2f28eac": {"__data__": {"id_": "13086624-1ee4-4e4a-9f47-bf37d2f28eac", "embedding": null, "metadata": {"window": "And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n", "original_text": "Please go \nahead.   \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "598733c1-304d-4325-9333-70dccc418ee0", "node_type": "1", "metadata": {"window": "But overall, that remains our viewpoint, and there's nothing here that is, I'll say, over ly constructive \nfrom that point, just a little bit of prudence until we get some of these risks and uncertainties defined.  \n And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.  ", "original_text": "Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1a85dc5625b312ab0727bcc1360a6d52ad8ac23754e752bc68a1be65386eaef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1f82a8a-e438-459e-9c05-bcf08cbc7f3b", "node_type": "1", "metadata": {"window": "And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?  ", "original_text": "Jailendra Singh:  Thank you and good morning, everyone.  "}, "hash": "d55745106bad8b9d37b7a68f5c657c2ec1e3aa7d1e5a580d519ac59a7ad6788a", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.   \n", "start_char_idx": 2163, "end_char_idx": 2184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1f82a8a-e438-459e-9c05-bcf08cbc7f3b": {"__data__": {"id_": "a1f82a8a-e438-459e-9c05-bcf08cbc7f3b", "embedding": null, "metadata": {"window": "And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?  ", "original_text": "Jailendra Singh:  Thank you and good morning, everyone.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13086624-1ee4-4e4a-9f47-bf37d2f28eac", "node_type": "1", "metadata": {"window": "And we also need to see underlying performance and cash flow over the course of the year.   And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n", "original_text": "Please go \nahead.   \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd3798027e43894709565283f3210860bdcaaf226ea13a012e0a6a765f469d27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30def53d-b8a8-45d3-bf12-08d4db8ab0fc", "node_type": "1", "metadata": {"window": "Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n", "original_text": "I  want to go back to your this inventory \nimpact on PPE in the quarter.  "}, "hash": "4ddabfef84f32b6568fa1b8ad877f9aa9cf1675a020301d49b201f4332365946", "class_name": "RelatedNodeInfo"}}, "text": "Jailendra Singh:  Thank you and good morning, everyone.  ", "start_char_idx": 2184, "end_char_idx": 2241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30def53d-b8a8-45d3-bf12-08d4db8ab0fc": {"__data__": {"id_": "30def53d-b8a8-45d3-bf12-08d4db8ab0fc", "embedding": null, "metadata": {"window": "Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n", "original_text": "I  want to go back to your this inventory \nimpact on PPE in the quarter.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1f82a8a-e438-459e-9c05-bcf08cbc7f3b", "node_type": "1", "metadata": {"window": "And \nthen as I mentioned before, we do hav e some additional flexibility as it relates to the precise timing of \nthe tax receivable.  \n Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?  ", "original_text": "Jailendra Singh:  Thank you and good morning, everyone.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a030bc6f277fad3868764b9ec3db942f02eefd608a17a1553abdd1acf86c82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37add67b-50ee-45bf-ac67-63f66a0e6242", "node_type": "1", "metadata": {"window": "Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.  ", "original_text": "Can you elaborate a little bit more on what products this relates to?  \n"}, "hash": "7572cbbed052c7652fb29df62fdfa847926ce30262c5e1aa023f095cdb5db8cd", "class_name": "RelatedNodeInfo"}}, "text": "I  want to go back to your this inventory \nimpact on PPE in the quarter.  ", "start_char_idx": 2241, "end_char_idx": 2315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37add67b-50ee-45bf-ac67-63f66a0e6242": {"__data__": {"id_": "37add67b-50ee-45bf-ac67-63f66a0e6242", "embedding": null, "metadata": {"window": "Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.  ", "original_text": "Can you elaborate a little bit more on what products this relates to?  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30def53d-b8a8-45d3-bf12-08d4db8ab0fc", "node_type": "1", "metadata": {"window": "Operator:  And up next, we will take a question from Jailendra Singh with Credit Suisse.   Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n", "original_text": "I  want to go back to your this inventory \nimpact on PPE in the quarter.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ac985b24d5b34d919dba3e0f391eab6cfb8469a690d52c5e5e8271981dffd3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3cb6b07-49ec-4c8b-883f-5754fe764c08", "node_type": "1", "metadata": {"window": "Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.  ", "original_text": "And is there a potential that you might have another write -down in fiscal '22?  "}, "hash": "3bfda1dc83028fafca5c2b962c5bb847d8b9e089053aab9f8f8f93ee066c9275", "class_name": "RelatedNodeInfo"}}, "text": "Can you elaborate a little bit more on what products this relates to?  \n", "start_char_idx": 2315, "end_char_idx": 2387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3cb6b07-49ec-4c8b-883f-5754fe764c08": {"__data__": {"id_": "b3cb6b07-49ec-4c8b-883f-5754fe764c08", "embedding": null, "metadata": {"window": "Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.  ", "original_text": "And is there a potential that you might have another write -down in fiscal '22?  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37add67b-50ee-45bf-ac67-63f66a0e6242", "node_type": "1", "metadata": {"window": "Please go \nahead.   \n Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.  ", "original_text": "Can you elaborate a little bit more on what products this relates to?  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cea104e7d0528bfbacd16808bbcc04c097fc788fe76afff9fb8bd4a5fdc3f27d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7953ca80-89e3-4db6-89a6-189de3bee157", "node_type": "1", "metadata": {"window": "I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.   So I'll go and start it.  ", "original_text": "And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n"}, "hash": "e49db31829a44b5b1571e152633c2e5f0285cb55247e2d835fddfc5af771ba25", "class_name": "RelatedNodeInfo"}}, "text": "And is there a potential that you might have another write -down in fiscal '22?  ", "start_char_idx": 2387, "end_char_idx": 2468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7953ca80-89e3-4db6-89a6-189de3bee157": {"__data__": {"id_": "7953ca80-89e3-4db6-89a6-189de3bee157", "embedding": null, "metadata": {"window": "I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.   So I'll go and start it.  ", "original_text": "And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3cb6b07-49ec-4c8b-883f-5754fe764c08", "node_type": "1", "metadata": {"window": "Jailendra Singh:  Thank you and good morning, everyone.   I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.  ", "original_text": "And is there a potential that you might have another write -down in fiscal '22?  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fbfa8893aeb73150fce373d016e0a1339859d5c051b31e9b1c9019eae24fafad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b51cdfb1-3896-425e-aec4-2ae5cf78b579", "node_type": "1", "metadata": {"window": "Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.  ", "original_text": "Jason Hollar:  Sure.  "}, "hash": "9fa8e1f9e29ca506aaf26bd9d02f00c6e72fc6d72cf219b92e72852652611a3c", "class_name": "RelatedNodeInfo"}}, "text": "And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n", "start_char_idx": 2468, "end_char_idx": 2568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b51cdfb1-3896-425e-aec4-2ae5cf78b579": {"__data__": {"id_": "b51cdfb1-3896-425e-aec4-2ae5cf78b579", "embedding": null, "metadata": {"window": "Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.  ", "original_text": "Jason Hollar:  Sure.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7953ca80-89e3-4db6-89a6-189de3bee157", "node_type": "1", "metadata": {"window": "I  want to go back to your this inventory \nimpact on PPE in the quarter.   Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.   So I'll go and start it.  ", "original_text": "And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d0dad1d58f436b304d10965ed1860cd651bf4017363b1f997d2f6fb1a8dd121", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2e79148-1465-4dd2-98d6-26059259a942", "node_type": "1", "metadata": {"window": "And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.  ", "original_text": "Yes.  "}, "hash": "e06691097950e422be8052985ffc4fa88a087f300b4991c7d17555c6ddc7ff86", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure.  ", "start_char_idx": 2568, "end_char_idx": 2590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2e79148-1465-4dd2-98d6-26059259a942": {"__data__": {"id_": "d2e79148-1465-4dd2-98d6-26059259a942", "embedding": null, "metadata": {"window": "And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.  ", "original_text": "Yes.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b51cdfb1-3896-425e-aec4-2ae5cf78b579", "node_type": "1", "metadata": {"window": "Can you elaborate a little bit more on what products this relates to?  \n And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.  ", "original_text": "Jason Hollar:  Sure.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac09cbe54cb3814b4e87c193e90817fbdbdbca6bd63cab72eccd826837990b9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53e55096-22a1-4bdb-a9cc-d1675e88de57", "node_type": "1", "metadata": {"window": "And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n", "original_text": "So I'll go and start it.  "}, "hash": "211c0d99561ee2d4ee69c305152c537dd5745d476ec27740292b1594cafaccb5", "class_name": "RelatedNodeInfo"}}, "text": "Yes.  ", "start_char_idx": 433, "end_char_idx": 439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53e55096-22a1-4bdb-a9cc-d1675e88de57": {"__data__": {"id_": "53e55096-22a1-4bdb-a9cc-d1675e88de57", "embedding": null, "metadata": {"window": "And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n", "original_text": "So I'll go and start it.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2e79148-1465-4dd2-98d6-26059259a942", "node_type": "1", "metadata": {"window": "And is there a potential that you might have another write -down in fiscal '22?   And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.  ", "original_text": "Yes.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1498df295b69573204c3fc4346e0c089d84ad303c9825bbf1a2db16aefe8c5b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10ec1ec1-f20c-4e47-a4ce-71aa2cf051b1", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.  ", "original_text": "And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.  "}, "hash": "3e25993641969a21a04863484bd6a87bccb6338bdd2c8955f8e5c9a916d1f21a", "class_name": "RelatedNodeInfo"}}, "text": "So I'll go and start it.  ", "start_char_idx": 2596, "end_char_idx": 2622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10ec1ec1-f20c-4e47-a4ce-71aa2cf051b1": {"__data__": {"id_": "10ec1ec1-f20c-4e47-a4ce-71aa2cf051b1", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure.   Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.  ", "original_text": "And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53e55096-22a1-4bdb-a9cc-d1675e88de57", "node_type": "1", "metadata": {"window": "And what kind of \ninitiatives you'r e putting in place to ensure that this does not happen again?  \n Jason Hollar:  Sure.   Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n", "original_text": "So I'll go and start it.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b1fe6b4b1e5d307b8abd7bb7dea1f8fc19f2e55495889e9523ba8ea0208b376", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2846b64-26e5-433b-85eb-270923dd3487", "node_type": "1", "metadata": {"window": "Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.  ", "original_text": "And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.  "}, "hash": "6587ec69a1de3d00b9bb3ed45e12d2960e99d824cc4794566b23e80c3c5c02e1", "class_name": "RelatedNodeInfo"}}, "text": "And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.  ", "start_char_idx": 2622, "end_char_idx": 2730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2846b64-26e5-433b-85eb-270923dd3487": {"__data__": {"id_": "f2846b64-26e5-433b-85eb-270923dd3487", "embedding": null, "metadata": {"window": "Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.  ", "original_text": "And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10ec1ec1-f20c-4e47-a4ce-71aa2cf051b1", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.  ", "original_text": "And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8362cc042bfd151b32a8153aa318082b56cf7f300c9221960144e20d5669c08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3699a346-226e-43e3-8469-69509b3e38ba", "node_type": "1", "metadata": {"window": "So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.  ", "original_text": "And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n"}, "hash": "342967fe88d90b4daaf09ab441495c1118ace8c43807ecc5cef13e4aec5f60a8", "class_name": "RelatedNodeInfo"}}, "text": "And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.  ", "start_char_idx": 2730, "end_char_idx": 2911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3699a346-226e-43e3-8469-69509b3e38ba": {"__data__": {"id_": "3699a346-226e-43e3-8469-69509b3e38ba", "embedding": null, "metadata": {"window": "So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.  ", "original_text": "And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2846b64-26e5-433b-85eb-270923dd3487", "node_type": "1", "metadata": {"window": "Yes.   So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.  ", "original_text": "And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10aa6f7dc0461d1cbb9e42a60eb6c05a03735280c9a35c8ecefc8d41ab9adfa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4e70211-e38f-4057-bc01-cccdda06551b", "node_type": "1", "metadata": {"window": "And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.  ", "original_text": "And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.  "}, "hash": "8001088b5e62fcd5892181324a2949f84b999ec219f2d01a19a651c14e70b01f", "class_name": "RelatedNodeInfo"}}, "text": "And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n", "start_char_idx": 2911, "end_char_idx": 3048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4e70211-e38f-4057-bc01-cccdda06551b": {"__data__": {"id_": "e4e70211-e38f-4057-bc01-cccdda06551b", "embedding": null, "metadata": {"window": "And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.  ", "original_text": "And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3699a346-226e-43e3-8469-69509b3e38ba", "node_type": "1", "metadata": {"window": "So I'll go and start it.   And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.  ", "original_text": "And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c3e6e45123d4da9c5f415641b0084c6359d8b540959f6a8434118831d9df4a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3d8c489-3c5a-43c4-9cf3-d87da419a298", "node_type": "1", "metadata": {"window": "And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.  ", "original_text": "So as Mike \nhighlighted, there were some highly c ommoditized products.  "}, "hash": "513f13cbc0fbdca49d9c75c6b815ae4d2645f917efd1007dd624721d6dd7689c", "class_name": "RelatedNodeInfo"}}, "text": "And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.  ", "start_char_idx": 3048, "end_char_idx": 3234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3d8c489-3c5a-43c4-9cf3-d87da419a298": {"__data__": {"id_": "f3d8c489-3c5a-43c4-9cf3-d87da419a298", "embedding": null, "metadata": {"window": "And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.  ", "original_text": "So as Mike \nhighlighted, there were some highly c ommoditized products.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4e70211-e38f-4057-bc01-cccdda06551b", "node_type": "1", "metadata": {"window": "And -- so as Mike mentioned, the key thing here is \nthat there's a lot of uncertainties with the pandemic.   And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.  ", "original_text": "And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a0d91abdd0b219c36234643d33e494d5967411b7899958972748ac2dd33262a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0415612-999d-4010-b648-18d4e826abd2", "node_type": "1", "metadata": {"window": "And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.   It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "original_text": "So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.  "}, "hash": "7920dd00c26afcb8873730521b9285c2d0df0d7853155970d5b55cb3ef5eaa53", "class_name": "RelatedNodeInfo"}}, "text": "So as Mike \nhighlighted, there were some highly c ommoditized products.  ", "start_char_idx": 3234, "end_char_idx": 3307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0415612-999d-4010-b648-18d4e826abd2": {"__data__": {"id_": "e0415612-999d-4010-b648-18d4e826abd2", "embedding": null, "metadata": {"window": "And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.   It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "original_text": "So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3d8c489-3c5a-43c4-9cf3-d87da419a298", "node_type": "1", "metadata": {"window": "And we were, first and foremost, going to put our \ncustomer commitments in front of us, and that resulted in a higher level of inventory that we carried \nover that period of time.   And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.  ", "original_text": "So as Mike \nhighlighted, there were some highly c ommoditized products.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9908bedd8deaa2e5279ad16225b88c916cdaae1764e93ce72abe0e354a9785eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6772a21e-7836-43b6-a263-6e72bd55196a", "node_type": "1", "metadata": {"window": "And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.   It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "original_text": "We saw that move more \ndramatically over the period.  "}, "hash": "b42a545c054c046d488ba84e33864fc4b33365e12976e148d8e1f5e66141af66", "class_name": "RelatedNodeInfo"}}, "text": "So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.  ", "start_char_idx": 3307, "end_char_idx": 3422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6772a21e-7836-43b6-a263-6e72bd55196a": {"__data__": {"id_": "6772a21e-7836-43b6-a263-6e72bd55196a", "embedding": null, "metadata": {"window": "And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.   It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "original_text": "We saw that move more \ndramatically over the period.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0415612-999d-4010-b648-18d4e826abd2", "node_type": "1", "metadata": {"window": "And that happened while there was obviously increasing demand, higher \nprices and lower -- longer than normal t ypes of supply chains.  \n And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.   It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "original_text": "So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1464822daf04b1f70bb686bcc7d16c9f1987108eb916b2e23e3afb04244cbb07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "434fb24b-548a-4fe9-a773-0b29f4fbe4b6", "node_type": "1", "metadata": {"window": "So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.   It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "original_text": "And given it was a subset of our inventory, it was relatively defi ned.  "}, "hash": "60ba4d58e723bca8f4fc89e5237a942364ce4999612c2ce3dd86b38ff46859c3", "class_name": "RelatedNodeInfo"}}, "text": "We saw that move more \ndramatically over the period.  ", "start_char_idx": 3422, "end_char_idx": 3476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "434fb24b-548a-4fe9-a773-0b29f4fbe4b6": {"__data__": {"id_": "434fb24b-548a-4fe9-a773-0b29f4fbe4b6", "embedding": null, "metadata": {"window": "So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.   It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "original_text": "And given it was a subset of our inventory, it was relatively defi ned.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6772a21e-7836-43b6-a263-6e72bd55196a", "node_type": "1", "metadata": {"window": "And then we step back -- every quarter, we would step back and do our analysis and determine what \nthe net realizable value that is and then make any adjustments that may be necessary.   So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.   It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "original_text": "We saw that move more \ndramatically over the period.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34a12590d2ce348b83e7e1c2662a29520ed6cd4827c8a20a05815bae30c8e5ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b586dbc-8445-4adc-8157-533baba095c3", "node_type": "1", "metadata": {"window": "So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.   It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "original_text": "It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  "}, "hash": "74e88353c1351e7b17101e29c0ce1acc8e15f87a75b1779cea57be3f0d358b18", "class_name": "RelatedNodeInfo"}}, "text": "And given it was a subset of our inventory, it was relatively defi ned.  ", "start_char_idx": 3476, "end_char_idx": 3549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b586dbc-8445-4adc-8157-533baba095c3": {"__data__": {"id_": "9b586dbc-8445-4adc-8157-533baba095c3", "embedding": null, "metadata": {"window": "So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.   It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "original_text": "It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67be94d141f4cbdf187f4d99f642ab958f63beb440b258f54fd65cac43af0a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "434fb24b-548a-4fe9-a773-0b29f4fbe4b6", "node_type": "1", "metadata": {"window": "So as Mike \nhighlighted, there were some highly c ommoditized products.   So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.   It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "original_text": "And given it was a subset of our inventory, it was relatively defi ned.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cf5e6abcdd596e9ede36d2d588a639f3cf2bff6c1a35b86b5a4f45e45849dc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2045a540-c06f-4aac-ac48-a2d718557034", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n", "original_text": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.  "}, "hash": "7890973959d4bfb0137086f571592a9cda60b5de210a0038c9cddfc29eb6a38d", "class_name": "RelatedNodeInfo"}}, "text": "It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "start_char_idx": 3549, "end_char_idx": 3653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2045a540-c06f-4aac-ac48-a2d718557034": {"__data__": {"id_": "2045a540-c06f-4aac-ac48-a2d718557034", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n", "original_text": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b586dbc-8445-4adc-8157-533baba095c3", "node_type": "1", "metadata": {"window": "So it's a subset of our PPE that -- think \nof it as those products that would have more volatile type of pricing.   We saw that move more \ndramatically over the period.   And given it was a subset of our inventory, it was relatively defi ned.   It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "original_text": "It \nwas a relatively large percentage reduction within that, but it was contained to a certain subset.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de98ce06b52981bd101fe58ce6d7ac6d3a723d2407717a46263a60e47a965b28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f24f3ba-278e-4ed4-9150-181b97f2bd5b", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.  ", "original_text": "Anything else to add, \nMike?  \n"}, "hash": "c7ed2eacf22f83d0f92bb05189636580846a1887ad59fa2b06ba24b8d6004416", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.  ", "start_char_idx": 0, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f24f3ba-278e-4ed4-9150-181b97f2bd5b": {"__data__": {"id_": "1f24f3ba-278e-4ed4-9150-181b97f2bd5b", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.  ", "original_text": "Anything else to add, \nMike?  \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2045a540-c06f-4aac-ac48-a2d718557034", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n", "original_text": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c32a4144c82a03df10043c3ead48f0a703ac971a43c5c408fed177ede7bf2b99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d5c9c28-0641-407b-9a43-4ad49e79b86a", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n", "original_text": "Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.  "}, "hash": "2114dafce56d6011076d751e056188970aa9abf60c64c5449744f809aa213741", "class_name": "RelatedNodeInfo"}}, "text": "Anything else to add, \nMike?  \n", "start_char_idx": 314, "end_char_idx": 345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d5c9c28-0641-407b-9a43-4ad49e79b86a": {"__data__": {"id_": "7d5c9c28-0641-407b-9a43-4ad49e79b86a", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n", "original_text": "Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f24f3ba-278e-4ed4-9150-181b97f2bd5b", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.  ", "original_text": "Anything else to add, \nMike?  \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15e309ae79c79a8802f395d4d7c803effa9da6262dc840bfea39d1dc2e246b35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b639ab71-c07c-49fd-95be-294bad0e81ab", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.  ", "original_text": "And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n"}, "hash": "46f950491b90f28dd78d8b823d04133a8c4ab5612ced74c4ef6b4be5511b080d", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.  ", "start_char_idx": 345, "end_char_idx": 567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b639ab71-c07c-49fd-95be-294bad0e81ab": {"__data__": {"id_": "b639ab71-c07c-49fd-95be-294bad0e81ab", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.  ", "original_text": "And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d5c9c28-0641-407b-9a43-4ad49e79b86a", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n", "original_text": "Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae5c121a109646b9589fe464a2c5de0f30a67f04f7f80662d5b4c9fa09a23eab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b9f7e51-490a-40aa-b1fe-4c4c8f56c179", "node_type": "1", "metadata": {"window": "Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.  ", "original_text": "Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.  "}, "hash": "9092430ed74da34b085ea2f7b7a349bc9a661ce009b4ef9addb7516c45cf5d21", "class_name": "RelatedNodeInfo"}}, "text": "And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n", "start_char_idx": 567, "end_char_idx": 681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b9f7e51-490a-40aa-b1fe-4c4c8f56c179": {"__data__": {"id_": "1b9f7e51-490a-40aa-b1fe-4c4c8f56c179", "embedding": null, "metadata": {"window": "Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.  ", "original_text": "Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b639ab71-c07c-49fd-95be-294bad0e81ab", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.  ", "original_text": "And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab951b033b89c67cce57d980dd877a5716ed7c24c5c5f96b2bee588c66d8e4ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80d3a580-0cd3-4c39-a55f-136a5292511f", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.  ", "original_text": "Please go ahead.   \n"}, "hash": "70a5cc03cf510ee0982ecbeba329fb2c305efb53657b1b3918bee570c526c55e", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.  ", "start_char_idx": 681, "end_char_idx": 755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80d3a580-0cd3-4c39-a55f-136a5292511f": {"__data__": {"id_": "80d3a580-0cd3-4c39-a55f-136a5292511f", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.  ", "original_text": "Please go ahead.   \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b9f7e51-490a-40aa-b1fe-4c4c8f56c179", "node_type": "1", "metadata": {"window": "Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.  ", "original_text": "Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f365cf8541b0b02c43ab1234dd95bfab0984d766ed29d3b37dcbd4232a9ce5da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8de11be3-9683-4290-b716-70b8cb66800a", "node_type": "1", "metadata": {"window": "And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.  ", "original_text": "Ricky Goldwasser:  Yes, hi, good morning.  "}, "hash": "ef95e79b77ad0741d5dfeca12072bdac6a3ae77bdfac7216c7c0a530769591e2", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.   \n", "start_char_idx": 755, "end_char_idx": 775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8de11be3-9683-4290-b716-70b8cb66800a": {"__data__": {"id_": "8de11be3-9683-4290-b716-70b8cb66800a", "embedding": null, "metadata": {"window": "And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.  ", "original_text": "Ricky Goldwasser:  Yes, hi, good morning.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80d3a580-0cd3-4c39-a55f-136a5292511f", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.  ", "original_text": "Please go ahead.   \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "164c65790815adf03592293cbf336c617d8c6248bbf58bfb942d616a92b54f65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bef3d203-bede-4185-a5d0-89fae344bb8a", "node_type": "1", "metadata": {"window": "Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.  ", "original_text": "And thanks for all the details you provided in your \nprepared remarks.  "}, "hash": "28aee090973ba212cce8b528623a62479c36c10cdbcd6cf4d9e789c5cd33c8b3", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  Yes, hi, good morning.  ", "start_char_idx": 775, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bef3d203-bede-4185-a5d0-89fae344bb8a": {"__data__": {"id_": "bef3d203-bede-4185-a5d0-89fae344bb8a", "embedding": null, "metadata": {"window": "Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.  ", "original_text": "And thanks for all the details you provided in your \nprepared remarks.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8de11be3-9683-4290-b716-70b8cb66800a", "node_type": "1", "metadata": {"window": "And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.  ", "original_text": "Ricky Goldwasser:  Yes, hi, good morning.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc9fb5bf49899aaa75bc2fd33c3fc52d279dd01d0dcfcc968f8ee48174d9c5b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a67ef7db-1801-4e36-b583-6f01f4ba4579", "node_type": "1", "metadata": {"window": "Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?  ", "original_text": "Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.  "}, "hash": "c83efeebc88c3d07ae53aa5b38c2a84e743026381b4d13e96600a798921374a2", "class_name": "RelatedNodeInfo"}}, "text": "And thanks for all the details you provided in your \nprepared remarks.  ", "start_char_idx": 818, "end_char_idx": 890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a67ef7db-1801-4e36-b583-6f01f4ba4579": {"__data__": {"id_": "a67ef7db-1801-4e36-b583-6f01f4ba4579", "embedding": null, "metadata": {"window": "Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?  ", "original_text": "Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bef3d203-bede-4185-a5d0-89fae344bb8a", "node_type": "1", "metadata": {"window": "Operator:  Next, we will hear from Ricky Goldwasser from Morgan Stanley.   Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.  ", "original_text": "And thanks for all the details you provided in your \nprepared remarks.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68ed38ab24e9ed2b2fa413d52c8ca62e841c9e4130bb45abfb01ff0dd0c4efea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66332817-5837-41a1-91df-cbb5ebd83006", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?  ", "original_text": "So specifically, you talked about the customer renewal.  "}, "hash": "2acb027cc7c7cc4b0b62068ac92d18a05ee1cc941bf6f1cbf4ca3421d0ab348e", "class_name": "RelatedNodeInfo"}}, "text": "Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.  ", "start_char_idx": 890, "end_char_idx": 987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66332817-5837-41a1-91df-cbb5ebd83006": {"__data__": {"id_": "66332817-5837-41a1-91df-cbb5ebd83006", "embedding": null, "metadata": {"window": "Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?  ", "original_text": "So specifically, you talked about the customer renewal.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a67ef7db-1801-4e36-b583-6f01f4ba4579", "node_type": "1", "metadata": {"window": "Please go ahead.   \n Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?  ", "original_text": "Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a86db268f2f54aa09b6ebbca4a476f06ab28239d82ea0c1e28c8c7482a3e0a9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34d59930-881c-4a13-b7cb-5a4b6d3bb701", "node_type": "1", "metadata": {"window": "And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?  ", "original_text": "It seems like it's CVS.  "}, "hash": "2253839d8ce6f59bd607e8402d2f026d5e32e05a0f37961bb2fb711a7b59041d", "class_name": "RelatedNodeInfo"}}, "text": "So specifically, you talked about the customer renewal.  ", "start_char_idx": 987, "end_char_idx": 1044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34d59930-881c-4a13-b7cb-5a4b6d3bb701": {"__data__": {"id_": "34d59930-881c-4a13-b7cb-5a4b6d3bb701", "embedding": null, "metadata": {"window": "And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?  ", "original_text": "It seems like it's CVS.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66332817-5837-41a1-91df-cbb5ebd83006", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Yes, hi, good morning.   And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?  ", "original_text": "So specifically, you talked about the customer renewal.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0527d0efa24827e2eb688f220003f7e780954c6d3f4e98e01180722fb2587c07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9535f72f-73e6-439a-a95e-84dd302eda8b", "node_type": "1", "metadata": {"window": "Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?  ", "original_text": "Can you \nmaybe help us quantify what the impact is in 2022?  "}, "hash": "f20d841b3c1e371750992925725a00b1a4aebfb65e948aa05e87648fa300b721", "class_name": "RelatedNodeInfo"}}, "text": "It seems like it's CVS.  ", "start_char_idx": 1044, "end_char_idx": 1069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9535f72f-73e6-439a-a95e-84dd302eda8b": {"__data__": {"id_": "9535f72f-73e6-439a-a95e-84dd302eda8b", "embedding": null, "metadata": {"window": "Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?  ", "original_text": "Can you \nmaybe help us quantify what the impact is in 2022?  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34d59930-881c-4a13-b7cb-5a4b6d3bb701", "node_type": "1", "metadata": {"window": "And thanks for all the details you provided in your \nprepared remarks.   Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?  ", "original_text": "It seems like it's CVS.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a748492624375180bba0dcf97115f986b3c5d1eda0bf027ff14afff9061504a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fcd2fab-271a-4a52-b714-fb25baedd923", "node_type": "1", "metadata": {"window": "So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n", "original_text": "And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?  "}, "hash": "abb329daa51e2660c263b9b2e8a2bac478098f6b26cdd1fc26d23fb4858c8362", "class_name": "RelatedNodeInfo"}}, "text": "Can you \nmaybe help us quantify what the impact is in 2022?  ", "start_char_idx": 1069, "end_char_idx": 1130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fcd2fab-271a-4a52-b714-fb25baedd923": {"__data__": {"id_": "9fcd2fab-271a-4a52-b714-fb25baedd923", "embedding": null, "metadata": {"window": "So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n", "original_text": "And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9535f72f-73e6-439a-a95e-84dd302eda8b", "node_type": "1", "metadata": {"window": "Just a couple of follow -up questions to understand sort of t he moving parts in the \nguidance.   So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?  ", "original_text": "Can you \nmaybe help us quantify what the impact is in 2022?  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5b8f1ef9da779a248fddd18daa8a0318927114343a3779641948a601501b5fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b65a5a90-6dd6-4e82-bf9e-731bebab1d73", "node_type": "1", "metadata": {"window": "It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.  ", "original_text": "And then the second question towards at the \nmoving parts are on the investment that you're making?  "}, "hash": "4b3cdd4c18f4f4b7e4634745e6847ec21f14fc8cce42cc4d33b058859df2cd4e", "class_name": "RelatedNodeInfo"}}, "text": "And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?  ", "start_char_idx": 1130, "end_char_idx": 1233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b65a5a90-6dd6-4e82-bf9e-731bebab1d73": {"__data__": {"id_": "b65a5a90-6dd6-4e82-bf9e-731bebab1d73", "embedding": null, "metadata": {"window": "It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.  ", "original_text": "And then the second question towards at the \nmoving parts are on the investment that you're making?  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fcd2fab-271a-4a52-b714-fb25baedd923", "node_type": "1", "metadata": {"window": "So specifically, you talked about the customer renewal.   It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n", "original_text": "And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48200bb51d7d4b081a27391f91842995f9b6b125881f97f05076e26bf6031be6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcb45c9a-a0ad-4d46-87b8-d615fa308871", "node_type": "1", "metadata": {"window": "Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.  ", "original_text": "Should we think about them as sort of a \nonetime investment in 2022?  "}, "hash": "665b3aa5ffb7ec3d689ac15b4085833748e349d98f02865aebc3420b940113fc", "class_name": "RelatedNodeInfo"}}, "text": "And then the second question towards at the \nmoving parts are on the investment that you're making?  ", "start_char_idx": 1233, "end_char_idx": 1334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcb45c9a-a0ad-4d46-87b8-d615fa308871": {"__data__": {"id_": "dcb45c9a-a0ad-4d46-87b8-d615fa308871", "embedding": null, "metadata": {"window": "Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.  ", "original_text": "Should we think about them as sort of a \nonetime investment in 2022?  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b65a5a90-6dd6-4e82-bf9e-731bebab1d73", "node_type": "1", "metadata": {"window": "It seems like it's CVS.   Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.  ", "original_text": "And then the second question towards at the \nmoving parts are on the investment that you're making?  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db83aed5b8445d75a4887883a7c6131507a9a593067ce2b4dc6bca5544eb7e7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bb28e27-8f0c-4cbc-bb07-97e601fb64c9", "node_type": "1", "metadata": {"window": "And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n", "original_text": "Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n"}, "hash": "9843a2f9565cf64c04b3cf17d0a08b1d508e79369ff9f3871517bb549db43a73", "class_name": "RelatedNodeInfo"}}, "text": "Should we think about them as sort of a \nonetime investment in 2022?  ", "start_char_idx": 1334, "end_char_idx": 1404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bb28e27-8f0c-4cbc-bb07-97e601fb64c9": {"__data__": {"id_": "3bb28e27-8f0c-4cbc-bb07-97e601fb64c9", "embedding": null, "metadata": {"window": "And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n", "original_text": "Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcb45c9a-a0ad-4d46-87b8-d615fa308871", "node_type": "1", "metadata": {"window": "Can you \nmaybe help us quantify what the impact is in 2022?   And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.  ", "original_text": "Should we think about them as sort of a \nonetime investment in 2022?  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea005d79cac6a0f23d671a30805a14d0e1f06de49495b55d1e0592c34a557fb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91933740-75b8-41e7-b291-c4c8d74fc05e", "node_type": "1", "metadata": {"window": "And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.  ", "original_text": "Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.  "}, "hash": "c6bcc7b470abf6bd6cc331bb5f498edaef76e26a9245aceb603f05995ac99b6d", "class_name": "RelatedNodeInfo"}}, "text": "Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n", "start_char_idx": 1404, "end_char_idx": 1506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91933740-75b8-41e7-b291-c4c8d74fc05e": {"__data__": {"id_": "91933740-75b8-41e7-b291-c4c8d74fc05e", "embedding": null, "metadata": {"window": "And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.  ", "original_text": "Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bb28e27-8f0c-4cbc-bb07-97e601fb64c9", "node_type": "1", "metadata": {"window": "And also if there are any other renewals that we \nshould be considering in the ne xt 12 to 18 months?   And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n", "original_text": "Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee84536aec546baf4774f6885e693c0e21883d50ff8eb697b25365150ccb4b23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4f84938-e6a9-4ebd-939a-30b595771b93", "node_type": "1", "metadata": {"window": "Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.  ", "original_text": "The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.  "}, "hash": "1f11a90a2774ede54e724a64ab5a83579d21ce61d88fcdb57fbf3aa86dc9e362", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.  ", "start_char_idx": 1506, "end_char_idx": 1624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4f84938-e6a9-4ebd-939a-30b595771b93": {"__data__": {"id_": "f4f84938-e6a9-4ebd-939a-30b595771b93", "embedding": null, "metadata": {"window": "Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.  ", "original_text": "The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91933740-75b8-41e7-b291-c4c8d74fc05e", "node_type": "1", "metadata": {"window": "And then the second question towards at the \nmoving parts are on the investment that you're making?   Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.  ", "original_text": "Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "907b12553ca9ac5f6c47a102e9b5bb0bee27889399dc978bd4b4def113ee6f6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c53f349-d6ed-459c-9f61-89af75c02af6", "node_type": "1", "metadata": {"window": "Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.  ", "original_text": "That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n"}, "hash": "c391d70546ca370a1ccd1a1b189f9cfc565b4700c2e05ec0b2c9a6a238d1a0a6", "class_name": "RelatedNodeInfo"}}, "text": "The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.  ", "start_char_idx": 1624, "end_char_idx": 1768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c53f349-d6ed-459c-9f61-89af75c02af6": {"__data__": {"id_": "4c53f349-d6ed-459c-9f61-89af75c02af6", "embedding": null, "metadata": {"window": "Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.  ", "original_text": "That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4f84938-e6a9-4ebd-939a-30b595771b93", "node_type": "1", "metadata": {"window": "Should we think about them as sort of a \nonetime investment in 2022?   Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.  ", "original_text": "The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec4dd5da38abcfe42856011a8113fc76d4db68be56e97cf33728f9849074c37e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93cac9f9-fc97-4223-8d9a-1ceb8b6d090d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .  ", "original_text": "What Jason was talking about in renewals was just the normal renewals.  "}, "hash": "931715d40936e583baa3ba7a18aa7c29f420d896734f1d3c9bf589991ed73eb4", "class_name": "RelatedNodeInfo"}}, "text": "That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n", "start_char_idx": 1768, "end_char_idx": 2114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93cac9f9-fc97-4223-8d9a-1ceb8b6d090d": {"__data__": {"id_": "93cac9f9-fc97-4223-8d9a-1ceb8b6d090d", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .  ", "original_text": "What Jason was talking about in renewals was just the normal renewals.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c53f349-d6ed-459c-9f61-89af75c02af6", "node_type": "1", "metadata": {"window": "Or should we now factor just kind of like ongoing levels of invest ments \nto support future growth?  \n Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.  ", "original_text": "That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbc975056cc31da0c6da9352e322b05336d707b4c2acd026ae4282a47f4de41c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbc79305-3525-4189-9ef2-53c3d6e7f262", "node_type": "1", "metadata": {"window": "The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n", "original_text": "There was nothing \nunexpected in the fourth quarter customer renew als.  "}, "hash": "0427310d5164b4157ff052d4a6faf107350acc21b5d64eea5cb4ab3287aaaaef", "class_name": "RelatedNodeInfo"}}, "text": "What Jason was talking about in renewals was just the normal renewals.  ", "start_char_idx": 2114, "end_char_idx": 2186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbc79305-3525-4189-9ef2-53c3d6e7f262": {"__data__": {"id_": "fbc79305-3525-4189-9ef2-53c3d6e7f262", "embedding": null, "metadata": {"window": "The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n", "original_text": "There was nothing \nunexpected in the fourth quarter customer renew als.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93cac9f9-fc97-4223-8d9a-1ceb8b6d090d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, I'll start talk about the renewals and then I'll have Jason make a comment on \nthe investments.   The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .  ", "original_text": "What Jason was talking about in renewals was just the normal renewals.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e045ae194f942f8c4fa037b51290b89fd750d5aa2be922b5f387c2c669f9bbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ada2ee72-ea31-4b7c-98f5-4fa1bdd18415", "node_type": "1", "metadata": {"window": "That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.  ", "original_text": "They basically came in as planned.  "}, "hash": "dbb6b904a7a7b11b66c537e62a5efad6d3b786ee4b83089283460ec54ad726c0", "class_name": "RelatedNodeInfo"}}, "text": "There was nothing \nunexpected in the fourth quarter customer renew als.  ", "start_char_idx": 2186, "end_char_idx": 2259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ada2ee72-ea31-4b7c-98f5-4fa1bdd18415": {"__data__": {"id_": "ada2ee72-ea31-4b7c-98f5-4fa1bdd18415", "embedding": null, "metadata": {"window": "That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.  ", "original_text": "They basically came in as planned.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbc79305-3525-4189-9ef2-53c3d6e7f262", "node_type": "1", "metadata": {"window": "The renewal that we're talking about had the -- Red Oak renewal is not at all \nincluded in what Jason was ta lking about on customer renewals.   That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n", "original_text": "There was nothing \nunexpected in the fourth quarter customer renew als.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e85b17df59d80ce23574c0f6ef2e2c53cceb1c7fe6df713421a78f8afb44c535", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d39b1e73-0513-4d91-8150-779d4f93becd", "node_type": "1", "metadata": {"window": "What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.  ", "original_text": "And so that \nwas not anything  unexpected .  "}, "hash": "f09c71563124469fe9c528403105229768a25a6152c73706f404a27573612680", "class_name": "RelatedNodeInfo"}}, "text": "They basically came in as planned.  ", "start_char_idx": 2259, "end_char_idx": 2295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d39b1e73-0513-4d91-8150-779d4f93becd": {"__data__": {"id_": "d39b1e73-0513-4d91-8150-779d4f93becd", "embedding": null, "metadata": {"window": "What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.  ", "original_text": "And so that \nwas not anything  unexpected .  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ada2ee72-ea31-4b7c-98f5-4fa1bdd18415", "node_type": "1", "metadata": {"window": "That's considered in our overall \ngenerics program performance, which we expect to be in -- to be something that we would expect to \nbe a tailwind next year, and we feel really good about where we're headed with all the var ious \ncomponents of our generics program and excited to continue to partner with CVS, moving forward \nwith on Red Oak.   \n What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.  ", "original_text": "They basically came in as planned.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22877513c97a471e5f17dd50bf9bd120d9f5203dd7ccd6c1cc212d2d1416b819", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76ef0e13-dd68-4ded-bc99-5760605f3e5f", "node_type": "1", "metadata": {"window": "There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.  ", "original_text": "I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n"}, "hash": "fe2b650796c2b3f159e31db8a1f2586f36f9c38c79c17a585faecfc7b1df3b03", "class_name": "RelatedNodeInfo"}}, "text": "And so that \nwas not anything  unexpected .  ", "start_char_idx": 2295, "end_char_idx": 2340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76ef0e13-dd68-4ded-bc99-5760605f3e5f": {"__data__": {"id_": "76ef0e13-dd68-4ded-bc99-5760605f3e5f", "embedding": null, "metadata": {"window": "There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.  ", "original_text": "I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d39b1e73-0513-4d91-8150-779d4f93becd", "node_type": "1", "metadata": {"window": "What Jason was talking about in renewals was just the normal renewals.   There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.  ", "original_text": "And so that \nwas not anything  unexpected .  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4dbdf4195a9affa642ce262f6dfa80dcd26d285227041851a35af4d16e18f117", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3800ae91-0d59-4e0d-b645-4afd0bdbf0f0", "node_type": "1", "metadata": {"window": "They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.  ", "original_text": "Jason Hollar:  Yes.  "}, "hash": "ae5f52b6ef50a52c4fc8fc508941e34d46d02e2e867d59bd8591cb89173ff2ed", "class_name": "RelatedNodeInfo"}}, "text": "I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n", "start_char_idx": 2340, "end_char_idx": 2465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3800ae91-0d59-4e0d-b645-4afd0bdbf0f0": {"__data__": {"id_": "3800ae91-0d59-4e0d-b645-4afd0bdbf0f0", "embedding": null, "metadata": {"window": "They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76ef0e13-dd68-4ded-bc99-5760605f3e5f", "node_type": "1", "metadata": {"window": "There was nothing \nunexpected in the fourth quarter customer renew als.   They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.  ", "original_text": "I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd80c92bee7e403f198661fb70cfc11347a219db1970fda9c6d8a5835724f53b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e4f7a1e-4356-4611-84ee-8bc5d840ad16", "node_type": "1", "metadata": {"window": "And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.  ", "original_text": "As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.  "}, "hash": "b2f00f61be240962472c1c5118cbab69c41cbd9b4385baa334e8a9660ed7ed91", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes.  ", "start_char_idx": 2465, "end_char_idx": 2486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e4f7a1e-4356-4611-84ee-8bc5d840ad16": {"__data__": {"id_": "4e4f7a1e-4356-4611-84ee-8bc5d840ad16", "embedding": null, "metadata": {"window": "And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.  ", "original_text": "As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3800ae91-0d59-4e0d-b645-4afd0bdbf0f0", "node_type": "1", "metadata": {"window": "They basically came in as planned.   And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5077c396a47ad149259c44b9ea26dc466f8296c6e966dc02f9424ec1fb02d285", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4557164f-3586-4918-950f-b9a49c2419f5", "node_type": "1", "metadata": {"window": "I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.  ", "original_text": "Our growth business, as we expect to contribute.  "}, "hash": "39d472168a2440b0c577d0d61f070e2b7c9383f9c707e6202330cbfea5887ed9", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.  ", "start_char_idx": 2486, "end_char_idx": 2587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4557164f-3586-4918-950f-b9a49c2419f5": {"__data__": {"id_": "4557164f-3586-4918-950f-b9a49c2419f5", "embedding": null, "metadata": {"window": "I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.  ", "original_text": "Our growth business, as we expect to contribute.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e4f7a1e-4356-4611-84ee-8bc5d840ad16", "node_type": "1", "metadata": {"window": "And so that \nwas not anything  unexpected .   I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.  ", "original_text": "As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0ecbaf0a7e5f86680c612978858b1bb04f9c05954634791b4bb561967b37d17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f3b9b04-5cf6-4af3-9df9-3583ff610d9d", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n", "original_text": "As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.  "}, "hash": "fa337b3d477fe58f35b37d3f5d203c0467d9040e1d96c5dfc1fa2b7f4c4d1a06", "class_name": "RelatedNodeInfo"}}, "text": "Our growth business, as we expect to contribute.  ", "start_char_idx": 2587, "end_char_idx": 2637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f3b9b04-5cf6-4af3-9df9-3583ff610d9d": {"__data__": {"id_": "5f3b9b04-5cf6-4af3-9df9-3583ff610d9d", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n", "original_text": "As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4557164f-3586-4918-950f-b9a49c2419f5", "node_type": "1", "metadata": {"window": "I would consider it, as we look forward, we don't see customer \nrenewals  being any different or unusual for us in FY '22.  \n Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.  ", "original_text": "Our growth business, as we expect to contribute.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffe628253d0208650ffa8187930bd64811b06c5c6bc59eb48d802f460152a047", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17eb8fd3-572a-4adc-800b-4cc6666d06d7", "node_type": "1", "metadata": {"window": "As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.  ", "original_text": "And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.  "}, "hash": "ff42d6c383095338e88546bdbe7bfadeadce9d20f59eb2b7ad3e24799ce8c8e4", "class_name": "RelatedNodeInfo"}}, "text": "As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.  ", "start_char_idx": 2637, "end_char_idx": 2749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17eb8fd3-572a-4adc-800b-4cc6666d06d7": {"__data__": {"id_": "17eb8fd3-572a-4adc-800b-4cc6666d06d7", "embedding": null, "metadata": {"window": "As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.  ", "original_text": "And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f3b9b04-5cf6-4af3-9df9-3583ff610d9d", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n", "original_text": "As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24eb666d113cae48effc81707b7f9e5ae53e2a09b0d054f146d04f5799c292d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6b906e4-c81d-474e-a3eb-63cf35e8e0c6", "node_type": "1", "metadata": {"window": "Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.  ", "original_text": "And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.  "}, "hash": "8bdcc03db0e83a82b0e7a1e93ac372e292978d355b633480e21c64e06754c984", "class_name": "RelatedNodeInfo"}}, "text": "And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.  ", "start_char_idx": 2749, "end_char_idx": 2840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6b906e4-c81d-474e-a3eb-63cf35e8e0c6": {"__data__": {"id_": "f6b906e4-c81d-474e-a3eb-63cf35e8e0c6", "embedding": null, "metadata": {"window": "Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.  ", "original_text": "And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17eb8fd3-572a-4adc-800b-4cc6666d06d7", "node_type": "1", "metadata": {"window": "As it relates to the other  moving pieces for Pharma, that are a part of that \nunderlying guidance.   Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.  ", "original_text": "And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6af34e2beeacf7bf656d03c592cb33e49865bfc7d432ed7d74b32b55f3ffd3eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fac49038-a4f2-48ff-a2fc-3eafe000bd8c", "node_type": "1", "metadata": {"window": "As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.  ", "original_text": "But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n"}, "hash": "33a40aa235d6bd38418cdaeb44ee0843be2638c522e1f3977dcdf1fa29f4cd77", "class_name": "RelatedNodeInfo"}}, "text": "And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.  ", "start_char_idx": 2840, "end_char_idx": 2938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fac49038-a4f2-48ff-a2fc-3eafe000bd8c": {"__data__": {"id_": "fac49038-a4f2-48ff-a2fc-3eafe000bd8c", "embedding": null, "metadata": {"window": "As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.  ", "original_text": "But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6b906e4-c81d-474e-a3eb-63cf35e8e0c6", "node_type": "1", "metadata": {"window": "Our growth business, as we expect to contribute.   As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.  ", "original_text": "And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "728e909edb90f379c025ac85dea5818b56ec58cc2c0c4dd9820750c64f139a9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1622df8-5bf2-41f6-af1c-b7c891a927bc", "node_type": "1", "metadata": {"window": "And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.  ", "original_text": "And then your question regarding investments.  "}, "hash": "e29b22115e1ac67a0230e88dbba87c2632230bae256d498b29465dbbab211998", "class_name": "RelatedNodeInfo"}}, "text": "But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n", "start_char_idx": 2938, "end_char_idx": 3082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1622df8-5bf2-41f6-af1c-b7c891a927bc": {"__data__": {"id_": "e1622df8-5bf2-41f6-af1c-b7c891a927bc", "embedding": null, "metadata": {"window": "And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.  ", "original_text": "And then your question regarding investments.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fac49038-a4f2-48ff-a2fc-3eafe000bd8c", "node_type": "1", "metadata": {"window": "As Mike mentioned, we \nexpect double -digit growth for our growth businesses, top line as well as bottom line.   And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.  ", "original_text": "But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a331df9febaa4bcf76328b23d66875b9d82a7c5f7213563fd7edaf1f0162771a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "973ff8d2-6a1a-4de2-bb89-4419f724c7d7", "node_type": "1", "metadata": {"window": "And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.   But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "original_text": "Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.  "}, "hash": "ad2d3bfd97d9af74969121df3f90614e764f5887f1ed4111b36bca03020f9dd1", "class_name": "RelatedNodeInfo"}}, "text": "And then your question regarding investments.  ", "start_char_idx": 3082, "end_char_idx": 3129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "973ff8d2-6a1a-4de2-bb89-4419f724c7d7": {"__data__": {"id_": "973ff8d2-6a1a-4de2-bb89-4419f724c7d7", "embedding": null, "metadata": {"window": "And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.   But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "original_text": "Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1622df8-5bf2-41f6-af1c-b7c891a927bc", "node_type": "1", "metadata": {"window": "And for the \nPharma busi ness, that would be, of course, Specialty, Nuclear and Outcomes.   And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.  ", "original_text": "And then your question regarding investments.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7399d6a5ad6cb0035a83cf302c4be3e34d498863857362d86e464a07d0223417", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "957701d5-d68b-413e-bb44-5cf434b6913a", "node_type": "1", "metadata": {"window": "But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.   But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "original_text": "We are finalizing that multiyear journey now and are starting to depreciate those assets.  "}, "hash": "7c5e572f1a07dd298044fa3299fc4c4a22aa6f9941eef63e978cb2d1951fd4fd", "class_name": "RelatedNodeInfo"}}, "text": "Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.  ", "start_char_idx": 3129, "end_char_idx": 3292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "957701d5-d68b-413e-bb44-5cf434b6913a": {"__data__": {"id_": "957701d5-d68b-413e-bb44-5cf434b6913a", "embedding": null, "metadata": {"window": "But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.   But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "original_text": "We are finalizing that multiyear journey now and are starting to depreciate those assets.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "973ff8d2-6a1a-4de2-bb89-4419f724c7d7", "node_type": "1", "metadata": {"window": "And then we have the \nyear-over-year COVID benefit that I mentioned would be a key part of that.   But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.   But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "original_text": "Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b82c2546fe812f7926db723e79b0f7c7b960daf09463d7f7701ccc1f51c5cc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a8ba96b-23d9-4faf-b77a-95a07d263863", "node_type": "1", "metadata": {"window": "And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.   But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "original_text": "So \nthere will be elevated depreciation that, of course, is more fixed in nature.  "}, "hash": "72a11febfeb46e1992d124ea70a07559d5114664d761e1a02b4b5dbd640b14cd", "class_name": "RelatedNodeInfo"}}, "text": "We are finalizing that multiyear journey now and are starting to depreciate those assets.  ", "start_char_idx": 3292, "end_char_idx": 3383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a8ba96b-23d9-4faf-b77a-95a07d263863": {"__data__": {"id_": "6a8ba96b-23d9-4faf-b77a-95a07d263863", "embedding": null, "metadata": {"window": "And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.   But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "original_text": "So \nthere will be elevated depreciation that, of course, is more fixed in nature.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "957701d5-d68b-413e-bb44-5cf434b6913a", "node_type": "1", "metadata": {"window": "But as Mike mentioned, \nthat the customer renewals is not something that we would anticipate t o be significantly different year -\nover-year.  \n And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.   But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "original_text": "We are finalizing that multiyear journey now and are starting to depreciate those assets.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4d3e0945dc30287997a1c3d047a38a1f57e932d871744b60c2233a813b41fcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dad1326c-9a2f-4dce-9afe-8fcbcda6fd10", "node_type": "1", "metadata": {"window": "Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.   But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "original_text": "But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus "}, "hash": "51903d2ba5e268387a278835b7131171c42de4231c60112a00d516091c3de0c5", "class_name": "RelatedNodeInfo"}}, "text": "So \nthere will be elevated depreciation that, of course, is more fixed in nature.  ", "start_char_idx": 3383, "end_char_idx": 3466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dad1326c-9a2f-4dce-9afe-8fcbcda6fd10": {"__data__": {"id_": "dad1326c-9a2f-4dce-9afe-8fcbcda6fd10", "embedding": null, "metadata": {"window": "Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.   But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "original_text": "But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0d5db7f47f75140be6a1aa7284afb91f4d6fa9bf9d0f32ce5e076dabbf47d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a8ba96b-23d9-4faf-b77a-95a07d263863", "node_type": "1", "metadata": {"window": "And then your question regarding investments.   Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.   But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "original_text": "So \nthere will be elevated depreciation that, of course, is more fixed in nature.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab0c2cad597d24c82396f66bb9d634f92576add9ff3d4dee2aaaeb6b1aa51af2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6190c7d1-fe02-4725-a8c6-e7754b71b504", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.  ", "original_text": " \nPage 11 of 15 \n \ncapital.  "}, "hash": "a4d3b059d0a3ebe1542a2eb09d85b8ac2ab8d9417e30a94ab9f82bdef9951bdd", "class_name": "RelatedNodeInfo"}}, "text": "But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "start_char_idx": 3466, "end_char_idx": 3584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6190c7d1-fe02-4725-a8c6-e7754b71b504": {"__data__": {"id_": "6190c7d1-fe02-4725-a8c6-e7754b71b504", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.  ", "original_text": " \nPage 11 of 15 \n \ncapital.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dad1326c-9a2f-4dce-9afe-8fcbcda6fd10", "node_type": "1", "metadata": {"window": "Those investments are a mixture of -- we've spent \nquite heavily over the last couple of several years on the capital side of getting these IT systems in \nplace.   We are finalizing that multiyear journey now and are starting to depreciate those assets.   So \nthere will be elevated depreciation that, of course, is more fixed in nature.   But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "original_text": "But there's also a \ncomponent of the final testing and rollout launch of these systems tend to be more expense versus ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "859faa2f3b589fb798e68531811a9bb1a8c08c77b0f780e52146ae98e92ce241", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b749eb8f-7470-44d2-8f87-9c01e831f693", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n", "original_text": "And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.  "}, "hash": "753557ac121c770167e7879b6dc3b4dfaa642a7bba588a7d3882689e96f6f111", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 15 \n \ncapital.  ", "start_char_idx": 0, "end_char_idx": 29, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b749eb8f-7470-44d2-8f87-9c01e831f693": {"__data__": {"id_": "b749eb8f-7470-44d2-8f87-9c01e831f693", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n", "original_text": "And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6190c7d1-fe02-4725-a8c6-e7754b71b504", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.  ", "original_text": " \nPage 11 of 15 \n \ncapital.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0f19a843fffee4140dad5d7e8f4d2431ec0b4e92ba1055a8524a43c9f3e57b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57992df9-1f81-444a-8620-a30e9a62b1ed", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.  ", "original_text": "But for the balance of this year, we would \nexpect it to b e elevated.  "}, "hash": "010a2b1d572612443c4a59ba35c0ff77b51e89451d78668351f71230817a031f", "class_name": "RelatedNodeInfo"}}, "text": "And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.  ", "start_char_idx": 29, "end_char_idx": 188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57992df9-1f81-444a-8620-a30e9a62b1ed": {"__data__": {"id_": "57992df9-1f81-444a-8620-a30e9a62b1ed", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.  ", "original_text": "But for the balance of this year, we would \nexpect it to b e elevated.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b749eb8f-7470-44d2-8f87-9c01e831f693", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n", "original_text": "And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "494e0382d1017eb880f5ee796b185270326a2891c283b7f21bd51dcd1e6aef8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bef77ed3-2a8c-47c7-9d77-4889c0fd3c66", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n", "original_text": "And then thereafter, some portion of it will come down later on.  "}, "hash": "e61e8c34f36de51e23ceb43279e83d84ad9005534e7b6851aaa692a60356dacf", "class_name": "RelatedNodeInfo"}}, "text": "But for the balance of this year, we would \nexpect it to b e elevated.  ", "start_char_idx": 188, "end_char_idx": 260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bef77ed3-2a8c-47c7-9d77-4889c0fd3c66": {"__data__": {"id_": "bef77ed3-2a8c-47c7-9d77-4889c0fd3c66", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n", "original_text": "And then thereafter, some portion of it will come down later on.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57992df9-1f81-444a-8620-a30e9a62b1ed", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.  ", "original_text": "But for the balance of this year, we would \nexpect it to b e elevated.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a010793c7e43e3c3f87133b88bd8116248691bb41416b7d377c32e2a1258a16f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03f9c85d-d991-41fa-bd3a-24c77ca2b07a", "node_type": "1", "metadata": {"window": "And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.  ", "original_text": "Next \nquestion.   \n"}, "hash": "cf8e45c37aa17822e15f8cea9cd1f791c2f2db844e0ac7a3260cbde4b760013d", "class_name": "RelatedNodeInfo"}}, "text": "And then thereafter, some portion of it will come down later on.  ", "start_char_idx": 260, "end_char_idx": 326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03f9c85d-d991-41fa-bd3a-24c77ca2b07a": {"__data__": {"id_": "03f9c85d-d991-41fa-bd3a-24c77ca2b07a", "embedding": null, "metadata": {"window": "And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.  ", "original_text": "Next \nquestion.   \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bef77ed3-2a8c-47c7-9d77-4889c0fd3c66", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n", "original_text": "And then thereafter, some portion of it will come down later on.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3f2a49a9796925bbf2874a38ec5711d8258bb19cc6c0a503da0b4c8f492f894", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6e2e55c-5dfe-4b3a-9cea-81039d56270c", "node_type": "1", "metadata": {"window": "But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.  ", "original_text": "Operator:  And up next, we'll hear from Eric Percher from Nephron Research.  "}, "hash": "9736974c2e8c43a7c9e99627f68376465adef4857c1b23a0a6455ca183b1b0d4", "class_name": "RelatedNodeInfo"}}, "text": "Next \nquestion.   \n", "start_char_idx": 326, "end_char_idx": 345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6e2e55c-5dfe-4b3a-9cea-81039d56270c": {"__data__": {"id_": "c6e2e55c-5dfe-4b3a-9cea-81039d56270c", "embedding": null, "metadata": {"window": "But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.  ", "original_text": "Operator:  And up next, we'll hear from Eric Percher from Nephron Research.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03f9c85d-d991-41fa-bd3a-24c77ca2b07a", "node_type": "1", "metadata": {"window": "And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.  ", "original_text": "Next \nquestion.   \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "468bb49e0da6fde08f62c2bb06043d7db66c8e2d74dc3ce458a114907570df80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2fc8185-14f8-482c-9df3-4c07f23809f3", "node_type": "1", "metadata": {"window": "And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n", "original_text": "Please go ahead.   \n"}, "hash": "627779073ccaab084c228df84c170133eef9132c44b5eb18fa10565d617e9ec9", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And up next, we'll hear from Eric Percher from Nephron Research.  ", "start_char_idx": 345, "end_char_idx": 422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2fc8185-14f8-482c-9df3-4c07f23809f3": {"__data__": {"id_": "c2fc8185-14f8-482c-9df3-4c07f23809f3", "embedding": null, "metadata": {"window": "And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n", "original_text": "Please go ahead.   \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6e2e55c-5dfe-4b3a-9cea-81039d56270c", "node_type": "1", "metadata": {"window": "But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.  ", "original_text": "Operator:  And up next, we'll hear from Eric Percher from Nephron Research.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad32c21a7180ef5675437b8e5de8768986916493ba477d60f108b85575e07b2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5d6c526-4252-4b85-88ff-ad2fa21b10ca", "node_type": "1", "metadata": {"window": "Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?  ", "original_text": "Eric Percher:  Thank you.  "}, "hash": "058913a02991005d5e0180a1d3f47cc709a2fe06a45382e9f0f9c3fcb1d2ee00", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.   \n", "start_char_idx": 422, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5d6c526-4252-4b85-88ff-ad2fa21b10ca": {"__data__": {"id_": "c5d6c526-4252-4b85-88ff-ad2fa21b10ca", "embedding": null, "metadata": {"window": "Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?  ", "original_text": "Eric Percher:  Thank you.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2fc8185-14f8-482c-9df3-4c07f23809f3", "node_type": "1", "metadata": {"window": "And then thereafter, some portion of it will come down later on.   Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n", "original_text": "Please go ahead.   \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93aaaa342d768a2256f28b6bf0ee55233825fd69d66010aac1d3c53f8978f197", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd88dc31-5af6-4e3e-b107-7ea533601c9c", "node_type": "1", "metadata": {"window": "Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n", "original_text": "I wanted to ask about the generic vol ume commentary around certain \nclasses.  "}, "hash": "4b1a7ab05b11ed973d1ceebca5a7cd1e0a41e0d538c18cd4228811653de60c8e", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:  Thank you.  ", "start_char_idx": 442, "end_char_idx": 469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd88dc31-5af6-4e3e-b107-7ea533601c9c": {"__data__": {"id_": "cd88dc31-5af6-4e3e-b107-7ea533601c9c", "embedding": null, "metadata": {"window": "Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n", "original_text": "I wanted to ask about the generic vol ume commentary around certain \nclasses.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5d6c526-4252-4b85-88ff-ad2fa21b10ca", "node_type": "1", "metadata": {"window": "Next \nquestion.   \n Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?  ", "original_text": "Eric Percher:  Thank you.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc3f5f1c6a01b66a7577c47dda4fec924f027f3194b1c14fa74c86ff6866ad2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5992f2b-72f5-431a-9161-fc8056fd746e", "node_type": "1", "metadata": {"window": "Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.  ", "original_text": "I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n"}, "hash": "0d0cca9d0ab733673c24abcdd2e4cee5ebe2a4cc05bed71f407ad720d9b76657", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to ask about the generic vol ume commentary around certain \nclasses.  ", "start_char_idx": 469, "end_char_idx": 548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5992f2b-72f5-431a-9161-fc8056fd746e": {"__data__": {"id_": "d5992f2b-72f5-431a-9161-fc8056fd746e", "embedding": null, "metadata": {"window": "Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.  ", "original_text": "I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd88dc31-5af6-4e3e-b107-7ea533601c9c", "node_type": "1", "metadata": {"window": "Operator:  And up next, we'll hear from Eric Percher from Nephron Research.   Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n", "original_text": "I wanted to ask about the generic vol ume commentary around certain \nclasses.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44fddb8a38b5e3d298f0c2f02203a9ae959251a2480da5e306b35018669da756", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2f06b5e-38e3-4d17-b527-25e1c787e53d", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.  ", "original_text": "So what are the classes where you're seeing this?  "}, "hash": "c5b446443332461271884dc455a25d16aa08e16f229d67ba429cc9bfbfc68215", "class_name": "RelatedNodeInfo"}}, "text": "I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n", "start_char_idx": 548, "end_char_idx": 642, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2f06b5e-38e3-4d17-b527-25e1c787e53d": {"__data__": {"id_": "e2f06b5e-38e3-4d17-b527-25e1c787e53d", "embedding": null, "metadata": {"window": "Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.  ", "original_text": "So what are the classes where you're seeing this?  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5992f2b-72f5-431a-9161-fc8056fd746e", "node_type": "1", "metadata": {"window": "Please go ahead.   \n Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.  ", "original_text": "I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f4d9f455a174ac284a6cb68c5dd10a5f318e310152242f199bd61f0eb8b0baf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ad66116-ad2f-4ff8-a19e-8f90df92f574", "node_type": "1", "metadata": {"window": "I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.  ", "original_text": "And any other specifics on how that's impacting \nthe generic program?  \n"}, "hash": "d4ddd42bc9b60599549f0dde3a59d313cf082a85a2fde15eb0d5d59cd8b19778", "class_name": "RelatedNodeInfo"}}, "text": "So what are the classes where you're seeing this?  ", "start_char_idx": 642, "end_char_idx": 693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ad66116-ad2f-4ff8-a19e-8f90df92f574": {"__data__": {"id_": "9ad66116-ad2f-4ff8-a19e-8f90df92f574", "embedding": null, "metadata": {"window": "I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.  ", "original_text": "And any other specifics on how that's impacting \nthe generic program?  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2f06b5e-38e3-4d17-b527-25e1c787e53d", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you.   I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.  ", "original_text": "So what are the classes where you're seeing this?  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f110a662a06aebcd47c0686a3076baa4960953de9d32b184edb624261cb12f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e23a5ebb-c11a-4425-acc6-8adc66d27d28", "node_type": "1", "metadata": {"window": "I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "a3681b8d5b645e64729e912ecf2b34593c781e920f4b31344a106d211c4fe5b2", "class_name": "RelatedNodeInfo"}}, "text": "And any other specifics on how that's impacting \nthe generic program?  \n", "start_char_idx": 693, "end_char_idx": 765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e23a5ebb-c11a-4425-acc6-8adc66d27d28": {"__data__": {"id_": "e23a5ebb-c11a-4425-acc6-8adc66d27d28", "embedding": null, "metadata": {"window": "I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ad66116-ad2f-4ff8-a19e-8f90df92f574", "node_type": "1", "metadata": {"window": "I wanted to ask about the generic vol ume commentary around certain \nclasses.   I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.  ", "original_text": "And any other specifics on how that's impacting \nthe generic program?  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbe66295ef8bf434702e835d85112ed1d453350709d25bf2ec0a5087275e1106", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61ccc4a2-a44a-4d4c-ab7b-7623b552c195", "node_type": "1", "metadata": {"window": "So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.  ", "original_text": "Thanks for the question.  "}, "hash": "c193b3a6585465e2456f777f3d829d92ccd576a6391efccc57b27df0d77d8697", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 765, "end_char_idx": 787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61ccc4a2-a44a-4d4c-ab7b-7623b552c195": {"__data__": {"id_": "61ccc4a2-a44a-4d4c-ab7b-7623b552c195", "embedding": null, "metadata": {"window": "So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.  ", "original_text": "Thanks for the question.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e23a5ebb-c11a-4425-acc6-8adc66d27d28", "node_type": "1", "metadata": {"window": "I know that we saw a clear increase in acute volumes from March into April and the quarter.  \n So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f13b763ced333a0a15df5668be321b747fba1bb15e3464baa650e83ef487b987", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "455cb3d3-8df5-423b-867a-86f2f54805da", "node_type": "1", "metadata": {"window": "And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.  ", "original_text": "So a couple of things on that.  "}, "hash": "f990c772d114ab453ba32e84ec61628d356b3d2322543c97d0f0fed431cf6108", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question.  ", "start_char_idx": 787, "end_char_idx": 813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "455cb3d3-8df5-423b-867a-86f2f54805da": {"__data__": {"id_": "455cb3d3-8df5-423b-867a-86f2f54805da", "embedding": null, "metadata": {"window": "And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.  ", "original_text": "So a couple of things on that.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61ccc4a2-a44a-4d4c-ab7b-7623b552c195", "node_type": "1", "metadata": {"window": "So what are the classes where you're seeing this?   And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.  ", "original_text": "Thanks for the question.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d65e7398d65e256cb18943c6d4a23d567d084ff4072ca3f6726e5f09451089b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1d3eddc-99ea-4f7e-a441-e5aa48cea36c", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n", "original_text": "We did see some \nsequential growth from Q3 to Q4 on generic volumes.  "}, "hash": "9fbf49426477a90fb53e277ca4b7f05bff3c8cf6846c6d1d05d8da600d6ea954", "class_name": "RelatedNodeInfo"}}, "text": "So a couple of things on that.  ", "start_char_idx": 813, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1d3eddc-99ea-4f7e-a441-e5aa48cea36c": {"__data__": {"id_": "b1d3eddc-99ea-4f7e-a441-e5aa48cea36c", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n", "original_text": "We did see some \nsequential growth from Q3 to Q4 on generic volumes.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "455cb3d3-8df5-423b-867a-86f2f54805da", "node_type": "1", "metadata": {"window": "And any other specifics on how that's impacting \nthe generic program?  \n Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.  ", "original_text": "So a couple of things on that.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f995d4304fe399c82dfd2e330d1792f7cc1e2b1b38c2aa1f4acbf91327dff797", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1394024-12b4-46a6-962f-4c780d981739", "node_type": "1", "metadata": {"window": "Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.  ", "original_text": "So that continues to be a positive sign.  "}, "hash": "ff91150a2e4b647852566457f4646adf8854f6794ddc9978f5115d8ae8dc28cf", "class_name": "RelatedNodeInfo"}}, "text": "We did see some \nsequential growth from Q3 to Q4 on generic volumes.  ", "start_char_idx": 845, "end_char_idx": 915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1394024-12b4-46a6-962f-4c780d981739": {"__data__": {"id_": "c1394024-12b4-46a6-962f-4c780d981739", "embedding": null, "metadata": {"window": "Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.  ", "original_text": "So that continues to be a positive sign.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1d3eddc-99ea-4f7e-a441-e5aa48cea36c", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n", "original_text": "We did see some \nsequential growth from Q3 to Q4 on generic volumes.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11f2c7d7e6b77a9a953881cc970d261f52a13d2805895347ddfa341d60b2154d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8488c376-55e5-461f-9705-068f3cadf02e", "node_type": "1", "metadata": {"window": "So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.  ", "original_text": "We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.  "}, "hash": "80b1beb58f54eed58f4fe9386af69f4fa0853ff95f4e1856628f6d0d0b07a870", "class_name": "RelatedNodeInfo"}}, "text": "So that continues to be a positive sign.  ", "start_char_idx": 915, "end_char_idx": 957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8488c376-55e5-461f-9705-068f3cadf02e": {"__data__": {"id_": "8488c376-55e5-461f-9705-068f3cadf02e", "embedding": null, "metadata": {"window": "So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.  ", "original_text": "We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1394024-12b4-46a6-962f-4c780d981739", "node_type": "1", "metadata": {"window": "Thanks for the question.   So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.  ", "original_text": "So that continues to be a positive sign.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2416a4415bbd237b21b5e5621f7b3a60a4dfc2a67cb3a96ff7ecdf96dc16ad4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0873c7e3-a194-4c44-928f-27443a1ce468", "node_type": "1", "metadata": {"window": "We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n", "original_text": "What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n"}, "hash": "198092d585e09a6d28d6ec271936ca659cbd1fd075dbef0848346bce1f3349a6", "class_name": "RelatedNodeInfo"}}, "text": "We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.  ", "start_char_idx": 957, "end_char_idx": 1115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0873c7e3-a194-4c44-928f-27443a1ce468": {"__data__": {"id_": "0873c7e3-a194-4c44-928f-27443a1ce468", "embedding": null, "metadata": {"window": "We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n", "original_text": "What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8488c376-55e5-461f-9705-068f3cadf02e", "node_type": "1", "metadata": {"window": "So a couple of things on that.   We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.  ", "original_text": "We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15cdf0cac43fc393df5d6a8517849df82290e41ec9c19a3207d256ab60862e0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb7755b3-f63f-45d3-ab3d-b3b43f4169a1", "node_type": "1", "metadata": {"window": "So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n", "original_text": "Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.  "}, "hash": "63f4b476016db4fdb6b4a1e6cc520ceaef38db9212cfb2cb3da8fcf37e187127", "class_name": "RelatedNodeInfo"}}, "text": "What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n", "start_char_idx": 1115, "end_char_idx": 1368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb7755b3-f63f-45d3-ab3d-b3b43f4169a1": {"__data__": {"id_": "eb7755b3-f63f-45d3-ab3d-b3b43f4169a1", "embedding": null, "metadata": {"window": "So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n", "original_text": "Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0873c7e3-a194-4c44-928f-27443a1ce468", "node_type": "1", "metadata": {"window": "We did see some \nsequential growth from Q3 to Q4 on generic volumes.   So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n", "original_text": "What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75100a135604a69d33f90222a3a3649822715383e9727495620347005b2b036e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e21f7f9b-8908-416c-9469-6bed4e301c9b", "node_type": "1", "metadata": {"window": "We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.  ", "original_text": "So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.  "}, "hash": "5a95179c713a99fe5223dc14d4d434f2f9abf17d15bd87334ac45b6060020a0c", "class_name": "RelatedNodeInfo"}}, "text": "Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.  ", "start_char_idx": 1368, "end_char_idx": 1608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e21f7f9b-8908-416c-9469-6bed4e301c9b": {"__data__": {"id_": "e21f7f9b-8908-416c-9469-6bed4e301c9b", "embedding": null, "metadata": {"window": "We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.  ", "original_text": "So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb7755b3-f63f-45d3-ab3d-b3b43f4169a1", "node_type": "1", "metadata": {"window": "So that continues to be a positive sign.   We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n", "original_text": "Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96550f43b1e7038426f18907469f16cfe998e794bf3467337921c128b8a1381b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0215c48-15bb-4112-8e82-d24dbeadd1a3", "node_type": "1", "metadata": {"window": "What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n", "original_text": "Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n"}, "hash": "c5cf4a48e86e9edda199f409c9b3671896b6a9de64eca49e2ed64a95dd5246fc", "class_name": "RelatedNodeInfo"}}, "text": "So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.  ", "start_char_idx": 1608, "end_char_idx": 1732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0215c48-15bb-4112-8e82-d24dbeadd1a3": {"__data__": {"id_": "b0215c48-15bb-4112-8e82-d24dbeadd1a3", "embedding": null, "metadata": {"window": "What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n", "original_text": "Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e21f7f9b-8908-416c-9469-6bed4e301c9b", "node_type": "1", "metadata": {"window": "We do \nexpect our -- impact from COVID -19 on all generic volumes to b e back at pre -COVID levels by the \nend of the calendar year or by the end of our Q2.   What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.  ", "original_text": "So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd50a8c53de920b0d9f346c7a6c91f1c193f0011f8cea6453469597a25bafec9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21477dec-3713-4697-b87d-33cfae9acc02", "node_type": "1", "metadata": {"window": "Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.  ", "original_text": "Kevin Moran:  Next question, please.  \n"}, "hash": "5a830f50b64afe56516b81b1ffae30940c2d756a383a95b30b0bf23477141efe", "class_name": "RelatedNodeInfo"}}, "text": "Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n", "start_char_idx": 1732, "end_char_idx": 1870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21477dec-3713-4697-b87d-33cfae9acc02": {"__data__": {"id_": "21477dec-3713-4697-b87d-33cfae9acc02", "embedding": null, "metadata": {"window": "Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.  ", "original_text": "Kevin Moran:  Next question, please.  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0215c48-15bb-4112-8e82-d24dbeadd1a3", "node_type": "1", "metadata": {"window": "What we're referring to here is we're still seeing, \nagain, ramping up, but we're still seeing some less than pre -COVID volumes on areas like anti -\ninfectives, antibacterial s, antibiotics, antivirals and some pain medications that we've not seen.   \n Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n", "original_text": "Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4ae3543b5c541028448d24deab42ee044128ee94b9f41a5dc3dc6187c15d5e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f0a714a-6009-4f54-a382-c8d3e877d6f0", "node_type": "1", "metadata": {"window": "So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n", "original_text": "Operator:  And next, we'll hear from Steven Valiquette with Barclays.  "}, "hash": "8d78a39fe9d31f5926d13d7edb0c3c95f9694338765aee1bff52f85f64d1479d", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Next question, please.  \n", "start_char_idx": 1870, "end_char_idx": 1909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f0a714a-6009-4f54-a382-c8d3e877d6f0": {"__data__": {"id_": "9f0a714a-6009-4f54-a382-c8d3e877d6f0", "embedding": null, "metadata": {"window": "So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n", "original_text": "Operator:  And next, we'll hear from Steven Valiquette with Barclays.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21477dec-3713-4697-b87d-33cfae9acc02", "node_type": "1", "metadata": {"window": "Our thoughts are as life continues to get more and more back to normal, if that's the right word, kids \nare back in school, et cetera, we would start to see those drugs being needed  more than they \nprobably have historically been needed.   So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.  ", "original_text": "Kevin Moran:  Next question, please.  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b07adb01022afe910c1c0a734df6e2ae4fd99a472b13e511e7cf0954dded15bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76c846bd-b2f2-4ad8-842e-354520d4e301", "node_type": "1", "metadata": {"window": "Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.  ", "original_text": "Please go ahead.   \n"}, "hash": "a7126947ba9d7f1d1567aa104f3b07a917c8d9f48b3665163e4aa4cc27129c40", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And next, we'll hear from Steven Valiquette with Barclays.  ", "start_char_idx": 1909, "end_char_idx": 1980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76c846bd-b2f2-4ad8-842e-354520d4e301": {"__data__": {"id_": "76c846bd-b2f2-4ad8-842e-354520d4e301", "embedding": null, "metadata": {"window": "Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.  ", "original_text": "Please go ahead.   \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f0a714a-6009-4f54-a382-c8d3e877d6f0", "node_type": "1", "metadata": {"window": "So again, expect them to be back to pre -COVID levels by \nthe end of the year, but that's really what we're talking about.   Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n", "original_text": "Operator:  And next, we'll hear from Steven Valiquette with Barclays.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45cf2895125e707148cf2e63201330ae9730ac2a0c44b4f0816d7d4d7222a7c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1fb2654-5dad-412c-a981-356020f3980d", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n", "original_text": "Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.  "}, "hash": "863f63b33cc70fc709d9836ed9c61f5580951c2ccb149ee3394ad78b132833e0", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.   \n", "start_char_idx": 422, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1fb2654-5dad-412c-a981-356020f3980d": {"__data__": {"id_": "a1fb2654-5dad-412c-a981-356020f3980d", "embedding": null, "metadata": {"window": "Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n", "original_text": "Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76c846bd-b2f2-4ad8-842e-354520d4e301", "node_type": "1", "metadata": {"window": "Very similar to the exact same thing, \nwe talked about last quarter, and it's kind of continuing to play out as we mentioned back then.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.  ", "original_text": "Please go ahead.   \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49fab2adefa56c340d70ee2c49af58c9333903ff3b45391baf948498e72d7059", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b53de240-b68f-4f95-bccd-187355ea5350", "node_type": "1", "metadata": {"window": "Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n", "original_text": "So I'm curious if \nyou're seeing those same trends as well?  \n"}, "hash": "5ec31184739bf6155ecbcfe80bfb00e0bfb6145eab31d0b3e879c3aa68b73f61", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.  ", "start_char_idx": 2000, "end_char_idx": 2086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b53de240-b68f-4f95-bccd-187355ea5350": {"__data__": {"id_": "b53de240-b68f-4f95-bccd-187355ea5350", "embedding": null, "metadata": {"window": "Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n", "original_text": "So I'm curious if \nyou're seeing those same trends as well?  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1fb2654-5dad-412c-a981-356020f3980d", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n", "original_text": "Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "534733301689d79bcb26a564d8d4ec28e361cc7ed18ebe3ae98683c2817fd4a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17e86000-d65a-4f5e-ae92-7c55c68b0c5c", "node_type": "1", "metadata": {"window": "Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.  ", "original_text": "Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.  "}, "hash": "f607fe9274156a7437afe15ea07811a0b17dd8cc6f579d1b256711b542092a78", "class_name": "RelatedNodeInfo"}}, "text": "So I'm curious if \nyou're seeing those same trends as well?  \n", "start_char_idx": 2086, "end_char_idx": 2148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17e86000-d65a-4f5e-ae92-7c55c68b0c5c": {"__data__": {"id_": "17e86000-d65a-4f5e-ae92-7c55c68b0c5c", "embedding": null, "metadata": {"window": "Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.  ", "original_text": "Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b53de240-b68f-4f95-bccd-187355ea5350", "node_type": "1", "metadata": {"window": "Operator:  And next, we'll hear from Steven Valiquette with Barclays.   Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n", "original_text": "So I'm curious if \nyou're seeing those same trends as well?  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fc3fd0e19630ca5b91d5c100b1f74bba5c61d319ad8bab76af8dad5cfb3aac0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bd617c7-83c3-4e31-b7b1-30d3fd24d5d8", "node_type": "1", "metadata": {"window": "Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.  ", "original_text": "So if you could try it again.  \n"}, "hash": "cfda243a9e47ed964475428c94371d5732aa83f30efde0a20f0f28bb79fa7171", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.  ", "start_char_idx": 2148, "end_char_idx": 2224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bd617c7-83c3-4e31-b7b1-30d3fd24d5d8": {"__data__": {"id_": "5bd617c7-83c3-4e31-b7b1-30d3fd24d5d8", "embedding": null, "metadata": {"window": "Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.  ", "original_text": "So if you could try it again.  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17e86000-d65a-4f5e-ae92-7c55c68b0c5c", "node_type": "1", "metadata": {"window": "Please go ahead.   \n Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.  ", "original_text": "Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "553a24e662fd353b33709dcdad38336e7212dc684bd0100b9195e1dc5cc400dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b247d4ae-b6ae-4b68-b626-c1e877e03111", "node_type": "1", "metadata": {"window": "So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?  ", "original_text": "Thank you.  \n"}, "hash": "0406c5a9a21928dec905ad7c8f949f5bff01ff556edf0cbb06248dd83e149641", "class_name": "RelatedNodeInfo"}}, "text": "So if you could try it again.  \n", "start_char_idx": 2224, "end_char_idx": 2256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b247d4ae-b6ae-4b68-b626-c1e877e03111": {"__data__": {"id_": "b247d4ae-b6ae-4b68-b626-c1e877e03111", "embedding": null, "metadata": {"window": "So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?  ", "original_text": "Thank you.  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bd617c7-83c3-4e31-b7b1-30d3fd24d5d8", "node_type": "1", "metadata": {"window": "Steven Valiquette:  ((Inaudible)) cost categories that are trending ab ove baseline.   So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.  ", "original_text": "So if you could try it again.  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f270d2938c583edd149a4f85fbb6dae5a4e8058c8133c53f4fbe11c9e394738", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bb76b9c-c896-4571-8f01-99374b28805a", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.  ", "original_text": "Steven Valiquette:  Yes.  "}, "hash": "62266bc4839f4365755c082ec0e1bd185977b8f1227f9e5baf98a05012f0b0d5", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n", "start_char_idx": 2256, "end_char_idx": 2269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bb76b9c-c896-4571-8f01-99374b28805a": {"__data__": {"id_": "1bb76b9c-c896-4571-8f01-99374b28805a", "embedding": null, "metadata": {"window": "Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.  ", "original_text": "Steven Valiquette:  Yes.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b247d4ae-b6ae-4b68-b626-c1e877e03111", "node_type": "1", "metadata": {"window": "So I'm curious if \nyou're seeing those same trends as well?  \n Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?  ", "original_text": "Thank you.  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76fc5c244e4c56c01a6fe0938e07b12590d6ef2511bcb29397a1cbe3950c7313", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "339ef681-c517-423f-b6e3-a47b0ffb25d8", "node_type": "1", "metadata": {"window": "So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S. ", "original_text": "Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.  "}, "hash": "3a491eb2e64229827c70fa19e8d12bd8e3c53a46780a9697b113f4fdd9b0e861", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette:  Yes.  ", "start_char_idx": 2269, "end_char_idx": 2295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "339ef681-c517-423f-b6e3-a47b0ffb25d8": {"__data__": {"id_": "339ef681-c517-423f-b6e3-a47b0ffb25d8", "embedding": null, "metadata": {"window": "So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S. ", "original_text": "Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bb76b9c-c896-4571-8f01-99374b28805a", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  I'm sorry, we didn't catch the beginning of your question.   So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.  ", "original_text": "Steven Valiquette:  Yes.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebc1a39617eb3a7b7b29bf4a217092647281c0845cf23d3494e63850015d8078", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a1b844f-4973-455a-9b25-edbbf95215ea", "node_type": "1", "metadata": {"window": "Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?  ", "original_text": "So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?  "}, "hash": "a172a23dc47b45b3f66ad8c448b0ddb37e9fb7ace02f0ac6218370d3c7b57a43", "class_name": "RelatedNodeInfo"}}, "text": "Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.  ", "start_char_idx": 2295, "end_char_idx": 2432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a1b844f-4973-455a-9b25-edbbf95215ea": {"__data__": {"id_": "7a1b844f-4973-455a-9b25-edbbf95215ea", "embedding": null, "metadata": {"window": "Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?  ", "original_text": "So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "339ef681-c517-423f-b6e3-a47b0ffb25d8", "node_type": "1", "metadata": {"window": "So if you could try it again.  \n Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S. ", "original_text": "Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ed4e3dec845882f0dcdb3da2013fcfc777a54dc01fa0c1d563dd0696451a30e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38931ca2-f3a9-4616-9129-77671aa6545c", "node_type": "1", "metadata": {"window": "Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n", "original_text": "You cited that  in the press release.  "}, "hash": "8d77a4ca481c68e74ea7aef29ea7520cf12d247268ad4ff08f5b2150d8e566f0", "class_name": "RelatedNodeInfo"}}, "text": "So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?  ", "start_char_idx": 2432, "end_char_idx": 2579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38931ca2-f3a9-4616-9129-77671aa6545c": {"__data__": {"id_": "38931ca2-f3a9-4616-9129-77671aa6545c", "embedding": null, "metadata": {"window": "Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n", "original_text": "You cited that  in the press release.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a1b844f-4973-455a-9b25-edbbf95215ea", "node_type": "1", "metadata": {"window": "Thank you.  \n Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?  ", "original_text": "So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32999e9559407a4a2e85183f42d477613ea47baad32ccefa32d7570118d70d1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f490abf-87ad-48e6-9fd9-ac2dc02941ae", "node_type": "1", "metadata": {"window": "Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.  ", "original_text": "I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S. "}, "hash": "e2b0680950d248bcf3475fd9e697b47bcf711a30d077315b6dd553c97c991742", "class_name": "RelatedNodeInfo"}}, "text": "You cited that  in the press release.  ", "start_char_idx": 2579, "end_char_idx": 2618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f490abf-87ad-48e6-9fd9-ac2dc02941ae": {"__data__": {"id_": "0f490abf-87ad-48e6-9fd9-ac2dc02941ae", "embedding": null, "metadata": {"window": "Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.  ", "original_text": "I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S. ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38931ca2-f3a9-4616-9129-77671aa6545c", "node_type": "1", "metadata": {"window": "Steven Valiquette:  Yes.   Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n", "original_text": "You cited that  in the press release.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f07ffe19995791f40fe093d0f7f78d0b12c436c4f7d2ae86bef3e99cf1016cac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97c2efa4-8a90-4893-bc7e-3dad769f8c7b", "node_type": "1", "metadata": {"window": "So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.  ", "original_text": "or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?  "}, "hash": "461ff2de98439b7ee797de14713c74126919da527568c5dfd6072e07c6989b9b", "class_name": "RelatedNodeInfo"}}, "text": "I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S. ", "start_char_idx": 2618, "end_char_idx": 2697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97c2efa4-8a90-4893-bc7e-3dad769f8c7b": {"__data__": {"id_": "97c2efa4-8a90-4893-bc7e-3dad769f8c7b", "embedding": null, "metadata": {"window": "So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.  ", "original_text": "or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f490abf-87ad-48e6-9fd9-ac2dc02941ae", "node_type": "1", "metadata": {"window": "Sorry, I knew at some point it would h appen, I would be pinged to ask two \nquestions on two calls at the same time, that just happens.   So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.  ", "original_text": "I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S. ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0d3a6c107334febfd8b89e37bb6797497ffd3912e6e455894189d2f1f6a3531", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d828b0d-fcea-4546-8287-58333d33492a", "node_type": "1", "metadata": {"window": "You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.  ", "original_text": "And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n"}, "hash": "667b54aa1cefb4e4588872e2ed06e781510bc62f4718f3cff117b7b0916c0a6b", "class_name": "RelatedNodeInfo"}}, "text": "or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?  ", "start_char_idx": 2697, "end_char_idx": 2808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d828b0d-fcea-4546-8287-58333d33492a": {"__data__": {"id_": "6d828b0d-fcea-4546-8287-58333d33492a", "embedding": null, "metadata": {"window": "You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.  ", "original_text": "And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97c2efa4-8a90-4893-bc7e-3dad769f8c7b", "node_type": "1", "metadata": {"window": "So I guess I'm curious to if you could \nprovide more color on the elevated supply chain cost you mentioned for the Medical segment in fiscal \n4Q?   You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.  ", "original_text": "or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a50516f3a5be8cb85d8188a39ae08b54000bdfacc4e8b45086b4389dafe290d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4feb52e-1536-476e-9133-c9f8da83db2c", "node_type": "1", "metadata": {"window": "I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.  ", "original_text": "Mike Kaufmann:  I'll start with your second piece first.  "}, "hash": "3f011503b30812ebd395d05bf4a13fd12d41470c1bd5dbf1abe93574f0ae9579", "class_name": "RelatedNodeInfo"}}, "text": "And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n", "start_char_idx": 2808, "end_char_idx": 2882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4feb52e-1536-476e-9133-c9f8da83db2c": {"__data__": {"id_": "d4feb52e-1536-476e-9133-c9f8da83db2c", "embedding": null, "metadata": {"window": "I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.  ", "original_text": "Mike Kaufmann:  I'll start with your second piece first.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d828b0d-fcea-4546-8287-58333d33492a", "node_type": "1", "metadata": {"window": "You cited that  in the press release.   I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.  ", "original_text": "And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5dbcebfa7202b637f08700520b5b61f58f71cf755c915bec4d54b9bfa074cf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9eadb7d0-5cbf-4ea6-a726-b8d5b010b75f", "node_type": "1", "metadata": {"window": "or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n", "original_text": "Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.  "}, "hash": "7240ee4968bb6091790d33a4431dce64aacf3cad6507e027a8ace34860e3cb1c", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  I'll start with your second piece first.  ", "start_char_idx": 2882, "end_char_idx": 2940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9eadb7d0-5cbf-4ea6-a726-b8d5b010b75f": {"__data__": {"id_": "9eadb7d0-5cbf-4ea6-a726-b8d5b010b75f", "embedding": null, "metadata": {"window": "or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n", "original_text": "Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4feb52e-1536-476e-9133-c9f8da83db2c", "node_type": "1", "metadata": {"window": "I guess I'm curious, geographically, is this cost pressure \nmainly in the U.S.  or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.  ", "original_text": "Mike Kaufmann:  I'll start with your second piece first.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ceb6e116490b18f944e84a42237f3b93467938b82d1d2b1635c77b58f543cd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db6870e0-6772-4041-abec-9e456d4643e6", "node_type": "1", "metadata": {"window": "And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "original_text": "Of course, there could have been elevated costs \non some of their raw m aterials and products.  "}, "hash": "3342d30390cb4a73ac23b68bebcd44ffa5637418aea33da082f6cbd27b7b45ab", "class_name": "RelatedNodeInfo"}}, "text": "Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.  ", "start_char_idx": 2940, "end_char_idx": 3042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db6870e0-6772-4041-abec-9e456d4643e6": {"__data__": {"id_": "db6870e0-6772-4041-abec-9e456d4643e6", "embedding": null, "metadata": {"window": "And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "original_text": "Of course, there could have been elevated costs \non some of their raw m aterials and products.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9eadb7d0-5cbf-4ea6-a726-b8d5b010b75f", "node_type": "1", "metadata": {"window": "or is it international as well, in addition to some other color just on mechanically \nwhat's happening there?   And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n", "original_text": "Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6bbfa7a1bbccfbb2c8394c5ffd03767e854515b538341ed5d06c663368ac6d72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6361ab0e-6376-4654-b39d-f9eaf385f15f", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "original_text": "And Cordis being more international, obviously, it had \nmore FX potential fluctuation.  "}, "hash": "af4fa339600c7b163e8971c65280dd7b3bdd0d2a0d4ffa72cef0df35b99ea137", "class_name": "RelatedNodeInfo"}}, "text": "Of course, there could have been elevated costs \non some of their raw m aterials and products.  ", "start_char_idx": 3042, "end_char_idx": 3138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6361ab0e-6376-4654-b39d-f9eaf385f15f": {"__data__": {"id_": "6361ab0e-6376-4654-b39d-f9eaf385f15f", "embedding": null, "metadata": {"window": "Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "original_text": "And Cordis being more international, obviously, it had \nmore FX potential fluctuation.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db6870e0-6772-4041-abec-9e456d4643e6", "node_type": "1", "metadata": {"window": "And does the sale of Cordis alleviate this i n any way into fiscal '22?  \n Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "original_text": "Of course, there could have been elevated costs \non some of their raw m aterials and products.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11f6dd070e1d92e222a8b1c9e9d08460977398108bc92e5b95dc5c4e01ee7c3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30f6a666-8b9f-4b07-ae2e-da9d24869687", "node_type": "1", "metadata": {"window": "Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "original_text": "But don't see Cordis being a factor there.   \n"}, "hash": "78eecfeb3eed3c384e578b9d378c68961e72aa3b1e504d6acb3864df39ee9d42", "class_name": "RelatedNodeInfo"}}, "text": "And Cordis being more international, obviously, it had \nmore FX potential fluctuation.  ", "start_char_idx": 3138, "end_char_idx": 3226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30f6a666-8b9f-4b07-ae2e-da9d24869687": {"__data__": {"id_": "30f6a666-8b9f-4b07-ae2e-da9d24869687", "embedding": null, "metadata": {"window": "Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "original_text": "But don't see Cordis being a factor there.   \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6361ab0e-6376-4654-b39d-f9eaf385f15f", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  I'll start with your second piece first.   Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "original_text": "And Cordis being more international, obviously, it had \nmore FX potential fluctuation.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b80f57ff9bfe4a68c2d67b84ecc7ea81a6eaed7255162c64dba736cd3f3d6e06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "304ea542-8869-4945-afc4-7ed501ecae87", "node_type": "1", "metadata": {"window": "Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "original_text": "As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to "}, "hash": "ad5ebb3db4d6f2b22cb8f02f548fb93d8b3d969086d4024e8935d8d9f9b2edfa", "class_name": "RelatedNodeInfo"}}, "text": "But don't see Cordis being a factor there.   \n", "start_char_idx": 3226, "end_char_idx": 3272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "304ea542-8869-4945-afc4-7ed501ecae87": {"__data__": {"id_": "304ea542-8869-4945-afc4-7ed501ecae87", "embedding": null, "metadata": {"window": "Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "original_text": "As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa5a7cd678c390484ee20366b470d3b4fe413f8f4dfd2447c1b0633aadcaa29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30f6a666-8b9f-4b07-ae2e-da9d24869687", "node_type": "1", "metadata": {"window": "Really, I don't see Cordis alleviating that at \nleast towards the at least with the guidance we set.   Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "original_text": "But don't see Cordis being a factor there.   \n", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dee52805168f21b45ba7af90aeee05eb4ef5ec88236ec2fa04e4498f77f48a32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9998046b-b6ed-405c-a45c-98ba2e8a26aa", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.  ", "original_text": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n"}, "hash": "3f1e335aaf64f63e986aa5a1c205ca56128e6a5eaef9891f2d791d76342904ef", "class_name": "RelatedNodeInfo"}}, "text": "As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "start_char_idx": 3272, "end_char_idx": 3481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9998046b-b6ed-405c-a45c-98ba2e8a26aa": {"__data__": {"id_": "9998046b-b6ed-405c-a45c-98ba2e8a26aa", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.  ", "original_text": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "304ea542-8869-4945-afc4-7ed501ecae87", "node_type": "1", "metadata": {"window": "Of course, there could have been elevated costs \non some of their raw m aterials and products.   And Cordis being more international, obviously, it had \nmore FX potential fluctuation.   But don't see Cordis being a factor there.   \n As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "original_text": "As far as the elevated supply chain cost, what we started seeing in the fourth quarter is, I think, which \nyou're hearing a lot of companies talking about, we're seeing increased fuel costs, we're starting to ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff25ca10cbfd9d772d2c7d0787a82fa3f88a7a820460dc04531eb9588e68676c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b3cf2f2-6f32-402a-b2ab-44f5892131be", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.  ", "original_text": "So we're just -- wages, et cetera.  "}, "hash": "0ef7cb021b33eea65a7eb82a4070dae9f5b0d208db6780cd72972070c659e177", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n", "start_char_idx": 0, "end_char_idx": 173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b3cf2f2-6f32-402a-b2ab-44f5892131be": {"__data__": {"id_": "8b3cf2f2-6f32-402a-b2ab-44f5892131be", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.  ", "original_text": "So we're just -- wages, et cetera.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9998046b-b6ed-405c-a45c-98ba2e8a26aa", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.  ", "original_text": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32b0c3e8cf769487a7056403e6971d0c725f9e42628a546b69b6bc77ad50f2ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c99b665e-3b85-411b-a542-9f8ac817e810", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.  ", "original_text": "So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.  "}, "hash": "3a032b69493bbc5162ced15a5cbc30e38870842bf8c497311233bbcac2e8c66f", "class_name": "RelatedNodeInfo"}}, "text": "So we're just -- wages, et cetera.  ", "start_char_idx": 173, "end_char_idx": 209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c99b665e-3b85-411b-a542-9f8ac817e810": {"__data__": {"id_": "c99b665e-3b85-411b-a542-9f8ac817e810", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.  ", "original_text": "So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b3cf2f2-6f32-402a-b2ab-44f5892131be", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.  ", "original_text": "So we're just -- wages, et cetera.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8ddbee1199904f9a0e9be1791a487cf00355388b7e699bc3960f203201a5f6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54a791b2-5158-4843-b33b-5006f9531e7d", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n", "original_text": "Again, we saw that in Q4.  "}, "hash": "0d0e4fc2b032bdcba63bd470610bd0b3a89c0ea3bfd4772e55faf1d6e45d07e0", "class_name": "RelatedNodeInfo"}}, "text": "So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.  ", "start_char_idx": 209, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54a791b2-5158-4843-b33b-5006f9531e7d": {"__data__": {"id_": "54a791b2-5158-4843-b33b-5006f9531e7d", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n", "original_text": "Again, we saw that in Q4.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c99b665e-3b85-411b-a542-9f8ac817e810", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.  ", "original_text": "So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c82e8655d42cea16e4bfe1e070a4f75039f265cb29a910ed5742e3ca55ffd41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4bdc96c-31ba-494c-a7aa-8fc18dd43931", "node_type": "1", "metadata": {"window": "So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.  ", "original_text": "We expect that to continue in for the \nfirst couple of quarters.  "}, "hash": "16a953c5e913cb303c7af132dea9a4671635b9ec702f36556c8b9dd1e8f8f064", "class_name": "RelatedNodeInfo"}}, "text": "Again, we saw that in Q4.  ", "start_char_idx": 318, "end_char_idx": 345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4bdc96c-31ba-494c-a7aa-8fc18dd43931": {"__data__": {"id_": "c4bdc96c-31ba-494c-a7aa-8fc18dd43931", "embedding": null, "metadata": {"window": "So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.  ", "original_text": "We expect that to continue in for the \nfirst couple of quarters.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54a791b2-5158-4843-b33b-5006f9531e7d", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n", "original_text": "Again, we saw that in Q4.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d2002c2e1db2213e0566dcdd8ca03eca046c58ea4fd7000c8d80f5f242a6aa3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c71513b5-cddd-4f80-8b40-6e1222f8ef1e", "node_type": "1", "metadata": {"window": "So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n", "original_text": "And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.  "}, "hash": "b06304798e27887af61be04fb0bbbf18d67918318deca35fc7397206bfd1cfc0", "class_name": "RelatedNodeInfo"}}, "text": "We expect that to continue in for the \nfirst couple of quarters.  ", "start_char_idx": 345, "end_char_idx": 411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c71513b5-cddd-4f80-8b40-6e1222f8ef1e": {"__data__": {"id_": "c71513b5-cddd-4f80-8b40-6e1222f8ef1e", "embedding": null, "metadata": {"window": "So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n", "original_text": "And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4bdc96c-31ba-494c-a7aa-8fc18dd43931", "node_type": "1", "metadata": {"window": "So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.  ", "original_text": "We expect that to continue in for the \nfirst couple of quarters.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7330e620eff63ed196b909040ddcb67ffe1ce58a3a2fed06921f751b8f52fc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b67659b-e820-4bba-be84-9adeb378a5ea", "node_type": "1", "metadata": {"window": "Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n", "original_text": "So we'll be monitoring that and \nkeeping our eyes on that.  \n"}, "hash": "6ad9e5e6efd3078a9a6372a759ecacd5a00c48c0c2b12820e5d085c5b25ea5b6", "class_name": "RelatedNodeInfo"}}, "text": "And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.  ", "start_char_idx": 411, "end_char_idx": 664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b67659b-e820-4bba-be84-9adeb378a5ea": {"__data__": {"id_": "4b67659b-e820-4bba-be84-9adeb378a5ea", "embedding": null, "metadata": {"window": "Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n", "original_text": "So we'll be monitoring that and \nkeeping our eyes on that.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c71513b5-cddd-4f80-8b40-6e1222f8ef1e", "node_type": "1", "metadata": {"window": "So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n", "original_text": "And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "306cb1503a70725eb25e0281fb080d3e9d24c3738ecca31e2c942514fbb6a90e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e03086d-56fd-447f-acc5-2089eb0945a8", "node_type": "1", "metadata": {"window": "We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.  ", "original_text": "Operator:  All right.  "}, "hash": "b8d45c1cdb6707d40d08b1261f5dc62667ffc93ba692f45f59a09e6d22829d60", "class_name": "RelatedNodeInfo"}}, "text": "So we'll be monitoring that and \nkeeping our eyes on that.  \n", "start_char_idx": 664, "end_char_idx": 725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e03086d-56fd-447f-acc5-2089eb0945a8": {"__data__": {"id_": "5e03086d-56fd-447f-acc5-2089eb0945a8", "embedding": null, "metadata": {"window": "We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.  ", "original_text": "Operator:  All right.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b67659b-e820-4bba-be84-9adeb378a5ea", "node_type": "1", "metadata": {"window": "Again, we saw that in Q4.   We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n", "original_text": "So we'll be monitoring that and \nkeeping our eyes on that.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "886ca791136890cd4fb39e043d85eb7d3b7eb7c613fbaa27f4725c301fa3829d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a447d7fd-b0b8-4efc-aae6-5695afaf5a75", "node_type": "1", "metadata": {"window": "And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.  ", "original_text": "And our next question will come from Elizabeth Anderson with Evercore ISI.  \n"}, "hash": "ff91e35ee681432afe232e451a570b303458e175e2d605486a4a9fda010dcd7b", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  All right.  ", "start_char_idx": 725, "end_char_idx": 748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a447d7fd-b0b8-4efc-aae6-5695afaf5a75": {"__data__": {"id_": "a447d7fd-b0b8-4efc-aae6-5695afaf5a75", "embedding": null, "metadata": {"window": "And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.  ", "original_text": "And our next question will come from Elizabeth Anderson with Evercore ISI.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e03086d-56fd-447f-acc5-2089eb0945a8", "node_type": "1", "metadata": {"window": "We expect that to continue in for the \nfirst couple of quarters.   And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.  ", "original_text": "Operator:  All right.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69ab3e61fb29fcf1cfd367eddce97de83699e41bdf2997b3e77d96af698376a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30756745-7ba9-4c40-894d-7cebfc3dc31a", "node_type": "1", "metadata": {"window": "So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?  ", "original_text": "Please go ahead.   \n"}, "hash": "ff03e88919854e8bf76fe45f6de88176001a9b06e842aa85821befb8602fc6f3", "class_name": "RelatedNodeInfo"}}, "text": "And our next question will come from Elizabeth Anderson with Evercore ISI.  \n", "start_char_idx": 748, "end_char_idx": 825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30756745-7ba9-4c40-894d-7cebfc3dc31a": {"__data__": {"id_": "30756745-7ba9-4c40-894d-7cebfc3dc31a", "embedding": null, "metadata": {"window": "So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?  ", "original_text": "Please go ahead.   \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a447d7fd-b0b8-4efc-aae6-5695afaf5a75", "node_type": "1", "metadata": {"window": "And then as things get back to more normal, we'll be able to see some either \nreductions in those or we'll be able to take some of those costs and where possible that appropri ately \npass it through to customers if it's a more permanent type of thing.   So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.  ", "original_text": "And our next question will come from Elizabeth Anderson with Evercore ISI.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec84ff9fa60ded463a1e1015e611ec8ff8a8042106ca91a57f3db1f56e56374f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8fad3f0-418e-445f-8941-e80ae342ced5", "node_type": "1", "metadata": {"window": "Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n", "original_text": "(Edu ardo):  Hi, good morning.  "}, "hash": "3112d0fee245b0f50fd01d799fddfeedd9c511d951b5932fd1627bc994b5294c", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.   \n", "start_char_idx": 825, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8fad3f0-418e-445f-8941-e80ae342ced5": {"__data__": {"id_": "a8fad3f0-418e-445f-8941-e80ae342ced5", "embedding": null, "metadata": {"window": "Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n", "original_text": "(Edu ardo):  Hi, good morning.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30756745-7ba9-4c40-894d-7cebfc3dc31a", "node_type": "1", "metadata": {"window": "So we'll be monitoring that and \nkeeping our eyes on that.  \n Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?  ", "original_text": "Please go ahead.   \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58e5e6b0a5bae969477218d97bf5fe762314f72fed500ab9ffc4971b550f8233", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89e543f9-777d-4238-a7cc-9009d75edbad", "node_type": "1", "metadata": {"window": "And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.  ", "original_text": "This is (Eduardo) on for Elizabeth.  "}, "hash": "3de0f578c44959cc0b2edd7394e2e476b1cbbde32b3e6fa4a9eb0cf6924b3512", "class_name": "RelatedNodeInfo"}}, "text": "(Edu ardo):  Hi, good morning.  ", "start_char_idx": 845, "end_char_idx": 877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89e543f9-777d-4238-a7cc-9009d75edbad": {"__data__": {"id_": "89e543f9-777d-4238-a7cc-9009d75edbad", "embedding": null, "metadata": {"window": "And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.  ", "original_text": "This is (Eduardo) on for Elizabeth.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8fad3f0-418e-445f-8941-e80ae342ced5", "node_type": "1", "metadata": {"window": "Operator:  All right.   And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n", "original_text": "(Edu ardo):  Hi, good morning.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ee8011065d24bb03f57313de1e00ca77d1c0240e6195221442c644a8d594a24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "313a1594-18a4-490e-93c2-7e4177edafeb", "node_type": "1", "metadata": {"window": "Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.  ", "original_text": "Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?  "}, "hash": "1bcd5cf70dd842f6b2e699eb640c37075b38c7410c48c6ad3e71419198baa1ae", "class_name": "RelatedNodeInfo"}}, "text": "This is (Eduardo) on for Elizabeth.  ", "start_char_idx": 877, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "313a1594-18a4-490e-93c2-7e4177edafeb": {"__data__": {"id_": "313a1594-18a4-490e-93c2-7e4177edafeb", "embedding": null, "metadata": {"window": "Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.  ", "original_text": "Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89e543f9-777d-4238-a7cc-9009d75edbad", "node_type": "1", "metadata": {"window": "And our next question will come from Elizabeth Anderson with Evercore ISI.  \n Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.  ", "original_text": "This is (Eduardo) on for Elizabeth.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82944ca2c437c35a1364f25fb11e3aa924cfb39a85e91845f6b07b9ba41125b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef7730c9-8d43-411d-801e-a3847d94d6ae", "node_type": "1", "metadata": {"window": "(Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.  ", "original_text": "And I guess what \nareas of the enterprise you expect to generate those savings from?  \n"}, "hash": "f29081ac596232d01f4d78f47b91524e8b2d9a9b3fed55475c76f7d2ad75fd6a", "class_name": "RelatedNodeInfo"}}, "text": "Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?  ", "start_char_idx": 914, "end_char_idx": 1021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef7730c9-8d43-411d-801e-a3847d94d6ae": {"__data__": {"id_": "ef7730c9-8d43-411d-801e-a3847d94d6ae", "embedding": null, "metadata": {"window": "(Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.  ", "original_text": "And I guess what \nareas of the enterprise you expect to generate those savings from?  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "313a1594-18a4-490e-93c2-7e4177edafeb", "node_type": "1", "metadata": {"window": "Please go ahead.   \n (Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.  ", "original_text": "Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1f1efd0adb57c8bf392dbc55236a98664d1b8bd926ba4c039e2f06deee3517f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f983f2cc-1086-4b3e-a81f-19e34fa1028c", "node_type": "1", "metadata": {"window": "This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n", "original_text": "Jason Hollar:  Sure.  "}, "hash": "1b4fe9b682f1a0f3f4f9a811d7fa4d4b52714b43fdcadf72922fe43a3bd0c2a7", "class_name": "RelatedNodeInfo"}}, "text": "And I guess what \nareas of the enterprise you expect to generate those savings from?  \n", "start_char_idx": 1021, "end_char_idx": 1108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f983f2cc-1086-4b3e-a81f-19e34fa1028c": {"__data__": {"id_": "f983f2cc-1086-4b3e-a81f-19e34fa1028c", "embedding": null, "metadata": {"window": "This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n", "original_text": "Jason Hollar:  Sure.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef7730c9-8d43-411d-801e-a3847d94d6ae", "node_type": "1", "metadata": {"window": "(Edu ardo):  Hi, good morning.   This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.  ", "original_text": "And I guess what \nareas of the enterprise you expect to generate those savings from?  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ec7d2038387620c24e65b388d71010f71855f0dbda5930e5bb3a512d400f788", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "537b8a07-d1a8-4a0e-aa10-321f8bc61655", "node_type": "1", "metadata": {"window": "Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n", "original_text": "Yes, I would say it's very much a continuation of what we've done to date.  "}, "hash": "f75b18dad2fbc03de53f3bb88cec9f01ed3841e209eabb410ea7280494289def", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure.  ", "start_char_idx": 1108, "end_char_idx": 1130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "537b8a07-d1a8-4a0e-aa10-321f8bc61655": {"__data__": {"id_": "537b8a07-d1a8-4a0e-aa10-321f8bc61655", "embedding": null, "metadata": {"window": "Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n", "original_text": "Yes, I would say it's very much a continuation of what we've done to date.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f983f2cc-1086-4b3e-a81f-19e34fa1028c", "node_type": "1", "metadata": {"window": "This is (Eduardo) on for Elizabeth.   Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n", "original_text": "Jason Hollar:  Sure.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2f27721e54d18d8baf2095a754269766f92dcca62f5e62601d7adee9d4f17cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3d7f095-2e90-49d9-bbad-738efbe47411", "node_type": "1", "metadata": {"window": "And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.  ", "original_text": "As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.  "}, "hash": "be8378e953c4b627b231244a7438e5d7ecf915f2cf425cd4f6e3490890f52939", "class_name": "RelatedNodeInfo"}}, "text": "Yes, I would say it's very much a continuation of what we've done to date.  ", "start_char_idx": 1130, "end_char_idx": 1206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3d7f095-2e90-49d9-bbad-738efbe47411": {"__data__": {"id_": "f3d7f095-2e90-49d9-bbad-738efbe47411", "embedding": null, "metadata": {"window": "And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.  ", "original_text": "As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "537b8a07-d1a8-4a0e-aa10-321f8bc61655", "node_type": "1", "metadata": {"window": "Can you guys maybe provide \nsome more color on the $250 million of additional cost savings opportunities?   And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n", "original_text": "Yes, I would say it's very much a continuation of what we've done to date.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b27d931dcbc7a2f8f8f17d994944f4c288c1b43a77acf181afdf5bd6d39dc2f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9a0f3a2-749a-41a8-8e01-b1a105ff32af", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.  ", "original_text": "And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n"}, "hash": "5c348cf98a5a8555132aa426bb9547bb6b0017a0f904650a634cc56a2e2703f9", "class_name": "RelatedNodeInfo"}}, "text": "As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.  ", "start_char_idx": 1206, "end_char_idx": 1359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9a0f3a2-749a-41a8-8e01-b1a105ff32af": {"__data__": {"id_": "c9a0f3a2-749a-41a8-8e01-b1a105ff32af", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.  ", "original_text": "And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3d7f095-2e90-49d9-bbad-738efbe47411", "node_type": "1", "metadata": {"window": "And I guess what \nareas of the enterprise you expect to generate those savings from?  \n Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.  ", "original_text": "As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee6afb9f2f3516f59a84ee42183982106a0f28f07cac30e0df659dca5357ca29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbe9cd2f-7183-43db-b10b-0dadfa8bd8ea", "node_type": "1", "metadata": {"window": "Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n", "original_text": "As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n"}, "hash": "b0fa7d4fdddda00c2bedd8a8b0508724786bd9ca56ec54e7f7e898a92b09ec4c", "class_name": "RelatedNodeInfo"}}, "text": "And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n", "start_char_idx": 1359, "end_char_idx": 1514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbe9cd2f-7183-43db-b10b-0dadfa8bd8ea": {"__data__": {"id_": "bbe9cd2f-7183-43db-b10b-0dadfa8bd8ea", "embedding": null, "metadata": {"window": "Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n", "original_text": "As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9a0f3a2-749a-41a8-8e01-b1a105ff32af", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.  ", "original_text": "And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c06186fee1a7dffc4953be63944bc371e69ba38a07333634f814da3e0d9ce20b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10a0992e-67e9-4962-b2b7-229ed9aedd18", "node_type": "1", "metadata": {"window": "As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.  ", "original_text": "We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.  "}, "hash": "26e4be3d7fd3cd069e5865fa8b6aa286bf90878bcb4d4ae3865ac4d3ae1d5ff9", "class_name": "RelatedNodeInfo"}}, "text": "As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n", "start_char_idx": 1514, "end_char_idx": 1821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10a0992e-67e9-4962-b2b7-229ed9aedd18": {"__data__": {"id_": "10a0992e-67e9-4962-b2b7-229ed9aedd18", "embedding": null, "metadata": {"window": "As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.  ", "original_text": "We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbe9cd2f-7183-43db-b10b-0dadfa8bd8ea", "node_type": "1", "metadata": {"window": "Yes, I would say it's very much a continuation of what we've done to date.   As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n", "original_text": "As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "720c21e9161cf70e04855ce14f331ac8dec4c58ef726f22e94618533246902d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13f16076-011b-427a-b9fc-c4f8a3d39f0d", "node_type": "1", "metadata": {"window": "And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.  ", "original_text": "We talked about the simplification of our international operating structure.  "}, "hash": "adecf37182b1f68477c1dbbfcf337a85c13c2b71e8624bded11bf7d69a385fe3", "class_name": "RelatedNodeInfo"}}, "text": "We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.  ", "start_char_idx": 1821, "end_char_idx": 1937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13f16076-011b-427a-b9fc-c4f8a3d39f0d": {"__data__": {"id_": "13f16076-011b-427a-b9fc-c4f8a3d39f0d", "embedding": null, "metadata": {"window": "And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.  ", "original_text": "We talked about the simplification of our international operating structure.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10a0992e-67e9-4962-b2b7-229ed9aedd18", "node_type": "1", "metadata": {"window": "As \nyou certainly recall, our initial target was the $500 million, and we've come close to accomplishing \nthat after the -- just the first three years.   And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.  ", "original_text": "We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad077efdcbc7753305aaf9044d33f725e600ce821b97abe2b23b6361b67ecae3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80d65d99-9c7d-44d8-9328-25c2735ba716", "node_type": "1", "metadata": {"window": "As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n", "original_text": "That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n"}, "hash": "25d9795a34986a0026e369a8f2b398ea94076b948059f7cae254fd0fa9da0866", "class_name": "RelatedNodeInfo"}}, "text": "We talked about the simplification of our international operating structure.  ", "start_char_idx": 1937, "end_char_idx": 2015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80d65d99-9c7d-44d8-9328-25c2735ba716": {"__data__": {"id_": "80d65d99-9c7d-44d8-9328-25c2735ba716", "embedding": null, "metadata": {"window": "As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n", "original_text": "That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13f16076-011b-427a-b9fc-c4f8a3d39f0d", "node_type": "1", "metadata": {"window": "And that was in varied areas, everywhere from \nmanufacturing, our footprint work there to our distribution work, all the way up to our functional areas.  \n As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.  ", "original_text": "We talked about the simplification of our international operating structure.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f2cc6f355b815f3ac1a5457d95b0892ab321d0370e02a6eb4e6915832f9a82d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58df4464-a750-4f6b-a527-6e2e4ae2215a", "node_type": "1", "metadata": {"window": "We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n", "original_text": "Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.  "}, "hash": "0c9dc7821a865900ac71f95b66d691105a3e7dafd22e8edde8994f32a64c737a", "class_name": "RelatedNodeInfo"}}, "text": "That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n", "start_char_idx": 2015, "end_char_idx": 2222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58df4464-a750-4f6b-a527-6e2e4ae2215a": {"__data__": {"id_": "58df4464-a750-4f6b-a527-6e2e4ae2215a", "embedding": null, "metadata": {"window": "We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n", "original_text": "Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80d65d99-9c7d-44d8-9328-25c2735ba716", "node_type": "1", "metadata": {"window": "As we go forward, what we're seeing in this next stage is the ability to go from more of the \ntransactional first  order benefits like rate negotiation in areas like transportation and going further into \nreally redesigning networks and getting into more augmented intelligence and things of that nature.  \n We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n", "original_text": "That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14ae6be727d594e8bd4cfe7b6fbfaa5ffe7f24c03ab29672edb920e18cc3ee61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55a56c9b-e8d5-4d0b-9c77-a80fe1dcdecb", "node_type": "1", "metadata": {"window": "We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.  ", "original_text": "We've been investing a lot of time on that.  "}, "hash": "acb03389ff6f4d53e7116f7411e16f4d9a5acf2a3b9bbe190d8027e3cf02546c", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.  ", "start_char_idx": 2222, "end_char_idx": 2448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55a56c9b-e8d5-4d0b-9c77-a80fe1dcdecb": {"__data__": {"id_": "55a56c9b-e8d5-4d0b-9c77-a80fe1dcdecb", "embedding": null, "metadata": {"window": "We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.  ", "original_text": "We've been investing a lot of time on that.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58df4464-a750-4f6b-a527-6e2e4ae2215a", "node_type": "1", "metadata": {"window": "We have -- one area that is allowing us to unlock additional va lue in this next stage is the Cordis \ndivestiture.   We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n", "original_text": "Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65e13bb69bc89e869cf8287804fea4b1a72f9b704e2d96b8ec7d800980472d67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64696e33-5399-4c6f-a466-39f0d14011ba", "node_type": "1", "metadata": {"window": "That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.  ", "original_text": "Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n"}, "hash": "6eb8a95da068d7450d3a5bcde361354144458d2875c19847279bb61e50072f53", "class_name": "RelatedNodeInfo"}}, "text": "We've been investing a lot of time on that.  ", "start_char_idx": 2448, "end_char_idx": 2493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64696e33-5399-4c6f-a466-39f0d14011ba": {"__data__": {"id_": "64696e33-5399-4c6f-a466-39f0d14011ba", "embedding": null, "metadata": {"window": "That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.  ", "original_text": "Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55a56c9b-e8d5-4d0b-9c77-a80fe1dcdecb", "node_type": "1", "metadata": {"window": "We talked about the simplification of our international operating structure.   That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.  ", "original_text": "We've been investing a lot of time on that.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68eff2fd0a8f543683ebb5b0dc362eab4f466d6e3105a1dad799106417874675", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c8c6e72-cfa1-4a5c-9c19-98bae3ba0f5c", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n", "original_text": "Kevin Moran:  Next question, please.  \n"}, "hash": "5a97e2f79e7db6ca806318d8b5f2ba0e491f4743f559b2b2bb702288ce72ac18", "class_name": "RelatedNodeInfo"}}, "text": "Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n", "start_char_idx": 2493, "end_char_idx": 2804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c8c6e72-cfa1-4a5c-9c19-98bae3ba0f5c": {"__data__": {"id_": "1c8c6e72-cfa1-4a5c-9c19-98bae3ba0f5c", "embedding": null, "metadata": {"window": "Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n", "original_text": "Kevin Moran:  Next question, please.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64696e33-5399-4c6f-a466-39f0d14011ba", "node_type": "1", "metadata": {"window": "That's an \nenabler for us to continue to go after additional opportunities there, and then just continue on at all \nfronts given that we've got good momentum in place already for the existing initiatives.  \n Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.  ", "original_text": "Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49072c42440fe47824c5d87cec540261dcd55931ce313dcb2e2f2862e568619e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "739ebb2c-40c7-465e-aef0-3403c075eebd", "node_type": "1", "metadata": {"window": "We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.  ", "original_text": "Operator:  All right.  "}, "hash": "e03651566732aa399aae00d85aa5f3dfbc2da31b0a486b6da83afb2263a4f9de", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Next question, please.  \n", "start_char_idx": 2804, "end_char_idx": 2843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "739ebb2c-40c7-465e-aef0-3403c075eebd": {"__data__": {"id_": "739ebb2c-40c7-465e-aef0-3403c075eebd", "embedding": null, "metadata": {"window": "We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.  ", "original_text": "Operator:  All right.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c8c6e72-cfa1-4a5c-9c19-98bae3ba0f5c", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  The only thing I would add is that, just to emphasize something Jason mentioned is \naround the use of digital to really get after being able to use bots, AI, RPA, et  cetera, to get after our \ncost structure.   We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n", "original_text": "Kevin Moran:  Next question, please.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a0e7dc3cf3e127484e6589d237286d0f6516ecd47a442b644c34d5065a7646a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c10980c8-b972-4c7a-a220-4c0f718446cd", "node_type": "1", "metadata": {"window": "Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.  ", "original_text": "And up next, we'll hear from Lisa Gill with JPMorgan.  "}, "hash": "03a047e872f70d6c2c6d7372b4947c1cd775284c76b6f44e814ca9f0a8048f1e", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  All right.  ", "start_char_idx": 725, "end_char_idx": 748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c10980c8-b972-4c7a-a220-4c0f718446cd": {"__data__": {"id_": "c10980c8-b972-4c7a-a220-4c0f718446cd", "embedding": null, "metadata": {"window": "Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.  ", "original_text": "And up next, we'll hear from Lisa Gill with JPMorgan.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "739ebb2c-40c7-465e-aef0-3403c075eebd", "node_type": "1", "metadata": {"window": "We've been investing a lot of time on that.   Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.  ", "original_text": "Operator:  All right.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6768f79406fea5150fcbc1b1a40dbde4ed96cf7b6602479666545667a870c196", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c08f397-4bac-4f84-a526-07ad4b2f7666", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?  ", "original_text": "Please go ahead.   \n"}, "hash": "f61c29e361eaaaad79b616c023c5637c19d3547474165e4a1a7500a2942945aa", "class_name": "RelatedNodeInfo"}}, "text": "And up next, we'll hear from Lisa Gill with JPMorgan.  ", "start_char_idx": 2866, "end_char_idx": 2921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c08f397-4bac-4f84-a526-07ad4b2f7666": {"__data__": {"id_": "7c08f397-4bac-4f84-a526-07ad4b2f7666", "embedding": null, "metadata": {"window": "Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?  ", "original_text": "Please go ahead.   \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c10980c8-b972-4c7a-a220-4c0f718446cd", "node_type": "1", "metadata": {"window": "Our IT team has done a nice job of \nbuilding out both people, resources and our businesses and functions are all embracing this as well \nas making sure we're doing work i n the right locations are all in other important factors that we see \nbeing able to give us some tailwinds going forward on cost savings.  \n Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.  ", "original_text": "And up next, we'll hear from Lisa Gill with JPMorgan.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f12052a32ed42879c221372eb8e952f0ee562e95f6ece60588e0ac4fff27676", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a917768-ab56-4197-91b6-b05eb4b06d99", "node_type": "1", "metadata": {"window": "Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?  ", "original_text": "Lisa Gill:  Hi, thanks so much.  "}, "hash": "6d427e88855cb777dee8f007c986e793cea03252409fb9bdce7ffdbf3c461ece", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.   \n", "start_char_idx": 825, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a917768-ab56-4197-91b6-b05eb4b06d99": {"__data__": {"id_": "5a917768-ab56-4197-91b6-b05eb4b06d99", "embedding": null, "metadata": {"window": "Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?  ", "original_text": "Lisa Gill:  Hi, thanks so much.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c08f397-4bac-4f84-a526-07ad4b2f7666", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?  ", "original_text": "Please go ahead.   \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0074b7c19e751b66f96282f129abf111f00b9b90ccec02654781ffbc52655730", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27ff3e2a-83fd-4ba1-8bff-48718cc0a2e0", "node_type": "1", "metadata": {"window": "And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.  ", "original_text": "Good morning.  "}, "hash": "68a0b563cd4747b12fb7350cf07be422214e526fd63eb176c1155628ea68374a", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Hi, thanks so much.  ", "start_char_idx": 2941, "end_char_idx": 2974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27ff3e2a-83fd-4ba1-8bff-48718cc0a2e0": {"__data__": {"id_": "27ff3e2a-83fd-4ba1-8bff-48718cc0a2e0", "embedding": null, "metadata": {"window": "And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.  ", "original_text": "Good morning.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a917768-ab56-4197-91b6-b05eb4b06d99", "node_type": "1", "metadata": {"window": "Operator:  All right.   And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?  ", "original_text": "Lisa Gill:  Hi, thanks so much.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "870e2861c79577bbb7c846dc60e21c50ce752669a7b5e324c2f9e78af129b13a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f994fb3-afe4-4abe-ba18-5dfb1bb1ff88", "node_type": "1", "metadata": {"window": "Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?  ", "original_text": "I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?  "}, "hash": "35be2552863ed1969e82dc86c4045b4184b4e76502128d5395b46e0e7fc23f88", "class_name": "RelatedNodeInfo"}}, "text": "Good morning.  ", "start_char_idx": 2974, "end_char_idx": 2989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f994fb3-afe4-4abe-ba18-5dfb1bb1ff88": {"__data__": {"id_": "9f994fb3-afe4-4abe-ba18-5dfb1bb1ff88", "embedding": null, "metadata": {"window": "Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?  ", "original_text": "I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27ff3e2a-83fd-4ba1-8bff-48718cc0a2e0", "node_type": "1", "metadata": {"window": "And up next, we'll hear from Lisa Gill with JPMorgan.   Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.  ", "original_text": "Good morning.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bd6769fecfdbc464ce6aea473b1cf67f1273615c85ee29c866a4fbea410f973", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4c19b37-102b-4f4d-b43d-ce3ed87c07d7", "node_type": "1", "metadata": {"window": "Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?   Just any drivers or help you can give a round that on a longer -term basis.  ", "original_text": "And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?  "}, "hash": "90ad1768e5101d57d595c411ca393c3c2ad1e63556b882642ae88b2f4ae1cf49", "class_name": "RelatedNodeInfo"}}, "text": "I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?  ", "start_char_idx": 2989, "end_char_idx": 3224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4c19b37-102b-4f4d-b43d-ce3ed87c07d7": {"__data__": {"id_": "c4c19b37-102b-4f4d-b43d-ce3ed87c07d7", "embedding": null, "metadata": {"window": "Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?   Just any drivers or help you can give a round that on a longer -term basis.  ", "original_text": "And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f994fb3-afe4-4abe-ba18-5dfb1bb1ff88", "node_type": "1", "metadata": {"window": "Please go ahead.   \n Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?  ", "original_text": "I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ee0c23e75f4a74943cff0e34d4eedbeb336d332d979ab100723bc4c9ebcb37c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b91404aa-af72-4522-a986-bd810ea230f5", "node_type": "1", "metadata": {"window": "Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?   Just any drivers or help you can give a round that on a longer -term basis.  ", "original_text": "That would \nbe kind of my first que stion.  "}, "hash": "2d3afbea38264418b8518d962ce49556b198ff310c9a3c5c72bdf9876d47bf3c", "class_name": "RelatedNodeInfo"}}, "text": "And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?  ", "start_char_idx": 3224, "end_char_idx": 3329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b91404aa-af72-4522-a986-bd810ea230f5": {"__data__": {"id_": "b91404aa-af72-4522-a986-bd810ea230f5", "embedding": null, "metadata": {"window": "Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?   Just any drivers or help you can give a round that on a longer -term basis.  ", "original_text": "That would \nbe kind of my first que stion.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4c19b37-102b-4f4d-b43d-ce3ed87c07d7", "node_type": "1", "metadata": {"window": "Lisa Gill:  Hi, thanks so much.   Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?   Just any drivers or help you can give a round that on a longer -term basis.  ", "original_text": "And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d925fe73440bca0878fab100088c6378f757ce61ee284bdc6c31f4dad3b04cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f7a35f6-55e7-4f66-bd68-0f2e16623bd1", "node_type": "1", "metadata": {"window": "I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?   Just any drivers or help you can give a round that on a longer -term basis.  ", "original_text": "And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?  "}, "hash": "8906715b7d39f37655bd4b30607674f6741836ec306dbf74fe119e0b42703f30", "class_name": "RelatedNodeInfo"}}, "text": "That would \nbe kind of my first que stion.  ", "start_char_idx": 3329, "end_char_idx": 3373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f7a35f6-55e7-4f66-bd68-0f2e16623bd1": {"__data__": {"id_": "6f7a35f6-55e7-4f66-bd68-0f2e16623bd1", "embedding": null, "metadata": {"window": "I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?   Just any drivers or help you can give a round that on a longer -term basis.  ", "original_text": "And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b91404aa-af72-4522-a986-bd810ea230f5", "node_type": "1", "metadata": {"window": "Good morning.   I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?   Just any drivers or help you can give a round that on a longer -term basis.  ", "original_text": "That would \nbe kind of my first que stion.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e676e6e07064aefd426f8893ee2fff2f5dd242f6491a55bd1e709945f5f73d03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a935cafd-d14d-49a1-9c0f-1af1d7f351c9", "node_type": "1", "metadata": {"window": "And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?   Just any drivers or help you can give a round that on a longer -term basis.  ", "original_text": "Just any drivers or help you can give a round that on a longer -term basis.  "}, "hash": "4e23df568c208ca9c6b2edf5d45d8d2d451429ba0824ff7a3f1fa16ee75abc08", "class_name": "RelatedNodeInfo"}}, "text": "And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?  ", "start_char_idx": 3373, "end_char_idx": 3587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a935cafd-d14d-49a1-9c0f-1af1d7f351c9": {"__data__": {"id_": "a935cafd-d14d-49a1-9c0f-1af1d7f351c9", "embedding": null, "metadata": {"window": "And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?   Just any drivers or help you can give a round that on a longer -term basis.  ", "original_text": "Just any drivers or help you can give a round that on a longer -term basis.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73d6664f650076cd8dafb8c4873c8628c2542241e90e3602c2441ff9014a1210", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f7a35f6-55e7-4f66-bd68-0f2e16623bd1", "node_type": "1", "metadata": {"window": "I just really want to understand as we think about \nnormalization in your Pharma segment, so beyond the renewal,  do you see low single -digit to mid -\nsingle -digit normalization in Pharma segment profit growth over the longer term?   And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?   Just any drivers or help you can give a round that on a longer -term basis.  ", "original_text": "And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df5144b062feb5d1c0e9fcf5326d1398cdf384438c12ef5ab3ca8bb96334a593", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6be4d02-d6cd-44a8-afe3-01ffeaf2f219", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.  ", "original_text": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.  "}, "hash": "2594140942f91bc7efa55b6107ef91a4847cbba85781c4afa5e5f73e4201da13", "class_name": "RelatedNodeInfo"}}, "text": "Just any drivers or help you can give a round that on a longer -term basis.  ", "start_char_idx": 3587, "end_char_idx": 3664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6be4d02-d6cd-44a8-afe3-01ffeaf2f219": {"__data__": {"id_": "c6be4d02-d6cd-44a8-afe3-01ffeaf2f219", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.  ", "original_text": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a935cafd-d14d-49a1-9c0f-1af1d7f351c9", "node_type": "1", "metadata": {"window": "And where are \nspecific opportunities that you see to maybe further accelerate that growth beyond 2022?   That would \nbe kind of my first que stion.   And do things like Specialty and Nuclear that you talk about returning to \ndouble digit, I know they're on the smaller side, do they help to accelerate that low single -digit to mid -\nsingle -digit normalization?   Just any drivers or help you can give a round that on a longer -term basis.  ", "original_text": "Just any drivers or help you can give a round that on a longer -term basis.  ", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a55d71dcec5407e4126446451c0dea85446737abff98a962c0742bf6b7259152", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1d2f9a0-3aaf-4649-a4a9-ef1ad45f53d9", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.  ", "original_text": "Thanks, Lisa.  "}, "hash": "c2feb881b9b74953e0527c79ae10f40f92e0adf95041bc9ca5f934b8be944ffe", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.  ", "start_char_idx": 0, "end_char_idx": 41, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1d2f9a0-3aaf-4649-a4a9-ef1ad45f53d9": {"__data__": {"id_": "b1d2f9a0-3aaf-4649-a4a9-ef1ad45f53d9", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.  ", "original_text": "Thanks, Lisa.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6be4d02-d6cd-44a8-afe3-01ffeaf2f219", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.  ", "original_text": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00733c9e7373ff35db2cc12cb8b105e0802bab24de46a051f827986e717eb766", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b3b01d8-af77-4f28-879c-598dfe6a42d2", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.  ", "original_text": "Appreciate it.  "}, "hash": "ed6f77a33523eb08dd3037fb9d3b7dc207c6827d5f6d8b90469f1c273514b3e6", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Lisa.  ", "start_char_idx": 41, "end_char_idx": 56, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b3b01d8-af77-4f28-879c-598dfe6a42d2": {"__data__": {"id_": "3b3b01d8-af77-4f28-879c-598dfe6a42d2", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.  ", "original_text": "Appreciate it.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1d2f9a0-3aaf-4649-a4a9-ef1ad45f53d9", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.  ", "original_text": "Thanks, Lisa.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1598dd4d389714edcc71559c971c5fd18fc874ac0d00e06a7145ca272c911f6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97ef15a0-e4b8-44ae-85f5-a0cba3398f6d", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n", "original_text": "Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.  "}, "hash": "925a8bf8d5908b34ecf49793fce03ca1fc59ec79acee1856a1545d1e99286c59", "class_name": "RelatedNodeInfo"}}, "text": "Appreciate it.  ", "start_char_idx": 56, "end_char_idx": 72, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97ef15a0-e4b8-44ae-85f5-a0cba3398f6d": {"__data__": {"id_": "97ef15a0-e4b8-44ae-85f5-a0cba3398f6d", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n", "original_text": "Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b3b01d8-af77-4f28-879c-598dfe6a42d2", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.  ", "original_text": "Appreciate it.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c8a90957790b9ceafc142509fbcf34ade3f5f4f1029c4dce27e82ea72e17779", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44af5ef2-595e-416c-85dc-da6adb1a67f6", "node_type": "1", "metadata": {"window": "Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.  ", "original_text": "We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.  "}, "hash": "0990a8242092e19e1f9ffd4cfb03e7704de42f27f8a86735f9535841f22e01c0", "class_name": "RelatedNodeInfo"}}, "text": "Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.  ", "start_char_idx": 72, "end_char_idx": 408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44af5ef2-595e-416c-85dc-da6adb1a67f6": {"__data__": {"id_": "44af5ef2-595e-416c-85dc-da6adb1a67f6", "embedding": null, "metadata": {"window": "Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.  ", "original_text": "We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97ef15a0-e4b8-44ae-85f5-a0cba3398f6d", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n", "original_text": "Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0e25a087406ba3e3783f33b5377298a39730f48424f542ceabb117830e1c306", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3346484c-7e96-454e-afbd-357bfff266a8", "node_type": "1", "metadata": {"window": "Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.  ", "original_text": "We see all of them \nnext year being able to grow top and bottom lines by double digits.  "}, "hash": "9ef91e666b8f7280083e8e028be8f34a763ec7707c9676c4a8c3556c6cbe9560", "class_name": "RelatedNodeInfo"}}, "text": "We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.  ", "start_char_idx": 408, "end_char_idx": 511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3346484c-7e96-454e-afbd-357bfff266a8": {"__data__": {"id_": "3346484c-7e96-454e-afbd-357bfff266a8", "embedding": null, "metadata": {"window": "Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.  ", "original_text": "We see all of them \nnext year being able to grow top and bottom lines by double digits.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44af5ef2-595e-416c-85dc-da6adb1a67f6", "node_type": "1", "metadata": {"window": "Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.  ", "original_text": "We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4cf66526b8cee62af0c80100528267402089bf3b916752ca2e8441dec1b0f05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eb16b38-eec2-4ec2-96aa-500e0e7c0ece", "node_type": "1", "metadata": {"window": "Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.  ", "original_text": "And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n"}, "hash": "25d7c5f8723729ca189dcc73c8381b07364af3fb0469aa7ca79abe0b46c8f652", "class_name": "RelatedNodeInfo"}}, "text": "We see all of them \nnext year being able to grow top and bottom lines by double digits.  ", "start_char_idx": 511, "end_char_idx": 600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8eb16b38-eec2-4ec2-96aa-500e0e7c0ece": {"__data__": {"id_": "8eb16b38-eec2-4ec2-96aa-500e0e7c0ece", "embedding": null, "metadata": {"window": "Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.  ", "original_text": "And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3346484c-7e96-454e-afbd-357bfff266a8", "node_type": "1", "metadata": {"window": "Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.  ", "original_text": "We see all of them \nnext year being able to grow top and bottom lines by double digits.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64e1e4eab798c7a88a394b1795e9fd77e5c767254270c1c63bcdbd3b2033c31c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a27bedc-8b23-47c2-9fcb-6f983488dd5b", "node_type": "1", "metadata": {"window": "We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n", "original_text": "So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.  "}, "hash": "abf783be8d74deff9082db82d1bf490228bf3d11209a07a64fec672709b2cf43", "class_name": "RelatedNodeInfo"}}, "text": "And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n", "start_char_idx": 600, "end_char_idx": 717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a27bedc-8b23-47c2-9fcb-6f983488dd5b": {"__data__": {"id_": "3a27bedc-8b23-47c2-9fcb-6f983488dd5b", "embedding": null, "metadata": {"window": "We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n", "original_text": "So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8eb16b38-eec2-4ec2-96aa-500e0e7c0ece", "node_type": "1", "metadata": {"window": "Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.   We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.  ", "original_text": "And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b24c610581c13a919ea53f188db36a6f9f8c68400d633412fa59e758eb17bfa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01da8bb4-e96d-4717-b27c-217587191877", "node_type": "1", "metadata": {"window": "We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.  ", "original_text": "We feel really good about the pipeline of products \nin Nuclear.  "}, "hash": "8d944f3e4f56e8140282442f125a451a8918040cae02187881f7f166eb160506", "class_name": "RelatedNodeInfo"}}, "text": "So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.  ", "start_char_idx": 717, "end_char_idx": 870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01da8bb4-e96d-4717-b27c-217587191877": {"__data__": {"id_": "01da8bb4-e96d-4717-b27c-217587191877", "embedding": null, "metadata": {"window": "We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.  ", "original_text": "We feel really good about the pipeline of products \nin Nuclear.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a27bedc-8b23-47c2-9fcb-6f983488dd5b", "node_type": "1", "metadata": {"window": "We do expect continued \ndouble -digit growth from Nuclear and Specialty and our Outcomes busine sses.   We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n", "original_text": "So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7f6717808bfd6c11e3a21cb954de42379131670b705aca3b106e4b9e7ffcbb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b08c4133-d9fc-4662-9bf3-8f3bee33e3cd", "node_type": "1", "metadata": {"window": "And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.  ", "original_text": "And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.  "}, "hash": "3500fead8ee492cd1195986ae4fce6624750459b567b4fca93affa6c44fd5664", "class_name": "RelatedNodeInfo"}}, "text": "We feel really good about the pipeline of products \nin Nuclear.  ", "start_char_idx": 870, "end_char_idx": 935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b08c4133-d9fc-4662-9bf3-8f3bee33e3cd": {"__data__": {"id_": "b08c4133-d9fc-4662-9bf3-8f3bee33e3cd", "embedding": null, "metadata": {"window": "And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.  ", "original_text": "And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01da8bb4-e96d-4717-b27c-217587191877", "node_type": "1", "metadata": {"window": "We see all of them \nnext year being able to grow top and bottom lines by double digits.   And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.  ", "original_text": "We feel really good about the pipeline of products \nin Nuclear.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "645f833cf65b4db7dddbdd2a4854d169371bd42602feddbb45fd0ea59327db75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b824bbb7-cf29-42f2-83c8-01ed38a1b810", "node_type": "1", "metadata": {"window": "So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n", "original_text": "So we \nfeel good about all of those businesses.  \n"}, "hash": "8f164ebc7007ffd1fdf1c05709c4bfa8a1c0b8388c0414a83caeaff92ceb4063", "class_name": "RelatedNodeInfo"}}, "text": "And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.  ", "start_char_idx": 935, "end_char_idx": 1217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b824bbb7-cf29-42f2-83c8-01ed38a1b810": {"__data__": {"id_": "b824bbb7-cf29-42f2-83c8-01ed38a1b810", "embedding": null, "metadata": {"window": "So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n", "original_text": "So we \nfeel good about all of those businesses.  \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b08c4133-d9fc-4662-9bf3-8f3bee33e3cd", "node_type": "1", "metadata": {"window": "And we continue to see those \nbusinesses continue to be a bigger and bigger portion of the overall Pharma segment.  \n So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.  ", "original_text": "And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fc59060f335b050a3a8d0383d5be2a1ee15f061219d94f6d160842b0dfcafef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2c3fc3e-2208-4d4f-b517-2cd2a6cff6fa", "node_type": "1", "metadata": {"window": "We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n", "original_text": "And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.  "}, "hash": "0e8a8308543f64935aae072076d98b3ea04152b8111a7b7e3f5b93df6149c64d", "class_name": "RelatedNodeInfo"}}, "text": "So we \nfeel good about all of those businesses.  \n", "start_char_idx": 1217, "end_char_idx": 1267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2c3fc3e-2208-4d4f-b517-2cd2a6cff6fa": {"__data__": {"id_": "b2c3fc3e-2208-4d4f-b517-2cd2a6cff6fa", "embedding": null, "metadata": {"window": "We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n", "original_text": "And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b824bbb7-cf29-42f2-83c8-01ed38a1b810", "node_type": "1", "metadata": {"window": "So as they continue to grow at those rates and are a bigger portion of the segment, obviously, they're \ngoing to continue to have more and more impact.   We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n", "original_text": "So we \nfeel good about all of those businesses.  \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adb5d868c939f7c3afd31b0b41cbd5d9815a218d10d1bdadbc85580b75366f40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9dc7a45-9799-49bb-93eb-bd9d1ee39f01", "node_type": "1", "metadata": {"window": "And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.  ", "original_text": "We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.  "}, "hash": "9791c00849a1524923c1c452190bbf6a03764cfca821474a7b3f6952fa40beef", "class_name": "RelatedNodeInfo"}}, "text": "And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.  ", "start_char_idx": 1267, "end_char_idx": 1416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9dc7a45-9799-49bb-93eb-bd9d1ee39f01": {"__data__": {"id_": "b9dc7a45-9799-49bb-93eb-bd9d1ee39f01", "embedding": null, "metadata": {"window": "And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.  ", "original_text": "We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2c3fc3e-2208-4d4f-b517-2cd2a6cff6fa", "node_type": "1", "metadata": {"window": "We feel really good about the pipeline of products \nin Nuclear.   And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n", "original_text": "And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99a2e942455403fc05f3893ea59b2d019f36c14afb07699982889b7945ffffe6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5cec5fa-8f47-4b83-b40f-3dae613634f2", "node_type": "1", "metadata": {"window": "So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n", "original_text": "And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n"}, "hash": "5bd69458ac3004dfa0ebdcaad4ec773115d2ac7b150a427ce70f3ca8baf2782b", "class_name": "RelatedNodeInfo"}}, "text": "We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.  ", "start_char_idx": 1416, "end_char_idx": 1590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5cec5fa-8f47-4b83-b40f-3dae613634f2": {"__data__": {"id_": "a5cec5fa-8f47-4b83-b40f-3dae613634f2", "embedding": null, "metadata": {"window": "So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n", "original_text": "And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9dc7a45-9799-49bb-93eb-bd9d1ee39f01", "node_type": "1", "metadata": {"window": "And with the work we're doing in our center for advancement of Theranostics, we already  \nhave a significant amount of manufacturers committed to joining us in the center when we open it and \nworking together on some new both treatments and diagnostics for cancer and other areas.   So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.  ", "original_text": "We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4ae497424c561b04a0f09f69243fbb8d283ce15b1a114bfd25ac7d3789b7d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fecae755-58de-47b9-88c4-f5393f4e88e4", "node_type": "1", "metadata": {"window": "And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.  ", "original_text": "Kevin Moran:  Next question, please.  \n"}, "hash": "d19a053b336671c0906c73daa719390c55f4ffe2a3ec05ed640479d74d928bf3", "class_name": "RelatedNodeInfo"}}, "text": "And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n", "start_char_idx": 1590, "end_char_idx": 1694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fecae755-58de-47b9-88c4-f5393f4e88e4": {"__data__": {"id_": "fecae755-58de-47b9-88c4-f5393f4e88e4", "embedding": null, "metadata": {"window": "And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.  ", "original_text": "Kevin Moran:  Next question, please.  \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5cec5fa-8f47-4b83-b40f-3dae613634f2", "node_type": "1", "metadata": {"window": "So we \nfeel good about all of those businesses.  \n And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n", "original_text": "And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6dcd3e8efe8f559068aecf33228896b9ec0884ffa6c23b8ad76cbb841a05b15d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3faf9e88-095c-4689-8c25-1797983bd7c4", "node_type": "1", "metadata": {"window": "We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.  ", "original_text": "Operator:  And next, we'll hear from George Hill with Deutsche Bank.  "}, "hash": "9d8eae708427765573ad86f1d383dee0a45e3a6ead6aa804875b5844e42e47a8", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Next question, please.  \n", "start_char_idx": 1694, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3faf9e88-095c-4689-8c25-1797983bd7c4": {"__data__": {"id_": "3faf9e88-095c-4689-8c25-1797983bd7c4", "embedding": null, "metadata": {"window": "We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.  ", "original_text": "Operator:  And next, we'll hear from George Hill with Deutsche Bank.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fecae755-58de-47b9-88c4-f5393f4e88e4", "node_type": "1", "metadata": {"window": "And then as far a s the core PD business goes, we think we are well positioned with some very large \nand important customers, that you're aware of.   We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.  ", "original_text": "Kevin Moran:  Next question, please.  \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e222dfecd3c600d1032da8c3fb861ef7a04c6ad1732e5d533625688b51f72d5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c5b4dc4-e42b-42b9-be28-075072d41d51", "node_type": "1", "metadata": {"window": "And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?  ", "original_text": "Pl ease go ahead.   \n"}, "hash": "513e0948a96182139d585de79cf0581011200e0eb9f27e15b9c8ba3451818f22", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And next, we'll hear from George Hill with Deutsche Bank.  ", "start_char_idx": 1733, "end_char_idx": 1803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c5b4dc4-e42b-42b9-be28-075072d41d51": {"__data__": {"id_": "1c5b4dc4-e42b-42b9-be28-075072d41d51", "embedding": null, "metadata": {"window": "And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?  ", "original_text": "Pl ease go ahead.   \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3faf9e88-095c-4689-8c25-1797983bd7c4", "node_type": "1", "metadata": {"window": "We've got eight more years now on our agreement \nrelated to Red Oak, and we feel good about that partnership and that's continu ed positive impact on \nour generics program.   And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.  ", "original_text": "Operator:  And next, we'll hear from George Hill with Deutsche Bank.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d9669f39ddd2f107398c0524f3a1a511929853962bc3ff240e1fdac2c9443b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4da1471-94c1-40d1-87ab-cce303a0d616", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.  ", "original_text": "George Hill:  Hey, good morning, guys.  "}, "hash": "d4511e3b7dcb88469ffd823dd1126bed1c3f928c7e3a22dc5624ca7e3ba54fe8", "class_name": "RelatedNodeInfo"}}, "text": "Pl ease go ahead.   \n", "start_char_idx": 1803, "end_char_idx": 1824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4da1471-94c1-40d1-87ab-cce303a0d616": {"__data__": {"id_": "d4da1471-94c1-40d1-87ab-cce303a0d616", "embedding": null, "metadata": {"window": "Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.  ", "original_text": "George Hill:  Hey, good morning, guys.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c5b4dc4-e42b-42b9-be28-075072d41d51", "node_type": "1", "metadata": {"window": "And so those are some of the things, I would say, make us feel good about \nthat growth going forward.  \n Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?  ", "original_text": "Pl ease go ahead.   \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d54b40c3f0d311a3c324ff83865817a3427133169533e35ee6cdfecabf5949e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1ec1960-f0db-443b-903d-3149a629cec1", "node_type": "1", "metadata": {"window": "Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n", "original_text": "And thanks for taking the questions.  "}, "hash": "e578b54628b65d3d45f6dfb9a070546b25708fb0297365bb98266d75cdd46738", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Hey, good morning, guys.  ", "start_char_idx": 1824, "end_char_idx": 1864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1ec1960-f0db-443b-903d-3149a629cec1": {"__data__": {"id_": "e1ec1960-f0db-443b-903d-3149a629cec1", "embedding": null, "metadata": {"window": "Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n", "original_text": "And thanks for taking the questions.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4da1471-94c1-40d1-87ab-cce303a0d616", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.  ", "original_text": "George Hill:  Hey, good morning, guys.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20be9df2e306493b0a7b75f734b64ff9c4e8496f1708eb0fa0555c8ab370cf73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "284b1c6c-085d-490b-986d-de91cdd3828d", "node_type": "1", "metadata": {"window": "Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.  ", "original_text": "I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?  "}, "hash": "1df4c50ea792260af03530607bb2fb79157eb441a450626a3f8bcb15fa742177", "class_name": "RelatedNodeInfo"}}, "text": "And thanks for taking the questions.  ", "start_char_idx": 1864, "end_char_idx": 1902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "284b1c6c-085d-490b-986d-de91cdd3828d": {"__data__": {"id_": "284b1c6c-085d-490b-986d-de91cdd3828d", "embedding": null, "metadata": {"window": "Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.  ", "original_text": "I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1ec1960-f0db-443b-903d-3149a629cec1", "node_type": "1", "metadata": {"window": "Operator:  And next, we'll hear from George Hill with Deutsche Bank.   Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n", "original_text": "And thanks for taking the questions.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "624f08c0dedaba0e8b2c49c6733cbbaef3714d4bce275b8107b7874b734b26d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ac7904a-e94f-440b-b5ca-7769a933b782", "node_type": "1", "metadata": {"window": "George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.  ", "original_text": "And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.  "}, "hash": "550d80f3d0a66611b000c0561616cec975d197c853cac48e84b0d9aa859cde16", "class_name": "RelatedNodeInfo"}}, "text": "I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?  ", "start_char_idx": 1902, "end_char_idx": 2056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ac7904a-e94f-440b-b5ca-7769a933b782": {"__data__": {"id_": "9ac7904a-e94f-440b-b5ca-7769a933b782", "embedding": null, "metadata": {"window": "George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.  ", "original_text": "And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "284b1c6c-085d-490b-986d-de91cdd3828d", "node_type": "1", "metadata": {"window": "Pl ease go ahead.   \n George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.  ", "original_text": "I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9f659d086be0c56fb72292984fbd0cba135f04fef4b6630862eacfc6dd4b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e39f74f3-210e-4790-b967-bd4a7ca9dc50", "node_type": "1", "metadata": {"window": "And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.  ", "original_text": "As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n"}, "hash": "833cc874b17c154e39628c77c1c9f3c45e040ba107d9ac18527bb9802e3de931", "class_name": "RelatedNodeInfo"}}, "text": "And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.  ", "start_char_idx": 2056, "end_char_idx": 2174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e39f74f3-210e-4790-b967-bd4a7ca9dc50": {"__data__": {"id_": "e39f74f3-210e-4790-b967-bd4a7ca9dc50", "embedding": null, "metadata": {"window": "And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.  ", "original_text": "As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ac7904a-e94f-440b-b5ca-7769a933b782", "node_type": "1", "metadata": {"window": "George Hill:  Hey, good morning, guys.   And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.  ", "original_text": "And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16557d38351a0c8ba10b54da3ada5694b8f7ad953366583fdb7c3c1aeaba8889", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6960db19-1f85-4722-80fc-34b35c9717b5", "node_type": "1", "metadata": {"window": "I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.  ", "original_text": "Mike Kaufmann:  Yes, two very good questions.  "}, "hash": "f7581a05cb2ea4a9661ffdcb6a5cd055ddc66831bd86fa167f0e828b72161977", "class_name": "RelatedNodeInfo"}}, "text": "As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n", "start_char_idx": 2174, "end_char_idx": 2388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6960db19-1f85-4722-80fc-34b35c9717b5": {"__data__": {"id_": "6960db19-1f85-4722-80fc-34b35c9717b5", "embedding": null, "metadata": {"window": "I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.  ", "original_text": "Mike Kaufmann:  Yes, two very good questions.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e39f74f3-210e-4790-b967-bd4a7ca9dc50", "node_type": "1", "metadata": {"window": "And thanks for taking the questions.   I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.  ", "original_text": "As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "758a490924bcbff7d319ebdf943fd3cda4606457337463d7f623436fb69708f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ad9a262-514c-4518-a1d7-e2da83e5316c", "node_type": "1", "metadata": {"window": "And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n", "original_text": "So first of all, on brand.  "}, "hash": "4ea5dca58d553bed2ebc5fca3fe014b00c2bc5ef9c0a54b15a9775db584371aa", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, two very good questions.  ", "start_char_idx": 2388, "end_char_idx": 2435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ad9a262-514c-4518-a1d7-e2da83e5316c": {"__data__": {"id_": "3ad9a262-514c-4518-a1d7-e2da83e5316c", "embedding": null, "metadata": {"window": "And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n", "original_text": "So first of all, on brand.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6960db19-1f85-4722-80fc-34b35c9717b5", "node_type": "1", "metadata": {"window": "I guess Mike, first, I \nwould ask you, with the renewal of the Red Oak agreement, are there any substantive changes to the \neconomics of that agreement?   And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.  ", "original_text": "Mike Kaufmann:  Yes, two very good questions.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3743f3a294794a5c923d4bcc241d12c8e2d36bf269a5c09d9f0ed5a8a1d42da4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "386a7bfc-2149-4fae-aa1b-d38d838aeb72", "node_type": "1", "metadata": {"window": "As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.  ", "original_text": "What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.  "}, "hash": "23848a6a0d03ae3f24f31ee48b17770a28701bfc466c5fb0937bb4198b217f9b", "class_name": "RelatedNodeInfo"}}, "text": "So first of all, on brand.  ", "start_char_idx": 2435, "end_char_idx": 2463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "386a7bfc-2149-4fae-aa1b-d38d838aeb72": {"__data__": {"id_": "386a7bfc-2149-4fae-aa1b-d38d838aeb72", "embedding": null, "metadata": {"window": "As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.  ", "original_text": "What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ad9a262-514c-4518-a1d7-e2da83e5316c", "node_type": "1", "metadata": {"window": "And then number two, you guys called out contingent brand inflation \nin the press -- I'm sorry, in the presentation.   As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n", "original_text": "So first of all, on brand.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9715357bc0d116dc3fe5308ebf683efe3dece4be76749bfa9fc6b3e998fb2cc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69fe565c-139b-490b-95b4-e32989db7ed9", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.  ", "original_text": "So we're not \nseeing any real changes there.  "}, "hash": "efdd9a5d53294f3d688e41b21093f2a14f393d6bf96758f893df5a6113e43187", "class_name": "RelatedNodeInfo"}}, "text": "What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.  ", "start_char_idx": 2463, "end_char_idx": 2584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69fe565c-139b-490b-95b4-e32989db7ed9": {"__data__": {"id_": "69fe565c-139b-490b-95b4-e32989db7ed9", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.  ", "original_text": "So we're not \nseeing any real changes there.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "386a7bfc-2149-4fae-aa1b-d38d838aeb72", "node_type": "1", "metadata": {"window": "As the business is starting to mix back towards brand \ngrowth, are you seeing any changes in the underlying economics of the brand relationships and the \namount of profit that's exposed to brand price inflation?  \n Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.  ", "original_text": "What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "336b1f71344722be1266be02923f0f70c16417f952180ff971fe53998098d6d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e9de60d-52aa-480e-9ce5-b631d1daaeeb", "node_type": "1", "metadata": {"window": "So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.  ", "original_text": "And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n"}, "hash": "b5989ff7dd41955f3900161900430ed28467e49f2165ad8aadb5d4a6a3d06c1e", "class_name": "RelatedNodeInfo"}}, "text": "So we're not \nseeing any real changes there.  ", "start_char_idx": 2584, "end_char_idx": 2630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e9de60d-52aa-480e-9ce5-b631d1daaeeb": {"__data__": {"id_": "6e9de60d-52aa-480e-9ce5-b631d1daaeeb", "embedding": null, "metadata": {"window": "So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.  ", "original_text": "And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69fe565c-139b-490b-95b4-e32989db7ed9", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, two very good questions.   So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.  ", "original_text": "So we're not \nseeing any real changes there.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c909e084d7ad5ade4856080464f73a91a4e5b54b68a44a3a145ff011359bf135", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9214b6b6-2259-4cfb-b533-f01bb4dbc1d4", "node_type": "1", "metadata": {"window": "What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.   And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "original_text": "As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.  "}, "hash": "3d20d259f90f8a90b16781312f8bb67596a27fd34b29c206a3294b3c2b43206e", "class_name": "RelatedNodeInfo"}}, "text": "And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n", "start_char_idx": 2630, "end_char_idx": 2918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9214b6b6-2259-4cfb-b533-f01bb4dbc1d4": {"__data__": {"id_": "9214b6b6-2259-4cfb-b533-f01bb4dbc1d4", "embedding": null, "metadata": {"window": "What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.   And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "original_text": "As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e9de60d-52aa-480e-9ce5-b631d1daaeeb", "node_type": "1", "metadata": {"window": "So first of all, on brand.   What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.  ", "original_text": "And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f841f41b3bfd62117db2070cb5cb765f428b44bf70b00275cd1d25d00ec315eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7aa07b9-59c6-4d14-a793-e36b8a181365", "node_type": "1", "metadata": {"window": "So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.   And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "original_text": "We have very strong relationships with manufacturers.  "}, "hash": "7d6db3f4157d662aa0e0a58563be61761ce61565dbc7084dcb1bdfa3653d51bf", "class_name": "RelatedNodeInfo"}}, "text": "As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.  ", "start_char_idx": 2918, "end_char_idx": 3028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7aa07b9-59c6-4d14-a793-e36b8a181365": {"__data__": {"id_": "e7aa07b9-59c6-4d14-a793-e36b8a181365", "embedding": null, "metadata": {"window": "So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.   And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "original_text": "We have very strong relationships with manufacturers.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9214b6b6-2259-4cfb-b533-f01bb4dbc1d4", "node_type": "1", "metadata": {"window": "What we're seeing there is \nwe're expecting the overall inflation rate to just be similar for the last couple of years.   So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.   And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "original_text": "As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44d2ba75673ad4fb96c3c59d18dccb75f6b734a194da5a5e2fa9c82282f3dd9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "953e3f5a-4916-4131-b2d6-cb6f8e20b6d6", "node_type": "1", "metadata": {"window": "And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.   And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "original_text": "And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.  "}, "hash": "74160b3fa3d2d992d9c13fe512d9bdf4c4df50e8485b784700968577f8d1c98d", "class_name": "RelatedNodeInfo"}}, "text": "We have very strong relationships with manufacturers.  ", "start_char_idx": 3028, "end_char_idx": 3083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "953e3f5a-4916-4131-b2d6-cb6f8e20b6d6": {"__data__": {"id_": "953e3f5a-4916-4131-b2d6-cb6f8e20b6d6", "embedding": null, "metadata": {"window": "And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.   And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "original_text": "And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7aa07b9-59c6-4d14-a793-e36b8a181365", "node_type": "1", "metadata": {"window": "So we're not \nseeing any real changes there.   And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.   And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "original_text": "We have very strong relationships with manufacturers.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56d3bff652a6a4d8a687a66981ef47722d7e2be2a81ef1a29e1462c02db14cf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "babd3396-9f1a-41b2-8950-e75b519b5a88", "node_type": "1", "metadata": {"window": "As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.   And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "original_text": "And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a "}, "hash": "8c11905365a64442c0d3185b62295c1c5c2307ebff085d32a739f52933c7f901", "class_name": "RelatedNodeInfo"}}, "text": "And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.  ", "start_char_idx": 3083, "end_char_idx": 3356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "babd3396-9f1a-41b2-8950-e75b519b5a88": {"__data__": {"id_": "babd3396-9f1a-41b2-8950-e75b519b5a88", "embedding": null, "metadata": {"window": "As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.   And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "original_text": "And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b21338ab-85c0-4d94-80a0-ff396d888d23", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "519033db471f2b2873ba402424520297e85e58ffcf78e9e5d11b0f8677b35140", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "953e3f5a-4916-4131-b2d6-cb6f8e20b6d6", "node_type": "1", "metadata": {"window": "And as Jason mentioned, the reason you said getting less dollars is \nbecause more of the suppliers that were contingent to inflation have moved to non -contingent, and \nwe've renegotiated a couple of those DSAs ov er the last year so that we will no longer be contingent \nto inflation.  \n As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.   And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "original_text": "And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b15ff4c0ff2fea044e2f7b6d6b6dc9db0a9bd725bf21bd5657fccdd4992880ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b20425a-b09d-407e-9020-f23d826a5e30", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.  ", "original_text": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n"}, "hash": "3a128bb269118fc829318165072dfb21b6a50c0d4ebbf1c8914b8dcc7d85ee93", "class_name": "RelatedNodeInfo"}}, "text": "And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "start_char_idx": 3356, "end_char_idx": 3610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b20425a-b09d-407e-9020-f23d826a5e30": {"__data__": {"id_": "1b20425a-b09d-407e-9020-f23d826a5e30", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.  ", "original_text": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "babd3396-9f1a-41b2-8950-e75b519b5a88", "node_type": "1", "metadata": {"window": "As far as overall rates go, I would say, we continue to feel very good about our overall value \nproposition.   We have very strong relationships with manufacturers.   And as you know, when  any time \nthere's changes in their portfolios, sometimes that means they should get a lower price when they \nhave higher cost drugs coming out and sometimes they need to pay more fees when they lose, say, a \nhigh-priced item to a patent expiration.   And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "original_text": "And so t hose types of moving parts in terms of volume and \naverage line extension are taken into account with each negotiation, and the team has done an \nexcellent job working with our manufacturing partners and continue to have what I consider to be a ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aeb52adbf2ff4177d4c0bd831581cf3be24fe29449b3370f6c5b17b696abb03d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15fa7a73-ac0b-4774-a6d5-48edda634509", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.  ", "original_text": "As far as the Red Oak, we won't be able to get into any specifics there.  "}, "hash": "ac7ce233ef1bd51ad06b59f3860e88299789f4fcb032aa0171ca250a2009a4e0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n", "start_char_idx": 0, "end_char_idx": 143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15fa7a73-ac0b-4774-a6d5-48edda634509": {"__data__": {"id_": "15fa7a73-ac0b-4774-a6d5-48edda634509", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.  ", "original_text": "As far as the Red Oak, we won't be able to get into any specifics there.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b20425a-b09d-407e-9020-f23d826a5e30", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.  ", "original_text": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eed7518aca491a67e63ed9c5cc06404a72d09c3ff2aebee5fcc4b150feeba4c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c16e092-9afc-4e60-902b-a8cf4546fdb6", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.  ", "original_text": "But as you can imagine, it's \nbeen an excellent seven -year relationship.  "}, "hash": "e2b5128878f143e21288c924baf20348eb16e58040a4c83530f42b8c783df1df", "class_name": "RelatedNodeInfo"}}, "text": "As far as the Red Oak, we won't be able to get into any specifics there.  ", "start_char_idx": 143, "end_char_idx": 217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c16e092-9afc-4e60-902b-a8cf4546fdb6": {"__data__": {"id_": "9c16e092-9afc-4e60-902b-a8cf4546fdb6", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.  ", "original_text": "But as you can imagine, it's \nbeen an excellent seven -year relationship.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15fa7a73-ac0b-4774-a6d5-48edda634509", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.  ", "original_text": "As far as the Red Oak, we won't be able to get into any specifics there.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0999df8b41c672d39397231779bf2a83c718855f873d937255866078d39ba6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb19d9a1-7099-4441-a857-97dc042c17b7", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n", "original_text": "Th e team there continues to remain intact.  "}, "hash": "e31ffbe197fab0fd342c6d019ef2306ab59958686ba3fe815f93005a6bd50009", "class_name": "RelatedNodeInfo"}}, "text": "But as you can imagine, it's \nbeen an excellent seven -year relationship.  ", "start_char_idx": 217, "end_char_idx": 292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb19d9a1-7099-4441-a857-97dc042c17b7": {"__data__": {"id_": "eb19d9a1-7099-4441-a857-97dc042c17b7", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n", "original_text": "Th e team there continues to remain intact.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c16e092-9afc-4e60-902b-a8cf4546fdb6", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.  ", "original_text": "But as you can imagine, it's \nbeen an excellent seven -year relationship.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ba282d374fcb4469319c179b1634cfe0912f64c631958b8f6de117edefc9b6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ba65fe6-162a-4438-960a-0351e6b61546", "node_type": "1", "metadata": {"window": "As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.  ", "original_text": "They have \ndecades of generic buying experience.  "}, "hash": "2ea941417b2971e3485677ba343b67288fecd1cf397210678cdb3687655a2055", "class_name": "RelatedNodeInfo"}}, "text": "Th e team there continues to remain intact.  ", "start_char_idx": 292, "end_char_idx": 337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ba65fe6-162a-4438-960a-0351e6b61546": {"__data__": {"id_": "0ba65fe6-162a-4438-960a-0351e6b61546", "embedding": null, "metadata": {"window": "As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.  ", "original_text": "They have \ndecades of generic buying experience.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb19d9a1-7099-4441-a857-97dc042c17b7", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n", "original_text": "Th e team there continues to remain intact.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2751a41abf9af902fd9ba48825f1ae4a1eaa3079664db0c8d7674ad37c7ab1a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90609998-188b-448f-b33e-128b753c2afd", "node_type": "1", "metadata": {"window": "But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n", "original_text": "The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.  "}, "hash": "e66873f3ac87d9757e02644d759c5dc4d22a51ec7041e8cb8e89c02e3bac0e49", "class_name": "RelatedNodeInfo"}}, "text": "They have \ndecades of generic buying experience.  ", "start_char_idx": 337, "end_char_idx": 387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90609998-188b-448f-b33e-128b753c2afd": {"__data__": {"id_": "90609998-188b-448f-b33e-128b753c2afd", "embedding": null, "metadata": {"window": "But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n", "original_text": "The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ba65fe6-162a-4438-960a-0351e6b61546", "node_type": "1", "metadata": {"window": "As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.  ", "original_text": "They have \ndecades of generic buying experience.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "542076d6e9fbd013c7c9d5efb5cb72183a18eac0bfb0e04afacddfe89049196a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83e27a91-6508-4f13-bbda-cae5d3e63b1d", "node_type": "1", "metadata": {"window": "Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n", "original_text": "And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n"}, "hash": "501a117f965d2dda7e30b69033b5b3689f2f0a3f761938baa0ffd9116044426b", "class_name": "RelatedNodeInfo"}}, "text": "The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.  ", "start_char_idx": 387, "end_char_idx": 619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83e27a91-6508-4f13-bbda-cae5d3e63b1d": {"__data__": {"id_": "83e27a91-6508-4f13-bbda-cae5d3e63b1d", "embedding": null, "metadata": {"window": "Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n", "original_text": "And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90609998-188b-448f-b33e-128b753c2afd", "node_type": "1", "metadata": {"window": "But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n", "original_text": "The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e93fb6f649b55fe1ee0e7bafe442948928146f1fdb64710016fdbde99056296", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f766952-649f-4f7f-8e0e-447854e9d135", "node_type": "1", "metadata": {"window": "They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.  ", "original_text": "So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.  "}, "hash": "ab5043bd7758b81a5e1188f03dfd065f017fe3e159e12ff1a96544c3ad79ef59", "class_name": "RelatedNodeInfo"}}, "text": "And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n", "start_char_idx": 619, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f766952-649f-4f7f-8e0e-447854e9d135": {"__data__": {"id_": "3f766952-649f-4f7f-8e0e-447854e9d135", "embedding": null, "metadata": {"window": "They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.  ", "original_text": "So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83e27a91-6508-4f13-bbda-cae5d3e63b1d", "node_type": "1", "metadata": {"window": "Th e team there continues to remain intact.   They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n", "original_text": "And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca68eeac1c20bab478249ea4efcfcb072269a5f0731ff9729fe4eaed562907a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8765a05e-e006-4e65-aaa1-e33035e525b8", "node_type": "1", "metadata": {"window": "The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n", "original_text": "We feel very good about where we are with our Red Oak extension.  \n"}, "hash": "940535c498851192bf4cf858301fc22be771f6ade28f3449a5781c83d57ea7d4", "class_name": "RelatedNodeInfo"}}, "text": "So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.  ", "start_char_idx": 720, "end_char_idx": 848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8765a05e-e006-4e65-aaa1-e33035e525b8": {"__data__": {"id_": "8765a05e-e006-4e65-aaa1-e33035e525b8", "embedding": null, "metadata": {"window": "The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n", "original_text": "We feel very good about where we are with our Red Oak extension.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f766952-649f-4f7f-8e0e-447854e9d135", "node_type": "1", "metadata": {"window": "They have \ndecades of generic buying experience.   The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.  ", "original_text": "So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a86680e40ba3bf86225a01047131ee6d2b70029b1dfbc525db9240158f76cea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9e7cd83-860e-4488-86f1-877b9cadff11", "node_type": "1", "metadata": {"window": "And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.  ", "original_text": "We\u2019ll take one last question.   \n"}, "hash": "ba149f4c5698e30f1732bd1d4e734641ac7006f5891b6a57c32e0ef4822f065e", "class_name": "RelatedNodeInfo"}}, "text": "We feel very good about where we are with our Red Oak extension.  \n", "start_char_idx": 848, "end_char_idx": 915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9e7cd83-860e-4488-86f1-877b9cadff11": {"__data__": {"id_": "d9e7cd83-860e-4488-86f1-877b9cadff11", "embedding": null, "metadata": {"window": "And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.  ", "original_text": "We\u2019ll take one last question.   \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8765a05e-e006-4e65-aaa1-e33035e525b8", "node_type": "1", "metadata": {"window": "The leadership there and the team has -- just a great group of \nindividuals, again, with experience that continues to bring new ideas together to the market to be abl e \nto help us continue to get the best cost in the marketplace.   And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n", "original_text": "We feel very good about where we are with our Red Oak extension.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a4dab4123a6313a3354c3f7604d5b9d0a0df67b075d326d5df0b478fd7b7aeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e34e3738-110d-4eb8-89c3-77ae5e9d03f5", "node_type": "1", "metadata": {"window": "So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.  ", "original_text": "Operator:  And our last question will come from Charles Rhyee from Cowen.  "}, "hash": "f4555c9615665382dbcae0ff80fc5107cbf23e3985d9610d17da2394e1b67566", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ll take one last question.   \n", "start_char_idx": 915, "end_char_idx": 948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e34e3738-110d-4eb8-89c3-77ae5e9d03f5": {"__data__": {"id_": "e34e3738-110d-4eb8-89c3-77ae5e9d03f5", "embedding": null, "metadata": {"window": "So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.  ", "original_text": "Operator:  And our last question will come from Charles Rhyee from Cowen.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9e7cd83-860e-4488-86f1-877b9cadff11", "node_type": "1", "metadata": {"window": "And we continue to partner well with CVS \nat Board meetings, et cetera, to continue to drive that.  \n So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.  ", "original_text": "We\u2019ll take one last question.   \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "155fa2f22f3557b0c48691ab43753c77de8d1d531d76b8b88b23a863342f4a8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cdd6957-e933-4922-a02c-fc3016ae670b", "node_type": "1", "metadata": {"window": "We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.  ", "original_text": "Please go ahead.  \n"}, "hash": "ddcf43fb3c284bb7e174ac830f4a2298ee759b55b0a413a5640e2e6f5a18e7c3", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And our last question will come from Charles Rhyee from Cowen.  ", "start_char_idx": 948, "end_char_idx": 1023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cdd6957-e933-4922-a02c-fc3016ae670b": {"__data__": {"id_": "3cdd6957-e933-4922-a02c-fc3016ae670b", "embedding": null, "metadata": {"window": "We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.  ", "original_text": "Please go ahead.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e34e3738-110d-4eb8-89c3-77ae5e9d03f5", "node_type": "1", "metadata": {"window": "So we feel that the -- both companies took into -- in the context all the market conditions on  generics \nwhen we renegotiate.   We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.  ", "original_text": "Operator:  And our last question will come from Charles Rhyee from Cowen.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ffcadebea49003db3d56f2f2d4da017772e949a8a747e5f9889024c1ceb3251", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1601cfc1-7251-4ed9-b04e-02d393cf17ae", "node_type": "1", "metadata": {"window": "We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.  ", "original_text": "Charles Rhyee:  Yes.  "}, "hash": "cbca8dbc388d6ae01abb27cccba8100eba408a22da335ed488f5d8ab20c77218", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n", "start_char_idx": 1023, "end_char_idx": 1042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1601cfc1-7251-4ed9-b04e-02d393cf17ae": {"__data__": {"id_": "1601cfc1-7251-4ed9-b04e-02d393cf17ae", "embedding": null, "metadata": {"window": "We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.  ", "original_text": "Charles Rhyee:  Yes.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cdd6957-e933-4922-a02c-fc3016ae670b", "node_type": "1", "metadata": {"window": "We feel very good about where we are with our Red Oak extension.  \n We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.  ", "original_text": "Please go ahead.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caa6b3e7ea4079d3e526128d8aa16ab457b4e47d445b30adeea13de37222e057", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca72b27d-1582-4330-a542-9c118c709c12", "node_type": "1", "metadata": {"window": "Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?  ", "original_text": "Thanks -- thanks for squeezing me in here.  "}, "hash": "1c3043cfea3e1c3ab931ba774e8dead86fc0bd0d210a257437a31e9c83fff069", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  Yes.  ", "start_char_idx": 1042, "end_char_idx": 1064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca72b27d-1582-4330-a542-9c118c709c12": {"__data__": {"id_": "ca72b27d-1582-4330-a542-9c118c709c12", "embedding": null, "metadata": {"window": "Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?  ", "original_text": "Thanks -- thanks for squeezing me in here.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1601cfc1-7251-4ed9-b04e-02d393cf17ae", "node_type": "1", "metadata": {"window": "We\u2019ll take one last question.   \n Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.  ", "original_text": "Charles Rhyee:  Yes.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0f82c5ad07d51fb1023766a52cad3b22aea0f3e467ebdccd81855ba83634561", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93f048f9-547c-4cb0-93b3-b2a3e83bc7bd", "node_type": "1", "metadata": {"window": "Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?  ", "original_text": "Maybe, Mike -- maybe a question \non opioids and the settlement here.  "}, "hash": "77d1c46128cdd8100c488e0c39fa7f5ea8f8e4266c0d61112ceddcf5b6ca6ece", "class_name": "RelatedNodeInfo"}}, "text": "Thanks -- thanks for squeezing me in here.  ", "start_char_idx": 1064, "end_char_idx": 1108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93f048f9-547c-4cb0-93b3-b2a3e83bc7bd": {"__data__": {"id_": "93f048f9-547c-4cb0-93b3-b2a3e83bc7bd", "embedding": null, "metadata": {"window": "Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?  ", "original_text": "Maybe, Mike -- maybe a question \non opioids and the settlement here.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca72b27d-1582-4330-a542-9c118c709c12", "node_type": "1", "metadata": {"window": "Operator:  And our last question will come from Charles Rhyee from Cowen.   Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?  ", "original_text": "Thanks -- thanks for squeezing me in here.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4718f0366296ea139f291391d53d2aa3d275b5142991fe22f784a601b7b757d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a71248ec-8f98-434d-a3ad-d0d05f18dcb3", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.   ", "original_text": "I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.  "}, "hash": "eaf0a9f9b0a840fb98bee5deddcd13e2bcfa682ac270f5d0b0dfa1c7da44cef3", "class_name": "RelatedNodeInfo"}}, "text": "Maybe, Mike -- maybe a question \non opioids and the settlement here.  ", "start_char_idx": 1108, "end_char_idx": 1178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a71248ec-8f98-434d-a3ad-d0d05f18dcb3": {"__data__": {"id_": "a71248ec-8f98-434d-a3ad-d0d05f18dcb3", "embedding": null, "metadata": {"window": "Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.   ", "original_text": "I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93f048f9-547c-4cb0-93b3-b2a3e83bc7bd", "node_type": "1", "metadata": {"window": "Please go ahead.  \n Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?  ", "original_text": "Maybe, Mike -- maybe a question \non opioids and the settlement here.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e84324b456131e741902f854c39c784cb52bbd894fd874427794f72e8f8bbc50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d95c6f65-aee3-403d-aca6-977e3f46e17b", "node_type": "1", "metadata": {"window": "Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?  ", "original_text": "What's the minimum participation that's required und er this settlement for \nit to go into effect?  "}, "hash": "5ba4e121ab664ebdce5daa9580806599a93e2448e0c4e6b12ec55e2a6b39ead0", "class_name": "RelatedNodeInfo"}}, "text": "I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.  ", "start_char_idx": 1178, "end_char_idx": 1282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d95c6f65-aee3-403d-aca6-977e3f46e17b": {"__data__": {"id_": "d95c6f65-aee3-403d-aca6-977e3f46e17b", "embedding": null, "metadata": {"window": "Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?  ", "original_text": "What's the minimum participation that's required und er this settlement for \nit to go into effect?  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a71248ec-8f98-434d-a3ad-d0d05f18dcb3", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Yes.   Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.   ", "original_text": "I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf883846b9e36d3336824e747911e16b7abe2455876234f5739de8dcebc790ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad2f5502-2de1-48ec-9b88-5db50bc3630f", "node_type": "1", "metadata": {"window": "Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?  ", "original_text": "So in other words, is it like half the participants have to at least participate?  "}, "hash": "d832c641e433a255d60ae96b3cec745631b1dd749be5e222045355b6025cd6e6", "class_name": "RelatedNodeInfo"}}, "text": "What's the minimum participation that's required und er this settlement for \nit to go into effect?  ", "start_char_idx": 1282, "end_char_idx": 1382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad2f5502-2de1-48ec-9b88-5db50bc3630f": {"__data__": {"id_": "ad2f5502-2de1-48ec-9b88-5db50bc3630f", "embedding": null, "metadata": {"window": "Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?  ", "original_text": "So in other words, is it like half the participants have to at least participate?  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d95c6f65-aee3-403d-aca6-977e3f46e17b", "node_type": "1", "metadata": {"window": "Thanks -- thanks for squeezing me in here.   Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?  ", "original_text": "What's the minimum participation that's required und er this settlement for \nit to go into effect?  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0afa2dc288462ba816080481260714aa915eeca96ad78cd5266257541584dfb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4359f946-2952-4466-bd60-ee3d7e23a996", "node_type": "1", "metadata": {"window": "I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n", "original_text": "And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.   "}, "hash": "28136a924a94f1a838b5b1f1993a3d1b9aca18a564baecc712da9826b2860400", "class_name": "RelatedNodeInfo"}}, "text": "So in other words, is it like half the participants have to at least participate?  ", "start_char_idx": 1382, "end_char_idx": 1465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4359f946-2952-4466-bd60-ee3d7e23a996": {"__data__": {"id_": "4359f946-2952-4466-bd60-ee3d7e23a996", "embedding": null, "metadata": {"window": "I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n", "original_text": "And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.   ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad2f5502-2de1-48ec-9b88-5db50bc3630f", "node_type": "1", "metadata": {"window": "Maybe, Mike -- maybe a question \non opioids and the settlement here.   I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?  ", "original_text": "So in other words, is it like half the participants have to at least participate?  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2f0b5625e2e7bece3a47ddb19a3bf9d4d44ce33e2d520fdbfb2adbe0b778679", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f694cff-0a47-43a2-b5d9-68355724ab76", "node_type": "1", "metadata": {"window": "What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.  ", "original_text": "So I just wondered what that minimum requirement is?  "}, "hash": "d0669f17889ffc0016ecb104258ace668886535564909c005fa26f4ca8115f0d", "class_name": "RelatedNodeInfo"}}, "text": "And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.   ", "start_char_idx": 1465, "end_char_idx": 1597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f694cff-0a47-43a2-b5d9-68355724ab76": {"__data__": {"id_": "8f694cff-0a47-43a2-b5d9-68355724ab76", "embedding": null, "metadata": {"window": "What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.  ", "original_text": "So I just wondered what that minimum requirement is?  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4359f946-2952-4466-bd60-ee3d7e23a996", "node_type": "1", "metadata": {"window": "I think there's like 150 days or so that -- for the plaintiffs to accept \nthe terms of the settlement.   What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n", "original_text": "And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.   ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fe760d31ede322a4ffa0b2957e2ca4846673fd86a08065fedc4e6135d63d9ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "264a9f10-3c90-406f-9ebd-84af38a15c17", "node_type": "1", "metadata": {"window": "So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.  ", "original_text": "And what \nhappens if you don't hit that threshold?  "}, "hash": "db229828f14a370638b3c1d5fa05649ee7b99e05c841e4998eb3257eec3e861d", "class_name": "RelatedNodeInfo"}}, "text": "So I just wondered what that minimum requirement is?  ", "start_char_idx": 1597, "end_char_idx": 1651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "264a9f10-3c90-406f-9ebd-84af38a15c17": {"__data__": {"id_": "264a9f10-3c90-406f-9ebd-84af38a15c17", "embedding": null, "metadata": {"window": "So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.  ", "original_text": "And what \nhappens if you don't hit that threshold?  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f694cff-0a47-43a2-b5d9-68355724ab76", "node_type": "1", "metadata": {"window": "What's the minimum participation that's required und er this settlement for \nit to go into effect?   So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.  ", "original_text": "So I just wondered what that minimum requirement is?  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "054bc49a22d6b06871ebaaafca5e79c0d33aa7b0c1cb3d70f6aad50b95d34fc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35f5638a-efe7-42e3-9c12-104674711fea", "node_type": "1", "metadata": {"window": "And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.  ", "original_text": "Thanks.   \n"}, "hash": "5d9fe616afaa61e059961e76ec3ef4ff401da00ec9f20b2b4156160e0bf999d9", "class_name": "RelatedNodeInfo"}}, "text": "And what \nhappens if you don't hit that threshold?  ", "start_char_idx": 1651, "end_char_idx": 1703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35f5638a-efe7-42e3-9c12-104674711fea": {"__data__": {"id_": "35f5638a-efe7-42e3-9c12-104674711fea", "embedding": null, "metadata": {"window": "And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.  ", "original_text": "Thanks.   \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "264a9f10-3c90-406f-9ebd-84af38a15c17", "node_type": "1", "metadata": {"window": "So in other words, is it like half the participants have to at least participate?   And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.  ", "original_text": "And what \nhappens if you don't hit that threshold?  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "186207707b28a997c72a8760b8412cdffd428d3d926ced5dec67a774810703b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "076e11db-95ba-44a3-a575-e1dfb7439c95", "node_type": "1", "metadata": {"window": "So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "c484ee10ee85e61ba4879b4c1731467ba9c3d798ed4866dc2cd6da8be5fe4d23", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.   \n", "start_char_idx": 1703, "end_char_idx": 1714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "076e11db-95ba-44a3-a575-e1dfb7439c95": {"__data__": {"id_": "076e11db-95ba-44a3-a575-e1dfb7439c95", "embedding": null, "metadata": {"window": "So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35f5638a-efe7-42e3-9c12-104674711fea", "node_type": "1", "metadata": {"window": "And \nthen it's my understanding that the amount that you would pay out would scale down depending on \nthe number of participants.    So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.  ", "original_text": "Thanks.   \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a6ebdf811b00ca5dbc507b5dbaea4dc1e3ec83ed087496c6bf37f89b194a5a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e314459-3096-401d-95cd-45133145c254", "node_type": "1", "metadata": {"window": "And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.  ", "original_text": "Thanks for the question.  "}, "hash": "0719c27a89ec9d92f53f92f34f6fae336fcc4148593b7d887a4b2480be74c4f4", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 1714, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e314459-3096-401d-95cd-45133145c254": {"__data__": {"id_": "8e314459-3096-401d-95cd-45133145c254", "embedding": null, "metadata": {"window": "And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.  ", "original_text": "Thanks for the question.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "076e11db-95ba-44a3-a575-e1dfb7439c95", "node_type": "1", "metadata": {"window": "So I just wondered what that minimum requirement is?   And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29388299b6bafe7da1e61404ed6e1cdb6fde2bff2075c3f65a93fea43fe1466c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6707d795-5655-4f91-aedd-3405725b6ed0", "node_type": "1", "metadata": {"window": "Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n", "original_text": "So you're right.  "}, "hash": "bc141d5b30c0200098b4928b376e074c7dd69f16ea02be49044a6146547eab2c", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question.  ", "start_char_idx": 1736, "end_char_idx": 1762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6707d795-5655-4f91-aedd-3405725b6ed0": {"__data__": {"id_": "6707d795-5655-4f91-aedd-3405725b6ed0", "embedding": null, "metadata": {"window": "Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n", "original_text": "So you're right.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e314459-3096-401d-95cd-45133145c254", "node_type": "1", "metadata": {"window": "And what \nhappens if you don't hit that threshold?   Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.  ", "original_text": "Thanks for the question.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d735e4663732088fddd3dc707b43804a1729cfcd577380c8689c0916cc1d9eb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57de8efe-bd55-458b-9c09-884ae8f38ed0", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.  ", "original_text": "So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.  "}, "hash": "a3e2884fb39be8cec31bb86ca7cc77639b4fc22b0f572d106c93387fe4d03eee", "class_name": "RelatedNodeInfo"}}, "text": "So you're right.  ", "start_char_idx": 1762, "end_char_idx": 1780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57de8efe-bd55-458b-9c09-884ae8f38ed0": {"__data__": {"id_": "57de8efe-bd55-458b-9c09-884ae8f38ed0", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.  ", "original_text": "So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6707d795-5655-4f91-aedd-3405725b6ed0", "node_type": "1", "metadata": {"window": "Thanks.   \n Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n", "original_text": "So you're right.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b368ea6f67ecb5af0e77209ea2b187bbb85c7e4d899f8ee30449403ac4fa3df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2567fb41-9499-4509-9f42-ab22399209c7", "node_type": "1", "metadata": {"window": "Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.  ", "original_text": "So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.  "}, "hash": "7472578286a05f4bce0a8b682b29fb34c4cc1b5e7de39bef1b4ca6580058ad09", "class_name": "RelatedNodeInfo"}}, "text": "So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.  ", "start_char_idx": 1780, "end_char_idx": 1869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2567fb41-9499-4509-9f42-ab22399209c7": {"__data__": {"id_": "2567fb41-9499-4509-9f42-ab22399209c7", "embedding": null, "metadata": {"window": "Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.  ", "original_text": "So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57de8efe-bd55-458b-9c09-884ae8f38ed0", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.  ", "original_text": "So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe9bf928b33680255efcd1ea00087a6bfcfebd7b12ef3856fc5100f14a4d4330", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "629a5669-bf0d-4495-b040-8ce38e337e66", "node_type": "1", "metadata": {"window": "So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.  ", "original_text": "So it will decline at states not -- and cities and counties do not participate.  \n"}, "hash": "2a1992764d352dd67835ef91b8f80779be7540100a60f6306b13afd113ef78c7", "class_name": "RelatedNodeInfo"}}, "text": "So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.  ", "start_char_idx": 1869, "end_char_idx": 2030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "629a5669-bf0d-4495-b040-8ce38e337e66": {"__data__": {"id_": "629a5669-bf0d-4495-b040-8ce38e337e66", "embedding": null, "metadata": {"window": "So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.  ", "original_text": "So it will decline at states not -- and cities and counties do not participate.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2567fb41-9499-4509-9f42-ab22399209c7", "node_type": "1", "metadata": {"window": "Thanks for the question.   So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.  ", "original_text": "So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8de956ac144b103f4959c96c832d8993ab9ac96e4ed1c500254f14a0f33fd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e55ef38-1988-4873-991d-08e2540c14f2", "node_type": "1", "metadata": {"window": "So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.  ", "original_text": "Second thing, to your point, it is multi -steps.  "}, "hash": "e29d166b9255d10061f678ac26ac461844992affd1d86f2e074a448c0d483582", "class_name": "RelatedNodeInfo"}}, "text": "So it will decline at states not -- and cities and counties do not participate.  \n", "start_char_idx": 2030, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e55ef38-1988-4873-991d-08e2540c14f2": {"__data__": {"id_": "7e55ef38-1988-4873-991d-08e2540c14f2", "embedding": null, "metadata": {"window": "So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.  ", "original_text": "Second thing, to your point, it is multi -steps.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "629a5669-bf0d-4495-b040-8ce38e337e66", "node_type": "1", "metadata": {"window": "So you're right.   So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.  ", "original_text": "So it will decline at states not -- and cities and counties do not participate.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12645fa3a5a3f86823bc5da50bcd4bcb7cb7548dc30f4f8d531244d7173bf38d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80bf3135-a4f2-4e41-be8a-a87e8b22a778", "node_type": "1", "metadata": {"window": "So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.  ", "original_text": "There's a point where we get some insights to where the \nstates are.  "}, "hash": "a7381c38803b0ea446da1c733076e08be08c9524b8ec6b1147cdb38f5e088b0e", "class_name": "RelatedNodeInfo"}}, "text": "Second thing, to your point, it is multi -steps.  ", "start_char_idx": 2112, "end_char_idx": 2162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80bf3135-a4f2-4e41-be8a-a87e8b22a778": {"__data__": {"id_": "80bf3135-a4f2-4e41-be8a-a87e8b22a778", "embedding": null, "metadata": {"window": "So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.  ", "original_text": "There's a point where we get some insights to where the \nstates are.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e55ef38-1988-4873-991d-08e2540c14f2", "node_type": "1", "metadata": {"window": "So the total number that is accrued \nassumes all 50 state, cities and coun ties are in.   So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.  ", "original_text": "Second thing, to your point, it is multi -steps.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27ec71c317ac5909871cc56a30e49803ef9aa0de7f5d370387189b250cc603af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69c5d470-1f1a-4607-a75f-3776384b9abf", "node_type": "1", "metadata": {"window": "So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n", "original_text": "Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.  "}, "hash": "dc5f610ffb1477a8dd26c86ec562440b0f4fa76b5f3d60976791c16e313aea18", "class_name": "RelatedNodeInfo"}}, "text": "There's a point where we get some insights to where the \nstates are.  ", "start_char_idx": 2162, "end_char_idx": 2232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69c5d470-1f1a-4607-a75f-3776384b9abf": {"__data__": {"id_": "69c5d470-1f1a-4607-a75f-3776384b9abf", "embedding": null, "metadata": {"window": "So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n", "original_text": "Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80bf3135-a4f2-4e41-be8a-a87e8b22a778", "node_type": "1", "metadata": {"window": "So if any single state or cities and counties within \nstates do not elect to be part of it, the number will come down based on agreed upon proration by \nstate.   So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.  ", "original_text": "There's a point where we get some insights to where the \nstates are.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c6ef606dd7f912ba5634ef6434de55b0853642ca5bd395435ba49a84457fe5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c26d411e-b4fe-487f-ba15-8a5bc395df0c", "node_type": "1", "metadata": {"window": "Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.  ", "original_text": "And after all of that, we will take a look at what we call -- we're calling \ncritical mass.  "}, "hash": "a1a82ee85b59b0f8c4e699ea899863f62aec5ad05c79e7e3e7a5a6e7a8a2c710", "class_name": "RelatedNodeInfo"}}, "text": "Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.  ", "start_char_idx": 2232, "end_char_idx": 2351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c26d411e-b4fe-487f-ba15-8a5bc395df0c": {"__data__": {"id_": "c26d411e-b4fe-487f-ba15-8a5bc395df0c", "embedding": null, "metadata": {"window": "Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.  ", "original_text": "And after all of that, we will take a look at what we call -- we're calling \ncritical mass.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69c5d470-1f1a-4607-a75f-3776384b9abf", "node_type": "1", "metadata": {"window": "So it will decline at states not -- and cities and counties do not participate.  \n Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n", "original_text": "Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f083141cae7c4c77b78cdbe6fa4150c0425f0201e8187c4fda31b49334ffd69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c61cccf-1c38-44b4-a58f-d7debb4f0f69", "node_type": "1", "metadata": {"window": "There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.  ", "original_text": "There is no set number.  "}, "hash": "7397287e98c2e4e7fd1418999c81e40858ba8af93fd0c8c9aaee80f004791367", "class_name": "RelatedNodeInfo"}}, "text": "And after all of that, we will take a look at what we call -- we're calling \ncritical mass.  ", "start_char_idx": 2351, "end_char_idx": 2444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c61cccf-1c38-44b4-a58f-d7debb4f0f69": {"__data__": {"id_": "8c61cccf-1c38-44b4-a58f-d7debb4f0f69", "embedding": null, "metadata": {"window": "There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.  ", "original_text": "There is no set number.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c26d411e-b4fe-487f-ba15-8a5bc395df0c", "node_type": "1", "metadata": {"window": "Second thing, to your point, it is multi -steps.   There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.  ", "original_text": "And after all of that, we will take a look at what we call -- we're calling \ncritical mass.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1044cd46ac18fc5f0b332d3723117f764f92e8f0029509734495552f8cb68a39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b0c1d17-8f70-4a9b-972c-794029a431cb", "node_type": "1", "metadata": {"window": "Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.  ", "original_text": "So there's no minimum.   \n"}, "hash": "b17385732c3ac890ee22b82b8ed4fa2c3c5358739e6055aae07e120e1e77d615", "class_name": "RelatedNodeInfo"}}, "text": "There is no set number.  ", "start_char_idx": 2444, "end_char_idx": 2469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b0c1d17-8f70-4a9b-972c-794029a431cb": {"__data__": {"id_": "4b0c1d17-8f70-4a9b-972c-794029a431cb", "embedding": null, "metadata": {"window": "Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.  ", "original_text": "So there's no minimum.   \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c61cccf-1c38-44b4-a58f-d7debb4f0f69", "node_type": "1", "metadata": {"window": "There's a point where we get some insights to where the \nstates are.   Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.  ", "original_text": "There is no set number.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f3dfc168c252d59452f9f87350fccde5c58f21b2aad315000a59f41ffe42086", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72a299c8-e3da-4da4-a37a-49f431496dd6", "node_type": "1", "metadata": {"window": "And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.  ", "original_text": "Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.  "}, "hash": "d3f1cbff9437ab2bd8f61026b768670155b32b9e46455b70164a108a5b6e1004", "class_name": "RelatedNodeInfo"}}, "text": "So there's no minimum.   \n", "start_char_idx": 2469, "end_char_idx": 2495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72a299c8-e3da-4da4-a37a-49f431496dd6": {"__data__": {"id_": "72a299c8-e3da-4da4-a37a-49f431496dd6", "embedding": null, "metadata": {"window": "And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.  ", "original_text": "Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b0c1d17-8f70-4a9b-972c-794029a431cb", "node_type": "1", "metadata": {"window": "Then there'll be another point where we'll get to understand where the cities and counties \nand the subdivisions are.   And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.  ", "original_text": "So there's no minimum.   \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93949f33012d0f8173c46850d186947050eddc885b40a2c34a18425b8d2ef344", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a66552b-2235-40a9-8804-3584df1c69d8", "node_type": "1", "metadata": {"window": "There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n", "original_text": "That may not happen and anything less than that.  "}, "hash": "d6e25a322336bf5ada0d2d3755ff09cfcb6262190d63b369db612c758cc1555b", "class_name": "RelatedNodeInfo"}}, "text": "Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.  ", "start_char_idx": 2495, "end_char_idx": 2613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a66552b-2235-40a9-8804-3584df1c69d8": {"__data__": {"id_": "0a66552b-2235-40a9-8804-3584df1c69d8", "embedding": null, "metadata": {"window": "There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n", "original_text": "That may not happen and anything less than that.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72a299c8-e3da-4da4-a37a-49f431496dd6", "node_type": "1", "metadata": {"window": "And after all of that, we will take a look at what we call -- we're calling \ncritical mass.   There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.  ", "original_text": "Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddde27907232ef52a80cd9bc2f7ba7d665ea202ec85dba9a878ad78cb00c6a87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8c5508c-180e-46a8-8d5f-7dc3d4d8860a", "node_type": "1", "metadata": {"window": "So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.  ", "original_text": "And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.  "}, "hash": "8b61b188b52453efcf6e16f449ac470bd57446543e7cc1ec12813ef5478037c7", "class_name": "RelatedNodeInfo"}}, "text": "That may not happen and anything less than that.  ", "start_char_idx": 2613, "end_char_idx": 2663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8c5508c-180e-46a8-8d5f-7dc3d4d8860a": {"__data__": {"id_": "b8c5508c-180e-46a8-8d5f-7dc3d4d8860a", "embedding": null, "metadata": {"window": "So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.  ", "original_text": "And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a66552b-2235-40a9-8804-3584df1c69d8", "node_type": "1", "metadata": {"window": "There is no set number.   So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n", "original_text": "That may not happen and anything less than that.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d72e0eb38045598bddf1be0af41b9d37ba77b3ccb8cfe230e9bb1fa05093901", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df17284a-489e-4e9f-a336-23d869b3755f", "node_type": "1", "metadata": {"window": "Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.  ", "original_text": "It's highly dependent on the states that \ndo and don't participate.  "}, "hash": "bcb0a8971651e1bba0618c7366551fc39bf6c6a27d3c9472c3f1d679db7c206d", "class_name": "RelatedNodeInfo"}}, "text": "And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.  ", "start_char_idx": 2663, "end_char_idx": 2766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df17284a-489e-4e9f-a336-23d869b3755f": {"__data__": {"id_": "df17284a-489e-4e9f-a336-23d869b3755f", "embedding": null, "metadata": {"window": "Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.  ", "original_text": "It's highly dependent on the states that \ndo and don't participate.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8c5508c-180e-46a8-8d5f-7dc3d4d8860a", "node_type": "1", "metadata": {"window": "So there's no minimum.   \n Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.  ", "original_text": "And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fe60f2d5a8796f06b090a5976705f2602181415f2bf59e26f89c81d956da1cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9d34ada-8694-4999-b5c8-e8f8d2c53384", "node_type": "1", "metadata": {"window": "That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n", "original_text": "So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n"}, "hash": "968dba94e92d669900bc5a47db54d800df51ae80a36c30922381fe6aa5f8a583", "class_name": "RelatedNodeInfo"}}, "text": "It's highly dependent on the states that \ndo and don't participate.  ", "start_char_idx": 2766, "end_char_idx": 2835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9d34ada-8694-4999-b5c8-e8f8d2c53384": {"__data__": {"id_": "d9d34ada-8694-4999-b5c8-e8f8d2c53384", "embedding": null, "metadata": {"window": "That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n", "original_text": "So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df17284a-489e-4e9f-a336-23d869b3755f", "node_type": "1", "metadata": {"window": "Our goal has been and continues to be to get 100% participation on all 50 states in order to have the \nmost clarity.   That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.  ", "original_text": "It's highly dependent on the states that \ndo and don't participate.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c20c61fb4e05946070f506c3ed12518dd193f963829dae5e6c0f59209d403a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef6dc8c4-55d2-4513-a09c-3bd818e80bfb", "node_type": "1", "metadata": {"window": "And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n Mike Kaufmann:  Good clarification.   ", "original_text": "Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.  "}, "hash": "3c6a23a8b9fa7c6c29a821db76ea8fc559385c303a045ac803f5b9bbc9744a79", "class_name": "RelatedNodeInfo"}}, "text": "So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n", "start_char_idx": 2835, "end_char_idx": 2987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef6dc8c4-55d2-4513-a09c-3bd818e80bfb": {"__data__": {"id_": "ef6dc8c4-55d2-4513-a09c-3bd818e80bfb", "embedding": null, "metadata": {"window": "And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n Mike Kaufmann:  Good clarification.   ", "original_text": "Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9d34ada-8694-4999-b5c8-e8f8d2c53384", "node_type": "1", "metadata": {"window": "That may not happen and anything less than that.   And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n", "original_text": "So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aef3fc66607b4d423bab8cd7c5ebefb47dc37c1132964bd8bece0867709d6a02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04dad935-42ab-447a-b59b-57912723e416", "node_type": "1", "metadata": {"window": "It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n Mike Kaufmann:  Good clarification.   ", "original_text": "It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.  "}, "hash": "33b3b8a8e1d9fc67c632812b191c01504f0832d4918f2de8d3566f9211b63b7a", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.  ", "start_char_idx": 2987, "end_char_idx": 3194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04dad935-42ab-447a-b59b-57912723e416": {"__data__": {"id_": "04dad935-42ab-447a-b59b-57912723e416", "embedding": null, "metadata": {"window": "It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n Mike Kaufmann:  Good clarification.   ", "original_text": "It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef6dc8c4-55d2-4513-a09c-3bd818e80bfb", "node_type": "1", "metadata": {"window": "And we, as a group, we'll have to sit \ndown and determine if that's enough clarity and participation.   It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n Mike Kaufmann:  Good clarification.   ", "original_text": "Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd5c069c1bbf4fd3a16c2f00b0873311f0f7ef5e192acc85165d4ea5cff134cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a175cb9-0cf8-471a-b571-15c74f835e2b", "node_type": "1", "metadata": {"window": "So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n Mike Kaufmann:  Good clarification.   ", "original_text": "So \nthere could certainly b e a difference there that we would need to evaluate.  \n"}, "hash": "2b9b203b417392be807d6aeda37521fee89c85841052b6bf04da7b996ec44b1d", "class_name": "RelatedNodeInfo"}}, "text": "It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.  ", "start_char_idx": 3194, "end_char_idx": 3386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a175cb9-0cf8-471a-b571-15c74f835e2b": {"__data__": {"id_": "5a175cb9-0cf8-471a-b571-15c74f835e2b", "embedding": null, "metadata": {"window": "So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n Mike Kaufmann:  Good clarification.   ", "original_text": "So \nthere could certainly b e a difference there that we would need to evaluate.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04dad935-42ab-447a-b59b-57912723e416", "node_type": "1", "metadata": {"window": "It's highly dependent on the states that \ndo and don't participate.   So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n Mike Kaufmann:  Good clarification.   ", "original_text": "It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.  ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39a7e5954475dae641e35c847499fae8dc4d396bc0fe4729ea68352458f8158a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d98fff9a-ca4e-4ba6-9aeb-e422e3490ee8", "node_type": "1", "metadata": {"window": "Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n Mike Kaufmann:  Good clarification.   ", "original_text": "Mike Kaufmann:  Good clarification.   "}, "hash": "1aa3da5b8f03d6b156209a76e69d785346a4ce99f6badb706610b7444c1d6817", "class_name": "RelatedNodeInfo"}}, "text": "So \nthere could certainly b e a difference there that we would need to evaluate.  \n", "start_char_idx": 3386, "end_char_idx": 3469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d98fff9a-ca4e-4ba6-9aeb-e422e3490ee8": {"__data__": {"id_": "d98fff9a-ca4e-4ba6-9aeb-e422e3490ee8", "embedding": null, "metadata": {"window": "Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n Mike Kaufmann:  Good clarification.   ", "original_text": "Mike Kaufmann:  Good clarification.   ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5790019c05c95064a0abdbb2d58838d5f7ce8b2570733d759588f01e2ecc70d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a175cb9-0cf8-471a-b571-15c74f835e2b", "node_type": "1", "metadata": {"window": "So we'll have to really step back and look at it as an o verall -- from an \noverall standpoint and make a decision on whether or not to move forward.  \n Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n Mike Kaufmann:  Good clarification.   ", "original_text": "So \nthere could certainly b e a difference there that we would need to evaluate.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97960579d02292d275d7fa04fd7f2a682698d8d1e031b4847d3f065cb21e379e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c00172f5-68e7-43d2-bcf5-839ae5f48564", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.  ", "original_text": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.  "}, "hash": "ae0c2bb970a97b6fd6d7e11dc9cf657fa37fc6109306365aec2b13878a231641", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Good clarification.   ", "start_char_idx": 3469, "end_char_idx": 3507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c00172f5-68e7-43d2-bcf5-839ae5f48564": {"__data__": {"id_": "c00172f5-68e7-43d2-bcf5-839ae5f48564", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.  ", "original_text": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d98fff9a-ca4e-4ba6-9aeb-e422e3490ee8", "node_type": "1", "metadata": {"window": "Jason Hollar:  One thing I'd like to just clarify, as Mike indicated, if not all 50 states choose or we from \nan arrangement to join, that would mean the cash paymen ts would be lower under that structure.   It \ndoes not necessarily mean the accrual change s.  And that would -- we look at the facts and \ncircumstances of the situation to determine what the proper accounting would be at that time.   So \nthere could certainly b e a difference there that we would need to evaluate.  \n Mike Kaufmann:  Good clarification.   ", "original_text": "Mike Kaufmann:  Good clarification.   ", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c344a5a8902715ea142b84904c292894b404b83255793117922df48b120a7f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3958513-9999-4dd3-ad94-b8a98d2d6e01", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n", "original_text": "I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n"}, "hash": "ebe884e12b46a79f7ea05aa13146d89eb3f517e87cda1c5ed25a64faf36bd4d3", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.  ", "start_char_idx": 0, "end_char_idx": 77, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3958513-9999-4dd3-ad94-b8a98d2d6e01": {"__data__": {"id_": "e3958513-9999-4dd3-ad94-b8a98d2d6e01", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n", "original_text": "I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c00172f5-68e7-43d2-bcf5-839ae5f48564", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.  ", "original_text": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810e57dea88752a4066e9b4ca1c1c8b1a58ff259f1a050604fb6345e7849af46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42ed4dd7-3146-4bf9-b945-3f080018875c", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.  ", "original_text": "Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.  "}, "hash": "b01a4508c8b8a02eab03bcd0d1b0ea85712a735e0de0430c7e66eedfa583b628", "class_name": "RelatedNodeInfo"}}, "text": "I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n", "start_char_idx": 77, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42ed4dd7-3146-4bf9-b945-3f080018875c": {"__data__": {"id_": "42ed4dd7-3146-4bf9-b945-3f080018875c", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.  ", "original_text": "Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3958513-9999-4dd3-ad94-b8a98d2d6e01", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n", "original_text": "I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78dec76a45a1e69504d9865ec3a72d0c0e70e279658a0f8f1cff85e9e64a4184", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64794e1f-31b7-48bf-b725-baecded1ff01", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.  ", "original_text": "I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.  "}, "hash": "9af8cd5552d79731acfca00c64b578cd5a3094b5d0b1c8ca4def97391ca0fd8d", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.  ", "start_char_idx": 158, "end_char_idx": 281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64794e1f-31b7-48bf-b725-baecded1ff01": {"__data__": {"id_": "64794e1f-31b7-48bf-b725-baecded1ff01", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.  ", "original_text": "I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42ed4dd7-3146-4bf9-b945-3f080018875c", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.  ", "original_text": "Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45860dd9dbd0454b575463e50274f156cbe70270985fdb75e84615e9efa35973", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35c465f5-ef3e-4cbc-b651-287ee7176577", "node_type": "1", "metadata": {"window": "I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.  ", "original_text": "We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n"}, "hash": "0e815a9d323efacec3ec6ecccca25a6a27d06e1aca97534c693d6b6d69a165c2", "class_name": "RelatedNodeInfo"}}, "text": "I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.  ", "start_char_idx": 281, "end_char_idx": 392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35c465f5-ef3e-4cbc-b651-287ee7176577": {"__data__": {"id_": "35c465f5-ef3e-4cbc-b651-287ee7176577", "embedding": null, "metadata": {"window": "I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.  ", "original_text": "We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64794e1f-31b7-48bf-b725-baecded1ff01", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.  ", "original_text": "I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d52fab165af5c5d03237337f8d25f283a84fd39af6371f59b65c31743a263b0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e872673-e104-4a2c-857a-77f7ef26c7f6", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.  ", "original_text": "Our guidance is for growth next year in each segment.  "}, "hash": "9943fe4cd50c2a6117fe14980ab5762473d17c87ae48594275e933993ce538c7", "class_name": "RelatedNodeInfo"}}, "text": "We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n", "start_char_idx": 392, "end_char_idx": 637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e872673-e104-4a2c-857a-77f7ef26c7f6": {"__data__": {"id_": "5e872673-e104-4a2c-857a-77f7ef26c7f6", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.  ", "original_text": "Our guidance is for growth next year in each segment.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35c465f5-ef3e-4cbc-b651-287ee7176577", "node_type": "1", "metadata": {"window": "I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.  ", "original_text": "We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acf57def3cb5e8133c86ecd1bfe9155097daf5961f85bc768d721e5ecad24e5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c54e143-34bb-40e2-bfb2-7fc08d807903", "node_type": "1", "metadata": {"window": "I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.  ", "original_text": "And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.  "}, "hash": "350cc28f83c5d5a7084994ddd9a824962ae0262f2888592edbfae1453dc4d538", "class_name": "RelatedNodeInfo"}}, "text": "Our guidance is for growth next year in each segment.  ", "start_char_idx": 637, "end_char_idx": 692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c54e143-34bb-40e2-bfb2-7fc08d807903": {"__data__": {"id_": "1c54e143-34bb-40e2-bfb2-7fc08d807903", "embedding": null, "metadata": {"window": "I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.  ", "original_text": "And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e872673-e104-4a2c-857a-77f7ef26c7f6", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.  ", "original_text": "Our guidance is for growth next year in each segment.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08683e903169e1adeafa115fe767be7d40ccceeca559ba11335ab904f0262530", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d196019-d1bc-47b1-9861-7f12632e7291", "node_type": "1", "metadata": {"window": "We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n", "original_text": "We have tailwinds behind our growth businesses.  "}, "hash": "a8c31f8ee62933484bb8cda4b06fdc0aecf781b4a94a63bec9654d042f5a0c03", "class_name": "RelatedNodeInfo"}}, "text": "And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.  ", "start_char_idx": 692, "end_char_idx": 851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d196019-d1bc-47b1-9861-7f12632e7291": {"__data__": {"id_": "7d196019-d1bc-47b1-9861-7f12632e7291", "embedding": null, "metadata": {"window": "We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n", "original_text": "We have tailwinds behind our growth businesses.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c54e143-34bb-40e2-bfb2-7fc08d807903", "node_type": "1", "metadata": {"window": "I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.   We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.  ", "original_text": "And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1942657499ab307692b0b2d8dbaaa9d98366bcc77ba31d1548293ac23f5ca42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63bdca92-2bed-4375-9a4a-7365984684c4", "node_type": "1", "metadata": {"window": "Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.  ", "original_text": "We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.  "}, "hash": "52ad93a6fddcfebaa566a42c4ff674176c2cbf94d5d9f646905d526bc4eb8200", "class_name": "RelatedNodeInfo"}}, "text": "We have tailwinds behind our growth businesses.  ", "start_char_idx": 851, "end_char_idx": 900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63bdca92-2bed-4375-9a4a-7365984684c4": {"__data__": {"id_": "63bdca92-2bed-4375-9a4a-7365984684c4", "embedding": null, "metadata": {"window": "Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.  ", "original_text": "We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d196019-d1bc-47b1-9861-7f12632e7291", "node_type": "1", "metadata": {"window": "We did see -- first, we did see underlying grow th in FY '21 in both of our \nsegments, if you exclude COVID -19, which gives us confidence as we move forward -- going forward \nwith the impacts of the pandemic hopefully beginning to dissipate.  \n Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n", "original_text": "We have tailwinds behind our growth businesses.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f211a904310412164e5f4ae125a10afc599096fe68763ddeda327e1902b066b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f395d083-44e3-492e-85ed-585d3bc965bb", "node_type": "1", "metadata": {"window": "And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.  ", "original_text": "And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.  "}, "hash": "00242870b7586536b47291869a3115c8c6d5981de009ae3400a3e88ba8d4d810", "class_name": "RelatedNodeInfo"}}, "text": "We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.  ", "start_char_idx": 900, "end_char_idx": 1026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f395d083-44e3-492e-85ed-585d3bc965bb": {"__data__": {"id_": "f395d083-44e3-492e-85ed-585d3bc965bb", "embedding": null, "metadata": {"window": "And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.  ", "original_text": "And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63bdca92-2bed-4375-9a4a-7365984684c4", "node_type": "1", "metadata": {"window": "Our guidance is for growth next year in each segment.   And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.  ", "original_text": "We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2393ddf6926bad91799e1b534a481745b479d225eb2972c0f21e5b4ee414fdc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ce52669-728d-47cf-95e8-7bd02284fe6a", "node_type": "1", "metadata": {"window": "We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.   You may now \ndisconnect.  ", "original_text": "And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n"}, "hash": "1e6382a0b5d548fc803333a51d4b322141e8ed07a8d6dff532a7f7d92a035f74", "class_name": "RelatedNodeInfo"}}, "text": "And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.  ", "start_char_idx": 1026, "end_char_idx": 1295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ce52669-728d-47cf-95e8-7bd02284fe6a": {"__data__": {"id_": "9ce52669-728d-47cf-95e8-7bd02284fe6a", "embedding": null, "metadata": {"window": "We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.   You may now \ndisconnect.  ", "original_text": "And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f395d083-44e3-492e-85ed-585d3bc965bb", "node_type": "1", "metadata": {"window": "And then also if you take normalized growth \nin each segment, when you normalize for noise like COVID and Cordis divestiture, we will grow in \nboth segments.   We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.  ", "original_text": "And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef03ef0aba70c81e34236e166b7f555e05e56b836d5aaaf6a2b77fe5a0a95e70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a9d2bfb-c729-44ef-a356-c441d7f955c8", "node_type": "1", "metadata": {"window": "We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.   You may now \ndisconnect.  ", "original_text": "Operator:  And this concludes today's call.  "}, "hash": "61bf2d8c3976477ad362134c7a267ade58e45dd6bc0b4663f6d0fb28bcce83a1", "class_name": "RelatedNodeInfo"}}, "text": "And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n", "start_char_idx": 1295, "end_char_idx": 1533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a9d2bfb-c729-44ef-a356-c441d7f955c8": {"__data__": {"id_": "8a9d2bfb-c729-44ef-a356-c441d7f955c8", "embedding": null, "metadata": {"window": "We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.   You may now \ndisconnect.  ", "original_text": "Operator:  And this concludes today's call.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ce52669-728d-47cf-95e8-7bd02284fe6a", "node_type": "1", "metadata": {"window": "We have tailwinds behind our growth businesses.   We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.   You may now \ndisconnect.  ", "original_text": "And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffd127cc5c8a4d93c1a53aa19205f8f0180b8acea614190f4e0f68005a6cfb6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcd0a86a-e7ce-44ea-85d0-13f48c0033e8", "node_type": "1", "metadata": {"window": "And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.   You may now \ndisconnect.  ", "original_text": "We thank you for your participation.  "}, "hash": "d527f47c6d4982ffcd6dcbdbf04accef75102479f766c6a172ee2556cd5586b3", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And this concludes today's call.  ", "start_char_idx": 1533, "end_char_idx": 1578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcd0a86a-e7ce-44ea-85d0-13f48c0033e8": {"__data__": {"id_": "dcd0a86a-e7ce-44ea-85d0-13f48c0033e8", "embedding": null, "metadata": {"window": "And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.   You may now \ndisconnect.  ", "original_text": "We thank you for your participation.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a9d2bfb-c729-44ef-a356-c441d7f955c8", "node_type": "1", "metadata": {"window": "We really expect all of our growth \nbusinesses as a group to  really grow at least double digits on the top and bottom line.   And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.   You may now \ndisconnect.  ", "original_text": "Operator:  And this concludes today's call.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7acc364648c826707632f6f2ac078eefcdfbb125f3b07efe1496c01281720685", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc17130a-2913-49bd-9e9a-701625bf3b01", "node_type": "1", "metadata": {"window": "And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.   You may now \ndisconnect.  ", "original_text": "You may now \ndisconnect.  "}, "hash": "e335e8e8a501695adeda17000a2baa5eb3e6f55b2ebd799940e3e389b726e3bb", "class_name": "RelatedNodeInfo"}}, "text": "We thank you for your participation.  ", "start_char_idx": 1578, "end_char_idx": 1616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc17130a-2913-49bd-9e9a-701625bf3b01": {"__data__": {"id_": "dc17130a-2913-49bd-9e9a-701625bf3b01", "embedding": null, "metadata": {"window": "And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.   You may now \ndisconnect.  ", "original_text": "You may now \ndisconnect.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "691e9bad-2b35-4c21-8984-421a82326418", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4757e9c4bf5f7704ea2241419412a098e5491301ccdee23e585a7f13703e551c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcd0a86a-e7ce-44ea-85d0-13f48c0033e8", "node_type": "1", "metadata": {"window": "And we have \ntaken some significant actions such as getting after an additional $250 million in cost savings; closing \nthe Cordis transaction, which will enable us to simplify our operating mod el; and extending our \nagreement with CVS are just a few of the examples.   And as the first question was in Jason's \ncomment, we do have very strong cash flow generation, which gives us a lot of flexibility to be more \nopportunistic in our capital deploymen t. \nSo with that, thanks again, and have a good day.  \n Operator:  And this concludes today's call.   We thank you for your participation.   You may now \ndisconnect.  ", "original_text": "We thank you for your participation.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4fb75e7c7cde77ee50ed50abe360432dd74f68bcb3a9589a51c6ccd32cd2d84", "class_name": "RelatedNodeInfo"}}, "text": "You may now \ndisconnect.  ", "start_char_idx": 1616, "end_char_idx": 1642, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"e2245dea-0889-4d04-ac46-c7585007f7f5": {"doc_hash": "f24b3c92fdc1dc9a225799bc988ea6261dc274d8c7a1418852cc1e5ef1e09c27", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "a9453aec-ec42-4db1-9c12-4bc3b73578e4": {"doc_hash": "8f66ba805eebd5b398e909b42a00cea74402c5eb137c25c212bf8d8dd5f184d1", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "eb93c1ae-3395-4d62-aafb-f49c08500db9": {"doc_hash": "e2b1bc296bca4efb6c910f1b3cf9b9be66f862262d8b43688696abd7e48a5eae", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "b24bc4d2-9504-412e-a1ad-31ea9aebfcd9": {"doc_hash": "354d5f786ec6b543e6caaf207583ba2865afb32e04965ae3bc99386d04f4d75d", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "0ebc3f9b-9abf-4b25-951c-219679a28bb4": {"doc_hash": "a722c8a6d34e31190cdd65ec2bf21d0551b03ff5b2f1a8e0a464407bedcae056", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "bd2593d9-854c-4aa2-834e-c9452387be22": {"doc_hash": "a7e2c7a4bdb35fb5e3c94c67e6a72fe2a9db3a7b9e7ecc3b4fdeafb6351f4bab", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "30a5a0f6-e5f6-449d-a73d-23ca7eb34d0d": {"doc_hash": "cd6c70ef24bd7928e9238414058db6061871771bbfaf197fc0d8bd8f81fb32e8", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "2c8c0fe2-7003-4ad4-b5a6-78e05cb3cab4": {"doc_hash": "3c7dff13788c353e1031e99906514e0b912dae22a2a8ec945e0370d272bc8ae8", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "add45d40-6923-4444-997a-dffac8f43dbd": {"doc_hash": "f5fbe4bb2efb536344e5dbeb11273d58711164ab23082017f8eddd1a4f5a4c10", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "275a9792-138a-4601-b02a-9d634a558f84": {"doc_hash": "85bda357cf049c33349415f37d13617ed294a94626bc67a3f7a7629386aaeba8", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "301ab9c6-6937-418c-8c39-d72d4e0352fd": {"doc_hash": "f9caad4defd040e6373622d1ee3eaf7cd0b1291d1b4121ec3919abf7fd7c5ec3", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "f720c0ee-4af9-4588-99b0-9097408f998f": {"doc_hash": "1aa1e9341fc7b49378074a5d4591e1d2f850552e59060e2e9d156d5f5896c355", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "ffc7079b-26a7-464a-a8b9-bc21a906eeee": {"doc_hash": "3f88f1f299c51e85d705d16d2669adc4745aa0779eb3ad81413fa23e01206586", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "e3472492-ce47-4337-8e75-a46c618ec3b7": {"doc_hash": "737e9fa4764fa33756e04292868affa8aec7f76f0753039ea20f6052e709e922", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "eabbdb28-f84a-4167-8299-8a16941ef2a8": {"doc_hash": "bc32a1cf3298a89484ac95f507077d261018634c1066ef428f655f51c144593f", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "4ec67509-d6ac-4051-a141-45806fc1fb77": {"doc_hash": "f264411f8dffd490327a26b970ebb8b69cfe6c06701b824943d379cfb90dd848", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "ce33a122-cbdc-457c-b0f0-b1b5af0dcee3": {"doc_hash": "36fab308ae55b291e934600a737dc45442097fe32a88986be302b86c1cd74324", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "254efc82-4482-4dc2-b827-97522417557a": {"doc_hash": "5dd9444d3e5f8f858822c11fdfc64643928482e7bcb0336a0a68c0227af047d7", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "e977aaf6-4405-4149-af4e-ce40265ba4fd": {"doc_hash": "bd2511a176b488dffa497f1f141a1406850206eddb27914996ba61baa1856988", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "bfe047fe-3ba8-4b37-87d8-edb3ae4f9b3b": {"doc_hash": "24289b2bb39faaaf4039c5fc02d1edaec24720449be4663c7e8d49b6f40d0e5e", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "a349f2b2-8a87-43e8-98d9-398073c5895d": {"doc_hash": "7ad93f7e67f8c5e2128e26a1c200e8d7f185d6ef1dae4862899f0752fa194515", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "9964c598-1ddf-4f96-90a0-24721423a22a": {"doc_hash": "dcc03843f370582d65396a92ad599bfd6a381916f1e0651aefd0f413283ffa7c", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "07656d67-f11d-487b-adc2-435a456c7c1c": {"doc_hash": "e2511c4b009791c5069b8cb1db38137986aaff18a10e781636401c4087b43ba8", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "2b3cd265-71cb-4531-b300-2784bd55ec8e": {"doc_hash": "4a5ccdab4e9bc78ae11a29b99e04edeccdc87b70ae69b16bfe90b2b50c69f8fd", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "97eb211c-459e-4d85-b795-8f779e400600": {"doc_hash": "4c5167f07942074dd8019da190bf4e6dbe9049759f7a40e1d613b4fee7cac7eb", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "d2aa092f-f798-42f2-a0de-4a9fc150b5e3": {"doc_hash": "c1f680de6e04354332a7b84c8a3d9eb4f91b6d055d490e037cb37594d305a7d7", "ref_doc_id": "5fc948e8-49e5-4c35-96f4-234a708a99f6"}, "90ad4290-cfab-49b1-8c00-ea279524b958": {"doc_hash": "9b1be87a9a4690347fb5d138fb0702e7742dc10cd0b9ea89930363f306a66f6d", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "54152de9-c381-4183-8bae-6bc46ce77f8b": {"doc_hash": "b44b99f8b4adb5549527fd67c55b221c93847664c4d85edf573797605ef97702", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "aff01caa-4f2f-430e-89d2-d4392d70086d": {"doc_hash": "90566cdb5d7830e3f086dd270b0f740441a3ef49bc5863b2b71be092d1963667", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "533e460f-0585-4e89-be96-f896ba07c55d": {"doc_hash": "b0993b8d817903ac3a32fbc157ee96d4906d7edc62d346eda631f20286c640a0", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "f8986fbc-edf7-4849-a126-2de35b42c199": {"doc_hash": "29f224fc0b6754d8a1c5ee2f0edb1dd32e49aff65e253b58ec32cd9b5f28aeb9", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "c8712cf6-77f3-45ff-bbc6-7568ff438187": {"doc_hash": "4c037dfbd2682014091b016fa7060f09d165e5e616bb811b17cb5216ca5af641", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "309df031-5f52-4058-af3b-20eb5a682624": {"doc_hash": "a091963e32154ff25aead8aaf049a54428b6faea0dbbac3354fb335743629159", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "a8a3eefe-abb1-429c-8eb5-940765393a0c": {"doc_hash": "36e6cdab5882b30fe03abe9ea0ed07794a29138366a746633056d3a10defdfd1", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "3dd401b5-151f-44ba-94e6-15af816cb305": {"doc_hash": "ccce8273ff9eef2b3b72f83737af2e86edffcdec2c5b427a4e1c7b65d4beec2c", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "a0e1b0c8-837b-4862-bbdb-0030f79a2be3": {"doc_hash": "9182c52037be69349b161d95e21df5db7bc9cfc83ef0d6ca1226d5d4f500bdf3", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "713247e5-0efe-43d9-96db-2ff58f3dbb9c": {"doc_hash": "7cdfd512c9165376886d515cb8f54ff794f3dc804373a34e8aca8a760c64d630", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "b60b9851-ffb5-4de5-8c39-6e66255aec5a": {"doc_hash": "a6d16bd88507060d4074e442378c7e40c0c1a6206ef81cd7fc9f33215c3f2cbe", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "725ee96c-b8b3-4432-8915-7ae04ca44928": {"doc_hash": "30c87dfa53aae6027a33ccb9a83b00702283eba8159723f07ad3889378c4a8d5", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "49e3837c-77ce-40c4-b845-881f183a4043": {"doc_hash": "39698dfb1de6c8303d2ca0beef7ac525c37fef4fed16192cf2036a0cba268645", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "a091da2c-fb59-43d3-bf7f-90ecb8b22fe3": {"doc_hash": "5460a36703275d8d1ba4208b6358c63075a6d6e2455982cb36ce767f7783fdcb", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "f4f5202a-67e9-4494-ab7a-8638bcae458f": {"doc_hash": "012f37adc15a5ac5ec31cad3b7bd0d5a4521df78c37caf85f4d0317cc2f16db6", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "68d7f5c3-53ed-40b4-9f92-3c5feb819a9f": {"doc_hash": "186dd9eed65024af98cd7785fbbeaf262e5339d9b2d515a2ff9e6800a09efe27", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "21b94426-9903-442a-b71a-ca8b79ec6a23": {"doc_hash": "db7f8d91e3e9acd651bafd63aa21cbeffdde304054a0e4ea558c52c5138cf5cd", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "ec75cb56-4e07-4d2a-8e2d-3f7f0ed28657": {"doc_hash": "d9dca274b28ee232a285966c8f30268f59d5e4e54565d5efc778879c051a8913", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "9e4e3465-3e02-4b3e-97e5-c27da80ec5f4": {"doc_hash": "2907f4641a50011b88456dc0708e1500ae1497c807aa3b12a462afda1101cb60", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "a74bbc4b-5866-45b0-9f8d-c6a04ff21cbc": {"doc_hash": "1b834312f88884c9f82ddfb60e1279fb8a3e689c64623f12a61ddc021b01ea58", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "38ac468c-edde-4297-8a5e-bcc74ea72323": {"doc_hash": "f2220d1d04209fc0762e77b025bedac19fcf2f330c67f5c2ae3b8200e613842f", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "35fb7340-7544-4ebe-aa8a-20b59eedf20b": {"doc_hash": "3b9a948ced6149c695b84fc620d2d6f9b266635e0ba63fc4c21370b497a1ec91", "ref_doc_id": "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06"}, "a5db360a-1a0c-4219-86c8-532af07c21f4": {"doc_hash": "a84116a1aa4688a15935f83b7558de4441e09751eb67532455fce08646ec6408", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "1e2d5108-81bd-4b34-b4fe-110ac67b84d0": {"doc_hash": "583f4a1e95342ce6269e7b80bdabcf95bfb92f3f15973e5a76b187694e96cc11", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "7cfd16f1-1369-4c65-8320-be38633045a9": {"doc_hash": "8932f292141666ab853b7504dc4b5af7d60f6318c55d599f3724de20fee98bf2", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "98759a3f-dd77-42ec-a3ff-b1db1e113eb4": {"doc_hash": "83d0b40d61c10e6af22c1c1977ea5721a52cf2fa2936b9f99f133c328ea3da99", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "98b5aef8-1755-4bd3-a08b-f3a76dbbd0ca": {"doc_hash": "f801a74f08e2cd00de2880370550f0f9964e30a6428386105d757dbd9b373e4d", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "cc671572-46a2-42b1-80f0-886dcc561f61": {"doc_hash": "d00726288e6fe0fa80cae80e0b1ebfd2da30d7f62b7da5db97581bff404fcbee", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "3240b546-e333-4b72-96be-c2aa262aee51": {"doc_hash": "9f6fe6be951d9cb3933add8edabef18b2e532ad8e36e22d63d73d6aa1e65b964", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "d155e7d3-a0d5-455b-8ade-6fbfa0ad310a": {"doc_hash": "bdf38b07afde932556eadf75ee3e407febbd2f89699cfd38ed8dbfd64841593e", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "d9052854-53cb-44a5-95e8-cc40b5ae10e4": {"doc_hash": "5acacf46a866f71729c694b582d7131b3d04952efcb1066034e29167f6427d0a", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "852b85c9-742c-40c9-9273-daca186e9c53": {"doc_hash": "737e7e345f4bedafde05777887452fa066d269a19732dc5f57e5999c81a515f6", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "bdff825a-32b1-46a5-b501-5fa52a264db8": {"doc_hash": "d3f3749c0a925b68f6065da0b0d23f7b2272a6f6afca59fd54ab3b28bc1541c3", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "4dabf534-8ab3-4689-a5d6-b4f08faba5a5": {"doc_hash": "f6f2570795c0ead55b9831f88d3d7095a21db34e6aa9a7c936712acfdeea4e1f", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "6593d985-cf2e-4a3a-9b48-92e419e7ad4b": {"doc_hash": "bfcea06e81598d081f9b8846f2cdbe1d6bbec1a2da819acb6eaf368132cead58", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "55580760-d6c0-4306-8157-868aa5f4cb73": {"doc_hash": "28c12b1eb9281db0845737277e89f3b601ec9df7153e32bf088b30096aad5f87", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "35545e8b-b3b5-4c21-8354-3322959ee8b6": {"doc_hash": "8f6d4551ec5223446608abbb202f4b0f1cec5dc52be512a96d81d1e6731f1db1", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "a28cbbbf-aae3-45d2-a807-ce37eecd5e8b": {"doc_hash": "6db07c2e7b81d5e1c5f22b9a1c77b4cae84f2ed8726c75ca33e5b7afa9198ae2", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "9d41c212-4abb-485d-92a6-199616f528c9": {"doc_hash": "c2043f07a04e6d563d1d52aecc6426a75e806b5153d01208976583cb01bc60fe", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "c35226a6-9094-47b5-acd3-32c350d7b522": {"doc_hash": "9946537e94b5372ec6487cfa1378a3719651c0993e000f77446b213eb967f175", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "d37402cb-af87-4d50-a0db-f6e1b9387234": {"doc_hash": "3b3599cc8240ce00145a81b8c590bce04c16f52d6fd18568d020edb11a4ce966", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "a1507b76-1373-40bb-987e-61198e7800aa": {"doc_hash": "9847179d99ff6ffa1cee2ff9e7f9e2c2bd84ff24e9abb83415abc4b52ee8e8f3", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "3b22d0d4-257a-4212-996b-26f9ce7731b0": {"doc_hash": "0cd127bc5645ac3e1e036100667efc42a943c557f26d9c492efae72c9df5b30d", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "9dd6cf46-d7f0-4a28-ae4f-2eab544cf835": {"doc_hash": "17a0a33e13d72db7f53af060a63bf09a37ae6514c409795adc32cec158ecb8df", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "5d725e47-ac3f-4651-b85b-b08fe8a91e69": {"doc_hash": "d969d1a0261d7dfc6436b1c08946fcd19adcf0182dc56777f11eecba2ab83f73", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "092b1f43-fd76-4a33-9e6e-7d48542902ed": {"doc_hash": "61c4f6695420b4a4b972cf414cc56af59c9b729bc18f5d0e1f76e3764f5e45b4", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "c59b699e-5af5-466e-9e01-042fee01a86c": {"doc_hash": "88f035030364a54e708ec7869f85a63f281d4c4d0fe0b492e25d57736e1df43a", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "6ddfdbd3-24ac-45f4-a9be-c1c5a9367fbf": {"doc_hash": "c9b039b272fb7bd7a558e23802f860da3ec5c11a90dafe6638079ec7dfcb7243", "ref_doc_id": "bd47821b-39f2-4b22-b3cb-1979088901de"}, "730404e6-0f63-4cb6-b84c-70432b82bb80": {"doc_hash": "f9d3957f68674e2f102b5363cc59743b23fd612e3ccbfda4dc11ebe75ddd5231", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "c20fbd52-519f-47e1-93cc-fd3f63605f8e": {"doc_hash": "c3edb4ab8ed6af92258f473d9a6fc9503972bba426cf6803af12635eb8617cc6", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "af293b42-f610-41e1-82ca-24f17f82c3a8": {"doc_hash": "dfa5cc1e5aa715d1b55ef6970af13549336920f9adae153a9fdefc70966e40d3", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "9e4ebb2b-a433-4574-b07f-4d517eb2e34c": {"doc_hash": "9afdc59d4ab9dfb65889d973b8080560dd3066fea48b4098718a0fd18d98beeb", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "d2e7bc3a-7cd8-4597-b71a-3a205189bf00": {"doc_hash": "54adc25e74618285353654bf8793f0506d58a0dba28308d6140becc43b642ccc", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "f5a46872-16b8-464b-9d97-a9fee53ca7e2": {"doc_hash": "e99fdc84b8218ca2c4a502a9c233631835f3c7c873a1d35525287b1fd9cf452b", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "62a03091-2ca0-4c5b-81ef-714dca1374f9": {"doc_hash": "9e9fde1d83094e84680d4b24455f637689d8c6b49df461dc1e4cfc3d777f01ad", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "135a01be-1d7f-40e7-b669-592aed9b9d9a": {"doc_hash": "c610e000c63ccd12f6b0d27d46c15effc6e1e07904edaad4ef5b525ed27367a1", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "31e1d917-4860-4a5f-b770-226496d24a2b": {"doc_hash": "acf82e27891da5a4b0b6ad11b0788d4a367902b691480067a49ed693c4f75ff5", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "f56f0e18-58cd-433a-8e0c-1219fba92147": {"doc_hash": "acab569fc0ffbc603be9efce90e32b97417ea9db9fa4272110ebcbf78a764d71", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "3ccc8044-3ecb-428a-881b-c43951c1e2ac": {"doc_hash": "6d6e323063ed092091ae44c15756d4c478f023c9b6c8366e966cb899bc077089", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "9705d73b-a692-42c2-a180-f30578d43b13": {"doc_hash": "082db3b05982f588a528b94f5618362695c88d04615a9ba9813b2383a4b99321", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "56cb433d-92db-417e-aa92-275632629c4f": {"doc_hash": "1f2a4251eb5c59de1dde5b7f54d05a03d98ce3ff44e0e460b716513f4fc9f77f", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "cbc4e744-8e1c-4939-bafc-95f4a2badb44": {"doc_hash": "f5372ceb652bf489d38dc0be18ad534a46a98635b14248f9ce6e13416f1c500b", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "5524fe0a-ef89-4369-b0d5-1bdd53ff06bd": {"doc_hash": "1acad7c18244f848f9f68f62fe02de91bac2cf81fc1f7e10e0c61a4e12dc16e8", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "97424113-9a7c-4cb5-83b6-f993e4556b9b": {"doc_hash": "8dc064a85e5636f80592da3423e0585fcec188e2970af208fd086a9b33105025", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "f386aa7e-6b6a-42b1-b33a-68cfb4dc6eae": {"doc_hash": "9e190c3e3590efc41942c0fcaf15d66954bccfacc50158b76447e47fa34ae6f4", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "b60bd30e-9ce1-48f3-8eaf-cfd6147cc009": {"doc_hash": "4e8e6df376042fe0a281dda4abad3fa1b762b12f5d9d3b7d15af099c7d385a25", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "4252d548-ba0d-491d-990d-b4f58cd3ba47": {"doc_hash": "203802f4048c541c19e5255ff262c6f3948ac03901980b81f7e59297990f807f", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "dd50d670-40c5-43e9-8240-1464a197e401": {"doc_hash": "4104f2e23043c7114d02ae93b4cbc14dc92adb081920c7079dc6e06891d319e6", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "b0842ab8-82ed-44bd-bbcd-4695cfb90090": {"doc_hash": "b4d6e6fb81dba3fd4b2cf9b222d0f141ed943e66cca26caefeb436298ddb2130", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "d770dcf6-8654-49be-ae4f-f919eb43a8d3": {"doc_hash": "9b790531755e249b29662d16b9950f1418b6dbdd91b5985fc7345a16e2002f4a", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "6112ac99-1e1b-46d1-9edb-4777a5a3fb0a": {"doc_hash": "d2f8650e47aeb6c0326741495dbd5661411803375e12004d7e2b455de49ef446", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "cf138164-7279-4d18-aea5-15aebebdfb7c": {"doc_hash": "9fdda7d723bcaa7a51d025baea4cd6c4249cb48aebe4d52846babf95b47ebfaf", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "d9412bd8-5d07-4242-8183-e24b7ab4a8d8": {"doc_hash": "bacc5971f47d2ec005816ae2e845965fda18f982c9de59004c16e8d1918fc2b0", "ref_doc_id": "702a1b13-4901-4a0e-af6c-20d16f3ee850"}, "dbc0688e-7f23-4469-82bf-96bebf9b99e9": {"doc_hash": "1e49e2c35e9874856e6b504914e4715dec6a99c03ac0b5672d21dd9abdfe5d17", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "69b374eb-40ac-4266-b78e-5a934a0ee6f3": {"doc_hash": "d0752bd4ab743fc6f2c284df0e485da411f8da208ce28da898ef1bfbcd0af4e4", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "849c7f7e-1bf3-4677-8926-b6d1a9b10895": {"doc_hash": "c05a2fede92f07257902048509e819db219f32bf79809a38e4e38693e9d510c5", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "27057e26-88c9-4d0a-831d-48b839236e70": {"doc_hash": "da07a3fa9fb53e0f6870812a466222a7bf86290e2f3fec0585f5fd0daa5a1314", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "55cd0d4e-271e-4324-8e4a-cf265d7fdacd": {"doc_hash": "13c0b8cf9317c9c1c350242a417122b843e4c899ea3655f8ef5c617aa5f8ec81", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "d7f47851-4562-44fd-94f2-dc57f9dbf115": {"doc_hash": "450382f904cfdeec63256fb5e6a90430d7f425865e04ffb79cb053316c72b970", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "5858a507-a87f-496a-bcb0-1f6ccdd2e394": {"doc_hash": "c597e2a2042493f19b5a7afe310598939c921cfc420b5f6af351987fd081c4fd", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "e3bf20f2-9a90-48da-a943-7939756d76c0": {"doc_hash": "178c6b75c77c78451717641e137def0ce6d48c45e97a761a7ff817fec5d640d3", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "2f8ea981-2a25-4dae-942f-b35070d1311d": {"doc_hash": "eb02f6028c71b3b022d7704ee085e551c0ba4bb69c87fa2bd2c9c91c5d028d8e", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "355faad5-e4a7-451a-844f-70321a94e959": {"doc_hash": "3d12fca6f1a935b90596179eb88531b5dc18f69ed617447464cbd9aab3309edd", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "a68c8237-1b2a-4cf3-a163-82b94b7fdd24": {"doc_hash": "99ff12fa4b45afe10dfbe6b3f406e620907d571c965f027fc0911bdddfa6af71", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "9c3e9391-6ed7-4f55-8baa-8087bd0b7bc3": {"doc_hash": "ce47750d6cf44239b5ac1b4cd2b11af41ea493f99d70a20ebb4e21e52a8998fd", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "d87aa1cf-b431-40e4-bae3-b14229d71f83": {"doc_hash": "6fa4713aaead56e74b5032bb310e59697e8ec6d52852afd98f8cdba071e20d03", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "f817ad04-f866-4339-82f5-2689d337f6db": {"doc_hash": "9de47177a6d6114f681ae3bf2a66c9d24405cc7a0b1347cb30df0498eae5616c", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "1a8e58bf-637e-4dad-8578-8f41b147afee": {"doc_hash": "f88df275403072328a0e32d7abb7c509bd443ea2026fb699f17cbcbc39eb4c67", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "75878e77-0b6d-454c-8bda-9ccc199091f1": {"doc_hash": "441d17262a046618e2a8096a8b3353b1d48eb684c6dfa373cbec3e9a53d8704a", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "18196012-223e-4e7b-a7ce-274bc1d1e276": {"doc_hash": "494e3a755dd65ded7fd7ec5a831d9ba4ee3e63bde278c909c5f93f4cb5d2c59a", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "0b820bec-5ade-4b3a-95e6-77386d7e07b0": {"doc_hash": "6d52ce92fe173975cad4101d5eac09d793af5ae1a9c337781bcad525ee6cbf9e", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "02e31643-affd-499c-8b00-4af7a1410b2b": {"doc_hash": "ad00f6f4c3c3465be2ab6e7ec431a512cf22f9b7a39376c553bc077eb671fbfe", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "55c825be-2d54-4ebe-bf25-8c3f274329ad": {"doc_hash": "76924058d212210c385ee4ae7f8819506b64051dab31345692f79ea056538642", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "68e215a6-1cf2-473a-b1ff-9220b7d7dc14": {"doc_hash": "ab8f5071351cfe230509eab0588e40a1c5c77b3088909b0055b9c4fab47c6cff", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "285d875f-067a-4e98-aab8-2b4a948757dd": {"doc_hash": "2c5b87ac8c420cf70c00bda04b9b7d98589b21bcffb92c6be5f0b876579c35e2", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "5df697bd-04ad-444b-99a4-1dd987629a77": {"doc_hash": "0ee863e5f9dd69174e707d3002b93faf2a84be298a309951f3e1fe973e59ded0", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "7f466fa7-7409-4ad3-91fa-2e92a2f1482e": {"doc_hash": "94b655d79596bcb545fb4138d7eaec0ebd94b79ff4f33aadc01554092667868f", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "49fc8353-d490-4847-bf0f-fc3788d1553f": {"doc_hash": "348a5fd7acde8f8c22e2a849ac35ef21e882b250514651f198933a7587a83a8b", "ref_doc_id": "63991299-8af0-42fb-9c98-6c628d1be1f9"}, "6cabf8c3-39df-4945-9dbe-e4ae7a1f0a0d": {"doc_hash": "485dc85087f53702a00d0720a0a1918e9e45744d6fd81aa52ce9890c218f53f8", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "8fa2ad87-25df-4ea9-962a-d9ab2d393269": {"doc_hash": "cc592c7f6014004dcfdcce3e7ccc94ef69d760bac4eb0b9bffbffe49590742e0", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "0173b9c1-f15e-4dbe-8701-a5b8545d4d68": {"doc_hash": "cca891c1875130f5c0727c790eb3849377ab6a85a921c8a8e778f957e4f95a1e", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "a99e9348-72a9-4b5f-aa82-dea758f9188d": {"doc_hash": "a884c7dc93877c1a9d3fc62b3900dfd5dfea47c19975808e94e207e65226533c", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "ca3f7a5a-8df2-41a9-a8dd-f43f3470e92c": {"doc_hash": "6d615009e2b7e3615f7c7c52beee8993daca9ba2b462ebcd5ef2cd3d11c8a2cb", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "24f6e02d-6693-4098-bb62-e03d17e049d8": {"doc_hash": "a8fe0e4e54db7def233d9303cd91ac81c2590d42aa25858fa4c9c7a31e3d6eb3", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "79dd1b5e-c675-4662-acbb-90b8cd7d9c49": {"doc_hash": "05c0d10cff97434fb740d55900adde61a37ebd49c487e747a6ea69d10b2b8b2e", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "43040cd7-3e00-496b-b492-a7b79af82fda": {"doc_hash": "780be9e21d72b0541836aa5a9ba44f35c82caf664f50d1e32b20939b4346a2e9", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "d533a742-f7ba-4be1-9bc1-e42648900761": {"doc_hash": "ec63944df4286483ce36d14b146623628f1aef98bd3d41054d82e334ccd42f8e", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "64ac07a0-f625-4adf-a309-62d75aba5e87": {"doc_hash": "94ec27a4bb93121cc0fd3dd4e21c940187a3c4a221345b34544b7bdf70032886", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "a8b11fc9-a169-4786-a6f4-a3ae79437030": {"doc_hash": "a34055816e02cc0fd89755581ed04f9a516c200e564cf55258fc8a514c1c647c", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "43cf2c62-6f8b-44da-ab2e-b50bb592fed9": {"doc_hash": "ea49d8665a4e4de967640bcb78bcdbde450c2004a456323e9a36751d07ac157e", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "99e6a32e-b62b-431c-ae6e-462faaa92c07": {"doc_hash": "62e10684368890e3c415843e21dc3030fef51c97314227d38fc3b9a5b2ac72f3", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "e66fc7c0-52c5-42e2-a231-a096e8f4f4b8": {"doc_hash": "fc6a18876eba6bbef76c12498704b4905314900b8ab30224be045e89a27633ab", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "8c280d6f-8244-4e83-a00d-64469b64f04d": {"doc_hash": "7b67553beec41fc8e6df5187bf43b82b439355476109853517b44e673270cecd", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "03bf5325-9dcc-4740-8bcb-9a8a50fc625b": {"doc_hash": "c4419e9f47010c2b0b0c6e04a33034619eedc31d1a1289383c78d536111b448b", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "23d2b9a4-f12e-4485-b702-a009a8cc1e8d": {"doc_hash": "026f2785c4a56caf1d6552363b9e361ceed8704b2ac73c58b434176195678abd", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "75a0c5f8-dd92-4cd9-80e9-d2f8d92dcc56": {"doc_hash": "d9d042a21db2260b19139545ff20caf7acfdc5df081b8a845264a0c3ce67120e", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "4b1b564c-8117-46f4-a0fc-7dd9b0434589": {"doc_hash": "4d298557551aea0281208f6102caa76b56354821ceb166d4b791a1fdfd9e921e", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "eef38633-9903-445c-9d3d-a6ab65ea5ed9": {"doc_hash": "31be1490b49177efb333bee6d433a51802420dbae6314001017d2f95de681a22", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "d9008ed4-35e7-47e4-80cd-d38b88618011": {"doc_hash": "4486d393e071dc546e4528a4d6aad0e2bfd3f6b8c5acd6f16c5f57922ce2ba80", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "fcf88c7a-328d-44ef-b997-e3b3477aea24": {"doc_hash": "ccb63b3ec4b95e9bdf79782bd0a253cfa651f25ed8da7ffe05e1ca814a91acba", "ref_doc_id": "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d"}, "fa4d9b2b-cfc3-4b25-9174-9c475a971c0f": {"doc_hash": "0608915843d13987db065832119511c67c67c2dac7d9d3289c86cecd1493050e", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "1baaf3cf-4d04-48bd-a1bb-a01ced51b8bf": {"doc_hash": "8a467a6cb2403422c7cb933f4643c69e0834cf36b2fb98a8212f98ce46ffc74b", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "e2a106f3-01f1-44ab-9f26-1a3b4e75a8b7": {"doc_hash": "222d3df69c1f2d6bc76d30da6b2d46cb06f34feb3f53ef95daf573cd84ec7b61", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "4c653496-af6a-4e20-93f4-9e1df47edf81": {"doc_hash": "b9770342e3f78ba63756b93586345e2eef666d17c8ac8a8f7065352296d169d9", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "53b8aa27-d662-4d86-8d44-53edebb760c3": {"doc_hash": "a210af4768d1a2614d0527ec5cf491c1a8a525a555ee0ef288f62b72ed932c1c", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "40c29df3-ec94-43c7-ad35-b392940a72cf": {"doc_hash": "00a9a5769a305f6a48694ab654c3d153d1510a12bbf3857562c3995f1391a9e7", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "849fc05f-8722-4e4e-80c2-27d036dda022": {"doc_hash": "09b0d31588ed30dec83c8dca20110cfa95c210301d7afa7683765f06e9551e89", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "52bf7572-de08-49f7-8585-cd6bd629e76d": {"doc_hash": "5c8ffc4b41248b95e460d77d275fd863b7ad77a35e16bbff4d9419f744038399", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "67a6dfc5-e465-4d02-8fd6-114574a6e6c3": {"doc_hash": "a076e9ba88d901a371830c281b38d66f5bb50ff06c2accfed54099c809d6969f", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "203595ae-8777-48b4-af4f-3fba2468b8b5": {"doc_hash": "f441ee70042708e366c2f7acff32eb6d0b8a97c57d9e4ba20d5b608399338428", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "38e479bf-a142-47ff-ae96-d4b58657826e": {"doc_hash": "6fba872bd38fc0377d1428b03526425ed26a6ecf588d2bf00a3e188f51cab1df", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "4c1c11cb-2e73-4e34-877d-8d24bbcaf875": {"doc_hash": "da774aebcafff1aae55e76f5747296034a7161cfc87d5bec8a8d11c60faa08ab", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "5ca73968-075f-4fa4-beb0-e7e12436590b": {"doc_hash": "52ed7f9db9b10bef8fe523f06b36c028f95b4c910eb17e4a1ef1b0542340bdd5", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "cc5215a9-fb78-43ea-8e53-7f0f791694bf": {"doc_hash": "114ace311fafc0e26fce87400f88f328f1d27a1df104201c20c5ba2c6eec2bc8", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "ec139860-a790-4eba-b4a6-5d5383bfb5e6": {"doc_hash": "15f95a4e1df82512279f59e2e92b1c7b678119f127529154851a53a69659524a", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "29288c44-a569-4859-8d00-5eef00de66ba": {"doc_hash": "86d4f6193e7990455cb43ce5da46fe36a0182c1b03592d7040b18d118d3e5947", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "7c3de4e1-3aab-477f-8ef2-9de739250a34": {"doc_hash": "b18801ab145b00bac1d3b6c75e3a0836fa73d3e3ee9defbbe07b8233579a4f27", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "b2f0f802-79a5-46a1-9822-fbc679f6da3b": {"doc_hash": "9c81bcc0835b118ed21e7eaf2f10297ab1fd613703e4a504bbdab24e1d234cb2", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "e8fafddc-dc20-4e4f-b593-2f4f185d028f": {"doc_hash": "48c75ac59e52a1879558064003a5f5a8cf95d7cc6605eb9fcd6e31a600638079", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "46995194-7c84-42db-ac6e-8d41583e1d49": {"doc_hash": "f735b57cae52ad6bfeb6ab3b8873cf2b5d94a8c871eac6b427c987cbf0e916a0", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "43371d05-f106-409a-90ba-c10e3a25462e": {"doc_hash": "8f0370f481ab87c82fee7b92ef02be5f68166d79373766116475f78bb67f6a17", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "0fbb70c2-292f-4148-b2d7-5c4456fa5b71": {"doc_hash": "c9b13ebb75b49697015215a0365854fa5dfe52dd20e3314209c1d9bf573ca20e", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "89b2b6f6-ff58-44ec-a26a-08aeb0a01031": {"doc_hash": "e0e761255e8f1d0aef3441e9407495fe9461e463b1aec90baa6f727f6e2b617d", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "81bc229c-46fb-4813-bae7-8038604ef379": {"doc_hash": "4ae65c90e5a90e006dd7ae54bb73aa30ee20074011d4543082be328dce0a0c64", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "5b5dc645-47f3-4bd0-9eba-5017811d6ade": {"doc_hash": "e4ff8742e7254a9370aaa6dbd9d66db87ee340ded129675bb3317e367a6fa3f8", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "4c3f0b33-e101-4197-9145-56315b5c8a83": {"doc_hash": "8a55f36933fcb1d0ddd3edca0941b865bb8b7a9f94c3e38c34b624cb4542f13d", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "898e4a68-f735-43a7-8037-4d029e8a2120": {"doc_hash": "37a620addba093096f18d9a316c9ed7ff53e85dc750b6874061538d9bfe18b62", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "b170628a-6e6d-4b86-9849-ea39b6515135": {"doc_hash": "ba13f38926b28b5483b3971542e2ce2c1b59f6588a8d6b0bbd00953237e7ddda", "ref_doc_id": "c87918aa-82a0-4625-9e1f-a71101645067"}, "d00b91fd-2b19-40c1-b417-eac55830905d": {"doc_hash": "d1c46727115249e7f9baa51ebd0b2abd2a094229aed3dd2071fa70d827112ac3", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "8d1a713a-3b29-4447-bce9-b37cb574e11a": {"doc_hash": "afe5385ca0ee940b324106177e8e8ddb15b64b849e433395e1e8fe904dbe48f1", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "effc2daa-9252-40d1-8dfc-80cec472e5bb": {"doc_hash": "a5e8646cba5fc4053a2ae775a3b1d81530fea76734dfefbcd4ed5ec17be5e03a", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "0fa5aba6-80c1-44c4-bea0-ede0ecb30ad3": {"doc_hash": "fb250373101280be6b883633c248b97c19dce628e5d79768b5c271f710371ccd", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "d53d790c-cc12-453d-b848-71936ceda947": {"doc_hash": "0786b03d594cdd6a6891d60092d59268c0665865358bc768ab602d080906ae38", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "e31b1500-3b97-4fb5-8dce-68b32ac21387": {"doc_hash": "02285d19d1307507b3d42fc8a31d82b853ac850d553ed71fe25da04d9516d6b5", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "64a84fda-561f-4c33-b427-9fb305a5ca6f": {"doc_hash": "d81d6459b5d67bae74069b8c440033b9da45f071dc80bc4066837f757eaf6fb8", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "5b185f0d-a2a9-4dcb-81dc-030ab09656e6": {"doc_hash": "d5a1027cd31527a1ac3bfd8cbf2cc0e9bbe2fa4db0be0a0b2ecfdf6f48ae014c", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "ef999eb8-bb70-45bc-91f0-5db70db79680": {"doc_hash": "4734e941389308e23348b79e833a0384e36de1f2090d27adec9d97d1db467366", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "fb323e65-8f05-43cd-b89a-e330e05ac1a8": {"doc_hash": "71b2c92736f3471f45637ab6edb10097bdb4b2193c265a8007117cd0c6a979af", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "f440b27f-3a59-46c9-b310-ae531541bd5e": {"doc_hash": "9c4123a92ecfe5c44f31cf9d8f09f1730769c1fe59cf3589faaf1d3c00e17cc4", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "ea4daf27-2a3a-4997-9bd1-afa121864425": {"doc_hash": "d401bc511ac4d57112f5640ad00996db71ae9d86e9ce122e0e8803c3a1049636", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "6767039a-0b9e-4238-a711-35a5d90a496a": {"doc_hash": "2efbb4bf926cb9b05953cd9773d64263f4d7c1f527696ea997e4a33bee80b425", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "e6f2bbee-38c2-4401-b0db-8f5745ce097d": {"doc_hash": "2146881a5e0dc2b0b88582c4df81c1de7f151c786fd342e9b9de91543adb3a14", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "d6f44f98-cd38-4b55-a754-1ef435570036": {"doc_hash": "632d77bc184f344b621b141835e295c5a7b8cd15f663bc79be2c7f4a3c5c9641", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "cb4ce76f-f78b-4c0b-b6d5-c1293e284468": {"doc_hash": "d47ba383be14c2255391801705f09950494c2da15cd618278c4236f9ab73376b", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "c537bbb2-9c7e-465f-84a0-5db1a7c8fda1": {"doc_hash": "775afb4ce2bb4a0ee87ec53927686cf3efdc5ee4a28d4d3d2dff30316d42efa0", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "6f957d7f-9b1b-444a-8602-0c01558d9945": {"doc_hash": "bfc3ec09231878f5daad3d85fb8ae9cc532d2e7dab44967aa2acda11199e5387", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "491b67d4-ca22-43c9-8735-01d88e669d27": {"doc_hash": "c7006d3d3ac7afbea6a292e0d79ce9883d7d2feb634e0dc6bc972a9b8752b046", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "be27846c-5f8a-4f48-8a58-2995908d59fc": {"doc_hash": "4c76068336a1ae9b22a7c81cc9344726c4b975cbb8b25b21bd56b799be6dab8a", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "02e9905a-1dc6-4827-8775-a026c5f6bcf7": {"doc_hash": "b8073d12afd3af35dc3ebaf49db13a08ffd625043c111c9d3fc7b6286169b8e1", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "0f550661-e410-4765-b6db-8eed7172125b": {"doc_hash": "c3606d71540cb56456983f5d4e4d451e0550139038a118b09b8f01863a7d2bca", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "904c40b7-a1cf-4a2a-ad01-7c4b4dd883d9": {"doc_hash": "ae6c4fea4c37cd41b7f3b7a72594bedf892454a38b604ada0f611489b9ea3619", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "c7fc9d9b-d945-491a-9bb2-5096b998b651": {"doc_hash": "74fcaadacb3a53fa4403dfb1606046c99e5498878524ec98550b98db8ab33077", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "899f14de-aa3b-4052-8fa8-34a73ec6ab52": {"doc_hash": "39545dedd6a8cdb13d7d5b5a68922477f8be49f16ee38f4f00dba02c38259820", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "f308450b-9306-45c8-b2c3-0a94c569718a": {"doc_hash": "f1d2a2f86cce68fb34452fa1d3cd724f27cb65583ce348fd376c446f718af921", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "8f4efe1d-0606-4825-9b6b-797a582bd12a": {"doc_hash": "7d065f0a76c09f40b1266637720f7a52f3a83c3f48c07d7499b8d5ff2f485269", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "a826f569-150b-43da-9ebb-225ed427d968": {"doc_hash": "1e718d775fb6266cdeb9f6efb7cb689ce9e69d5a82ca017190a97a691cc07819", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "8297610e-e4c0-4e85-835e-f3fc85b57af2": {"doc_hash": "37b7bf6a7948a65317fc4ab382b52c76d50f00f0d0d28526f41c7bc90d7d923d", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "7e517072-cc90-4c90-99c6-29a5c2fa5536": {"doc_hash": "1aa8223d8c6dae747d8f7642fca0ccc69e52daa8b45fd42086209c9c6f696b92", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "1ce28520-cc3e-45a0-913d-257a419901f6": {"doc_hash": "11da583dbdb2ee7b42fac3b46de35af2ba8d0e9fd142003726ea06e7a053c549", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "7ddf8e44-617b-45b5-953d-4796a85ebc85": {"doc_hash": "c551de1d35422520a3a7e4597ff539b365bd25c75ed2103f65e95c40e31429af", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "b64125c0-1c76-421a-8152-a28a21a09a0c": {"doc_hash": "622015d4be7bb6daee4884e7a84f2d8b0ebb1b83b2c4211b4e58e502d50d693f", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "cf5d61d2-cf60-493a-87c0-76720783f425": {"doc_hash": "70aed17cc5e23a57f4cc520b33b0d515eb34fd68d44f0fe7bd8f7a0c40d13498", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "4679fb83-2086-42a6-af48-1bd151773ab0": {"doc_hash": "d133d6b19129c2642f3e24e726a31ebcd96dc7afc50e4a25d8a05b99dfd0ce7f", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "cde3aca3-3a36-45bd-838a-0cda40251d70": {"doc_hash": "e6b3bb3fc59b3e33f96fba3f27dd2041d36b382b5b411e6e266fcdaad792e5d3", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "b6d04839-42f1-4757-8255-903a85c32a4c": {"doc_hash": "d9602322c4ddc0f52f90a414b9fc3ec7848d9437b192b9b1c58472b30b272fbb", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "97ad77e0-56cc-45ba-a0de-80590e56ead7": {"doc_hash": "b5b536cb6088ca18d8a3e51bf1dc96ddf5cb906cac9319904834ed44986a9528", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "206e3f0f-8f19-4cfc-9541-f8ce5b73bd2b": {"doc_hash": "64e15bffa502d80ea194d5e124869453e0f0bf89929295b63bea7edc0ef346f1", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "edf551b9-8e43-4d00-befb-95c3b66f5db4": {"doc_hash": "3c70fb157f665a5e7c967513c8d9a92707a8b9e7da87f57ac09e523cf1958709", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "a7e52848-e9ec-4a85-bc8a-9226e32ca242": {"doc_hash": "8414b63938a3e59af36f3d8a40f1aeec0bd72be8b6322ae8309797b1b5fe1851", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "769d7c32-314c-497d-8a4c-36d6f334372f": {"doc_hash": "3a070d4a1efa36541d14b2d5a5d9671ff2f913fb91f484490c262a26152f63bb", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "89c91f11-8c13-4b74-ba8a-7adbb7345883": {"doc_hash": "cfaff6ea2e446af44f32fb07367c300adef0e2699acd91bd5aa710e388913361", "ref_doc_id": "edc7c708-05c8-4f38-8771-da87d6779c94"}, "b93994cd-96e9-44e3-82f0-2154b5551630": {"doc_hash": "7cae789deb24b0a479425978ac0f6c9291e88761c8fd7066b99ee369bdf63195", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "0f12750c-6c5f-4511-88d3-0a87e3dcf924": {"doc_hash": "d88909bfda2edf12d70d7130ddfcac02f5475c8640603332790cc89722e8903a", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "cc1be5f7-7d91-43fb-91c7-b0523e2b83a1": {"doc_hash": "f213bff3da2ea953468332a02c26728da06ad29e83328e1c36ef2d955a1d896d", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "22405e1b-4d33-4b2d-920d-e85df60ec7c6": {"doc_hash": "adf159c114a1945f3989ed020a507a10b53f0bf1769e7ef5367352143bfec6ad", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "8e50f05e-9e57-4e5c-b654-0c54add01804": {"doc_hash": "20ff8e69e9cb7a8d954ced13aa9d1627ccae4f14ef94c396258737bd665c5dc0", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "3d908a2b-6780-4827-a37f-106ef5f86f82": {"doc_hash": "8b34d91e64fb2d8dda299a2343e5def3dd852dbabdfc21c6ca8c76479ddb6345", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "284f5dc5-893c-40b1-b028-5fafeec44e95": {"doc_hash": "abeec30de94d0d7d824fcf2b3a4795e33b46f012b2e89eac8bd30387768661e9", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "38226411-e441-43d0-aff3-5642249add52": {"doc_hash": "4b83bccd87e7c3a6a6185fbe5e7c7c4c3baace69dc6956712db06982decddf51", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "1a096722-c9e0-4084-8a59-18105d26414d": {"doc_hash": "33a13b2f9aaea5a54b7a92491a7eacb0c23e8ca37282d09b7c5adbf04b0266cc", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "ff961dbf-f124-4626-ab61-719adcaceac4": {"doc_hash": "bbc9c09639b485cf722d67c3d9c3f18c280a81ff7c4c7ea5df9a5f4366bd6e38", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "aa2a8f47-2a7a-444b-b663-664d053fd016": {"doc_hash": "92b945b08a7f7999d2be0a11a7de745887b224b93267826e9da454ef33730a2c", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "9160c7fc-97f6-4371-87ea-fd33c348dda8": {"doc_hash": "b440d26a02ebfb10b50f64906f2df13e95b65a0f7f3b56ee5a85b4e502867481", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "4a2bd59d-7763-4f28-8932-36de6ae53083": {"doc_hash": "d38e14ac3b89c4fd5f73399949397629a26e7215f8c2bed647fa3ac3dadb3d9c", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "5e658415-3ef2-444e-9b42-4267e2176ae3": {"doc_hash": "82b35e6d4e8eea0ab744e0cb547684cd1a07e3b03d3ddc08b2390d4e6a195316", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "73f37080-b75a-4213-948f-e7a31abafd7a": {"doc_hash": "edc3fc69d448873c21169d9ece40b52a91ec01d005779c9f3a0a9dbb992c6330", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "233a737a-efc8-452c-9254-6ec1d856f801": {"doc_hash": "3314935ddf6c8d4052a0993604ccbd46034cd1c6ae3f77340159a43ca82d0b0f", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "c70bac99-676e-45e1-ab75-18001952b176": {"doc_hash": "9a7f1516c816a55dc33b1829847f208821cc7f60aa7e87921246514bc6ee5032", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "bca89952-052d-4224-a694-29ae72ee7922": {"doc_hash": "dbe732eac8e129ffbe36a22677a98fcb568df748a692d6c20ff7217d65ca6c51", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "0ac9cfc2-4286-4986-8bd3-f2833160b29f": {"doc_hash": "b806cbe3eb3200efce117f9f9f46158e49f802b566f9b546448a841f4dcdf42a", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "598733c1-304d-4325-9333-70dccc418ee0": {"doc_hash": "d1a85dc5625b312ab0727bcc1360a6d52ad8ac23754e752bc68a1be65386eaef", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "13086624-1ee4-4e4a-9f47-bf37d2f28eac": {"doc_hash": "dd3798027e43894709565283f3210860bdcaaf226ea13a012e0a6a765f469d27", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "a1f82a8a-e438-459e-9c05-bcf08cbc7f3b": {"doc_hash": "82a030bc6f277fad3868764b9ec3db942f02eefd608a17a1553abdd1acf86c82", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "30def53d-b8a8-45d3-bf12-08d4db8ab0fc": {"doc_hash": "7ac985b24d5b34d919dba3e0f391eab6cfb8469a690d52c5e5e8271981dffd3b", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "37add67b-50ee-45bf-ac67-63f66a0e6242": {"doc_hash": "cea104e7d0528bfbacd16808bbcc04c097fc788fe76afff9fb8bd4a5fdc3f27d", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "b3cb6b07-49ec-4c8b-883f-5754fe764c08": {"doc_hash": "fbfa8893aeb73150fce373d016e0a1339859d5c051b31e9b1c9019eae24fafad", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "7953ca80-89e3-4db6-89a6-189de3bee157": {"doc_hash": "2d0dad1d58f436b304d10965ed1860cd651bf4017363b1f997d2f6fb1a8dd121", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "b51cdfb1-3896-425e-aec4-2ae5cf78b579": {"doc_hash": "ac09cbe54cb3814b4e87c193e90817fbdbdbca6bd63cab72eccd826837990b9e", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "d2e79148-1465-4dd2-98d6-26059259a942": {"doc_hash": "1498df295b69573204c3fc4346e0c089d84ad303c9825bbf1a2db16aefe8c5b2", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "53e55096-22a1-4bdb-a9cc-d1675e88de57": {"doc_hash": "3b1fe6b4b1e5d307b8abd7bb7dea1f8fc19f2e55495889e9523ba8ea0208b376", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "10ec1ec1-f20c-4e47-a4ce-71aa2cf051b1": {"doc_hash": "e8362cc042bfd151b32a8153aa318082b56cf7f300c9221960144e20d5669c08", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "f2846b64-26e5-433b-85eb-270923dd3487": {"doc_hash": "10aa6f7dc0461d1cbb9e42a60eb6c05a03735280c9a35c8ecefc8d41ab9adfa4", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "3699a346-226e-43e3-8469-69509b3e38ba": {"doc_hash": "7c3e6e45123d4da9c5f415641b0084c6359d8b540959f6a8434118831d9df4a2", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "e4e70211-e38f-4057-bc01-cccdda06551b": {"doc_hash": "3a0d91abdd0b219c36234643d33e494d5967411b7899958972748ac2dd33262a", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "f3d8c489-3c5a-43c4-9cf3-d87da419a298": {"doc_hash": "9908bedd8deaa2e5279ad16225b88c916cdaae1764e93ce72abe0e354a9785eb", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "e0415612-999d-4010-b648-18d4e826abd2": {"doc_hash": "1464822daf04b1f70bb686bcc7d16c9f1987108eb916b2e23e3afb04244cbb07", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "6772a21e-7836-43b6-a263-6e72bd55196a": {"doc_hash": "34a12590d2ce348b83e7e1c2662a29520ed6cd4827c8a20a05815bae30c8e5ce", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "434fb24b-548a-4fe9-a773-0b29f4fbe4b6": {"doc_hash": "4cf5e6abcdd596e9ede36d2d588a639f3cf2bff6c1a35b86b5a4f45e45849dc0", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "9b586dbc-8445-4adc-8157-533baba095c3": {"doc_hash": "de98ce06b52981bd101fe58ce6d7ac6d3a723d2407717a46263a60e47a965b28", "ref_doc_id": "5a835f15-8161-4610-9af2-0a41a3f1f4cd"}, "2045a540-c06f-4aac-ac48-a2d718557034": {"doc_hash": "c32a4144c82a03df10043c3ead48f0a703ac971a43c5c408fed177ede7bf2b99", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "1f24f3ba-278e-4ed4-9150-181b97f2bd5b": {"doc_hash": "15e309ae79c79a8802f395d4d7c803effa9da6262dc840bfea39d1dc2e246b35", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "7d5c9c28-0641-407b-9a43-4ad49e79b86a": {"doc_hash": "ae5c121a109646b9589fe464a2c5de0f30a67f04f7f80662d5b4c9fa09a23eab", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "b639ab71-c07c-49fd-95be-294bad0e81ab": {"doc_hash": "ab951b033b89c67cce57d980dd877a5716ed7c24c5c5f96b2bee588c66d8e4ff", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "1b9f7e51-490a-40aa-b1fe-4c4c8f56c179": {"doc_hash": "f365cf8541b0b02c43ab1234dd95bfab0984d766ed29d3b37dcbd4232a9ce5da", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "80d3a580-0cd3-4c39-a55f-136a5292511f": {"doc_hash": "164c65790815adf03592293cbf336c617d8c6248bbf58bfb942d616a92b54f65", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "8de11be3-9683-4290-b716-70b8cb66800a": {"doc_hash": "cc9fb5bf49899aaa75bc2fd33c3fc52d279dd01d0dcfcc968f8ee48174d9c5b6", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "bef3d203-bede-4185-a5d0-89fae344bb8a": {"doc_hash": "68ed38ab24e9ed2b2fa413d52c8ca62e841c9e4130bb45abfb01ff0dd0c4efea", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "a67ef7db-1801-4e36-b583-6f01f4ba4579": {"doc_hash": "a86db268f2f54aa09b6ebbca4a476f06ab28239d82ea0c1e28c8c7482a3e0a9e", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "66332817-5837-41a1-91df-cbb5ebd83006": {"doc_hash": "0527d0efa24827e2eb688f220003f7e780954c6d3f4e98e01180722fb2587c07", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "34d59930-881c-4a13-b7cb-5a4b6d3bb701": {"doc_hash": "a748492624375180bba0dcf97115f986b3c5d1eda0bf027ff14afff9061504a4", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "9535f72f-73e6-439a-a95e-84dd302eda8b": {"doc_hash": "c5b8f1ef9da779a248fddd18daa8a0318927114343a3779641948a601501b5fd", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "9fcd2fab-271a-4a52-b714-fb25baedd923": {"doc_hash": "48200bb51d7d4b081a27391f91842995f9b6b125881f97f05076e26bf6031be6", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "b65a5a90-6dd6-4e82-bf9e-731bebab1d73": {"doc_hash": "db83aed5b8445d75a4887883a7c6131507a9a593067ce2b4dc6bca5544eb7e7e", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "dcb45c9a-a0ad-4d46-87b8-d615fa308871": {"doc_hash": "ea005d79cac6a0f23d671a30805a14d0e1f06de49495b55d1e0592c34a557fb5", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "3bb28e27-8f0c-4cbc-bb07-97e601fb64c9": {"doc_hash": "ee84536aec546baf4774f6885e693c0e21883d50ff8eb697b25365150ccb4b23", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "91933740-75b8-41e7-b291-c4c8d74fc05e": {"doc_hash": "907b12553ca9ac5f6c47a102e9b5bb0bee27889399dc978bd4b4def113ee6f6d", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "f4f84938-e6a9-4ebd-939a-30b595771b93": {"doc_hash": "ec4dd5da38abcfe42856011a8113fc76d4db68be56e97cf33728f9849074c37e", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "4c53f349-d6ed-459c-9f61-89af75c02af6": {"doc_hash": "bbc975056cc31da0c6da9352e322b05336d707b4c2acd026ae4282a47f4de41c", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "93cac9f9-fc97-4223-8d9a-1ceb8b6d090d": {"doc_hash": "8e045ae194f942f8c4fa037b51290b89fd750d5aa2be922b5f387c2c669f9bbd", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "fbc79305-3525-4189-9ef2-53c3d6e7f262": {"doc_hash": "e85b17df59d80ce23574c0f6ef2e2c53cceb1c7fe6df713421a78f8afb44c535", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "ada2ee72-ea31-4b7c-98f5-4fa1bdd18415": {"doc_hash": "22877513c97a471e5f17dd50bf9bd120d9f5203dd7ccd6c1cc212d2d1416b819", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "d39b1e73-0513-4d91-8150-779d4f93becd": {"doc_hash": "4dbdf4195a9affa642ce262f6dfa80dcd26d285227041851a35af4d16e18f117", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "76ef0e13-dd68-4ded-bc99-5760605f3e5f": {"doc_hash": "cd80c92bee7e403f198661fb70cfc11347a219db1970fda9c6d8a5835724f53b", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "3800ae91-0d59-4e0d-b645-4afd0bdbf0f0": {"doc_hash": "5077c396a47ad149259c44b9ea26dc466f8296c6e966dc02f9424ec1fb02d285", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "4e4f7a1e-4356-4611-84ee-8bc5d840ad16": {"doc_hash": "f0ecbaf0a7e5f86680c612978858b1bb04f9c05954634791b4bb561967b37d17", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "4557164f-3586-4918-950f-b9a49c2419f5": {"doc_hash": "ffe628253d0208650ffa8187930bd64811b06c5c6bc59eb48d802f460152a047", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "5f3b9b04-5cf6-4af3-9df9-3583ff610d9d": {"doc_hash": "24eb666d113cae48effc81707b7f9e5ae53e2a09b0d054f146d04f5799c292d3", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "17eb8fd3-572a-4adc-800b-4cc6666d06d7": {"doc_hash": "6af34e2beeacf7bf656d03c592cb33e49865bfc7d432ed7d74b32b55f3ffd3eb", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "f6b906e4-c81d-474e-a3eb-63cf35e8e0c6": {"doc_hash": "728e909edb90f379c025ac85dea5818b56ec58cc2c0c4dd9820750c64f139a9d", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "fac49038-a4f2-48ff-a2fc-3eafe000bd8c": {"doc_hash": "a331df9febaa4bcf76328b23d66875b9d82a7c5f7213563fd7edaf1f0162771a", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "e1622df8-5bf2-41f6-af1c-b7c891a927bc": {"doc_hash": "7399d6a5ad6cb0035a83cf302c4be3e34d498863857362d86e464a07d0223417", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "973ff8d2-6a1a-4de2-bb89-4419f724c7d7": {"doc_hash": "9b82c2546fe812f7926db723e79b0f7c7b960daf09463d7f7701ccc1f51c5cc2", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "957701d5-d68b-413e-bb44-5cf434b6913a": {"doc_hash": "d4d3e0945dc30287997a1c3d047a38a1f57e932d871744b60c2233a813b41fcd", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "6a8ba96b-23d9-4faf-b77a-95a07d263863": {"doc_hash": "ab0c2cad597d24c82396f66bb9d634f92576add9ff3d4dee2aaaeb6b1aa51af2", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "dad1326c-9a2f-4dce-9afe-8fcbcda6fd10": {"doc_hash": "859faa2f3b589fb798e68531811a9bb1a8c08c77b0f780e52146ae98e92ce241", "ref_doc_id": "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa"}, "6190c7d1-fe02-4725-a8c6-e7754b71b504": {"doc_hash": "f0f19a843fffee4140dad5d7e8f4d2431ec0b4e92ba1055a8524a43c9f3e57b6", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "b749eb8f-7470-44d2-8f87-9c01e831f693": {"doc_hash": "494e0382d1017eb880f5ee796b185270326a2891c283b7f21bd51dcd1e6aef8a", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "57992df9-1f81-444a-8620-a30e9a62b1ed": {"doc_hash": "a010793c7e43e3c3f87133b88bd8116248691bb41416b7d377c32e2a1258a16f", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "bef77ed3-2a8c-47c7-9d77-4889c0fd3c66": {"doc_hash": "b3f2a49a9796925bbf2874a38ec5711d8258bb19cc6c0a503da0b4c8f492f894", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "03f9c85d-d991-41fa-bd3a-24c77ca2b07a": {"doc_hash": "468bb49e0da6fde08f62c2bb06043d7db66c8e2d74dc3ce458a114907570df80", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "c6e2e55c-5dfe-4b3a-9cea-81039d56270c": {"doc_hash": "ad32c21a7180ef5675437b8e5de8768986916493ba477d60f108b85575e07b2c", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "c2fc8185-14f8-482c-9df3-4c07f23809f3": {"doc_hash": "93aaaa342d768a2256f28b6bf0ee55233825fd69d66010aac1d3c53f8978f197", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "c5d6c526-4252-4b85-88ff-ad2fa21b10ca": {"doc_hash": "fc3f5f1c6a01b66a7577c47dda4fec924f027f3194b1c14fa74c86ff6866ad2e", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "cd88dc31-5af6-4e3e-b107-7ea533601c9c": {"doc_hash": "44fddb8a38b5e3d298f0c2f02203a9ae959251a2480da5e306b35018669da756", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "d5992f2b-72f5-431a-9161-fc8056fd746e": {"doc_hash": "5f4d9f455a174ac284a6cb68c5dd10a5f318e310152242f199bd61f0eb8b0baf", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "e2f06b5e-38e3-4d17-b527-25e1c787e53d": {"doc_hash": "7f110a662a06aebcd47c0686a3076baa4960953de9d32b184edb624261cb12f6", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "9ad66116-ad2f-4ff8-a19e-8f90df92f574": {"doc_hash": "cbe66295ef8bf434702e835d85112ed1d453350709d25bf2ec0a5087275e1106", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "e23a5ebb-c11a-4425-acc6-8adc66d27d28": {"doc_hash": "f13b763ced333a0a15df5668be321b747fba1bb15e3464baa650e83ef487b987", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "61ccc4a2-a44a-4d4c-ab7b-7623b552c195": {"doc_hash": "d65e7398d65e256cb18943c6d4a23d567d084ff4072ca3f6726e5f09451089b1", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "455cb3d3-8df5-423b-867a-86f2f54805da": {"doc_hash": "f995d4304fe399c82dfd2e330d1792f7cc1e2b1b38c2aa1f4acbf91327dff797", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "b1d3eddc-99ea-4f7e-a441-e5aa48cea36c": {"doc_hash": "11f2c7d7e6b77a9a953881cc970d261f52a13d2805895347ddfa341d60b2154d", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "c1394024-12b4-46a6-962f-4c780d981739": {"doc_hash": "a2416a4415bbd237b21b5e5621f7b3a60a4dfc2a67cb3a96ff7ecdf96dc16ad4", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "8488c376-55e5-461f-9705-068f3cadf02e": {"doc_hash": "15cdf0cac43fc393df5d6a8517849df82290e41ec9c19a3207d256ab60862e0e", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "0873c7e3-a194-4c44-928f-27443a1ce468": {"doc_hash": "75100a135604a69d33f90222a3a3649822715383e9727495620347005b2b036e", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "eb7755b3-f63f-45d3-ab3d-b3b43f4169a1": {"doc_hash": "96550f43b1e7038426f18907469f16cfe998e794bf3467337921c128b8a1381b", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "e21f7f9b-8908-416c-9469-6bed4e301c9b": {"doc_hash": "dd50a8c53de920b0d9f346c7a6c91f1c193f0011f8cea6453469597a25bafec9", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "b0215c48-15bb-4112-8e82-d24dbeadd1a3": {"doc_hash": "c4ae3543b5c541028448d24deab42ee044128ee94b9f41a5dc3dc6187c15d5e8", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "21477dec-3713-4697-b87d-33cfae9acc02": {"doc_hash": "b07adb01022afe910c1c0a734df6e2ae4fd99a472b13e511e7cf0954dded15bc", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "9f0a714a-6009-4f54-a382-c8d3e877d6f0": {"doc_hash": "45cf2895125e707148cf2e63201330ae9730ac2a0c44b4f0816d7d4d7222a7c5", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "76c846bd-b2f2-4ad8-842e-354520d4e301": {"doc_hash": "49fab2adefa56c340d70ee2c49af58c9333903ff3b45391baf948498e72d7059", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "a1fb2654-5dad-412c-a981-356020f3980d": {"doc_hash": "534733301689d79bcb26a564d8d4ec28e361cc7ed18ebe3ae98683c2817fd4a2", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "b53de240-b68f-4f95-bccd-187355ea5350": {"doc_hash": "5fc3fd0e19630ca5b91d5c100b1f74bba5c61d319ad8bab76af8dad5cfb3aac0", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "17e86000-d65a-4f5e-ae92-7c55c68b0c5c": {"doc_hash": "553a24e662fd353b33709dcdad38336e7212dc684bd0100b9195e1dc5cc400dc", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "5bd617c7-83c3-4e31-b7b1-30d3fd24d5d8": {"doc_hash": "7f270d2938c583edd149a4f85fbb6dae5a4e8058c8133c53f4fbe11c9e394738", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "b247d4ae-b6ae-4b68-b626-c1e877e03111": {"doc_hash": "76fc5c244e4c56c01a6fe0938e07b12590d6ef2511bcb29397a1cbe3950c7313", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "1bb76b9c-c896-4571-8f01-99374b28805a": {"doc_hash": "ebc1a39617eb3a7b7b29bf4a217092647281c0845cf23d3494e63850015d8078", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "339ef681-c517-423f-b6e3-a47b0ffb25d8": {"doc_hash": "9ed4e3dec845882f0dcdb3da2013fcfc777a54dc01fa0c1d563dd0696451a30e", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "7a1b844f-4973-455a-9b25-edbbf95215ea": {"doc_hash": "32999e9559407a4a2e85183f42d477613ea47baad32ccefa32d7570118d70d1e", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "38931ca2-f3a9-4616-9129-77671aa6545c": {"doc_hash": "f07ffe19995791f40fe093d0f7f78d0b12c436c4f7d2ae86bef3e99cf1016cac", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "0f490abf-87ad-48e6-9fd9-ac2dc02941ae": {"doc_hash": "f0d3a6c107334febfd8b89e37bb6797497ffd3912e6e455894189d2f1f6a3531", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "97c2efa4-8a90-4893-bc7e-3dad769f8c7b": {"doc_hash": "9a50516f3a5be8cb85d8188a39ae08b54000bdfacc4e8b45086b4389dafe290d", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "6d828b0d-fcea-4546-8287-58333d33492a": {"doc_hash": "c5dbcebfa7202b637f08700520b5b61f58f71cf755c915bec4d54b9bfa074cf1", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "d4feb52e-1536-476e-9133-c9f8da83db2c": {"doc_hash": "1ceb6e116490b18f944e84a42237f3b93467938b82d1d2b1635c77b58f543cd3", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "9eadb7d0-5cbf-4ea6-a726-b8d5b010b75f": {"doc_hash": "6bbfa7a1bbccfbb2c8394c5ffd03767e854515b538341ed5d06c663368ac6d72", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "db6870e0-6772-4041-abec-9e456d4643e6": {"doc_hash": "11f6dd070e1d92e222a8b1c9e9d08460977398108bc92e5b95dc5c4e01ee7c3a", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "6361ab0e-6376-4654-b39d-f9eaf385f15f": {"doc_hash": "b80f57ff9bfe4a68c2d67b84ecc7ea81a6eaed7255162c64dba736cd3f3d6e06", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "30f6a666-8b9f-4b07-ae2e-da9d24869687": {"doc_hash": "dee52805168f21b45ba7af90aeee05eb4ef5ec88236ec2fa04e4498f77f48a32", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "304ea542-8869-4945-afc4-7ed501ecae87": {"doc_hash": "ff25ca10cbfd9d772d2c7d0787a82fa3f88a7a820460dc04531eb9588e68676c", "ref_doc_id": "c77a0fa0-d84d-489c-805c-e2f79c14da3a"}, "9998046b-b6ed-405c-a45c-98ba2e8a26aa": {"doc_hash": "32b0c3e8cf769487a7056403e6971d0c725f9e42628a546b69b6bc77ad50f2ca", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "8b3cf2f2-6f32-402a-b2ab-44f5892131be": {"doc_hash": "f8ddbee1199904f9a0e9be1791a487cf00355388b7e699bc3960f203201a5f6f", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "c99b665e-3b85-411b-a542-9f8ac817e810": {"doc_hash": "0c82e8655d42cea16e4bfe1e070a4f75039f265cb29a910ed5742e3ca55ffd41", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "54a791b2-5158-4843-b33b-5006f9531e7d": {"doc_hash": "6d2002c2e1db2213e0566dcdd8ca03eca046c58ea4fd7000c8d80f5f242a6aa3", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "c4bdc96c-31ba-494c-a7aa-8fc18dd43931": {"doc_hash": "c7330e620eff63ed196b909040ddcb67ffe1ce58a3a2fed06921f751b8f52fc6", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "c71513b5-cddd-4f80-8b40-6e1222f8ef1e": {"doc_hash": "306cb1503a70725eb25e0281fb080d3e9d24c3738ecca31e2c942514fbb6a90e", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "4b67659b-e820-4bba-be84-9adeb378a5ea": {"doc_hash": "886ca791136890cd4fb39e043d85eb7d3b7eb7c613fbaa27f4725c301fa3829d", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "5e03086d-56fd-447f-acc5-2089eb0945a8": {"doc_hash": "69ab3e61fb29fcf1cfd367eddce97de83699e41bdf2997b3e77d96af698376a4", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "a447d7fd-b0b8-4efc-aae6-5695afaf5a75": {"doc_hash": "ec84ff9fa60ded463a1e1015e611ec8ff8a8042106ca91a57f3db1f56e56374f", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "30756745-7ba9-4c40-894d-7cebfc3dc31a": {"doc_hash": "58e5e6b0a5bae969477218d97bf5fe762314f72fed500ab9ffc4971b550f8233", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "a8fad3f0-418e-445f-8941-e80ae342ced5": {"doc_hash": "0ee8011065d24bb03f57313de1e00ca77d1c0240e6195221442c644a8d594a24", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "89e543f9-777d-4238-a7cc-9009d75edbad": {"doc_hash": "82944ca2c437c35a1364f25fb11e3aa924cfb39a85e91845f6b07b9ba41125b1", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "313a1594-18a4-490e-93c2-7e4177edafeb": {"doc_hash": "c1f1efd0adb57c8bf392dbc55236a98664d1b8bd926ba4c039e2f06deee3517f", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "ef7730c9-8d43-411d-801e-a3847d94d6ae": {"doc_hash": "9ec7d2038387620c24e65b388d71010f71855f0dbda5930e5bb3a512d400f788", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "f983f2cc-1086-4b3e-a81f-19e34fa1028c": {"doc_hash": "c2f27721e54d18d8baf2095a754269766f92dcca62f5e62601d7adee9d4f17cd", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "537b8a07-d1a8-4a0e-aa10-321f8bc61655": {"doc_hash": "b27d931dcbc7a2f8f8f17d994944f4c288c1b43a77acf181afdf5bd6d39dc2f0", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "f3d7f095-2e90-49d9-bbad-738efbe47411": {"doc_hash": "ee6afb9f2f3516f59a84ee42183982106a0f28f07cac30e0df659dca5357ca29", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "c9a0f3a2-749a-41a8-8e01-b1a105ff32af": {"doc_hash": "c06186fee1a7dffc4953be63944bc371e69ba38a07333634f814da3e0d9ce20b", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "bbe9cd2f-7183-43db-b10b-0dadfa8bd8ea": {"doc_hash": "720c21e9161cf70e04855ce14f331ac8dec4c58ef726f22e94618533246902d6", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "10a0992e-67e9-4962-b2b7-229ed9aedd18": {"doc_hash": "ad077efdcbc7753305aaf9044d33f725e600ce821b97abe2b23b6361b67ecae3", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "13f16076-011b-427a-b9fc-c4f8a3d39f0d": {"doc_hash": "0f2cc6f355b815f3ac1a5457d95b0892ab321d0370e02a6eb4e6915832f9a82d", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "80d65d99-9c7d-44d8-9328-25c2735ba716": {"doc_hash": "14ae6be727d594e8bd4cfe7b6fbfaa5ffe7f24c03ab29672edb920e18cc3ee61", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "58df4464-a750-4f6b-a527-6e2e4ae2215a": {"doc_hash": "65e13bb69bc89e869cf8287804fea4b1a72f9b704e2d96b8ec7d800980472d67", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "55a56c9b-e8d5-4d0b-9c77-a80fe1dcdecb": {"doc_hash": "68eff2fd0a8f543683ebb5b0dc362eab4f466d6e3105a1dad799106417874675", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "64696e33-5399-4c6f-a466-39f0d14011ba": {"doc_hash": "49072c42440fe47824c5d87cec540261dcd55931ce313dcb2e2f2862e568619e", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "1c8c6e72-cfa1-4a5c-9c19-98bae3ba0f5c": {"doc_hash": "0a0e7dc3cf3e127484e6589d237286d0f6516ecd47a442b644c34d5065a7646a", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "739ebb2c-40c7-465e-aef0-3403c075eebd": {"doc_hash": "6768f79406fea5150fcbc1b1a40dbde4ed96cf7b6602479666545667a870c196", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "c10980c8-b972-4c7a-a220-4c0f718446cd": {"doc_hash": "4f12052a32ed42879c221372eb8e952f0ee562e95f6ece60588e0ac4fff27676", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "7c08f397-4bac-4f84-a526-07ad4b2f7666": {"doc_hash": "0074b7c19e751b66f96282f129abf111f00b9b90ccec02654781ffbc52655730", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "5a917768-ab56-4197-91b6-b05eb4b06d99": {"doc_hash": "870e2861c79577bbb7c846dc60e21c50ce752669a7b5e324c2f9e78af129b13a", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "27ff3e2a-83fd-4ba1-8bff-48718cc0a2e0": {"doc_hash": "9bd6769fecfdbc464ce6aea473b1cf67f1273615c85ee29c866a4fbea410f973", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "9f994fb3-afe4-4abe-ba18-5dfb1bb1ff88": {"doc_hash": "1ee0c23e75f4a74943cff0e34d4eedbeb336d332d979ab100723bc4c9ebcb37c", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "c4c19b37-102b-4f4d-b43d-ce3ed87c07d7": {"doc_hash": "1d925fe73440bca0878fab100088c6378f757ce61ee284bdc6c31f4dad3b04cc", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "b91404aa-af72-4522-a986-bd810ea230f5": {"doc_hash": "e676e6e07064aefd426f8893ee2fff2f5dd242f6491a55bd1e709945f5f73d03", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "6f7a35f6-55e7-4f66-bd68-0f2e16623bd1": {"doc_hash": "df5144b062feb5d1c0e9fcf5326d1398cdf384438c12ef5ab3ca8bb96334a593", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "a935cafd-d14d-49a1-9c0f-1af1d7f351c9": {"doc_hash": "a55d71dcec5407e4126446451c0dea85446737abff98a962c0742bf6b7259152", "ref_doc_id": "27e45734-f5b2-4d91-8dd9-d6769eadaeca"}, "c6be4d02-d6cd-44a8-afe3-01ffeaf2f219": {"doc_hash": "00733c9e7373ff35db2cc12cb8b105e0802bab24de46a051f827986e717eb766", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "b1d2f9a0-3aaf-4649-a4a9-ef1ad45f53d9": {"doc_hash": "1598dd4d389714edcc71559c971c5fd18fc874ac0d00e06a7145ca272c911f6e", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "3b3b01d8-af77-4f28-879c-598dfe6a42d2": {"doc_hash": "2c8a90957790b9ceafc142509fbcf34ade3f5f4f1029c4dce27e82ea72e17779", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "97ef15a0-e4b8-44ae-85f5-a0cba3398f6d": {"doc_hash": "c0e25a087406ba3e3783f33b5377298a39730f48424f542ceabb117830e1c306", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "44af5ef2-595e-416c-85dc-da6adb1a67f6": {"doc_hash": "b4cf66526b8cee62af0c80100528267402089bf3b916752ca2e8441dec1b0f05", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "3346484c-7e96-454e-afbd-357bfff266a8": {"doc_hash": "64e1e4eab798c7a88a394b1795e9fd77e5c767254270c1c63bcdbd3b2033c31c", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "8eb16b38-eec2-4ec2-96aa-500e0e7c0ece": {"doc_hash": "3b24c610581c13a919ea53f188db36a6f9f8c68400d633412fa59e758eb17bfa", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "3a27bedc-8b23-47c2-9fcb-6f983488dd5b": {"doc_hash": "c7f6717808bfd6c11e3a21cb954de42379131670b705aca3b106e4b9e7ffcbb4", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "01da8bb4-e96d-4717-b27c-217587191877": {"doc_hash": "645f833cf65b4db7dddbdd2a4854d169371bd42602feddbb45fd0ea59327db75", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "b08c4133-d9fc-4662-9bf3-8f3bee33e3cd": {"doc_hash": "0fc59060f335b050a3a8d0383d5be2a1ee15f061219d94f6d160842b0dfcafef", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "b824bbb7-cf29-42f2-83c8-01ed38a1b810": {"doc_hash": "adb5d868c939f7c3afd31b0b41cbd5d9815a218d10d1bdadbc85580b75366f40", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "b2c3fc3e-2208-4d4f-b517-2cd2a6cff6fa": {"doc_hash": "99a2e942455403fc05f3893ea59b2d019f36c14afb07699982889b7945ffffe6", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "b9dc7a45-9799-49bb-93eb-bd9d1ee39f01": {"doc_hash": "ef4ae497424c561b04a0f09f69243fbb8d283ce15b1a114bfd25ac7d3789b7d4", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "a5cec5fa-8f47-4b83-b40f-3dae613634f2": {"doc_hash": "6dcd3e8efe8f559068aecf33228896b9ec0884ffa6c23b8ad76cbb841a05b15d", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "fecae755-58de-47b9-88c4-f5393f4e88e4": {"doc_hash": "e222dfecd3c600d1032da8c3fb861ef7a04c6ad1732e5d533625688b51f72d5f", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "3faf9e88-095c-4689-8c25-1797983bd7c4": {"doc_hash": "1d9669f39ddd2f107398c0524f3a1a511929853962bc3ff240e1fdac2c9443b1", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "1c5b4dc4-e42b-42b9-be28-075072d41d51": {"doc_hash": "6d54b40c3f0d311a3c324ff83865817a3427133169533e35ee6cdfecabf5949e", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "d4da1471-94c1-40d1-87ab-cce303a0d616": {"doc_hash": "20be9df2e306493b0a7b75f734b64ff9c4e8496f1708eb0fa0555c8ab370cf73", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "e1ec1960-f0db-443b-903d-3149a629cec1": {"doc_hash": "624f08c0dedaba0e8b2c49c6733cbbaef3714d4bce275b8107b7874b734b26d0", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "284b1c6c-085d-490b-986d-de91cdd3828d": {"doc_hash": "12e9f659d086be0c56fb72292984fbd0cba135f04fef4b6630862eacfc6dd4b7", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "9ac7904a-e94f-440b-b5ca-7769a933b782": {"doc_hash": "16557d38351a0c8ba10b54da3ada5694b8f7ad953366583fdb7c3c1aeaba8889", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "e39f74f3-210e-4790-b967-bd4a7ca9dc50": {"doc_hash": "758a490924bcbff7d319ebdf943fd3cda4606457337463d7f623436fb69708f6", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "6960db19-1f85-4722-80fc-34b35c9717b5": {"doc_hash": "3743f3a294794a5c923d4bcc241d12c8e2d36bf269a5c09d9f0ed5a8a1d42da4", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "3ad9a262-514c-4518-a1d7-e2da83e5316c": {"doc_hash": "9715357bc0d116dc3fe5308ebf683efe3dece4be76749bfa9fc6b3e998fb2cc0", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "386a7bfc-2149-4fae-aa1b-d38d838aeb72": {"doc_hash": "336b1f71344722be1266be02923f0f70c16417f952180ff971fe53998098d6d7", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "69fe565c-139b-490b-95b4-e32989db7ed9": {"doc_hash": "c909e084d7ad5ade4856080464f73a91a4e5b54b68a44a3a145ff011359bf135", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "6e9de60d-52aa-480e-9ce5-b631d1daaeeb": {"doc_hash": "f841f41b3bfd62117db2070cb5cb765f428b44bf70b00275cd1d25d00ec315eb", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "9214b6b6-2259-4cfb-b533-f01bb4dbc1d4": {"doc_hash": "44d2ba75673ad4fb96c3c59d18dccb75f6b734a194da5a5e2fa9c82282f3dd9d", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "e7aa07b9-59c6-4d14-a793-e36b8a181365": {"doc_hash": "56d3bff652a6a4d8a687a66981ef47722d7e2be2a81ef1a29e1462c02db14cf1", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "953e3f5a-4916-4131-b2d6-cb6f8e20b6d6": {"doc_hash": "b15ff4c0ff2fea044e2f7b6d6b6dc9db0a9bd725bf21bd5657fccdd4992880ba", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "babd3396-9f1a-41b2-8950-e75b519b5a88": {"doc_hash": "aeb52adbf2ff4177d4c0bd831581cf3be24fe29449b3370f6c5b17b696abb03d", "ref_doc_id": "b21338ab-85c0-4d94-80a0-ff396d888d23"}, "1b20425a-b09d-407e-9020-f23d826a5e30": {"doc_hash": "eed7518aca491a67e63ed9c5cc06404a72d09c3ff2aebee5fcc4b150feeba4c1", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "15fa7a73-ac0b-4774-a6d5-48edda634509": {"doc_hash": "c0999df8b41c672d39397231779bf2a83c718855f873d937255866078d39ba6a", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "9c16e092-9afc-4e60-902b-a8cf4546fdb6": {"doc_hash": "1ba282d374fcb4469319c179b1634cfe0912f64c631958b8f6de117edefc9b6d", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "eb19d9a1-7099-4441-a857-97dc042c17b7": {"doc_hash": "2751a41abf9af902fd9ba48825f1ae4a1eaa3079664db0c8d7674ad37c7ab1a8", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "0ba65fe6-162a-4438-960a-0351e6b61546": {"doc_hash": "542076d6e9fbd013c7c9d5efb5cb72183a18eac0bfb0e04afacddfe89049196a", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "90609998-188b-448f-b33e-128b753c2afd": {"doc_hash": "9e93fb6f649b55fe1ee0e7bafe442948928146f1fdb64710016fdbde99056296", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "83e27a91-6508-4f13-bbda-cae5d3e63b1d": {"doc_hash": "ca68eeac1c20bab478249ea4efcfcb072269a5f0731ff9729fe4eaed562907a7", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "3f766952-649f-4f7f-8e0e-447854e9d135": {"doc_hash": "6a86680e40ba3bf86225a01047131ee6d2b70029b1dfbc525db9240158f76cea", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "8765a05e-e006-4e65-aaa1-e33035e525b8": {"doc_hash": "6a4dab4123a6313a3354c3f7604d5b9d0a0df67b075d326d5df0b478fd7b7aeb", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "d9e7cd83-860e-4488-86f1-877b9cadff11": {"doc_hash": "155fa2f22f3557b0c48691ab43753c77de8d1d531d76b8b88b23a863342f4a8b", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "e34e3738-110d-4eb8-89c3-77ae5e9d03f5": {"doc_hash": "8ffcadebea49003db3d56f2f2d4da017772e949a8a747e5f9889024c1ceb3251", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "3cdd6957-e933-4922-a02c-fc3016ae670b": {"doc_hash": "caa6b3e7ea4079d3e526128d8aa16ab457b4e47d445b30adeea13de37222e057", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "1601cfc1-7251-4ed9-b04e-02d393cf17ae": {"doc_hash": "c0f82c5ad07d51fb1023766a52cad3b22aea0f3e467ebdccd81855ba83634561", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "ca72b27d-1582-4330-a542-9c118c709c12": {"doc_hash": "4718f0366296ea139f291391d53d2aa3d275b5142991fe22f784a601b7b757d4", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "93f048f9-547c-4cb0-93b3-b2a3e83bc7bd": {"doc_hash": "e84324b456131e741902f854c39c784cb52bbd894fd874427794f72e8f8bbc50", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "a71248ec-8f98-434d-a3ad-d0d05f18dcb3": {"doc_hash": "bf883846b9e36d3336824e747911e16b7abe2455876234f5739de8dcebc790ea", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "d95c6f65-aee3-403d-aca6-977e3f46e17b": {"doc_hash": "0afa2dc288462ba816080481260714aa915eeca96ad78cd5266257541584dfb0", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "ad2f5502-2de1-48ec-9b88-5db50bc3630f": {"doc_hash": "a2f0b5625e2e7bece3a47ddb19a3bf9d4d44ce33e2d520fdbfb2adbe0b778679", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "4359f946-2952-4466-bd60-ee3d7e23a996": {"doc_hash": "0fe760d31ede322a4ffa0b2957e2ca4846673fd86a08065fedc4e6135d63d9ec", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "8f694cff-0a47-43a2-b5d9-68355724ab76": {"doc_hash": "054bc49a22d6b06871ebaaafca5e79c0d33aa7b0c1cb3d70f6aad50b95d34fc6", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "264a9f10-3c90-406f-9ebd-84af38a15c17": {"doc_hash": "186207707b28a997c72a8760b8412cdffd428d3d926ced5dec67a774810703b5", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "35f5638a-efe7-42e3-9c12-104674711fea": {"doc_hash": "4a6ebdf811b00ca5dbc507b5dbaea4dc1e3ec83ed087496c6bf37f89b194a5a2", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "076e11db-95ba-44a3-a575-e1dfb7439c95": {"doc_hash": "29388299b6bafe7da1e61404ed6e1cdb6fde2bff2075c3f65a93fea43fe1466c", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "8e314459-3096-401d-95cd-45133145c254": {"doc_hash": "d735e4663732088fddd3dc707b43804a1729cfcd577380c8689c0916cc1d9eb8", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "6707d795-5655-4f91-aedd-3405725b6ed0": {"doc_hash": "3b368ea6f67ecb5af0e77209ea2b187bbb85c7e4d899f8ee30449403ac4fa3df", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "57de8efe-bd55-458b-9c09-884ae8f38ed0": {"doc_hash": "fe9bf928b33680255efcd1ea00087a6bfcfebd7b12ef3856fc5100f14a4d4330", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "2567fb41-9499-4509-9f42-ab22399209c7": {"doc_hash": "2b8de956ac144b103f4959c96c832d8993ab9ac96e4ed1c500254f14a0f33fd4", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "629a5669-bf0d-4495-b040-8ce38e337e66": {"doc_hash": "12645fa3a5a3f86823bc5da50bcd4bcb7cb7548dc30f4f8d531244d7173bf38d", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "7e55ef38-1988-4873-991d-08e2540c14f2": {"doc_hash": "27ec71c317ac5909871cc56a30e49803ef9aa0de7f5d370387189b250cc603af", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "80bf3135-a4f2-4e41-be8a-a87e8b22a778": {"doc_hash": "7c6ef606dd7f912ba5634ef6434de55b0853642ca5bd395435ba49a84457fe5f", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "69c5d470-1f1a-4607-a75f-3776384b9abf": {"doc_hash": "8f083141cae7c4c77b78cdbe6fa4150c0425f0201e8187c4fda31b49334ffd69", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "c26d411e-b4fe-487f-ba15-8a5bc395df0c": {"doc_hash": "1044cd46ac18fc5f0b332d3723117f764f92e8f0029509734495552f8cb68a39", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "8c61cccf-1c38-44b4-a58f-d7debb4f0f69": {"doc_hash": "1f3dfc168c252d59452f9f87350fccde5c58f21b2aad315000a59f41ffe42086", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "4b0c1d17-8f70-4a9b-972c-794029a431cb": {"doc_hash": "93949f33012d0f8173c46850d186947050eddc885b40a2c34a18425b8d2ef344", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "72a299c8-e3da-4da4-a37a-49f431496dd6": {"doc_hash": "ddde27907232ef52a80cd9bc2f7ba7d665ea202ec85dba9a878ad78cb00c6a87", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "0a66552b-2235-40a9-8804-3584df1c69d8": {"doc_hash": "2d72e0eb38045598bddf1be0af41b9d37ba77b3ccb8cfe230e9bb1fa05093901", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "b8c5508c-180e-46a8-8d5f-7dc3d4d8860a": {"doc_hash": "7fe60f2d5a8796f06b090a5976705f2602181415f2bf59e26f89c81d956da1cd", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "df17284a-489e-4e9f-a336-23d869b3755f": {"doc_hash": "3c20c61fb4e05946070f506c3ed12518dd193f963829dae5e6c0f59209d403a6", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "d9d34ada-8694-4999-b5c8-e8f8d2c53384": {"doc_hash": "aef3fc66607b4d423bab8cd7c5ebefb47dc37c1132964bd8bece0867709d6a02", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "ef6dc8c4-55d2-4513-a09c-3bd818e80bfb": {"doc_hash": "fd5c069c1bbf4fd3a16c2f00b0873311f0f7ef5e192acc85165d4ea5cff134cd", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "04dad935-42ab-447a-b59b-57912723e416": {"doc_hash": "39a7e5954475dae641e35c847499fae8dc4d396bc0fe4729ea68352458f8158a", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "5a175cb9-0cf8-471a-b571-15c74f835e2b": {"doc_hash": "97960579d02292d275d7fa04fd7f2a682698d8d1e031b4847d3f065cb21e379e", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "d98fff9a-ca4e-4ba6-9aeb-e422e3490ee8": {"doc_hash": "9c344a5a8902715ea142b84904c292894b404b83255793117922df48b120a7f1", "ref_doc_id": "e7d53cb1-efb1-4e83-8f0d-af5a077e591d"}, "c00172f5-68e7-43d2-bcf5-839ae5f48564": {"doc_hash": "810e57dea88752a4066e9b4ca1c1c8b1a58ff259f1a050604fb6345e7849af46", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "e3958513-9999-4dd3-ad94-b8a98d2d6e01": {"doc_hash": "78dec76a45a1e69504d9865ec3a72d0c0e70e279658a0f8f1cff85e9e64a4184", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "42ed4dd7-3146-4bf9-b945-3f080018875c": {"doc_hash": "45860dd9dbd0454b575463e50274f156cbe70270985fdb75e84615e9efa35973", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "64794e1f-31b7-48bf-b725-baecded1ff01": {"doc_hash": "d52fab165af5c5d03237337f8d25f283a84fd39af6371f59b65c31743a263b0d", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "35c465f5-ef3e-4cbc-b651-287ee7176577": {"doc_hash": "acf57def3cb5e8133c86ecd1bfe9155097daf5961f85bc768d721e5ecad24e5d", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "5e872673-e104-4a2c-857a-77f7ef26c7f6": {"doc_hash": "08683e903169e1adeafa115fe767be7d40ccceeca559ba11335ab904f0262530", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "1c54e143-34bb-40e2-bfb2-7fc08d807903": {"doc_hash": "e1942657499ab307692b0b2d8dbaaa9d98366bcc77ba31d1548293ac23f5ca42", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "7d196019-d1bc-47b1-9861-7f12632e7291": {"doc_hash": "3f211a904310412164e5f4ae125a10afc599096fe68763ddeda327e1902b066b", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "63bdca92-2bed-4375-9a4a-7365984684c4": {"doc_hash": "2393ddf6926bad91799e1b534a481745b479d225eb2972c0f21e5b4ee414fdc8", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "f395d083-44e3-492e-85ed-585d3bc965bb": {"doc_hash": "ef03ef0aba70c81e34236e166b7f555e05e56b836d5aaaf6a2b77fe5a0a95e70", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "9ce52669-728d-47cf-95e8-7bd02284fe6a": {"doc_hash": "ffd127cc5c8a4d93c1a53aa19205f8f0180b8acea614190f4e0f68005a6cfb6f", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "8a9d2bfb-c729-44ef-a356-c441d7f955c8": {"doc_hash": "7acc364648c826707632f6f2ac078eefcdfbb125f3b07efe1496c01281720685", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "dcd0a86a-e7ce-44ea-85d0-13f48c0033e8": {"doc_hash": "b4fb75e7c7cde77ee50ed50abe360432dd74f68bcb3a9589a51c6ccd32cd2d84", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}, "dc17130a-2913-49bd-9e9a-701625bf3b01": {"doc_hash": "d690f591b4af3688044054a9f8684b3de068c5d03a1b37de11980bdd8d1f378f", "ref_doc_id": "691e9bad-2b35-4c21-8984-421a82326418"}}, "docstore/ref_doc_info": {"5fc948e8-49e5-4c35-96f4-234a708a99f6": {"node_ids": ["e2245dea-0889-4d04-ac46-c7585007f7f5", "a9453aec-ec42-4db1-9c12-4bc3b73578e4", "eb93c1ae-3395-4d62-aafb-f49c08500db9", "b24bc4d2-9504-412e-a1ad-31ea9aebfcd9", "0ebc3f9b-9abf-4b25-951c-219679a28bb4", "bd2593d9-854c-4aa2-834e-c9452387be22", "30a5a0f6-e5f6-449d-a73d-23ca7eb34d0d", "2c8c0fe2-7003-4ad4-b5a6-78e05cb3cab4", "add45d40-6923-4444-997a-dffac8f43dbd", "275a9792-138a-4601-b02a-9d634a558f84", "301ab9c6-6937-418c-8c39-d72d4e0352fd", "f720c0ee-4af9-4588-99b0-9097408f998f", "ffc7079b-26a7-464a-a8b9-bc21a906eeee", "e3472492-ce47-4337-8e75-a46c618ec3b7", "eabbdb28-f84a-4167-8299-8a16941ef2a8", "4ec67509-d6ac-4051-a141-45806fc1fb77", "ce33a122-cbdc-457c-b0f0-b1b5af0dcee3", "254efc82-4482-4dc2-b827-97522417557a", "e977aaf6-4405-4149-af4e-ce40265ba4fd", "bfe047fe-3ba8-4b37-87d8-edb3ae4f9b3b", "a349f2b2-8a87-43e8-98d9-398073c5895d", "9964c598-1ddf-4f96-90a0-24721423a22a", "07656d67-f11d-487b-adc2-435a456c7c1c", "2b3cd265-71cb-4531-b300-2784bd55ec8e", "97eb211c-459e-4d85-b795-8f779e400600", "d2aa092f-f798-42f2-a0de-4a9fc150b5e3"], "metadata": {"window": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Incorporated Fourth Quarter Fiscal Year  \n2021 Earnings Conference Call.   Today's conference is being recorded.  At this time, I would like to \nturn the conference over to Vice President of Investor Relations, Kevin Moran.  ", "original_text": " \nPage 1 of 15 \n \nQ4 FY21 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b1450f53-5c26-4a29-bdd3-4ce9ac94ba06": {"node_ids": ["90ad4290-cfab-49b1-8c00-ea279524b958", "54152de9-c381-4183-8bae-6bc46ce77f8b", "aff01caa-4f2f-430e-89d2-d4392d70086d", "533e460f-0585-4e89-be96-f896ba07c55d", "f8986fbc-edf7-4849-a126-2de35b42c199", "c8712cf6-77f3-45ff-bbc6-7568ff438187", "309df031-5f52-4058-af3b-20eb5a682624", "a8a3eefe-abb1-429c-8eb5-940765393a0c", "3dd401b5-151f-44ba-94e6-15af816cb305", "a0e1b0c8-837b-4862-bbdb-0030f79a2be3", "713247e5-0efe-43d9-96db-2ff58f3dbb9c", "b60b9851-ffb5-4de5-8c39-6e66255aec5a", "725ee96c-b8b3-4432-8915-7ae04ca44928", "49e3837c-77ce-40c4-b845-881f183a4043", "a091da2c-fb59-43d3-bf7f-90ecb8b22fe3", "f4f5202a-67e9-4494-ab7a-8638bcae458f", "68d7f5c3-53ed-40b4-9f92-3c5feb819a9f", "21b94426-9903-442a-b71a-ca8b79ec6a23", "ec75cb56-4e07-4d2a-8e2d-3f7f0ed28657", "9e4e3465-3e02-4b3e-97e5-c27da80ec5f4", "a74bbc4b-5866-45b0-9f8d-c6a04ff21cbc", "38ac468c-edde-4297-8a5e-bcc74ea72323", "35fb7340-7544-4ebe-aa8a-20b59eedf20b"], "metadata": {"window": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n In FY '21, we grew revenue 6% versus the prior year and despite an estimated $200 million year -\nover-year operating earnings headwind related to COVID -19, we grew EPS.   We continue to \naggressively streamline our cost structure and surpassed our enterprise cost savings target for the \nthird consecutive year.   We generated st rong operating cash flow, prioritized returning cash to \nshareholders through dividends and share repurchases and took actions to further strengthen our \nbalance sheet.  \n", "original_text": " \nPage 2 of 15 \n \nWith the actions we've taken to date and our plans for FY '22, we feel confident in our strategy and \nare encouraged by the tailwinds behind our growth areas and strong cash flow generation.  \n", "page_label": "2", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bd47821b-39f2-4b22-b3cb-1979088901de": {"node_ids": ["a5db360a-1a0c-4219-86c8-532af07c21f4", "1e2d5108-81bd-4b34-b4fe-110ac67b84d0", "7cfd16f1-1369-4c65-8320-be38633045a9", "98759a3f-dd77-42ec-a3ff-b1db1e113eb4", "98b5aef8-1755-4bd3-a08b-f3a76dbbd0ca", "cc671572-46a2-42b1-80f0-886dcc561f61", "3240b546-e333-4b72-96be-c2aa262aee51", "d155e7d3-a0d5-455b-8ade-6fbfa0ad310a", "d9052854-53cb-44a5-95e8-cc40b5ae10e4", "852b85c9-742c-40c9-9273-daca186e9c53", "bdff825a-32b1-46a5-b501-5fa52a264db8", "4dabf534-8ab3-4689-a5d6-b4f08faba5a5", "6593d985-cf2e-4a3a-9b48-92e419e7ad4b", "55580760-d6c0-4306-8157-868aa5f4cb73", "35545e8b-b3b5-4c21-8354-3322959ee8b6", "a28cbbbf-aae3-45d2-a807-ce37eecd5e8b", "9d41c212-4abb-485d-92a6-199616f528c9", "c35226a6-9094-47b5-acd3-32c350d7b522", "d37402cb-af87-4d50-a0db-f6e1b9387234", "a1507b76-1373-40bb-987e-61198e7800aa", "3b22d0d4-257a-4212-996b-26f9ce7731b0", "9dd6cf46-d7f0-4a28-ae4f-2eab544cf835", "5d725e47-ac3f-4651-b85b-b08fe8a91e69", "092b1f43-fd76-4a33-9e6e-7d48542902ed", "c59b699e-5af5-466e-9e01-042fee01a86c", "6ddfdbd3-24ac-45f4-a9be-c1c5a9367fbf"], "metadata": {"window": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.   Our generics program continued to see generally consistent \nmarket dynamics.   With respect to other pr oduct types, including brand, specialty and consumer \nhealth, we largely saw volumes at or above pre -pandemic levels during the fourth quarter.  \n In Medical, depicted on slide seven, revenue increased 23% to $4.2 billion in the fourth quarter.  ", "original_text": " \nPage 3 of 15 \n \nAs we highlighted last quarter, we continued to experience softer volumes in certain therapeutic \nclasses within our generics program.  ", "page_label": "3", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "702a1b13-4901-4a0e-af6c-20d16f3ee850": {"node_ids": ["730404e6-0f63-4cb6-b84c-70432b82bb80", "c20fbd52-519f-47e1-93cc-fd3f63605f8e", "af293b42-f610-41e1-82ca-24f17f82c3a8", "9e4ebb2b-a433-4574-b07f-4d517eb2e34c", "d2e7bc3a-7cd8-4597-b71a-3a205189bf00", "f5a46872-16b8-464b-9d97-a9fee53ca7e2", "62a03091-2ca0-4c5b-81ef-714dca1374f9", "135a01be-1d7f-40e7-b669-592aed9b9d9a", "31e1d917-4860-4a5f-b770-226496d24a2b", "f56f0e18-58cd-433a-8e0c-1219fba92147", "3ccc8044-3ecb-428a-881b-c43951c1e2ac", "9705d73b-a692-42c2-a180-f30578d43b13", "56cb433d-92db-417e-aa92-275632629c4f", "cbc4e744-8e1c-4939-bafc-95f4a2badb44", "5524fe0a-ef89-4369-b0d5-1bdd53ff06bd", "97424113-9a7c-4cb5-83b6-f993e4556b9b", "f386aa7e-6b6a-42b1-b33a-68cfb4dc6eae", "b60bd30e-9ce1-48f3-8eaf-cfd6147cc009", "4252d548-ba0d-491d-990d-b4f58cd3ba47", "dd50d670-40c5-43e9-8240-1464a197e401", "b0842ab8-82ed-44bd-bbcd-4695cfb90090", "d770dcf6-8654-49be-ae4f-f919eb43a8d3", "6112ac99-1e1b-46d1-9edb-4777a5a3fb0a", "cf138164-7279-4d18-aea5-15aebebdfb7c", "d9412bd8-5d07-4242-8183-e24b7ab4a8d8"], "metadata": {"window": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.   Pharma segment profit decreased 4% to $1.7 billion due to volume declines in \nthe company's generics program, including the impact of COVID -19.   This was partially offset by \nfavorable brand sales mix.   Excluding COVID -19, we estimate the Pharma segment would have \ngrown low single digits in fiscal '21.  \n", "original_text": " \nPage 4 of 15 \n \nAs for the segment's full year results, beginning with Pharma on slide 10...  Pharma revenue \nincreas ed 6% to $146 billion, driven by sales growth from Pharmaceutical Distribution and Specialty \nSolutions customers.  ", "page_label": "4", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "63991299-8af0-42fb-9c98-6c628d1be1f9": {"node_ids": ["dbc0688e-7f23-4469-82bf-96bebf9b99e9", "69b374eb-40ac-4266-b78e-5a934a0ee6f3", "849c7f7e-1bf3-4677-8926-b6d1a9b10895", "27057e26-88c9-4d0a-831d-48b839236e70", "55cd0d4e-271e-4324-8e4a-cf265d7fdacd", "d7f47851-4562-44fd-94f2-dc57f9dbf115", "5858a507-a87f-496a-bcb0-1f6ccdd2e394", "e3bf20f2-9a90-48da-a943-7939756d76c0", "2f8ea981-2a25-4dae-942f-b35070d1311d", "355faad5-e4a7-451a-844f-70321a94e959", "a68c8237-1b2a-4cf3-a163-82b94b7fdd24", "9c3e9391-6ed7-4f55-8baa-8087bd0b7bc3", "d87aa1cf-b431-40e4-bae3-b14229d71f83", "f817ad04-f866-4339-82f5-2689d337f6db", "1a8e58bf-637e-4dad-8578-8f41b147afee", "75878e77-0b6d-454c-8bda-9ccc199091f1", "18196012-223e-4e7b-a7ce-274bc1d1e276", "0b820bec-5ade-4b3a-95e6-77386d7e07b0", "02e31643-affd-499c-8b00-4af7a1410b2b", "55c825be-2d54-4ebe-bf25-8c3f274329ad", "68e215a6-1cf2-473a-b1ff-9220b7d7dc14", "285d875f-067a-4e98-aab8-2b4a948757dd", "5df697bd-04ad-444b-99a4-1dd987629a77", "7f466fa7-7409-4ad3-91fa-2e92a2f1482e", "49fc8353-d490-4847-bf0f-fc3788d1553f"], "metadata": {"window": " \nPage 5 of 15 \n \nnuclear and outcomes.   We anticipate a similar c ontingent brand inflation rate as in fiscal '21 with \ncontinued less dollar contribution each year.   And we expect opioid -related legal costs of \napproximately $125 million, an increase of $10 million versus fiscal '21.  \n For Medical on slide 15...  We expect revenue to be approximately flat in fiscal '22, primarily due to \nthe prior year COVID -19 comparison with low double -digit segment profit growth.  ", "original_text": " \nPage 5 of 15 \n \nnuclear and outcomes.  ", "page_label": "5", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b8997cd9-3f7f-4b85-8a0c-46779eb14d9d": {"node_ids": ["6cabf8c3-39df-4945-9dbe-e4ae7a1f0a0d", "8fa2ad87-25df-4ea9-962a-d9ab2d393269", "0173b9c1-f15e-4dbe-8701-a5b8545d4d68", "a99e9348-72a9-4b5f-aa82-dea758f9188d", "ca3f7a5a-8df2-41a9-a8dd-f43f3470e92c", "24f6e02d-6693-4098-bb62-e03d17e049d8", "79dd1b5e-c675-4662-acbb-90b8cd7d9c49", "43040cd7-3e00-496b-b492-a7b79af82fda", "d533a742-f7ba-4be1-9bc1-e42648900761", "64ac07a0-f625-4adf-a309-62d75aba5e87", "a8b11fc9-a169-4786-a6f4-a3ae79437030", "43cf2c62-6f8b-44da-ab2e-b50bb592fed9", "99e6a32e-b62b-431c-ae6e-462faaa92c07", "e66fc7c0-52c5-42e2-a231-a096e8f4f4b8", "8c280d6f-8244-4e83-a00d-64469b64f04d", "03bf5325-9dcc-4740-8bcb-9a8a50fc625b", "23d2b9a4-f12e-4485-b702-a009a8cc1e8d", "75a0c5f8-dd92-4cd9-80e9-d2f8d92dcc56", "4b1b564c-8117-46f4-a0fc-7dd9b0434589", "eef38633-9903-445c-9d3d-a6ab65ea5ed9", "d9008ed4-35e7-47e4-80cd-d38b88618011", "fcf88c7a-328d-44ef-b997-e3b3477aea24"], "metadata": {"window": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.   To be clear, we are disappointed with this finish to the year and are \nmoving forward for the sense of urgency  to improve our operation and execute our strategy.   We're \nprioritizing investments in our strategic growth areas and expect these businesses to collectively \nrealize double digit growth in FY '22.   And across our business, we're enhancing our IT infrastruc ture \nin key areas to increase  capabilities and digitization , improve the customer experience and drive \nproductivity.  ", "original_text": " \nPage 6 of 15 \n \nMike Kaufmann:  Thanks, Jason.  ", "page_label": "6", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c87918aa-82a0-4625-9e1f-a71101645067": {"node_ids": ["fa4d9b2b-cfc3-4b25-9174-9c475a971c0f", "1baaf3cf-4d04-48bd-a1bb-a01ced51b8bf", "e2a106f3-01f1-44ab-9f26-1a3b4e75a8b7", "4c653496-af6a-4e20-93f4-9e1df47edf81", "53b8aa27-d662-4d86-8d44-53edebb760c3", "40c29df3-ec94-43c7-ad35-b392940a72cf", "849fc05f-8722-4e4e-80c2-27d036dda022", "52bf7572-de08-49f7-8585-cd6bd629e76d", "67a6dfc5-e465-4d02-8fd6-114574a6e6c3", "203595ae-8777-48b4-af4f-3fba2468b8b5", "38e479bf-a142-47ff-ae96-d4b58657826e", "4c1c11cb-2e73-4e34-877d-8d24bbcaf875", "5ca73968-075f-4fa4-beb0-e7e12436590b", "cc5215a9-fb78-43ea-8e53-7f0f791694bf", "ec139860-a790-4eba-b4a6-5d5383bfb5e6", "29288c44-a569-4859-8d00-5eef00de66ba", "7c3de4e1-3aab-477f-8ef2-9de739250a34", "b2f0f802-79a5-46a1-9822-fbc679f6da3b", "e8fafddc-dc20-4e4f-b593-2f4f185d028f", "46995194-7c84-42db-ac6e-8d41583e1d49", "43371d05-f106-409a-90ba-c10e3a25462e", "0fbb70c2-292f-4148-b2d7-5c4456fa5b71", "89b2b6f6-ff58-44ec-a26a-08aeb0a01031", "81bc229c-46fb-4813-bae7-8038604ef379", "5b5dc645-47f3-4bd0-9eba-5017811d6ade", "4c3f0b33-e101-4197-9145-56315b5c8a83", "898e4a68-f735-43a7-8037-4d029e8a2120", "b170628a-6e6d-4b86-9849-ea39b6515135"], "metadata": {"window": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n In addition, our Medical Services busine sses, OptiFreight\u00ae Logistics and WaveMark continue to \nenable clinically integrated and digitally automated supply chains.   Our At -Home business continues \nto focus on enabling and supporting comfortable home -based care for patients with acute and chronic \nconditions.   We continue to see volume growth as care is rapidly shifting to the home.  \n", "original_text": " \nPage 7 of 15 \n \nWe're laser -focused on enhancing supply chain resiliency, improving business continuity and \ninvesting in advanced planning capabilities to drive forward -looking insights to better serve our \ncustomers and their patients.  \n", "page_label": "7", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "edc7c708-05c8-4f38-8771-da87d6779c94": {"node_ids": ["d00b91fd-2b19-40c1-b417-eac55830905d", "8d1a713a-3b29-4447-bce9-b37cb574e11a", "effc2daa-9252-40d1-8dfc-80cec472e5bb", "0fa5aba6-80c1-44c4-bea0-ede0ecb30ad3", "d53d790c-cc12-453d-b848-71936ceda947", "e31b1500-3b97-4fb5-8dce-68b32ac21387", "64a84fda-561f-4c33-b427-9fb305a5ca6f", "5b185f0d-a2a9-4dcb-81dc-030ab09656e6", "ef999eb8-bb70-45bc-91f0-5db70db79680", "fb323e65-8f05-43cd-b89a-e330e05ac1a8", "f440b27f-3a59-46c9-b310-ae531541bd5e", "ea4daf27-2a3a-4997-9bd1-afa121864425", "6767039a-0b9e-4238-a711-35a5d90a496a", "e6f2bbee-38c2-4401-b0db-8f5745ce097d", "d6f44f98-cd38-4b55-a754-1ef435570036", "cb4ce76f-f78b-4c0b-b6d5-c1293e284468", "c537bbb2-9c7e-465f-84a0-5db1a7c8fda1", "6f957d7f-9b1b-444a-8602-0c01558d9945", "491b67d4-ca22-43c9-8735-01d88e669d27", "be27846c-5f8a-4f48-8a58-2995908d59fc", "02e9905a-1dc6-4827-8775-a026c5f6bcf7", "0f550661-e410-4765-b6db-8eed7172125b", "904c40b7-a1cf-4a2a-ad01-7c4b4dd883d9", "c7fc9d9b-d945-491a-9bb2-5096b998b651", "899f14de-aa3b-4052-8fa8-34a73ec6ab52", "f308450b-9306-45c8-b2c3-0a94c569718a", "8f4efe1d-0606-4825-9b6b-797a582bd12a", "a826f569-150b-43da-9ebb-225ed427d968", "8297610e-e4c0-4e85-835e-f3fc85b57af2", "7e517072-cc90-4c90-99c6-29a5c2fa5536", "1ce28520-cc3e-45a0-913d-257a419901f6", "7ddf8e44-617b-45b5-953d-4796a85ebc85", "b64125c0-1c76-421a-8152-a28a21a09a0c", "cf5d61d2-cf60-493a-87c0-76720783f425", "4679fb83-2086-42a6-af48-1bd151773ab0", "cde3aca3-3a36-45bd-838a-0cda40251d70", "b6d04839-42f1-4757-8255-903a85c32a4c", "97ad77e0-56cc-45ba-a0de-80590e56ead7", "206e3f0f-8f19-4cfc-9541-f8ce5b73bd2b", "edf551b9-8e43-4d00-befb-95c3b66f5db4", "a7e52848-e9ec-4a85-bc8a-9226e32ca242", "769d7c32-314c-497d-8a4c-36d6f334372f", "89c91f11-8c13-4b74-ba8a-7adbb7345883"], "metadata": {"window": " \nPage 8 of 15 \n \nJason Hollar:  Yes.   Thanks, Mike.   And first of all, yes, I think we had some really great cash flow this \nlast year.   So $2.4 billion of operating cash flow and that resulted in a $3.4 billion ending cash \nbalance, which does include the $500 million debt paydown that we completed in the fourth quarter.  \n", "original_text": " \nPage 8 of 15 \n \nJason Hollar:  Yes.  ", "page_label": "8", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5a835f15-8161-4610-9af2-0a41a3f1f4cd": {"node_ids": ["b93994cd-96e9-44e3-82f0-2154b5551630", "0f12750c-6c5f-4511-88d3-0a87e3dcf924", "cc1be5f7-7d91-43fb-91c7-b0523e2b83a1", "22405e1b-4d33-4b2d-920d-e85df60ec7c6", "8e50f05e-9e57-4e5c-b654-0c54add01804", "3d908a2b-6780-4827-a37f-106ef5f86f82", "284f5dc5-893c-40b1-b028-5fafeec44e95", "38226411-e441-43d0-aff3-5642249add52", "1a096722-c9e0-4084-8a59-18105d26414d", "ff961dbf-f124-4626-ab61-719adcaceac4", "aa2a8f47-2a7a-444b-b663-664d053fd016", "9160c7fc-97f6-4371-87ea-fd33c348dda8", "4a2bd59d-7763-4f28-8932-36de6ae53083", "5e658415-3ef2-444e-9b42-4267e2176ae3", "73f37080-b75a-4213-948f-e7a31abafd7a", "233a737a-efc8-452c-9254-6ec1d856f801", "c70bac99-676e-45e1-ab75-18001952b176", "bca89952-052d-4224-a694-29ae72ee7922", "0ac9cfc2-4286-4986-8bd3-f2833160b29f", "598733c1-304d-4325-9333-70dccc418ee0", "13086624-1ee4-4e4a-9f47-bf37d2f28eac", "a1f82a8a-e438-459e-9c05-bcf08cbc7f3b", "30def53d-b8a8-45d3-bf12-08d4db8ab0fc", "37add67b-50ee-45bf-ac67-63f66a0e6242", "b3cb6b07-49ec-4c8b-883f-5754fe764c08", "7953ca80-89e3-4db6-89a6-189de3bee157", "b51cdfb1-3896-425e-aec4-2ae5cf78b579", "d2e79148-1465-4dd2-98d6-26059259a942", "53e55096-22a1-4bdb-a9cc-d1675e88de57", "10ec1ec1-f20c-4e47-a4ce-71aa2cf051b1", "f2846b64-26e5-433b-85eb-270923dd3487", "3699a346-226e-43e3-8469-69509b3e38ba", "e4e70211-e38f-4057-bc01-cccdda06551b", "f3d8c489-3c5a-43c4-9cf3-d87da419a298", "e0415612-999d-4010-b648-18d4e826abd2", "6772a21e-7836-43b6-a263-6e72bd55196a", "434fb24b-548a-4fe9-a773-0b29f4fbe4b6", "9b586dbc-8445-4adc-8157-533baba095c3"], "metadata": {"window": " \nPage 9 of 15 \n \norder to make a final decision.   And so we do have some time left on that to make sure that we \nunderstand exactly with clarity where that's going to be.   But we're pleased with where we are as far \nas an initial step of finally getting something out there for people to consider.  \n And then let me now turn it over to Jason to go into a little bit more of the other details that you asked \nabout.  \n", "original_text": " \nPage 9 of 15 \n \norder to make a final decision.  ", "page_label": "9", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3cd66ea5-602d-46a1-bf0f-4aa5226c7baa": {"node_ids": ["2045a540-c06f-4aac-ac48-a2d718557034", "1f24f3ba-278e-4ed4-9150-181b97f2bd5b", "7d5c9c28-0641-407b-9a43-4ad49e79b86a", "b639ab71-c07c-49fd-95be-294bad0e81ab", "1b9f7e51-490a-40aa-b1fe-4c4c8f56c179", "80d3a580-0cd3-4c39-a55f-136a5292511f", "8de11be3-9683-4290-b716-70b8cb66800a", "bef3d203-bede-4185-a5d0-89fae344bb8a", "a67ef7db-1801-4e36-b583-6f01f4ba4579", "66332817-5837-41a1-91df-cbb5ebd83006", "34d59930-881c-4a13-b7cb-5a4b6d3bb701", "9535f72f-73e6-439a-a95e-84dd302eda8b", "9fcd2fab-271a-4a52-b714-fb25baedd923", "b65a5a90-6dd6-4e82-bf9e-731bebab1d73", "dcb45c9a-a0ad-4d46-87b8-d615fa308871", "3bb28e27-8f0c-4cbc-bb07-97e601fb64c9", "91933740-75b8-41e7-b291-c4c8d74fc05e", "f4f84938-e6a9-4ebd-939a-30b595771b93", "4c53f349-d6ed-459c-9f61-89af75c02af6", "93cac9f9-fc97-4223-8d9a-1ceb8b6d090d", "fbc79305-3525-4189-9ef2-53c3d6e7f262", "ada2ee72-ea31-4b7c-98f5-4fa1bdd18415", "d39b1e73-0513-4d91-8150-779d4f93becd", "76ef0e13-dd68-4ded-bc99-5760605f3e5f", "3800ae91-0d59-4e0d-b645-4afd0bdbf0f0", "4e4f7a1e-4356-4611-84ee-8bc5d840ad16", "4557164f-3586-4918-950f-b9a49c2419f5", "5f3b9b04-5cf6-4af3-9df9-3583ff610d9d", "17eb8fd3-572a-4adc-800b-4cc6666d06d7", "f6b906e4-c81d-474e-a3eb-63cf35e8e0c6", "fac49038-a4f2-48ff-a2fc-3eafe000bd8c", "e1622df8-5bf2-41f6-af1c-b7c891a927bc", "973ff8d2-6a1a-4de2-bb89-4419f724c7d7", "957701d5-d68b-413e-bb44-5cf434b6913a", "6a8ba96b-23d9-4faf-b77a-95a07d263863", "dad1326c-9a2f-4dce-9afe-8fcbcda6fd10"], "metadata": {"window": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.   Anything else to add, \nMike?  \n Mike Kaufmann:  Only I'd reiterate that our focus has always been and will continue t o be on our \ncustomer, and it was important to us from the very beginning of this pandemic to acquire critical PPE \nfor our customers.   And as Jason said, we did ramp up during a period of higher demand and higher \nprices and longer supply chains.  \n", "original_text": " \nPage 10 of 15 \n \nAnd again, we're not going to get into all the details product -by-product, but it was that type of product \nthat has a little bit less of the value a dd and then therefore, has a little bit easier to get more supply \ninto the market and that drove the prices down quicker than other products.  ", "page_label": "10", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c77a0fa0-d84d-489c-805c-e2f79c14da3a": {"node_ids": ["6190c7d1-fe02-4725-a8c6-e7754b71b504", "b749eb8f-7470-44d2-8f87-9c01e831f693", "57992df9-1f81-444a-8620-a30e9a62b1ed", "bef77ed3-2a8c-47c7-9d77-4889c0fd3c66", "03f9c85d-d991-41fa-bd3a-24c77ca2b07a", "c6e2e55c-5dfe-4b3a-9cea-81039d56270c", "c2fc8185-14f8-482c-9df3-4c07f23809f3", "c5d6c526-4252-4b85-88ff-ad2fa21b10ca", "cd88dc31-5af6-4e3e-b107-7ea533601c9c", "d5992f2b-72f5-431a-9161-fc8056fd746e", "e2f06b5e-38e3-4d17-b527-25e1c787e53d", "9ad66116-ad2f-4ff8-a19e-8f90df92f574", "e23a5ebb-c11a-4425-acc6-8adc66d27d28", "61ccc4a2-a44a-4d4c-ab7b-7623b552c195", "455cb3d3-8df5-423b-867a-86f2f54805da", "b1d3eddc-99ea-4f7e-a441-e5aa48cea36c", "c1394024-12b4-46a6-962f-4c780d981739", "8488c376-55e5-461f-9705-068f3cadf02e", "0873c7e3-a194-4c44-928f-27443a1ce468", "eb7755b3-f63f-45d3-ab3d-b3b43f4169a1", "e21f7f9b-8908-416c-9469-6bed4e301c9b", "b0215c48-15bb-4112-8e82-d24dbeadd1a3", "21477dec-3713-4697-b87d-33cfae9acc02", "9f0a714a-6009-4f54-a382-c8d3e877d6f0", "76c846bd-b2f2-4ad8-842e-354520d4e301", "a1fb2654-5dad-412c-a981-356020f3980d", "b53de240-b68f-4f95-bccd-187355ea5350", "17e86000-d65a-4f5e-ae92-7c55c68b0c5c", "5bd617c7-83c3-4e31-b7b1-30d3fd24d5d8", "b247d4ae-b6ae-4b68-b626-c1e877e03111", "1bb76b9c-c896-4571-8f01-99374b28805a", "339ef681-c517-423f-b6e3-a47b0ffb25d8", "7a1b844f-4973-455a-9b25-edbbf95215ea", "38931ca2-f3a9-4616-9129-77671aa6545c", "0f490abf-87ad-48e6-9fd9-ac2dc02941ae", "97c2efa4-8a90-4893-bc7e-3dad769f8c7b", "6d828b0d-fcea-4546-8287-58333d33492a", "d4feb52e-1536-476e-9133-c9f8da83db2c", "9eadb7d0-5cbf-4ea6-a726-b8d5b010b75f", "db6870e0-6772-4041-abec-9e456d4643e6", "6361ab0e-6376-4654-b39d-f9eaf385f15f", "30f6a666-8b9f-4b07-ae2e-da9d24869687", "304ea542-8869-4945-afc4-7ed501ecae87"], "metadata": {"window": " \nPage 11 of 15 \n \ncapital.   And so as we're right in that rollout stage, that expense will be elevated in that part, we would \nexpect to reduce longer term, certainly beyond fiscal '22.   But for the balance of this year, we would \nexpect it to b e elevated.   And then thereafter, some portion of it will come down later on.  ", "original_text": " \nPage 11 of 15 \n \ncapital.  ", "page_label": "11", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "27e45734-f5b2-4d91-8dd9-d6769eadaeca": {"node_ids": ["9998046b-b6ed-405c-a45c-98ba2e8a26aa", "8b3cf2f2-6f32-402a-b2ab-44f5892131be", "c99b665e-3b85-411b-a542-9f8ac817e810", "54a791b2-5158-4843-b33b-5006f9531e7d", "c4bdc96c-31ba-494c-a7aa-8fc18dd43931", "c71513b5-cddd-4f80-8b40-6e1222f8ef1e", "4b67659b-e820-4bba-be84-9adeb378a5ea", "5e03086d-56fd-447f-acc5-2089eb0945a8", "a447d7fd-b0b8-4efc-aae6-5695afaf5a75", "30756745-7ba9-4c40-894d-7cebfc3dc31a", "a8fad3f0-418e-445f-8941-e80ae342ced5", "89e543f9-777d-4238-a7cc-9009d75edbad", "313a1594-18a4-490e-93c2-7e4177edafeb", "ef7730c9-8d43-411d-801e-a3847d94d6ae", "f983f2cc-1086-4b3e-a81f-19e34fa1028c", "537b8a07-d1a8-4a0e-aa10-321f8bc61655", "f3d7f095-2e90-49d9-bbad-738efbe47411", "c9a0f3a2-749a-41a8-8e01-b1a105ff32af", "bbe9cd2f-7183-43db-b10b-0dadfa8bd8ea", "10a0992e-67e9-4962-b2b7-229ed9aedd18", "13f16076-011b-427a-b9fc-c4f8a3d39f0d", "80d65d99-9c7d-44d8-9328-25c2735ba716", "58df4464-a750-4f6b-a527-6e2e4ae2215a", "55a56c9b-e8d5-4d0b-9c77-a80fe1dcdecb", "64696e33-5399-4c6f-a466-39f0d14011ba", "1c8c6e72-cfa1-4a5c-9c19-98bae3ba0f5c", "739ebb2c-40c7-465e-aef0-3403c075eebd", "c10980c8-b972-4c7a-a220-4c0f718446cd", "7c08f397-4bac-4f84-a526-07ad4b2f7666", "5a917768-ab56-4197-91b6-b05eb4b06d99", "27ff3e2a-83fd-4ba1-8bff-48718cc0a2e0", "9f994fb3-afe4-4abe-ba18-5dfb1bb1ff88", "c4c19b37-102b-4f4d-b43d-ce3ed87c07d7", "b91404aa-af72-4522-a986-bd810ea230f5", "6f7a35f6-55e7-4f66-bd68-0f2e16623bd1", "a935cafd-d14d-49a1-9c0f-1af1d7f351c9"], "metadata": {"window": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n So we're just -- wages, et cetera.   So it's just those types of things that we're seeing general elevated \nsupply chain costs across the board.   Again, we saw that in Q4.  ", "original_text": " \nPage 12 of 15 \n \nsee the cost of, for instance, containers can be  3 to 10x what they cost to ship in prior to COVID just \ndue to ports being plugged, things like that.  \n", "page_label": "12", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b21338ab-85c0-4d94-80a0-ff396d888d23": {"node_ids": ["c6be4d02-d6cd-44a8-afe3-01ffeaf2f219", "b1d2f9a0-3aaf-4649-a4a9-ef1ad45f53d9", "3b3b01d8-af77-4f28-879c-598dfe6a42d2", "97ef15a0-e4b8-44ae-85f5-a0cba3398f6d", "44af5ef2-595e-416c-85dc-da6adb1a67f6", "3346484c-7e96-454e-afbd-357bfff266a8", "8eb16b38-eec2-4ec2-96aa-500e0e7c0ece", "3a27bedc-8b23-47c2-9fcb-6f983488dd5b", "01da8bb4-e96d-4717-b27c-217587191877", "b08c4133-d9fc-4662-9bf3-8f3bee33e3cd", "b824bbb7-cf29-42f2-83c8-01ed38a1b810", "b2c3fc3e-2208-4d4f-b517-2cd2a6cff6fa", "b9dc7a45-9799-49bb-93eb-bd9d1ee39f01", "a5cec5fa-8f47-4b83-b40f-3dae613634f2", "fecae755-58de-47b9-88c4-f5393f4e88e4", "3faf9e88-095c-4689-8c25-1797983bd7c4", "1c5b4dc4-e42b-42b9-be28-075072d41d51", "d4da1471-94c1-40d1-87ab-cce303a0d616", "e1ec1960-f0db-443b-903d-3149a629cec1", "284b1c6c-085d-490b-986d-de91cdd3828d", "9ac7904a-e94f-440b-b5ca-7769a933b782", "e39f74f3-210e-4790-b967-bd4a7ca9dc50", "6960db19-1f85-4722-80fc-34b35c9717b5", "3ad9a262-514c-4518-a1d7-e2da83e5316c", "386a7bfc-2149-4fae-aa1b-d38d838aeb72", "69fe565c-139b-490b-95b4-e32989db7ed9", "6e9de60d-52aa-480e-9ce5-b631d1daaeeb", "9214b6b6-2259-4cfb-b533-f01bb4dbc1d4", "e7aa07b9-59c6-4d14-a793-e36b8a181365", "953e3f5a-4916-4131-b2d6-cb6f8e20b6d6", "babd3396-9f1a-41b2-8950-e75b519b5a88"], "metadata": {"window": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.   Thanks, Lisa.   Appreciate it.   Actually, you hit a lot of it right there in your \nquestion, is that we did want to provide a normalized growth so that we could share with you what we \ndo believe on our  achievable longer -term growth rates for both of the businesses that we provided, \nthe normalized growth on -- specifically, the Pharma, I think you said it well.  ", "original_text": " \nPage 13 of 15 \n \nMike Kaufmann:  Yes.  ", "page_label": "13", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e7d53cb1-efb1-4e83-8f0d-af5a077e591d": {"node_ids": ["1b20425a-b09d-407e-9020-f23d826a5e30", "15fa7a73-ac0b-4774-a6d5-48edda634509", "9c16e092-9afc-4e60-902b-a8cf4546fdb6", "eb19d9a1-7099-4441-a857-97dc042c17b7", "0ba65fe6-162a-4438-960a-0351e6b61546", "90609998-188b-448f-b33e-128b753c2afd", "83e27a91-6508-4f13-bbda-cae5d3e63b1d", "3f766952-649f-4f7f-8e0e-447854e9d135", "8765a05e-e006-4e65-aaa1-e33035e525b8", "d9e7cd83-860e-4488-86f1-877b9cadff11", "e34e3738-110d-4eb8-89c3-77ae5e9d03f5", "3cdd6957-e933-4922-a02c-fc3016ae670b", "1601cfc1-7251-4ed9-b04e-02d393cf17ae", "ca72b27d-1582-4330-a542-9c118c709c12", "93f048f9-547c-4cb0-93b3-b2a3e83bc7bd", "a71248ec-8f98-434d-a3ad-d0d05f18dcb3", "d95c6f65-aee3-403d-aca6-977e3f46e17b", "ad2f5502-2de1-48ec-9b88-5db50bc3630f", "4359f946-2952-4466-bd60-ee3d7e23a996", "8f694cff-0a47-43a2-b5d9-68355724ab76", "264a9f10-3c90-406f-9ebd-84af38a15c17", "35f5638a-efe7-42e3-9c12-104674711fea", "076e11db-95ba-44a3-a575-e1dfb7439c95", "8e314459-3096-401d-95cd-45133145c254", "6707d795-5655-4f91-aedd-3405725b6ed0", "57de8efe-bd55-458b-9c09-884ae8f38ed0", "2567fb41-9499-4509-9f42-ab22399209c7", "629a5669-bf0d-4495-b040-8ce38e337e66", "7e55ef38-1988-4873-991d-08e2540c14f2", "80bf3135-a4f2-4e41-be8a-a87e8b22a778", "69c5d470-1f1a-4607-a75f-3776384b9abf", "c26d411e-b4fe-487f-ba15-8a5bc395df0c", "8c61cccf-1c38-44b4-a58f-d7debb4f0f69", "4b0c1d17-8f70-4a9b-972c-794029a431cb", "72a299c8-e3da-4da4-a37a-49f431496dd6", "0a66552b-2235-40a9-8804-3584df1c69d8", "b8c5508c-180e-46a8-8d5f-7dc3d4d8860a", "df17284a-489e-4e9f-a336-23d869b3755f", "d9d34ada-8694-4999-b5c8-e8f8d2c53384", "ef6dc8c4-55d2-4513-a09c-3bd818e80bfb", "04dad935-42ab-447a-b59b-57912723e416", "5a175cb9-0cf8-471a-b571-15c74f835e2b", "d98fff9a-ca4e-4ba6-9aeb-e422e3490ee8"], "metadata": {"window": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n As far as the Red Oak, we won't be able to get into any specifics there.   But as you can imagine, it's \nbeen an excellent seven -year relationship.   Th e team there continues to remain intact.  ", "original_text": " \nPage 14 of 15 \n \nfair market r ate for that and feel very good about that, being able to be something that we can \ncontinue going forward.  \n", "page_label": "14", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "691e9bad-2b35-4c21-8984-421a82326418": {"node_ids": ["c00172f5-68e7-43d2-bcf5-839ae5f48564", "e3958513-9999-4dd3-ad94-b8a98d2d6e01", "42ed4dd7-3146-4bf9-b945-3f080018875c", "64794e1f-31b7-48bf-b725-baecded1ff01", "35c465f5-ef3e-4cbc-b651-287ee7176577", "5e872673-e104-4a2c-857a-77f7ef26c7f6", "1c54e143-34bb-40e2-bfb2-7fc08d807903", "7d196019-d1bc-47b1-9861-7f12632e7291", "63bdca92-2bed-4375-9a4a-7365984684c4", "f395d083-44e3-492e-85ed-585d3bc965bb", "9ce52669-728d-47cf-95e8-7bd02284fe6a", "8a9d2bfb-c729-44ef-a356-c441d7f955c8", "dcd0a86a-e7ce-44ea-85d0-13f48c0033e8", "dc17130a-2913-49bd-9e9a-701625bf3b01"], "metadata": {"window": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.   I will now turn the conference back to Mike \nKaufmann for his closing remarks.  \n Mike Kaufmann:  Yes, I want to thank everybody for taking the time to be on the call and for the very \nhelpful questions.   I know there was a lot of noise in this quarter, but I just want to end with a few \nthoughts to keep in mind.  ", "original_text": " \nPage 15 of 15 \n \nOperator:  And that concludes our Q&A session for today.  ", "page_label": "15", "file_name": "CAH-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 181732, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}